



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

### MONDAY, AUGUST 16

#### 07:00 – 08:15 SUNRISE SYMPOSIA

**Session SUN01 ROTRF Symposium: Antibody-Mediated Rejection - an Ounce of Prevention is Worth a Pound of Cure**

**Monday, August 16, 2010 07:00 AM - 08:15 AM**  
**Room: MR 220 - 222**

Moderators: *Andrew . Bradley, Allan . Kirk*

SUN01.1 Humoral Immunity: Mechanisms of Graft Injury and Relationship to Cellular Immunity

W.M. Baldwin III  
Cleveland/UNITED STATES OF AMERICA

SUN01.2 Detection and Identification of Alloantibodies circa 2010: Myths and Realities

H. Gebel  
Atlanta/UNITED STATES OF AMERICA

SUN01.3 The 2 Key Questions for Desensitization: Who and How?

D. Glotz  
Paris/France

SUN01.4 Giving the Incompatible Patient Hope with Kidney Paired Donation

A. Bingaman  
San Antonio/UNITED STATES OF AMERICA

SUN01 - DISCUSSION



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

### Session SUN02 Non-HLA antibodies in transplantation (Absorber)

**Monday, August 16, 2010 07:00 AM - 08:15 AM**

**Room: MR 212 - 214**

Moderators: *Ron . Shapiro*

Introduction

R. Shapiro

Pittsburgh/UNITED STATES OF AMERICA

SUN02.1 Predictors of graft failure in kidney transplant recipients

J.M. Grinyó

Barcelona/SPAIN

SUN02.2 The role of non-HLA antibodies on acute rejection

K.J. Wood

Oxford/UNITED KINGDOM

SUN02.3 Testing for non-HLA antibodies, a clinical approach

A. Tambur

Chicago/UNITED STATES OF AMERICA

SUN02.4 Summary & Closing Remarks

R. Shapiro

Pittsburgh/UNITED STATES OF AMERICA

### Session SUN03 Optimal screening of donors and recipients

**Monday, August 16, 2010 07:00 AM - 08:15 AM**

**Room: MR 211**

Moderators: *Elmi . Muller, Jutta . Preiksaitis*



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

SUN03.1 Tuberculosis

M. Sester  
Homburg/GERMANY

SUN03.2 Chagas Disease and Strongyloides

R. Bestetti  
?/BRAZIL

SUN03.3 Use of NAT in Screening

A. Humar  
Edmonton/CANADA

SUN03.4 Tricky Screening Cases and Expanding the Organ Pool

M.G. Ison  
Chicago/UNITED STATES OF AMERICA

SUN03 - DISCUSSION

### **Session SUN04 Formation, detection and characterization of antibodies to transplantation antigens**

**Monday, August 16, 2010 07:00 AM - 08:15 AM**  
**Room: MR 202 - 204**

Moderators: *Susan . Fuggle, Nouredine . Berka*

SUN04.1 The immunogenicity of HLA

I. Doxiadis  
Leiden/NETHERLANDS

SUN04.2 Generation and determinants of cellular and humoral responses

A. Zeevi  
Pittsburgh/UNITED STATES OF AMERICA

SUN04.3 Solid phase immunoassays for antibody detection and quantitation



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

P.M. Campbell  
Edmonton/CANADA

SUN04.4 From antibody specificity to epitope matching

R.J. Duquesnoy  
Pittsburgh/UNITED STATES OF AMERICA

SUN04 - DISCUSSION

### Session SUN05 The Art of Patient Care

**Monday, August 16, 2010 07:00 AM - 08:15 AM**  
**Room: MR 205 - 207**

Moderators: *Susan* . Chernenko, *Clare* . Whittaker

SUN05.1 Nurse led health promotion clinics: A paradigm shift to patient centered care

J. Routledge  
London/UNITED KINGDOM

SUN05 - DISCUSSION

SUN05.2 Fairytale or nightmare? A patient's story on adherence

P. Harden  
Oxford/UNITED KINGDOM

SUN05 - DISCUSSION

### **08:30 – 08:30 PLENARY SESSION**

### Session PL01 The Genome and Beyond

**Monday, August 16, 2010 08:30 AM - 10:00 AM**  
**Room: Ballroom A/B**

Moderators: *Jeremy* . Chapman, *Marcelo* . Cantarovich



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

PL01.1 Vision and Future of Systems Biology

L. Hood

Seattle/UNITED STATES OF AMERICA

PL01.2 Beyond the Genome

J. Greenblatt

PL01.3 Monitoring Allograft Status in the 21st Century: A Noninvasive Molecular Approach

M. Suthanthiran

New York/UNITED STATES OF AMERICA

#### 10:30 – 12:00 CONCURRENT MORNING SYMPOSIA

##### Session O01 Experimental Immunobiology

**Monday, August 16, 2010 10:30 AM - 12:00 PM**

**Room: MR 202 - 204**

Moderators: *Caigan . Du, Philip . Acott*

O01.01 Ganciclovir attenuates murine cytomegalovirus associated renal allograft inflammation.

U. Saunders, B. Rha, L.L. Guo, J.F. George, W.J. Britt, M. Shimamura

Birmingham/UNITED STATES OF AMERICA

O01.02 Separating Antiviral Response from Heterologous Alloreactivity: V $\beta$ 4 CD8 T Cells May Not Directly Cause Allograft Rejection In Latent MHV68 Infection

J. Beus, S. Selvaraj, S. Gangappa, A. Kirk, C. Larsen, S. Speck, L.S. Kean

Atlanta/UNITED STATES OF AMERICA

O01.03 Modulation of the Wnt signaling pathway by WISE antibody improves long-term kidney transplant outcome in a rat renal transplant model

X. Yuan<sup>1</sup>, S. Vonderfecht<sup>2</sup>, X. Ge<sup>1</sup>, J. Lee<sup>2</sup>, A. Jurisch<sup>1</sup>, E. Valente<sup>2</sup>, J. Pretorius<sup>2</sup>, B. Tipton<sup>2</sup>, A.G. Winters<sup>2</sup>, L.C. Harris<sup>1</sup>, L. Zhang<sup>2</sup>, A. You<sup>2</sup>, Y. Gao<sup>2</sup>, C. Paszty<sup>2</sup>, W.G. Richards<sup>2</sup>, W.S. Simonet<sup>2</sup>, X. Qian<sup>2</sup>, S.G. Tullius<sup>1</sup>

<sup>1</sup>Boston/UNITED STATES OF AMERICA, <sup>2</sup>Thousand Oaks/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

001.04 NK cells mediate chronic kidney allograft injury in tolerant parent to F1 transplants

Z.-X. Zhang, J. Jiang, X. Huang, Z. Yin, W. Liu, B. Garcia, A.M. Jevnikar  
London/CANADA

001.05 Renal tubular cell (TEC) expression of SPI-6 (Serpine Protease Inhibitor-6) is required for protection from Granzyme B mediated effector cell injury following transplantation

K. Shek, Z.-X. Zhang, K. Khan, S. Wang, A. Lau, Z. Yin, W. Liu, B. Garcia, B. Singh, H. Wang, A.M. Jevnikar  
London/CANADA

001.06 BK virus high level replication in vitro reduced by cyclosporine A, proximal tubule cell type and culture environment (polarity) but not by Tacrolimus

P.D. Acott, P.A. O'Regan, A.O. Skotnicki, J.F.S. Crocker  
Halifax/CANADA

001.07 Adenovirus-mediated antisense ERK2 gene therapy down-regulates expression of T $\beta$ RI and TGF- $\beta$ , decreases infiltrates, and ameliorates chronic renal allograft fibrosis in a rat model

N. Gong, Z. Chen, X. Chen  
Wuhan/CHINA

001.08 Significant Prolongation of Renal Allograft Survival By Applying A Novel NF-kappa B Inhibitor, Dehydroxymethylepoxyquinomicin, In A Rat Acute Rejection model

K. Shinoda, K. Nakagawa, H. Kono, E. Kikuchi, A. Miyajima, M. Oya  
Tokyo/JAPAN

001.09 Ischemia reperfusion injury therapy: inhibitor of coagulation during preservation rescues chronic kidney inflammation, fibrosis and graft loss.

R. Thuillier, S. Giraud, O. Page, T. hauet  
Poitiers Cedex/FRANCE

### Session 002 T Cell Diversity and Functional Biology

**Monday, August 16, 2010 10:30 AM - 12:00 PM**

**Room: MR 205 - 207**

Moderators: *Leslie . Brent, David . White*



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O02.01 Regulatory T cell therapy prolongs human skin allograft survival in a humanised mouse model

F. Issa, J. Wieckiewicz, R. Goto, T. Goodacre, K.J. Wood  
Oxford/UNITED KINGDOM

O02.02 CD4+CD25+Tregs activated in vitro with IL-2 and IL-12p70 suppress rejection of fully allogeneic grafts in animals with no other immunosuppression.

B.M. Hall<sup>1</sup>, N.D. Verma<sup>1</sup>, R. Boyd<sup>1</sup>, C.M. Robinson<sup>1</sup>, G.T. Tran<sup>1</sup>, C. Wang<sup>2</sup>, G.A. Bishop<sup>2</sup>, S.J. Hodgkinson<sup>1</sup>  
<sup>1</sup>Eveleigh/AUSTRALIA, <sup>2</sup>Sydney/AUSTRALIA

O02.03 Combined administration of a novel mutant TGF- $\beta$ 1/Fc and rapamycin modulates the immune balance between Treg and Th17 and promotes allograft tolerance

W. Zhang, D. Zhang, Y. Wang, Y. Tian, W.P.A. Lee, X.X. Zheng  
Pittsburgh/UNITED STATES OF AMERICA

O02.04 CD4CD25 Positive Mast Cells in Long-Term Surviving Grafts Followed by T-Regulatory Therapy: MC-regs?

A. Andakyan, S. Burruss, L.-S. Hong, X. Shen, S. Romanov, F. Gao, M. Fishbein, N. Semiletova  
Los Angeles/UNITED STATES OF AMERICA

O02.05 Inducing Islet Allograft Tolerance by Combining Regulatory T Cell Therapy with Donor-specific T Cell Deletion

K. Lee<sup>1</sup>, G. Miao<sup>1</sup>, V. Nguyen<sup>1</sup>, H. Scholz<sup>2</sup>, T.V. Brennan<sup>1</sup>, S.-M. Kang<sup>1</sup>, Q. Tang<sup>1</sup>  
<sup>1</sup>San Francisco/UNITED STATES OF AMERICA, <sup>2</sup>Oslo/NORWAY

O02.06 Allogeneic Treg generated in vitro with retinoic acid and TGF- $\beta$  control cytokine production and allograft rejection.

C. Moore<sup>1</sup>, C. Fuentes<sup>1</sup>, V. Ramirez<sup>1</sup>, M.R. Bono<sup>1</sup>, J.A. Fierro<sup>1</sup>, K.J. Wood<sup>2</sup>, A. Bushell<sup>2</sup>, M. Roseblatt<sup>1</sup>  
<sup>1</sup>Santiago/CHILE, <sup>2</sup>Oxford/UNITED KINGDOM

O02.07 Generation of human T regulatory cells with the capacity to suppress islet allograft rejection in a xenogeneic mouse model.

A. McMurphy, D. Dai, J. Gillies, C.B. Verchere, M.K. Levings  
Vancouver/CANADA

O02.08 Contribution of regulatory T cells combined with low-dose Sirolimus, but not Tacrolimus, to delay acute rejection of renal allografts in cynomolgus monkeys



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

A. Ma, L. Song, S. Qi, Y. Hu, H. Dun, Z. Xiong, P. Daloze, H. Chen  
Montreal/CANADA

O02.09 Up regulation of FOXP3 expression in CD4+CD25+ IL-7R $\alpha$  low regulatory T cells in operational tolerance after pediatric living donor liver transplantation

H.A. Nafady Hego, Y. Li, S. Sakaguchi, S. Uemoto, T. Koshiba  
Kyoto/JAPAN

#### Session O03 Genomics and Biomarkers

**Monday, August 16, 2010 10:30 AM - 12:00 PM**  
**Room: MR 211**

Moderators: *Daniel . Salomon, Thomas . Mueller*

O03.08 A Highly Specific Novel 3 Gene-set Can Non-invasively Predict Operational Renal Allograft Tolerance

L. Li<sup>1</sup>, S. Heish<sup>1</sup>, J.D. Scandling<sup>2</sup>, T. Sigdel<sup>1</sup>, M. Sarwal<sup>1</sup>  
<sup>1</sup>Stanford/UNITED STATES OF AMERICA, <sup>2</sup>Palo Alto/UNITED STATES OF AMERICA

O03.01 Over-expression of human CD39 in mouse liver protects against ischemia reperfusion injury in a model of liver transplantation

B. LU<sup>1</sup>, S. Pommey<sup>1</sup>, S. Robson<sup>2</sup>, A. d'Apice<sup>1</sup>, P. Cowan<sup>1</sup>, K. Dwyer<sup>1</sup>  
<sup>1</sup>Fitzroy/AUSTRALIA, <sup>2</sup>02115/UNITED STATES OF AMERICA

O03.02 Assigning a probability of TCMR to kidney transplant biopsies.

J. Reeve, J. Sellarés, M. Mengel, B. Sis, L.G. Hidalgo, K.S. Famulski, P. Halloran  
Edmonton/CANADA

O03.03 Structural aspects of HLA class I epitopes recognized by human monoclonal antibodies

R.J. Duquesnoy<sup>1</sup>, M. Marrari<sup>1</sup>, A. Mulder<sup>2</sup>  
<sup>1</sup>Pittsburgh/UNITED STATES OF AMERICA, <sup>2</sup>Leiden/NETHERLANDS

O03.04 Acute Rejection of Cardiac Allografts results in a Unique Signature of MicroRNAs

L. Wei, M. Wang, A. Harris, O.M. Martinez, S.M. Krams  
Stanford/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O03.05 Oncostatin M is the key acute phase response gene in the renal epithelial and vascular compartment

T.F. Mueller<sup>1</sup>, W.L. Phan<sup>1</sup>, C. Compston<sup>1</sup>, S. Rose-John<sup>2</sup>, D. Perkins<sup>3</sup>, V.A. Luyckx<sup>1</sup>  
<sup>1</sup>Edmonton/CANADA, <sup>2</sup>Kiel/GERMANY, <sup>3</sup>San Diego/UNITED STATES OF AMERICA

O03.06 Genetic polymorphisms of adhesion molecules and kidney transplant survival

A. Heinold, G. Opelz, B. Döhler, S. Scherer, A. Ruhstroth, T.H. Tran  
Heidelberg/GERMANY

O03.07 Transcriptional profiling of liver grafts in spontaneous operational tolerance.

F. Bohne<sup>1</sup>, M. Martinez-Llordella<sup>1</sup>, J.J. Lozano<sup>1</sup>, M. Lopez<sup>1</sup>, C. Benitez<sup>1</sup>, R. Miquel<sup>1</sup>, G. Tisone<sup>2</sup>, A. Rimola<sup>1</sup>,  
A. Sanchez-Fueyo<sup>1</sup>  
<sup>1</sup>Barcelona/SPAIN, <sup>2</sup>Rome/ITALY

O03.09 Discerning gene expression profiles involved in loss of graft function with IF/TA: utility in diagnosis and disease progression.

M.J. Scian, D. Maluf, K.J. Archer, B.C. Whitehill, L.J. Suh, A. King, T.W. Gehr, A. Sharma, S. Kapoor, A. Cotterell, D.H. Massey, M.P. Posner, V. Mas  
Richmond/UNITED STATES OF AMERICA

### Session O04 Organ Donation and Allocation I

**Monday, August 16, 2010 10:30 AM - 12:00 PM**  
**Room: MR 109 - 110**

Moderators: *Bernard . Cohen*, *Valter . Garcia*

O04.01 Impact of the 2006 UK National Kidney Allocation Scheme

R.J. Johnson<sup>1</sup>, S.V. Fuggle<sup>1</sup>, L.L. Mumford<sup>1</sup>, J.A. Bradley<sup>2</sup>, J.L.R. Forsythe<sup>3</sup>, C. Rudge<sup>4</sup>  
<sup>1</sup>Bristol/UNITED KINGDOM, <sup>2</sup>Cambridge/UNITED KINGDOM, <sup>3</sup>Edinburgh/UNITED KINGDOM,  
<sup>4</sup>London/UNITED KINGDOM

O04.02 Comparison of Model for End-Stage liver disease (MELD) & United Kingdom End-Stage Liver Disease (UKELD) scores as a predictor for death on the liver transplant waiting list and as a predictor of mortality following liver transplantation

S. AROORI, P. Gupta, B. Gunson, P. Nightingale, J. Isaac, P. Muiesan, D. Mirza, D. Mayer, J. Buckels, S. Bramhall  
Birmingham/UNITED KINGDOM



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

004.03 Outcomes and Distributional Efficacy of Kidneys rejected by local and regional centers in the United States

L.K. Kayler, J. Sokolich, J. Magliocca, J. Schold  
Gainesville/UNITED STATES OF AMERICA

004.04 Primum non nocere: can living donation be justified as long as deceased donation is not optimally exploited?

L. Roels<sup>1</sup>, J. Smits<sup>2</sup>, B. Cohen<sup>1</sup>  
<sup>1</sup>Linden/BELGIUM, <sup>2</sup>Leiden/NETHERLANDS

004.05 Tools to compare organ procurement process

R. Deulofeu, J. Twose, M. Sanroma  
Barcelone/SPAIN

004.06 Family approach – retrospective analysis of family refusals

F. Schaub<sup>1</sup>, D. Norba<sup>2</sup>, G.R. Kirste<sup>2</sup>  
<sup>1</sup>Frankfurt Am Main/GERMANY, <sup>2</sup>Frankfurt/GERMANY

004.07 Organ scarcity, restriction of non-residents to European transplant wait lists and the prohibition of discrimination under EU Law

F. Ambagtsheer<sup>1</sup>, A. Rahmel<sup>2</sup>, W. Weimar<sup>1</sup>  
<sup>1</sup>Rotterdam/NETHERLANDS, <sup>2</sup>Leiden/NETHERLANDS

004.08 Paired living kidney donation in the UK

R.J. Johnson<sup>1</sup>, J. Allen<sup>1</sup>, S.V. Fuggle<sup>1</sup>, J.A. Bradley<sup>2</sup>  
<sup>1</sup>Bristol/UNITED KINGDOM, <sup>2</sup>Cambridge/UNITED KINGDOM

004.09 An assessment of the work required to evaluate living donors

C. Rose, P. Blezcinski, L. Sills, R. McCarrell, W. Gourlay, J. Gill, J. Gill  
Vancouver/CANADA

### Session O05 Induction Immunosuppression

**Monday, August 16, 2010 10:30 AM - 12:00 PM**  
**Room: Ballroom A/B**



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

Moderators: *Olwyn . Johnston, Arthur . Matas*

O05.01 Final 36 Month Results Of A Multicenter, Randomized Trial Comparing Three Induction Agents (Alemtuzumab, Thymoglobulin and Basiliximab) With Tacrolimus, Mycophenolate Mofetil and a Rapid Steroid Withdrawal in Renal Transplantation

M. Hanaway<sup>1</sup>, E.S. Woodle<sup>2</sup>, S. Mulgaonkar<sup>3</sup>, R. Peddi<sup>4</sup>, G. Harrison<sup>5</sup>, K. Vandeputte<sup>5</sup>, W. Fitzsimmons<sup>5</sup>, R. First<sup>5</sup>, J. Holman<sup>5</sup>

<sup>1</sup>Birmingham/UNITED STATES OF AMERICA, <sup>2</sup>Cincinnati/UNITED STATES OF AMERICA,

<sup>3</sup>Livingston/UNITED STATES OF AMERICA, <sup>4</sup>San Francisco/UNITED STATES OF AMERICA,

<sup>5</sup>Deerfield/UNITED STATES OF AMERICA

O05.02 Kidney transplantation with campath 1H and infliximab induction followed by either tacrolimus or sirolimus monotherapy: 12-months follow-up

O. Viklicky<sup>1</sup>, J. Slatinska<sup>1</sup>, H.-D. Volk<sup>2</sup>, B. Sawitzki<sup>2</sup>, M. Burgelova<sup>1</sup>, P. Reinke<sup>2</sup>

<sup>1</sup>Prague 4/CZECH REPUBLIC, <sup>2</sup>Berlin/GERMANY

O05.03 To Wean or Not to Wean Tacrolimus Monotherapy After Alemtuzumab Pretreatment in Living Donor Kidney Transplant Recipients: A Comparative Study.

H.P. Tan, A. CHAUDHARY, A. Humar, J. DONALDSON, A. Basu, C. Morgan, M. UNRUH, J. McCauley, C. Wu, N. Shah, P. Randhawa, R. Shapiro  
Pittsburgh/UNITED STATES OF AMERICA

O05.04 Induction immunosuppression improves graft survival in organ transplantation: a report of 15 years UNOS registry data

J. CAI, P.I. Terasaki

Los Angeles/UNITED STATES OF AMERICA

O05.05 Induction Immunosuppression in the Elderly Kidney Transplant Recipient: An analysis of OPTN/UNOS data informing a risk stratified approach

J. Gill<sup>1</sup>, M. Sampaio<sup>2</sup>, Y.W. Cho<sup>2</sup>, J. Gill<sup>3</sup>, S. Bunnapradist<sup>2</sup>

<sup>1</sup>Vancouver/CANADA, <sup>2</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>3</sup>Vancouver/CANADA

O05.06 Short- and long term kidney graft survival: the impact of intra-operative high-dose ATG-Fresenius induction and identification of important predictors

J. Kaden<sup>1</sup>, G. May<sup>1</sup>, A. Völp<sup>2</sup>, C. Wesslau<sup>1</sup>, D.K. Abendroth<sup>3</sup>

<sup>1</sup>Berlin/GERMANY, <sup>2</sup>Frankfurt/GERMANY, <sup>3</sup>Ulm/GERMANY



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O05.07 Interleukin-2 receptor antagonists versus ATG for kidney transplant recipients; an updated Cochrane systematic review.

A. Webster, L.P. Ruster, R. Mc Gee, S.L. Matheson, G.Y. Higgins, N.S. Willis, J.R. Chapman, J. Craig Sydney/AUSTRALIA

O05.08 Impact of IL2-RA Induction Therapy in the Prevention of Acute Rejection with TAC/MMF-Based Immunosuppression

J. Gralla, A. Wiseman  
Denver/UNITED STATES OF AMERICA

O05.09 One year follow up efficacy and safety of induction therapy comparison of anti-interleukin-2 receptor antibodies and thymoglobulin

L. Li, A. Chaudhuri, A. Chen, X. Zhao, M. Bezchinsky, M. Sarwal  
Stanford/UNITED STATES OF AMERICA

### Session O06 CMV Infection

**Monday, August 16, 2010 10:30 AM - 12:00 PM**  
**Room: MR 220 - 222**

Moderators: *Petra . Reinke, William . Rawlinson*

O06.01 The IMPACT STUDY: Extending Valganciclovir Prophylaxis in Kidney Transplant High Risk (D+/R) Recipients is Associated with Long-term Benefits.

A. Humar<sup>1</sup>, Y. LEBRANCHU<sup>2</sup>, F. Vincenti<sup>3</sup>, E. Blumberg<sup>4</sup>, J.D. PUNCH<sup>5</sup>, A.P. Limaye<sup>6</sup>, D. Abramowicz<sup>7</sup>, A.G. Jardine<sup>8</sup>, I.A. Hauser<sup>9</sup>, M. Farhan<sup>10</sup>, P. Peeters<sup>11</sup>  
<sup>1</sup>Edmonton/CANADA, <sup>2</sup>Tours/France, <sup>3</sup>San Francisco/UNITED STATES OF AMERICA,  
<sup>4</sup>Philadelphia/UNITED STATES OF AMERICA, <sup>5</sup>Ann Arbor/UNITED STATES OF AMERICA, <sup>6</sup>Seattle/UNITED STATES OF AMERICA, <sup>7</sup>Anderlecht/BELGIUM, <sup>8</sup>Glasgow/UNITED KINGDOM, <sup>9</sup>Frankfurt/M/GERMANY,  
<sup>10</sup>Welwyn Garden City/UNITED KINGDOM, <sup>11</sup>Ghent/BELGIUM

O06.02 The IMPACT Study: Phenotypic Analysis of Previously Uncharacterized Cytomegalovirus UL54 and UL97 Amino Acid Substitutions Detected in Virus from Patients Receiving 200 or 100 Days of Valganciclovir (Valcyte®) Prophylaxis

S. Chou<sup>1</sup>, G. Marousek<sup>1</sup>, V. Wong<sup>1</sup>, G. Boivin<sup>2</sup>, N. Goyette<sup>2</sup>, M. Farhan<sup>3</sup>, R. Elston<sup>3</sup>  
<sup>1</sup>Portland/UNITED STATES OF AMERICA, <sup>2</sup>Sainte-Foy/CANADA, <sup>3</sup>Welwyn Garden City/UNITED KINGDOM



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O06.03 The IMPACT study: 100-day vs 200-day prophylaxis with valganciclovir (Valcyte®) to reduce CMV disease post-transplant is cost-effective within US health care setting

A.G. Jardine<sup>1</sup>, I.A. Hauser<sup>2</sup>, C. Gahlemann<sup>3</sup>, K. Berenson<sup>4</sup>, E. Blumberg<sup>5</sup>, A. Humar<sup>6</sup>  
<sup>1</sup>Glasgow/UNITED KINGDOM, <sup>2</sup>Frankfurt/M/GERMANY, <sup>3</sup>Basel/SWITZERLAND, <sup>4</sup>New York/UNITED STATES OF AMERICA, <sup>5</sup>Philadelphia/UNITED STATES OF AMERICA, <sup>6</sup>Edmonton/CANADA

O06.04 Association of Cytomegalovirus (CMV) Infection and Disease with Death and with Graft Loss or Death after Liver Transplant in High Risk Recipients

W. Bosch, M.G. Heckman, N.N. Diehl, J.A. Shalev, W.C. Hellinger  
Jacksonville/UNITED STATES OF AMERICA

O06.05 Primary CMV Infections Are Common in Kidney Transplant Recipients after 6 Months Valganciclovir Prophylaxis

I. Helanterä, L. Kyllönen, I. Lautenschlager, K. Salmela, P. Koskinen  
Helsinki/FINLAND

O06.06 Monitoring with or without Pre-emptive Therapy versus Prophylaxis for Cytomegalovirus (CMV) in Renal Transplant Patients

T.A.K. Rana, J. Taylor, J.A. Akoh  
Plymouth/UNITED KINGDOM

O06.07 Development of primary CMV-specific T-cell responses in D+/R- transplant recipients during valganciclovir prophylaxis

C. La Rosa<sup>1</sup>, A.P. Limaye<sup>2</sup>, A. Krishnan<sup>1</sup>, G. Blumstein<sup>1</sup>, D.J. Diamond<sup>1</sup>  
<sup>1</sup>Duarte/UNITED STATES OF AMERICA, <sup>2</sup>Seattle/UNITED STATES OF AMERICA

O06.08 In vivo viral microRNA profiling in a large cohort of transplant patients with CMV disease

L.F. Lisboa<sup>1</sup>, D. Kumar<sup>1</sup>, X. Pang<sup>1</sup>, L. Tyrrell<sup>1</sup>, J. Huang<sup>1</sup>, A. Åsberg<sup>2</sup>, A. Hartmann<sup>2</sup>, A. Humar<sup>1</sup>  
<sup>1</sup>Edmonton/CANADA, <sup>2</sup>Oslo/NORWAY

O06.09 The IMPACT Study: Valganciclovir Pharmacokinetic Parameters Do Not Change When Extending Prophylaxis from 100 to 200 Days.

C. Washington<sup>1</sup>, H. Welker<sup>2</sup>, M. Farhan<sup>3</sup>, A. Humar<sup>4</sup>  
<sup>1</sup>South San Francisco/UNITED STATES OF AMERICA, <sup>2</sup>Basel/SWITZERLAND, <sup>3</sup>Welwyn Garden City/UNITED KINGDOM, <sup>4</sup>Edmonton/CANADA

### Session O07 A New Century of Pediatric Transplantation?



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

**Monday, August 16, 2010 10:30 AM - 12:00 PM**

**Room: MR 217 - 219**

Moderators: *Susan . Samuel, Anne . Dipchand*

O07.01 Can We Ignore HLA-DR Matching in Pediatric Kidney Transplantations?: an Analysis of OPTN/UNOS data

J. Cicciarelli, T. Shah, B. Hardy, I.V. Hutchinson, Y.W. Cho  
Los Angeles/UNITED STATES OF AMERICA

O07.02 The association between cytomegalovirus immune globulin (CMVIG) use and long-term recipient and graft survival in pediatric heart transplantation recipients

D.R. Snyderman<sup>1</sup>, K. Kistler<sup>2</sup>, J. Morris<sup>2</sup>, P. Ulsh<sup>3</sup>  
<sup>1</sup>Boston/UNITED STATES OF AMERICA, <sup>2</sup>Harrisburg/UNITED STATES OF AMERICA, <sup>3</sup>King Of Prussia/UNITED STATES OF AMERICA

O07.03 Two Decade Experience with Pediatric Intestinal Failure and Transplantation; Evolution and Future Progress

G.J. Bond, K. Soltys, R. Sindhi, K.M. Abu-Elmagd, G. Mazariegos  
Pittsburgh/UNITED STATES OF AMERICA

O07.04 Post-Transplant Lymphoproliferative Disorder in Australian and New Zealand Pediatric Renal Transplant Recipients

S. McTaggart<sup>1</sup>, D. Longmore<sup>1</sup>, L. Conwell<sup>1</sup>, S.P. McDonald<sup>2</sup>, J. Burke<sup>1</sup>  
<sup>1</sup>Brisbane/AUSTRALIA, <sup>2</sup>Adelaide/AUSTRALIA

O07.05 63 Pediatric Living Donor Kidney Transplantations Using Alemtuzumab Pretreatment and Tacrolimus Monotherapy: 6 Year Experience

H.P. Tan, A. CHAUDHARY, J. DONALDSON, D. Ellis, M.L. Moritz, A. Humar, A. Basu, C. Morgan, A.N. Vats, E. Erkan, A. Swiatecka-Urban, A. Barber, D. Connors, C. McFeaters, R. Shapiro  
Pittsburgh/UNITED STATES OF AMERICA

O07.06 Are liver transplanted children more impulsive? Attention and executive functioning after pediatric liver transplantation

T. Kaller, N. Langguth, B. Nashan, R. Ganschow, K.-H. Schulz  
Hamburg/GERMANY

O07.07 The Outcome of Corneal Transplantation in Infants, Children and Adolescents



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

K.A. Williams, M. Lowe, M.C. Keane, D.J. Coster  
Bedford Park/AUSTRALIA

O07.08 Pharmacokinetic Profile of Valganciclovir in Pediatric Transplant Recipients

E. Launay, N. Kassir, Y. Théoret, C. Litalien, M. Duval, F. Alvarez, D. Larocque, A.-L. Lapeyraque, V. Lamarre, P. Ovetchkine  
Montreal/CANADA

O07.09 Role of the liver transplantation in the management of hepatoblastoma in children

H. Ismail, D. Broniszczak, P. Kalicinski, P. Kluge, B. Dembowska-Baginska, A. Kosciesza, A. Lembas  
Warsaw/POLAND

### Session O08 Immunosuppression for Liver Transplantation

**Monday, August 16, 2010 10:30 AM - 12:00 PM**  
**Room: MR 118 - 120**

Moderators: *Douglas . Hanto, Hans . Schlitt*

O08.01 Early steroid-free immunosuppressive therapy with FK 506 after liver transplantation - 5-year results of a prospective randomized double-blinded placebo-controlled study

N. Weiler, M. Hoppe-Lotichius, T. Zimmermann, I. Kraemer, G. Otto  
Mainz/GERMANY

O08.02 Long term follow up of 22 operational tolerant liver transplant recipients.

P. tryphonopoulos, P. Ruiz, D. Wepler, D. Levi, S. Nishida, J. Moon, G. Selvaggi, A. Tekin, E. Island, M. Torres, A. Tzakis  
Miami/UNITED STATES OF AMERICA

O08.03 Predicting "operational tolerance" after liver transplantation

T.M. Manzia, R. Angelico, L. Toti, M. Manuelli, I. Bellini, D. Sforza, L. Perrone, G. Tisone  
Rome/ITALY

O08.04 Campath-1H induction immunosuppression in adult non-HCV liver transplant recipients. Eight year experience of a single Center.



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

P. tryphonopoulos, P. Ruiz, S. Nishida, D. Wepler, D. Levi, J. Moon, G. Selvaggi, E. Island, A. Tekin, M. Torres, T. Defranc, A. de Bonnefon, L. Arosemena, A. Tzakis  
Miami/UNITED STATES OF AMERICA

O08.05 Single centre experience in conversion of calcineurin inhibitor to sirolimus-based immunosuppression following liver transplantation.

S. Harper, W. Gelson, I. Harper, G. Alexander, P. Gibbs  
Cambridge/UNITED KINGDOM

O08.06 Sirolimus improves renal function but does not negatively influence outcomes in liver transplant recipients

J. Campsen, M. Zimmerman, S. Mandell, M. Kaplan, I. Kam  
Aurora/UNITED STATES OF AMERICA

O08.07 No immunologic graft failure in consecutive 17 cases of ABO-incompatible living donor liver transplantation under rituximab prophylaxis

G.-W. Song, S.-G. Lee, S. Hwang, C. Ahn, D. Moon, T. Ha, D.. Jung, P. Park, Y. Choi  
Seoul/KOREA

O08.08 Short-term, low-dose thymoglobuline: the best option to spare calcineurin inhibitors in liver transplant recipients with renal failure?

P.C. Casciato, S. Marciano, O.A. Galdame, A.G. Villamil, J.C. Bandi, E. de Santibañes, A.C. Gadano  
Buenos Aires/ARGENTINA

O08.09 Donor specific antibodies found in nearly all patients who chronically rejected their liver transplant.

J.G. O'Leary<sup>1</sup>, H. Kaneku<sup>2</sup>, B. Susskind<sup>1</sup>, L. Jennings<sup>1</sup>, J.E. Baker<sup>1</sup>, G. Klintmalm<sup>1</sup>, P.I. Terasaki<sup>2</sup>  
<sup>1</sup>Dallas/UNITED STATES OF AMERICA, <sup>2</sup>Los Angeles/UNITED STATES OF AMERICA

### Session O09 Optimizing Immediate Graft Function in Kidney Transplantation

**Monday, August 16, 2010 10:30 AM - 12:00 PM**  
**Room: Ballroom C**

Moderators: *Martí* . Manyalich, *Edward* . Cole



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O09.01 N-Octanoyl-Dopamine reduces inflammation and compared to Dopamine improves renal function in acute renal failure

C. Tsagogiorgas, M. Schneider, G. Lueg, M. Hottenrott, P. Schnuelle, B. Yard, S. Hoeger  
Mannheim/GERMANY

O09.02 CD73 deficiency and inhibition protect in kidney ischaemia reperfusion injury (IRI)

S. Rajakumar<sup>1</sup>, B. Lu<sup>1</sup>, S. Crikis<sup>1</sup>, S. Robson<sup>2</sup>, A. d'Apice<sup>3</sup>, P. Cowan<sup>1</sup>, K. Dwyer<sup>3</sup>  
<sup>1</sup>Melbourne/AUSTRALIA, <sup>2</sup>021115/UNITED STATES OF AMERICA, <sup>3</sup>Fitzroy/AUSTRALIA

O09.03 Renal Perfusion Pump vs. Cold Storage for Donation After Cardiac Death Kidneys: A Systematic Review

T.B. McGregor, V. Bathini, V. McAlister, P. Luke, A. Sener  
London/CANADA

O09.04 Curcumin treatment during preservation improves long term graft outcome

R. Thuillier<sup>1</sup>, H. Lathelize<sup>1</sup>, J. Paarkinen<sup>2</sup>, L. Vaahtera<sup>2</sup>, T. hauet<sup>1</sup>  
<sup>1</sup>Poitiers Cedex/FRANCE, <sup>2</sup>Helsinki/FINLAND

O09.05 Improving kidney preservation: HEMO2Life® supplementation rescues ischemia reperfusion injury

R. Thuillier<sup>1</sup>, T.M.T. ngo<sup>1</sup>, D. Dutheil<sup>2</sup>, F. zal<sup>2</sup>, T. hauet<sup>1</sup>  
<sup>1</sup>Poitiers Cedex/FRANCE, <sup>2</sup>Morlaix/FRANCE

O09.06 Tetrahydrobiopterin (BH4) Inhibits SAMPK and Reduces DGF Following Renal Ischemia

R. Sucher, P. Gehwolf, G. Rumberg, I. Kronberger, C. Margreiter, R. Öllinger, S. Schneeberger, E. Werner, B. Zelger, J. Pratschke, G. Brandacher  
Innsbruck/AUSTRIA

O09.07 Remote ischemic preconditioning using the hind limb as remote organ reduces ischemia-reperfusion injury of the kidney in rats.

M.C. Warlé, K. Wever, L. te Riet, G.A. Rongen, J.A. van der Vliet  
Nijmegen/NETHERLANDS

O09.08 Gingko biloba extract (EGb 761) ameliorates kidney injury and promotes renal function recovery in a rat model of ischemia-reperfusion injury.



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

L. LIU, C. Wang, W. LI, S. DENG, W. ZENG, L. Teng, X. HE  
Guangzhou/CHINA

O09.09 Liposomal curcumin ameliorates renal ischaemia-reperfusion injury via NFkB inhibition and anti-oxidant pathways.

N. Rogers, M. Stephenson, S. Kireta, P.T. Coates  
Adelaide/AUSTRALIA

### Session O10 Mesenchymal Stem Cells and Cellular Transplantation

**Monday, August 16, 2010 10:30 AM - 12:00 PM**  
**Room: MR 212 - 214**

Moderators: *Mario* . Abbud-Filho, *Michael* . Breimer

O10.01 Heme oxygenase-1 induction improves the survival of human embryonic stem cell-derived cardiomyocyte grafts in vitro and in vivo

J. Luo, B.P.J. Van Biber, M.A. Laflamme, M.D. Allen  
Seattle/UNITED STATES OF AMERICA

O10.03 Hybrid islet transplantation with marginal islet mass and adipose tissue-derived stem cells can elicit long-term islet graft survival and support normoglycemia in diabetic mice.

Y. Ohmura, M. Tanemura, T. Machida, T. Deguchi, H. Wada, S. Kobayashi, S. Marubashi, H. Eguchi, Y. Takeda, N. Kawaguchi, N. Matsuura, T. Ito, H. Nagano, Y. Doki, M. Mori  
Osaka/JAPAN

O10.04 Transplantation of fetal membrane-derived mesenchymal stem cells protect against renal ischemia reperfusion injury.

H. Tsuda, K. Yamahara, K. Yazawa, N. Ichimaru, J. Kaimori, Y. Isaka, T. Ikeda, S. Takahara  
Suita/JAPAN

O10.05 Biomaterial seeded with bone marrow derived cells did retard progression and impact differently distinct stages of chronic kidney disease

H. Caldas, I.M. Fernandes, D.M. Braile, E. Goloni-Bertollo, R.S. Kawasaki-Oyama, M.A.S. Baptista, M. Abbud-Filho  
Sao Jose Do Rio Preto/BRAZIL



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O10.06 Bone Marrow Derived Stromal Cells (BMSC) Therapy in Peripheral Nerve Regeneration: new surgical and therapeutic approach.

M. Madajka, A. Mendiola, B. Przybyla, M. Siemionow  
Cleveland/UNITED STATES OF AMERICA

O10.07 Allogenic Epineural Tube Nerve Gap Repair with Bone Marrow Stromal Cells (BMSC) Supportive Therapy Yields Comparable Outcomes to Autograft Repair

G. Brzezicki, A. Jundzill, A. Mendiola, A. Klimczak, J. Gatherwright, M. Siemionow  
Cleveland/UNITED STATES OF AMERICA

O10.08 Comparison of In-vivo Created Donor-Recipient Chimeric Cell Therapy and Bone Marrow Cell Therapy as a Supportive Treatments in Face Allograft Model

J. Cwykiel, F. Zor, A. Klimczak, M. Siemionow, M. Madajka  
Cleveland/UNITED STATES OF AMERICA

### Session O11 Late Breaking I

**Monday, August 16, 2010 10:30 AM - 12:00 PM**  
**Room: MR 121 - 122**

Moderators: *Pierre . Daloze*

O11.01 Longterm clinical recovery in Parkinsonian monkey recipients of CTLA4-Ig transgenic porcine neural precursors

R. Aron Badin<sup>1</sup>, A. Padoan<sup>2</sup>, M. Vadori<sup>3</sup>, M. Boldrin<sup>3</sup>, L. Cavicchioli<sup>2</sup>, G.M. De Benedictis<sup>2</sup>, F. Fante<sup>3</sup>, M. Seveso<sup>3</sup>, D. Sgarabotto<sup>2</sup>, C. Jan<sup>1</sup>, V. Daguin<sup>4</sup>, P. Naveilhan<sup>4</sup>, I. Neveu<sup>4</sup>, J.-P. Soulillou<sup>4</sup>, B. Vanhove<sup>4</sup>, M. Plat<sup>5</sup>, F. Bottè<sup>5</sup>, V. Eric<sup>5</sup>, L. Denaro<sup>2</sup>, R. Manara<sup>2</sup>, P. Zampieri<sup>2</sup>, D. D'avella<sup>2</sup>, D. Rubello<sup>6</sup>, E. Ancona<sup>2</sup>, P. Hantraye<sup>1</sup>, E. Cozzi<sup>2</sup>

<sup>1</sup>Fontenay-aux-Roses/France, <sup>2</sup>Padua/ITALY, <sup>3</sup>Legnaro, Padova/ITALY, <sup>4</sup>Nantes/France,

<sup>5</sup>Nouzilly/France, <sup>6</sup>Rovigo/ITALY

O11.02 A Novel Device for Longer Term LVAD Support – Single Centre Experience with HeartWare

F. Özalp, T. Butt, N. Wrightson, T. Pillay, D. O'Leary, G. MacGowan, S. Schueler  
Newcastle Upon Tyne/UNITED KINGDOM

O11.03 Hypothermic Ex Vivo Perfusion Prevents Ischemia Reperfusion Injury in Rat Lungs from Non-Heart-Beating Donors



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

D. Nakajima, T. Yamada, F. Chen, J. Sakamoto, F. Kojima, A. Ohsumi, T. Fujinaga, T. Shoji, H. Sakai, T. Bando, H. Date  
Kyoto/JAPAN

O11.04 Protective effect of ventilation before organ procurement on graft lungs donated after cardiac death in a canine lung transplantation model

J. Sakamoto, T. Yamada, F. Chen, D. Nakajima, R. Kikuchi, F. Kojima, A. Osumi, A. Takahashi, N. Satoda, T. Fujinaga, T. Shoji, H. Sakai, T. Bando, H. Date  
Kyoto/JAPAN

O11.05 Nonhuman Primates May Fail to Serve as an Adequate Model for Studying Extracorporeal Porcine Liver Perfusions

J.P. Waldman, M. Rees  
Toledo/UNITED STATES OF AMERICA

O11.06 Perfusion by oxygenated buffer containing prostaglandin E1 prior to cold preservation prevents warm ischemia-reperfusion injury in liver grafts from non-heart-beating donors

Y. HARA, Y. Akamatsu, Y. Kobayashi, T. Iwane, S. Satomi  
Sendai/JAPAN

O11.07 IL-15 reconstituted humanized mice - a cutting-edge model to study human NK cells in transplantation

A. Kroemer, H.J. Schlitt, E.K. Geissler, G. Brockhoff, A. Wege  
Regensburg/GERMANY

O11.08 Pre-transplant maternal-fetal immune status predicts allograft outcome

P. Dutta, M. Dart, A. David, S.M. Schumacher, W.J. Burlingham  
Madison/UNITED STATES OF AMERICA

### 12:15 – 13:15 MINI ORAL SESSIONS

#### Session MO01 Immune Regulation and Tolerance I

Monday, August 16, 2010 12:15 PM - 01:15 PM  
Room: MR 202 - 204

Moderators: *Johann . Pratschke, Leslie . Brent*



### TTS 2010 SCIENTIFIC PROGRAM

MO01.01 Induced CD4+CD25+Foxp3+ regulatory T cells and impaired development of CD8+CD44+CD62L+ memory T cells promote specific tolerance to cardiac allografts following Rapamycin treatment

P. Urbanellis, J. Wang, I. Shalev, W. He, O.A. Adeyi, M.J. Phillips, A. Bartczak, R. Khattar, D.R. Grant, G.A. Levy  
Toronto/CANADA

MO01.02 Increased Treg Stability upon Graft Tolerance Induction in Lymphopenic Hosts

D. Hanidziar<sup>1</sup>, T.B. Strom<sup>2</sup>, M. Koulmanda<sup>2</sup>  
<sup>1</sup>02215/UNITED STATES OF AMERICA, <sup>2</sup>5491/UNITED STATES OF AMERICA

MO01.03 Tribbles-1 is expressed by regulatory T cells and interacts with FOXP3

E. DUGAST<sup>1</sup>, L. Docherty<sup>2</sup>, E. Kiss-Toth<sup>2</sup>, S. Pettré<sup>1</sup>, R. Danger<sup>1</sup>, J.-P. Soulillou<sup>1</sup>, S. Brouard<sup>1</sup>, J. Ashton-Chess<sup>3</sup>  
<sup>1</sup>Nantes Cedex 1/France, <sup>2</sup>Sheffield/UNITED KINGDOM, <sup>3</sup>Nantes/France

MO01.04 Mechanistic insight into Induction of Mediating Generation of Myeloid-Derived Suppressor Cells by Liver Stromal Cells

C.-C. Hsieh, H.-R. Yang, H.S. Chou, L. Wang, L. Lu, J.J. Fung, S. Qian  
Cleveland/UNITED STATES OF AMERICA

MO01.05 Pretransplant treatment with donor-derived regulatory macrophages prolongs survival of fully mismatched allografts in unconditioned, non-immunosuppressed recipients

P. Riquelme, J.A. Hutchinson, E.K. Geissler  
Regensburg/GERMANY

MO01.06 De Novo expression of CD8 on CD4+CD8-CD25+Foxp3+ T regulatory cells, activated by alloantigen and IL-2, identifies alloantigen specific T regulatory cells.

B.M. Hall<sup>1</sup>, N.D. Verma<sup>2</sup>, R. Boyd<sup>1</sup>, C.M. Robinson<sup>1</sup>, G.T. Tran<sup>1</sup>, C. Wang<sup>3</sup>, G.A. Bishop<sup>3</sup>, S.J. Hodgkinson<sup>1</sup>  
<sup>1</sup>Eveleigh/AUSTRALIA, <sup>2</sup>Kensington/AUSTRALIA, <sup>3</sup>Sydney/AUSTRALIA

MO01.07 The direct alloreactivity pathway is more susceptible to regulation by nTreg than the indirect pathway.

G. Noël, C. Daniel  
Laval/CANADA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO01.08 The Janus kinase inhibitor CP-690,550 preserves the suppressive activity of human CD4+CD25brightFoxP3+ regulatory T cells and strongly inhibits effector T cells

C. Baan<sup>1</sup>, V. Sewgobind<sup>1</sup>, M. Quaedackers<sup>1</sup>, L.V.D. Laan<sup>1</sup>, G. Chan<sup>2</sup>, W. Weimar<sup>1</sup>  
<sup>1</sup>Rotterdam/NETHERLANDS, <sup>2</sup>New London/UNITED STATES OF AMERICA

MO01.09 Rapamycin Conditioned Dendritic Cells for In Vitro Differentiation of Donor-Specific CD4+CD25+Foxp3+ Regulatory T cells for Islet Transplantation

K.L. Pothoven, T. Kheradmand, J.L. Houlihan, X. Luo  
Chicago/UNITED STATES OF AMERICA

MO01.10 Adoptive Transfer of Ex vivo Donor Alloantigen-stimulated Regulatory T Cells Combined with Low Dose Tacrolimus Ameliorates Rejection of Lung Transplantation Between Fully Mismatched Miniature Swines

N. Satoda, Y. Li, H. Ohe, S. Sakaguchi, S. Uemoto, H. Date, T. Koshiba  
Kyoto/JAPAN

MO01.11 Human CD4+FOXP3+ T regulatory cells produce CXCL8 and recruit inflammatory immune cells

M. Himmel, S. Crome, S. Ivison, T. Steiner, M.K. Levings  
Vancouver/CANADA

MO01.12 CTLA4-Ig Mediated Tolerance Induction Relies on Interrelated Mechanisms Involving the Immunomodulatory EnzymeIDO and Treg

R. Sucher<sup>1</sup>, R. Oberhuber<sup>1</sup>, N. Fischler<sup>1</sup>, I. Kronberger<sup>1</sup>, R. Öllinger<sup>1</sup>, S. Schneeberger<sup>1</sup>, D. Fuchs<sup>1</sup>, E. Werner<sup>1</sup>, B. Zelger<sup>1</sup>, G. Tellides<sup>2</sup>, N. Pilat<sup>3</sup>, T. Wekerle<sup>3</sup>, R. Margreiter<sup>1</sup>, J. Pratschke<sup>1</sup>, G. Brandacher<sup>1</sup>  
<sup>1</sup>Innsbruck/AUSTRIA, <sup>2</sup>New Haven/UNITED STATES OF AMERICA, <sup>3</sup>Vienna/AUSTRIA

### Session MO02 Clinical and Ethical Aspects of Living Donor Transplantation

**Monday, August 16, 2010 12:15 PM - 01:15 PM**  
**Room: MR 109 - 110**

Moderators: *Francis . Delmonico, Jean . Shapiro*

MO02.01 Racial Disparities in Living Donor Rates: What Predicts the Likelihood of Receiving a Donor?



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

K. Ladin<sup>1</sup>, Y. Chretien<sup>2</sup>, J.R. Rodrigue<sup>1</sup>, D. Mandelbrot<sup>1</sup>, M. Pavlakis<sup>1</sup>, E. Langnas<sup>1</sup>, J. Lopez<sup>1</sup>, D.W. Hanto<sup>1</sup>

<sup>1</sup>Boston/UNITED STATES OF AMERICA, <sup>2</sup>Cambridge/UNITED STATES OF AMERICA

MO02.02 Increasing kidney function in living kidney donors proceeds for a long time after nephrectomy

J.M. Söfteland<sup>1</sup>, N. Kvarnström<sup>1</sup>, A. Lennerling<sup>1</sup>, M. Rizell<sup>1</sup>, A. Odén<sup>2</sup>, I. Fehrman-Ekholm<sup>1</sup>

<sup>1</sup>Göteborg/SWEDEN, <sup>2</sup>Romelanda/SWEDEN

MO02.03 Seven Non-simultaneous Extended Altruistic Donor (NEAD) Chains

M. Rees<sup>1</sup>, J. Kopke<sup>2</sup>, R. Pelletier<sup>3</sup>, D.L. Segev<sup>4</sup>, A. Fabrega<sup>5</sup>, J. Rogers<sup>6</sup>, O. Pankewycz<sup>7</sup>, A. Roth<sup>8</sup>, T. Taber<sup>9</sup>, U. Unver<sup>10</sup>, B. Nibhanupudy<sup>11</sup>, A.B. Leichtman<sup>12</sup>, C.T. Van Buren<sup>13</sup>, C. Young<sup>14</sup>, B. Galloway<sup>15</sup>, R.A. Montgomery<sup>4</sup>

<sup>1</sup>Toledo/UNITED STATES OF AMERICA, <sup>2</sup>Maumee/UNITED STATES OF AMERICA, <sup>3</sup>Columbus/UNITED STATES OF AMERICA, <sup>4</sup>Baltimore/UNITED STATES OF AMERICA, <sup>5</sup>Phoenix/UNITED STATES OF AMERICA, <sup>6</sup>Winston-Salem/UNITED STATES OF AMERICA, <sup>7</sup>Buffalo/UNITED STATES OF AMERICA, <sup>8</sup>Cambridge/UGANDA, <sup>9</sup>Indianapolis/UNITED STATES OF AMERICA, <sup>10</sup>Chestnut Hill/UNITED STATES OF AMERICA, <sup>11</sup>Orlando/UNITED STATES OF AMERICA, <sup>12</sup>Ann Arbor/UNITED STATES OF AMERICA, <sup>13</sup>Houston/UNITED STATES OF AMERICA, <sup>14</sup>Birmingham/UNITED STATES OF AMERICA, <sup>15</sup>Sacramento/UNITED STATES OF AMERICA

MO02.04 Long-term outcomes of living kidney donors – a single centre experience of 29 years

K.H. chu, K.Y. poon, A. cheuk, K.F. yim, C.M. lam, W. lee, H.L. tang, K.S. fung, K.L. tong  
Hong Kong/CHINA

MO02.05 Outcomes for donors and recipients following kidney donation from living donors, 65 years and older.

E. van Hardeveld, B. Bennett, S. Cohny, J. Pickering, T. Furlong  
Parkville/AUSTRALIA

MO02.06 100 Kidney Transplants Performed Via Kidney Paired Donation at the Johns Hopkins Hospital

B.E. Lonze, N.N. Dagher, C.E. Simpkins, J.E. Locke, D.L. Segev, A.L. Singer, J. Hiller, V. Collins, R.A. Montgomery

Baltimore/UNITED STATES OF AMERICA

MO02.07 Age does not affect survival of kidneys from elderly living donors

M. Laging, J.A. Kal-van Gestel, J.N. IJzermans, W. Weimar  
Rotterdam/NETHERLANDS



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO02.08 Living Kidney Donor Relationships in Caucasian and African-American Populations and Implications For Targeted Donor Education Programs

M. Cooper, M. Phelan, R.N. Barth, S. Fayek, S.T. Bartlett, B. Philosophe  
Baltimore/UNITED STATES OF AMERICA

MO02.09 Is Living Donor Outcome Effected By Leaving Behind a Kidney With Multiple Arteries?

M.D. Rizzari, T.M. Suszynski, K.J. Gillingham, H.N. Ibrahim, A.J. Matas  
Minneapolis/UNITED STATES OF AMERICA

### Session MO03 Induction Immunosuppression

**Monday, August 16, 2010 12:15 PM - 01:15 PM**

**Room: MR 211**

Moderators: *John . Najarian, Diego . Cantarovich*

MO03.01 Low Dose Rabbit Anti-Thymocyte Globulin Induction Therapy Results in Prolonged Selective CD4 T Cell Depletion Irrespective of Maintenance Immunosuppression

O. Pankewycz, R. Kohli, P.K. Wallace, M. Said, L. Feng, S.K. Patel, M. Alnimri, M.R. Laftavi  
Buffalo/UNITED STATES OF AMERICA

MO03.02 Low dose ATG induction for older kidney transplant recipients (old for old); single centre experience over 4 years.

G. Block, M. Meier, J. Steinhoff, C.B. Buerk, M. Nitschke  
Lübeck/GERMANY

MO03.03 Low dose rabbit anti-thymocyte globulin induction in low risk renal transplant recipients: 8 years follow up.

M.R. Laftavi, S.K. Patel, L. Feng, M. Said, H. Laftavi, R. Kohli, M. Alnimri, O. Pankewycz  
Buffalo/UNITED STATES OF AMERICA

MO03.04 Safety of rituximab as induction therapy in renal transplantation; results of an interim analysis

M.W.F. van den Hoogen, A.J. Hoitsma, L.B. Hilbrands  
Nijmegen/NETHERLANDS



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO03.05 Alemtuzumab (Campath-1H) induction and prednisone – free maintenance immunotherapy in kidney transplant Hispanic patients

Y.A. Baez, F.A. Giron  
Bogota/COLOMBIA

MO03.06 Basiliximab Induction versus Alemtuzumab Induction with Steroid Free Maintenance in Kidney Transplantation: Two-Year Outcomes

K. Samy, M. Rees, S. Selman, D. Malhotra, D. Kaw, S. Ratnam, J. Shapiro  
Toledo/UNITED STATES OF AMERICA

MO03.07 Alemtuzumab Induction and Tacrolimus Maintenance Immunosuppression with and without Mycophenolic Acid in Kidney Transplantation

K. Samy, M. Rees, S. Selman, D. Malhotra, D. Kaw, S. Ratnam, J. Shapiro  
Toledo/UNITED STATES OF AMERICA

MO03.08 Relationship Between Rejection and Infection after T-Cell Depleting Induction Therapy

A.C. Farney, J. Rogers, S. Al-Geizawi, A. Reeves-Daniel, E.L. Hartmann, P.L. Adams, S. Kaczorski, W. Doares, M. Gautreaux, S. Winfrey, S. Iskandar, R. Stratta  
Winston-Salem/UNITED STATES OF AMERICA

MO03.09 Effect of Induction Therapy on Acute Rejection risk and Severity, Infection and Malignancy-related mortality in Renal Transplant recipients

R.M. Croke  
Perth/AUSTRALIA

MO03.10 Campath Induction Does Not Predispose to Cytomegalovirus Disease

C. Gurk-Turner, J. Deyo, R. Munivenkatappa, B. Philosophe, R.N. Barth  
Baltimore/UNITED STATES OF AMERICA

MO03.11 IL2 Blocker Induction in Living Related Renal Transplantation

G. Basu, P. George, S. Varughese, A. Mohapatra, V.G. David, M. Sundaram, V. Tamilarasi, C.K. Jacob, G.T. John  
Vellore/INDIA

MO03.12 Interleukin-2 Receptor Antagonist Induction Therapy Leads To Increased Tacrolimus Levels After Kidney Transplantation



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. Lin<sup>1</sup>, A.K. Henning<sup>2</sup>, F. Akhlaghi<sup>1</sup>, R. Reisfield<sup>3</sup>, A. Vergara-Silva<sup>3</sup>, M.R. First<sup>3</sup>

<sup>1</sup>Kingston/UNITED STATES OF AMERICA, <sup>2</sup>Rockville/UNITED STATES OF AMERICA, <sup>3</sup>Deerfield/UNITED STATES OF AMERICA

#### Session MO04 Epidemiology and Clinical Outcomes

**Monday, August 16, 2010 12:15 PM - 01:15 PM**

**Room: MR 205 - 207**

Moderators: *Robert . Gaston, Sita . Gourishanka*

MO04.01 Hemodialysis versus peritoneal dialysis – what is the best bridging to renal transplantation

U. Ott, C. Ruester, M. Busch, H. Wunderlich, G. Wolf  
Jena/GERMANY

MO04.02 Spousal Donor Renal Transplants-a viable option

T.A. Sarguroh, R.R. Sen, R.R. Jagdale, J.P. Kothari, R.A. Sirsat, A. Almeida  
Mumbai/INDIA

MO04.03 The impact of pre-transplant phosphate levels on outcomes after kidney transplantation

R. Sapir-Pichhadze, S.J. Kim, K. Parmar  
Toronto/CANADA

MO04.04 The long-term outcomes of kidney transplants with multiple renal arteries

I.S. Moon, J.K. Hwang, J.I. Kim, S.C. Park, C.W. Yang, S.N. Kim, Y.-B. Koh  
Seoul/KOREA

MO04.05 Older Patients Who Are Transplanted Have An Excellent Outcome Provided They Are  
Cardiologically Tested

A. Asderakis, M. Stephens, M.A. Ilham  
4xw/UNITED KINGDOM

MO04.06 Kidney transplantation decreases rates of hospital separation for acute cardiac events but not  
cardiac failure compared to dialysis

S. Sen, S.P. McDonald  
Adelaide/AUSTRALIA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO04.07 The Evolving Outcomes of Kidney Transplant Recipients Over 70 Years of Age

I.A. Ghoneim, H.Y. Tiong, J.D. Schold, T. Srinivas, C.S. Modlin, D. Goldfarb, S.M. Flechner  
Cleveland/UNITED STATES OF AMERICA

MO04.08 Trends in Estimated Glomerular Filtration Rate During Years 1 to 5 Post-Transplant, Data from the Predicting Outcomes in Renal Transplant (PORT) International Data Collaboration

J. Snyder<sup>1</sup>, J. Liu<sup>1</sup>, M. Skeans<sup>1</sup>, A. Israni<sup>1</sup>, G. L'Italian<sup>2</sup>, B. Kasiske<sup>1</sup>  
<sup>1</sup>Minneapolis/UNITED STATES OF AMERICA, <sup>2</sup>Wallingford/UNITED STATES OF AMERICA

MO04.09 African American Race as a Risk Factor in Outcomes After Second and Third Kidney Transplantation

J. McGee, L.-C.P. Chou, A. Harbin, Y.-H. Hsueh, C.L. Yau, D.P. Slakey  
New Orleans/UNITED STATES OF AMERICA

MO04.10 The influence of Different Erythropoietin Regimes on Hemoglobin at 1 month post transplant

Y. Reddy, Y. Reddy, N. Fathima, G. Abraham  
Chennai/INDIA

MO04.11 Statistical Assessment of a Rate of Post-Transplant Lymphoproliferative Disorder among EBV-positive Kidney Recipients

L. Tracy<sup>1</sup>, L. Tracy<sup>1</sup>, P. Archdeacon<sup>1</sup>, E. Messersmith<sup>2</sup>  
<sup>1</sup>Silver Spring/UNITED STATES OF AMERICA, <sup>2</sup>Ann Arbor/UNITED STATES OF AMERICA

MO04.12 A Mixed Treatment Comparison of Efficacy and Cardiometabolic Safety of Belatacept, Cyclosporine and Tacrolimus for Immunosuppression Therapy in Adult Renal Transplant Recipients

S. Goring<sup>1</sup>, O. Eyawo<sup>1</sup>, E.J. Mills<sup>2</sup>, A. Levy<sup>3</sup>, G.J. L'Italien<sup>4</sup>, D. Trivedi<sup>5</sup>, B. Kasiske<sup>6</sup>  
<sup>1</sup>Vancouver/CANADA, <sup>2</sup>Ottawa/CANADA, <sup>3</sup>Halifax, Ns/CANADA, <sup>4</sup>Wallingford/UNITED STATES OF AMERICA, <sup>5</sup>Plainsboro/UNITED STATES OF AMERICA, <sup>6</sup>Minneapolis/UNITED STATES OF AMERICA

### Session MO05 Living Liver Donors and Techniques

**Monday, August 16, 2010 12:15 PM - 01:15 PM**  
**Room: MR 217 - 219**

Moderators: *David . Grant, Chung . Mau Lo*



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO05.02 Effects of Ischemic Preconditioning of the Graft in Adult Living Related Right Liver Transplantation

D. Azoulay, P. Andreani, S. De La Serna, E. Vibert, C. Salloum, R. Adam, D. Castaing  
Villejuif/FRANCE

MO05.03 Donor morbidity in right lobe living donor liver transplantation: 91 consecutive cases in a European centre

D. Azoulay, P. Bhangui, C. Salloum, P. Andreani, E. Hoti, F. Saliba, P. Ichai, D. Castaing  
Villejuif/FRANCE

MO05.04 The caval anastomosis technique does not influence renal function after orthotopic liver transplantation – a German single center experience

F. Rauchfuß, M. Druschlak, R. Voigt, M. Heise, U. Settmacher  
Jena/GERMANY

MO05.05 Cavo-portal and reno-portal anastomosis for liver transplantation in patients with diffuse portal vein thrombosis: long-term results in 20 consecutive patients from a single centre

C. Lim, C. Salloum, S. De La Serna, P. Bhangui, R. Adam, D. Castaing, D. Azoulay  
Villejuif/FRANCE

MO05.06 Contemporaneous portal and arterial reperfusion versus portal reperfusion first during liver transplantation: a prospective randomized study

U. Baccarani, A. Rossetto, D. Lorenzin, C. Musolino, C. Comuzzi, V. Bresadola, G.L. Adani  
Udine/ITALY

MO05.07 Long term outcome of ex situ right lobe split grafts in Liver Transplantation

R. Valente, F. Dar, T. Cherian, W. Jassem, J. O'Grady, K. Agarwal, V. Aluvihare, M. Heneghan, A. Suddle, H. Vilca Melendez, A. Prachalias, P. Srinivasan, M. Rela, N. Heaton  
London/UNITED KINGDOM

MO05.08 Prevention of ischemic type biliary lesions by arterial first reperfusion in orthotopic liver transplantation

F. Ulrich, S. Kohler, W.P. Hofmann, C. Sarrazin, S. Zeuzem, W.O. Bechstein, C. Mönch  
Frankfurt/GERMANY

MO05.09 The Pattern of Graft Volume Change After Living Donor Liver Transplantation



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

M.K. Ju, K.H. Huh, D.J. Joo, J.S. Choi, M.S. Kim, S.I. Kim  
Seoul/KOREA

MO05.10 Liver transplantation in the presence of diffuse portal vein thrombosis: A 10 year experience with cavoportal hemitransposition.

J.M. Söfteland, N. Kvarnström, S. Friman, M. Olausson  
Göteborg/SWEDEN

MO05.11 Importance of Liver Biopsy in the Selection of Living-Donors for Liver Transplantation

S. Sevmis, S. Aktas, H. Karakayali, B. Demirhan, H. Selcuk, M. Haberal  
Ankara/TURKEY

### Session MO06 Laboratory Immunology and Kidney Transplantation

**Monday, August 16, 2010 12:15 PM - 01:15 PM**  
**Room: MR 220 - 222**

Moderators: *Ronald . Kerman, Ian . Hutchinson*

MO06.01 Creatinine and Cystatin C-based Equations for the Estimation of Glomerular Filtration Rate in Kidney Transplantation: Correlation with Histopathology

E. Hur, C. Sen, A. Nart, S. Sen, A. Akgun, F.A. Tasli, M. Yilmaz, A. Uslu, H. Toz  
Izmir/TURKEY

MO06.02 Predicting Outcomes in Kidney Transplantation: A Comparison of Three Semi-Quantitative Proteinuria Tests

B. Kiberd  
Halifax/CANADA

MO06.03 Glomerulitis during Acute Cellular Rejection May be a Surrogate Marker of Vasculitis in Renal Allografts (Better Index for Diagnosis of Vasculitis)

P.L. Zhang, M.A. Farinola, D. Samarapungavan, M.T. Rooney, S.K. Hicks, S.R. Cohn, G.H. Reddy, L.L. Rocher, F. Dumler, R.K. Parasuraman  
Royal Oak/UNITED STATES OF AMERICA

MO06.04 Expression of E-cadherin, HSP(Heat Shock Protein)47, TGF- $\beta$ 1 and C4d in Chronic Allograft Nephropathy



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. Lee, Y. Chung, J. Park, D. Kim, S. Park, J. Kim, S. Hyun, E. Nam  
Seoul/KOREA

MO06.05 Donor-Specific HLA Antibodies Detected by Single Antigen Beads in Renal Transplant Patients: Impact on Clinical Outcome

J.P. Peräsaari, L. Kyllönen, K. Salmela, J. Merenmies  
Helsinki/FINLAND

MO06.06 A Banff cv2 lesion in a pre-implantation biopsy is the best predictor of delayed graft function following renal transplantation.

R. Munivenkatappa<sup>1</sup>, G. Malat<sup>2</sup>, S. Soundararajan<sup>2</sup>, K. Ranganna<sup>2</sup>, C. Drachenberg<sup>1</sup>, J.C. Papadimtriou<sup>1</sup>, S.A. Fayek<sup>1</sup>, R.N. Barth<sup>1</sup>, M. Cooper<sup>1</sup>, K. David<sup>1</sup>, E.J. Schweitzer<sup>1</sup>, S.T. Bartlett<sup>1</sup>, M. Kumar<sup>2</sup>, B. Philosophie<sup>1</sup>

<sup>1</sup>Baltimore/UNITED STATES OF AMERICA, <sup>2</sup>Philadelphia/UNITED STATES OF AMERICA

MO06.07 Biochemical markers of bone turnover and genotyping of polymorphisms and bone densitometry as standard test in the study of bone disease in renal transplant patients.

L. JIMENO-GARCIA, M.J. GONZALEZ-SORIANO, L. GIL-DEL CASTILLO, J.A. NOGUERA-VELASCO, I. TOVAR-ZAPATA, P. MARTINEZ-HERNANDEZ  
Murcia/SPAIN

MO06.08 Bortezomib Therapy for Antibody-Mediated Rejection: Effect on graft function and HLA Donor-Specific Antibody level.

L.E. Morales-Buenrostro, S.A. Leyva, L.A. Marino-Vazquez, O. Vega-Vega, G. Cantu  
Mexico City/MEXICO

MO06.09 A Graded Desensitization Treatment Protocol for Management of Living Donor Recipients with Donor Specific Antibody

R.J. Knight, S.J. Patel, K. Achkar, G. Land, S. Dilioglou, J. Hamilton, P. Barretto, A.O. Gaber  
Houston/UNITED STATES OF AMERICA

MO06.10 C4d binding correlated with strong HLA antibodies can cause graft failure

K. Mizutani<sup>1</sup>, M. Gotoh<sup>1</sup>, P.I. Terasaki<sup>2</sup>  
<sup>1</sup>Nagoya/JAPAN, <sup>2</sup>Los Angeles/UNITED STATES OF AMERICA

### Session MO07 Islet and Pancreas Transplantation I



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

**Monday, August 16, 2010 12:15 PM - 01:15 PM**

**Room: MR 212 - 214**

Moderators: *Richard . Allen, Frantisek . Saudek*

MO07.01 Human Islet Isolation Utilizing a Novel Mammalian Tissue Free Enzyme

D. O'Gorman, T. Kin, S. Imes, R. Pawlick, P. Senior, J. Shapiro  
Edmonton/CANADA

MO07.02 Factors affecting early graft function in Islet Transplantation

D.M. Thompson, Z. Ao, M. Meloche, J. Shapiro, P.A. Keown, B. Paty, M. Fung, S. Ho, M. Almeshel, J. Kondi, G. Meneilly, S.E. Kozak, S. Tong, M. Trinh, G. Warnock  
Vancouver/CANADA

MO07.03 HLA Class I Sensitization in Islet Transplant Recipients – Report from the Collaborative Islet Transplant Registry

B. Naziruddin<sup>1</sup>, S. Wease<sup>2</sup>, D. Stablein<sup>2</sup>, F. Barton<sup>2</sup>, T. Berney<sup>3</sup>, M.R. Rickels<sup>4</sup>, R. Alejandro<sup>5</sup>  
<sup>1</sup>Dallas/UNITED STATES OF AMERICA, <sup>2</sup>Rockville, Md/UNITED STATES OF AMERICA,  
<sup>3</sup>Geneva/SWITZERLAND, <sup>4</sup>Philadelphia, Pa/UNITED STATES OF AMERICA, <sup>5</sup>Miami/UNITED STATES OF AMERICA

MO07.04 Combination Therapy with B7-H4 and CTLA-4.Ig Prolongs Islet Allograft Survival

X. Wang<sup>1</sup>, J. Hao<sup>1</sup>, D. METZGER<sup>1</sup>, A. Mui<sup>1</sup>, Z. Ao<sup>1</sup>, C.B. Verchere<sup>1</sup>, L. chen<sup>2</sup>, D. OU<sup>1</sup>, G.L. Warnock<sup>1</sup>  
<sup>1</sup>Vancouver/CANADA, <sup>2</sup>Baltimore/UNITED STATES OF AMERICA

MO07.05 A novel approach to prevent early loss of transplanted islets by targeting donor islets with a PPAR $\gamma$  agonist prior to transplantation

T. Mera<sup>1</sup>, D. Kojima<sup>1</sup>, T. Itoh<sup>2</sup>, N. Matsuoka<sup>1</sup>, J. Ono<sup>1</sup>, S. Kodama<sup>1</sup>, Y. Yasunami<sup>1</sup>  
<sup>1</sup>Fukuoka/JAPAN, <sup>2</sup>Dallas/UNITED STATES OF AMERICA

MO07.06 Stimulating Mouse and Human Beta Cell Replication by GPR 119 Endogenous Ligand and Synthetic Agonist

J. Gao, L. Tian, G. Weng, N.V. Bhagroo, R.L. Sorenson, T.D. O'Brien, Z. Guo  
Minneapolis/UNITED STATES OF AMERICA

MO07.07 Macrophage recruitment and activation by human islet amyloid polypeptide: a role for amyloid-induced inflammation in islet transplant failure?



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

C. Westwell-Roper, D. Dai, K.J. Potter, C.B. Verchere  
Vancouver/CANADA

MO07.08 Rapamycin impairs proliferation of transplanted islet beta cells

G. Parnaud, N. Niclauss, D. Bosco, T. Berney  
Geneva/SWITZERLAND

MO07.09 Early loss of transplanted islets in the liver of mice triggered by HMGB1 is prevented by antithrombin III

D. Kojima<sup>1</sup>, T. Mera<sup>1</sup>, T. Itoh<sup>2</sup>, N. Matsuoka<sup>1</sup>, S. Kodama<sup>1</sup>, Y. Yasunami<sup>1</sup>  
<sup>1</sup>Fukuoka/JAPAN, <sup>2</sup>Dallas/UNITED STATES OF AMERICA

MO07.10 Cotransplantation with Liver Stromal Cells Protects Islet Allografts via Induction of Myeloid Derived Suppressor Cells (MDSC)

H.S. Chou, H.-R. Yang, L. Wang, J.J. Fung, S. Qian, L. Lu  
Cleveland/UNITED STATES OF AMERICA

### 13:30 – 15:00 STATE OF THE ART SYMPOSIA

#### Session SOTA01 Global strategies to improve deceased organ donation

**Monday, August 16, 2010 01:30 PM - 03:00 PM**  
**Room: MR 109 - 110**

Moderators: *Guenter . Kirste, John . Fung*

SOTA01.1 Strategic donation initiatives through DOPKI and the WHO

B. Dominguez-Gil  
Madrid/SPAIN

SOTA01.2 Improvement in organ donation in Australia

G. O'Callaghan  
Canberra/AUSTRALIA

SOTA01.3 Improving organ donation in Brasil and Latin America



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

E. Rocha

Rio De Janeiro/BRAZIL

SOTA01.4 Increasing utilization of deceased donor kidneys

K. O'Connor

Bellevue/UNITED STATES OF AMERICA

SOTA01 - DISCUSSION

### Session SOTA02 Hematopoietic Stem Cell Transplantation

**Monday, August 16, 2010 01:30 PM - 03:00 PM**

**Room: MR 220 - 222**

Moderators: *Wing-Yan . Au, Michael . Barnett*

SOTA02.1 Genetic networks in stem cell biology and function

G. Sauvageau

Montreal/CANADA

SOTA02.2 Hematopoietic stem self renewal, differentiation and cord blood transplantation

C. Smith

Vancouver/CANADA

SOTA02.3 Innovations in stem cell expansion and transplantation

J. Deeg

Seattle/UNITED STATES OF AMERICA

SOTA02 - DISCUSSION

### Session SOTA03 Induction immunosuppression

**Monday, August 16, 2010 01:30 PM - 03:00 PM**



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

**Room: Ballroom A/B**

Moderators: *Gabriel . Danovitch, Denis . Glotz*

SOTA03.1 New molecular targets for biological therapy

F. Vincenti

San Francisco/UNITED STATES OF AMERICA

SOTA03.2 Immunological consequences of different induction strategies

N. Najafian

Boston/UNITED STATES OF AMERICA

SOTA03.3 Induction therapy in renal transplant patients

D. Abramowicz

Anderlecht/BELGIUM

SOTA03.4 Induction therapy in non-renal transplant patients

L. Rostaing

Toulouse/FRANCE

SOTA03 - DISCUSSION

### **Session SOTA04 Allorecognition and response**

**Monday, August 16, 2010 01:30 PM - 03:00 PM**

**Room: MR 211**

Moderators: *Terry . Strom, Anthony . Jevnikar*

SOTA04.1 Complementary roles of innate and adaptive immunity

F. Lakkis

Pittsburgh/UNITED STATES OF AMERICA

SOTA04.2 B cell selection and anergy in humans

P. Wilson



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

SOTA04.3 B cells in rejection and tolerance

A.S. Chong  
Chicago/UNITED STATES OF AMERICA

SOTA04 - DISCUSSION

**Session SOTA05 Antibody-mediated rejection (AMR) The changing face of rejection in heart transplantation**

**Monday, August 16, 2010 01:30 PM - 03:00 PM**  
**Room: Ballroom C**

Moderators: *Mario . Deng, Stephan . Schueler*

SOTA05.1 Pretransplant sensitization

J. Kobashigawa  
Beverly Hills/UNITED STATES OF AMERICA

SOTA05.2 Clinical spectrum/presentation of AMR

A. Kfoury  
Murray/UNITED STATES OF AMERICA

SOTA05.3 Current therapies for AMR

A. Zuckermann  
Vienna/AUSTRIA

SOTA05 - DISCUSSION

**Session SOTA06 Living Donor Liver Transplantation**

**Monday, August 16, 2010 01:30 PM - 03:00 PM**  
**Room: MR 118 - 120**



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### **TTS 2010 SCIENTIFIC PROGRAM**

Moderators: *Roy . Calne, Peter . Neuhaus*

SOTA06.1 Right and Left grafts and the small-for-size syndrome

C.-M. Lo

Hong Kong/HONG KONG

SOTA06.2 Recipient outcomes in the A2ALL study

A. Shaked

Philadelphia/UNITED STATES OF AMERICA

SOTA06.3 Analysis of worldwide donor morbidity and mortality

D.R. Grant

Toronto/CANADA

SOTA06 - DISCUSSION

### **Session SOTA07 Islet transplantation: immunology and physiology**

**Monday, August 16, 2010 01:30 PM - 03:00 PM**

**Room: MR 212 - 214**

Moderators: *David . Thompson*

SOTA07.1 Significance of Autoimmunity in Clinical Islet Transplantation

R.G. Gill

Edmonton/CANADA

SOTA07.2 Significance of Alloimmunity in Clinical Islet Transplantation

B. Roep

NETHERLANDS

SOTA07.3 Results and Clinical Impact of Islet Autotransplantation: Lessons for Islet Allo-transplantation

SOTA07.4 Impact on Hypoglycemia and Metabolic Effect on Glucose/Insulin/Counter-regulation



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

M.R. Rickels

Philadelphia/UNITED STATES OF AMERICA

SOTA07 - DISCUSSION

### 15:30 – 17:00 AFTERNOON CONCURRENT SYMPOSIA

Session O12 Experimental Ischemia and Reperfusion Injury

**Monday, August 16, 2010 03:30 PM - 05:00 PM**

**Room: MR 220 - 222**

Moderators: *Matthew . Cooper, Ian . Alwayn*

O12.01 Development of Hepatic Ischemia and Reperfusion Injury is Independent of Myeloid Cell-Derived COX-2

S. Duarte, N. Kuriyama, T.-O. Ishikawa, R.W. Busuttil, H.R. Herschman, A.J. Coito  
Los Angeles/UNITED STATES OF AMERICA

O12.02 TIM-3 Signaling in Innate Immunity-Dominated Liver Injury Induced by Ischemia and Reperfusion (IRI)

Y. Uchida<sup>1</sup>, B. Ke<sup>1</sup>, M.C.S. Freitas<sup>1</sup>, N. Najafian<sup>2</sup>, R.W. Busuttil<sup>1</sup>, J.W. Kupiec-Weglinski<sup>1</sup>  
<sup>1</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>2</sup>Boston/UNITED STATES OF AMERICA

O12.03 Treatment with Diannexin post-reperfusion decreases DGF and improves GFR in renal transplant recipients of marginal kidney donors

M. Cooper<sup>1</sup>, S. Kapur<sup>2</sup>, R. Stratta<sup>3</sup>, A. D'Alessandro<sup>4</sup>, S. Mulgaonkar<sup>5</sup>, A. Allison<sup>6</sup>, M. Russell<sup>6</sup>, S. Knechtle<sup>7</sup>

<sup>1</sup>Baltimore/UNITED STATES OF AMERICA, <sup>2</sup>New York/UNITED STATES OF AMERICA, <sup>3</sup>Winston-Salem/UNITED STATES OF AMERICA, <sup>4</sup>Madison/UNITED STATES OF AMERICA, <sup>5</sup>Livingston/UNITED STATES OF AMERICA, <sup>6</sup>Mountain View/UNITED STATES OF AMERICA, <sup>7</sup>Atlanta/UNITED STATES OF AMERICA

O12.04 Augmentation of hepatic ischemia/reperfusion (I/R) injury in liver grafts lacking PD-L1 expression

S. Ueki, A. Castellaneta, O. Yoshida, K.S. Ozaki, M. Zhang, S. Kimura, A.W. Thomson, D. Geller, N. Murase

Pittsburgh/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O12.05 Double deficiency of C5aR/C3aR significantly prevents mice from renal ischemia/reperfusion injury

Q. Peng, G. Xing, K. Li, N. Wang, S.H. Sacks, W. Zhou  
London/UNITED KINGDOM

O12.06 Tenascin-C: A Critical Player in Hepatic Ischemia and Reperfusion Injury

N. Kuriyama<sup>1</sup>, S. Duarte<sup>1</sup>, T. Hamada<sup>2</sup>, R.W. Busuttill<sup>1</sup>, A.J. Coito<sup>1</sup>  
<sup>1</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>2</sup>Tsu/JAPAN

O12.07 Pretransplant Kidney-Specific Treatment to Eliminate the Need for Systemic Immunosuppression

P. Glowacki<sup>1</sup>, L. Brasile<sup>1</sup>, B. Stubenitsky<sup>2</sup>  
<sup>1</sup>Albany/UNITED STATES OF AMERICA, <sup>2</sup>Utrecht/NETHERLANDS

O12.08 Repeated-dose, lentiviral-mediated IL-10 airway gene delivery targeting chronic transplanted airway allograft obliteration

S. Hirayama, M. Sato, M. Liu, G. Zehong, S. Loisel-Meyer, D. Wagnetz, J.C. Yeung, M. Cypel, J.A. Medin, S. Keshavjee  
Toronto/CANADA

O12.09 A novel role of Phosphoinositide-3 kinase gamma inhibition in suppressing heart allograft rejection

T. Akiyoshi, J. Azzi, S. Yang, R. Moore, R. Abdi  
Boston/UNITED STATES OF AMERICA

### Session O13 Assays to Predict Allograft Rejection

**Monday, August 16, 2010 03:30 PM - 05:00 PM**  
**Room: MR 217 - 219**

Moderators: *Josep M. Campistol, David . Rush*

O13.01 Anti-Angiotensin Type 1 Receptor (AT1R) Antibody Associated with C4d+ Antibody Mediated Rejection (AMR) in Patients with No Donor HLA Specific Antibody (DHSA)

N. Reinsmoen<sup>1</sup>, C.-H. Lai<sup>1</sup>, H. Heidecke<sup>2</sup>, K. Cao<sup>1</sup>, G. Ong<sup>1</sup>, M. Naim<sup>1</sup>, Q. Wang<sup>1</sup>, J. Mirocha<sup>1</sup>, A. Vo<sup>1</sup>, S. Jordan<sup>1</sup>, D. Dragun<sup>2</sup>  
<sup>1</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>2</sup>Berlin/GERMANY



### TTS 2010 SCIENTIFIC PROGRAM

O13.02 Effect of Desensitization on DSA Strength and C4d Deposition

D.P. Lucas, M.S. Leffell, R.A. Montgomery, D.S. Warren, A.A. Zachary  
Baltimore/UNITED STATES OF AMERICA

O13.03 The immunogenicity of HLA determined at the structural and physiochemical level predicts the occurrence and magnitude of humoral immune responses to alloantigen and correlates with outcome following deceased donor kidney transplantation

V. Kosmoliaptsis<sup>1</sup>, L. Sharples<sup>1</sup>, A.N. Chaudhry<sup>1</sup>, R.J. Johnson<sup>2</sup>, S.V. Fuggle<sup>2</sup>, T.R. Dafforn<sup>3</sup>, D.J. Halsall<sup>1</sup>,  
J.A. Bradley<sup>1</sup>, C.J. Taylor<sup>1</sup>  
<sup>1</sup>Cambridge/UNITED KINGDOM, <sup>2</sup>Bristol/UNITED KINGDOM, <sup>3</sup>Birmingham/UNITED KINGDOM

O13.04 Early Post Transplant DeNovo HLA Antibodies Predict Decline in Lung Allograft Function at 18 months Post Transplant

A. Haroon, L. Singer, D.M. Hwang, M. Binnie, C. Chaparro, C.-W. Chow, M. DePerrot, A. Pierre, T.K. Waddell, K. Yasufuku, S. Azad, S. Keshavjee, K. Tinckam  
Toronto/CANADA

O13.05 Clinical Relevance of Pre- and Post- Transplant Alloantibodies Detected by Complement-Dependent Cytotoxicity and Luminex Methodologies in Liver Transplantation

F. Monteiro<sup>1</sup>, H. Rodrigues<sup>1</sup>, J.E. Kalil-Filho<sup>1</sup>, P. Adams<sup>2</sup>, M. Paredes<sup>1</sup>, P. Massarolo<sup>1</sup>, S. Mies<sup>1</sup>, M.C. Ribeiro de Castro<sup>1</sup>  
<sup>1</sup>Sao Paulo/BRAZIL, <sup>2</sup>Columbus/UNITED STATES OF AMERICA

O13.06 Recipient C5 Haplotype and Allograft Outcome in Living Donor Kidney Transplantation

J.C. Jeong<sup>1</sup>, Y.-H. Hwang<sup>1</sup>, S. Hurh<sup>1</sup>, H.-S. Kim<sup>1</sup>, H. Lee<sup>2</sup>, Y.J. Kim<sup>1</sup>, M.-G. Kim<sup>1</sup>, N.-I. Byeon<sup>1</sup>, M.H. Park<sup>1</sup>, J. Yang<sup>1</sup>, C. Ahn<sup>1</sup>  
<sup>1</sup>Seoul/KOREA, <sup>2</sup>Daejeon/KOREA

O13.07 Pre-transplant evaluation of donor-specific alloreactivity and FoxP3 expression: Association with acute graft rejection after kidney transplantation

F.W.R. Vondran, K. Timrott, J. Tross, S. Kollrich, W. Gwinner, F. Lehner, J. Klempnauer, T. Becker, R. Schwinzer  
Hannover/GERMANY

O13.08 Predicting late interstitial fibrosis/tubular atrophy in kidney allografts: a role for CD44 expression on renal tubuli



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

J. Kers<sup>1</sup>, Y.-C. Xu-Dubois<sup>2</sup>, F. Bemelman<sup>1</sup>, J. Roelofs<sup>1</sup>, M. Idu<sup>1</sup>, E. Rondeau<sup>2</sup>, I. ten Berge<sup>1</sup>, S. Florquin<sup>1</sup>  
<sup>1</sup>Amsterdam/NETHERLANDS, <sup>2</sup>Paris/France

O13.09 Levels of sMICA, as detected by a highly sensitive Luminex assay, highly associate with Graft Rejection

D. Fuerst<sup>1</sup>, M. Sadeghi<sup>2</sup>, I. LAHDOU<sup>2</sup>, K. Recker<sup>1</sup>, H. Schrezenmeier<sup>1</sup>, J. Mytilineos<sup>3</sup>  
<sup>1</sup>GERMANY, <sup>2</sup>Heidelberg/GERMANY, <sup>3</sup>Ulm/GERMANY

### Session O14 Molecular Mechanisms of Delayed Kidney Graft Function

**Monday, August 16, 2010 03:30 PM - 05:00 PM**  
**Room: MR 211**

Moderators: *Christophe . Legendre, Shiro . Takahara*

O14.01 High-mobility group box1 (HMGB1) contributes to kidney ischemia reperfusion injury through TLR4 signaling

J. Ma, H. Wu, P. Wang, K.R. WYBURN, S. Chadban  
Sydney/AUSTRALIA

O14.02 Hypoxia induced tubular cell (TEC) release of HMGB1 propagates renal injury by effects on TEC viability and NK cell activation

A. Lau, Z.-X. Zhang, S. Wang, A.M. Jevnikar  
London/CANADA

O14.03 Association between ICAM-1 and VCAM-1 gene polymorphisms and graft function in early period after kidney transplantation.

K. Kłoda, L.A. Domański, A. Pawlik, K. Safranow, J. Różański, M. Myślak, K. Serdyńska, M. Kurzawski, M. Drożdżik, K. Ciechanowski  
Stettin/POLAND

O14.04 Rho-Kinase inhibition mediated by hydroxyfasudil reduces alterations in gene expression profile associated with renal ischemia-reperfusion injury in a rat model of acute renal failure

D. Kentrup, S. Reuter, B. Edemir, A. Grabner, H. Pavenstädt, E. Schlatter, E. Büssemaker  
Münster/GERMANY

O14.05 HMGB-1 Mediates Injury In Renal Transplantation



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

D.K. Abendroth<sup>1</sup>, M. Marzinzig<sup>1</sup>, J. Kaden<sup>2</sup>  
<sup>1</sup>Ulm/GERMANY, <sup>2</sup>Berlin/GERMANY

O14.06 MiRNA and mRNA regulation of delayed graft function in zero-hour deceased organ donor kidney biopsies

J. Wilflingseder<sup>1</sup>, P. Perco<sup>1</sup>, A. Kainz<sup>1</sup>, B. Mayer<sup>1</sup>, R. Oberbauer<sup>2</sup>  
<sup>1</sup>Vienna/AUSTRIA, <sup>2</sup>Linz/AUSTRIA

O14.07 Multivariate Analysis of Causative Factors of Non-Function Kidney in 1856 Kidney Transplants from Non-heart-beating Deceased Donors.

S. Teraoka<sup>1</sup>, A. Aikawa<sup>1</sup>, K. Takahashi<sup>2</sup>, K. Uchida<sup>3</sup>, S. Satomi<sup>4</sup>, S. Takahara<sup>5</sup>, S. Oshima<sup>6</sup>, J. Ashikari<sup>1</sup>, K. Nomoto<sup>1</sup>  
<sup>1</sup>Tokyo/JAPAN, <sup>2</sup>Niigata/JAPAN, <sup>3</sup>Nagoya/JAPAN, <sup>4</sup>Sendai/JAPAN, <sup>5</sup>Suita/JAPAN, <sup>6</sup>Aichi/JAPAN

O14.08 High-dose antithrombin can not improve kidney function despite improved graft perfusion in human kidney transplantation – Final results of a prospective, controlled trial

J.N. Hoffmann, J.M. Fertmann, W.-D. Illner, H. Arbogast, W. Land, K.-W. Jauch  
Munich/GERMANY

O14.09 Diagnosing ischemia reperfusion injury: analysis of severity markers in a pig model of kidney transplantation

L. rossard, F. favreau, C. nadeau, R. Thuillier, T. hauet  
Poitiers Cedex/FRANCE

### Session O15 Access to Treatment and Quality of Life

**Monday, August 16, 2010 03:30 PM - 05:00 PM**  
**Room: MR 109 - 110**

Moderators: *Elias . David-Neto, Jeffrey . Zaltzman*

O15.01 Disparities in living donor kidney transplantation- The potential role of social networks

K. Ladin, E. Langnas, J.R. Rodrigue, M. Pavlakis, D. Mandelbrot, D.W. Hanto  
Boston/UNITED STATES OF AMERICA

O15.02 The Follow Up of Renal Transplant Recipients by Telephone Consultation: Three Years Experience from a Single UK Renal Unit.



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

A. Connor<sup>1</sup>, S. Fletcher<sup>2</sup>, R. Higgins<sup>2</sup>

<sup>1</sup>Oxford/UNITED KINGDOM, <sup>2</sup>Coventry/UNITED KINGDOM

O15.03 What Are My Chances? Age-based Disparities In Living Donor Kidney Transplantation

K. Ladin<sup>1</sup>, Y. Chretien<sup>2</sup>, E. Langnas<sup>1</sup>, J.R. Rodrigue<sup>1</sup>, M. Pavlakis<sup>1</sup>, D. Mandelbrot<sup>1</sup>, D.W. Hanto<sup>1</sup>

<sup>1</sup>Boston/UNITED STATES OF AMERICA, <sup>2</sup>Cambridge/UNITED STATES OF AMERICA

O15.04 Ten Concepts For Ethical Practice and Psychiatric Care Of Transplant Recipients and Living Organ Donors

O.S. Surman

Boston/UNITED STATES OF AMERICA

O15.05 Nonresident Alien Transplantation in the United States

F. Delmonico<sup>1</sup>, V. Ghimire<sup>1</sup>, G. Danovitch<sup>2</sup>

<sup>1</sup>Newton/UNITED STATES OF AMERICA, <sup>2</sup>Los Angeles/UNITED STATES OF AMERICA

O15.06 Clinical and socio-demographic determinants of utility among patients with renal transplantation

B. Herczeg<sup>1</sup>, M. Polgarne Hoschek<sup>2</sup>, I. mucusi<sup>1</sup>, M.Z. Molnar<sup>1</sup>, Z. Kalo<sup>1</sup>

<sup>1</sup>Budapest/HUNGARY, <sup>2</sup>Sopron/HUNGARY

O15.07 Interactive Model of Peer Support of Young Adult Transplant Recipients : The Starbucks Factor

P. Harden, D. Lonsdale, N. Bandler, K. Davies

Oxford/UNITED KINGDOM

O15.08 Qualitative studies better reflect patient distress versus standardized quality of life questionnaires

S. Abbey<sup>1</sup>, E. De Luca<sup>1</sup>, M. Shildrick<sup>2</sup>, P. McKeever<sup>1</sup>, J. Poole<sup>1</sup>, O. Mauthner<sup>1</sup>, H. Ross<sup>1</sup>

<sup>1</sup>Toronto/CANADA, <sup>2</sup>Belfast/IRELAND

O15.09 The quality of life of live related donor in India

S. GULERIA, S.K. Reddy, D. Bhowmik, S. mahajan, R. Sagar, V.K. Bansal, A. Gupta, S. Gupta, S.K. Agarwal

New Delhi/INDIA

**Session O16 Use of mTOR inhibitors and MPA I**



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

**Monday, August 16, 2010 03:30 PM - 05:00 PM**

**Room: Ballroom A/B**

Moderators: *Klemens . Budde, Josep . Grinyo*

O16.01 Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen After Calcineurin Inhibitor Withdrawal in de novo Renal Transplant Patients: 2 Years Follow-Up of the ZEUS Trial

T. Becker<sup>1</sup>, W. Arns<sup>2</sup>, K. Budde<sup>3</sup>, F. Pietruck<sup>4</sup>, U. Eisenberger<sup>5</sup>, W. Fischer<sup>6</sup>, S. Kramer<sup>6</sup>, C. Sommerer<sup>7</sup>, P. Reinke<sup>3</sup>

<sup>1</sup>Hanover/GERMANY, <sup>2</sup>Koeln-Merheim/GERMANY, <sup>3</sup>Berlin/GERMANY, <sup>4</sup>Essen/GERMANY, <sup>5</sup>Bern/SWITZERLAND, <sup>6</sup>Nuremberg/GERMANY, <sup>7</sup>Heidelberg/GERMANY

O16.02 Efficacy Benefit With Everolimus and Very Low Tacrolimus Exposure in De novo Renal Transplant Recipients: 12 Month Results of the ASSET Study

R. Hené<sup>1</sup>, R.M. Langer<sup>2</sup>, S. Vitko<sup>3</sup>, M. Christiaans<sup>4</sup>, K. Ciechanowski<sup>5</sup>, E. Cassuto<sup>6</sup>, J. Dominguez<sup>7</sup>, J. Wyzgal<sup>8</sup>, A.C. Henriques<sup>9</sup>, J. Pascual<sup>10</sup>

<sup>1</sup>Utrecht/NETHERLANDS, <sup>2</sup>Budapest/HUNGARY, <sup>3</sup>Prague/CZECH REPUBLIC, <sup>4</sup>Maastricht/NETHERLANDS, <sup>5</sup>Szczecin/POLAND, <sup>6</sup>Nice/FRANCE, <sup>7</sup>Santiago/CHILE, <sup>8</sup>Warszawa/POLAND, <sup>9</sup>Porto/PORTUGAL, <sup>10</sup>Barcelona/SPAIN

O16.03 De novo Everolimus Combined with Reduced Cyclosporine Exposure - Analysis of renal function at 12 Months in Renal Transplant Recipients

F. Shihab<sup>1</sup>, D. Cibrik<sup>2</sup>, Y.S. Kim<sup>3</sup>, T. Johnston<sup>4</sup>, R. Walker<sup>5</sup>, R. Roland<sup>6</sup>, G. Zibari<sup>7</sup>, K. Mange<sup>8</sup>, C. Panis<sup>8</sup>, Z. Wang<sup>8</sup>, H. Tedesco-Silva<sup>9</sup>

<sup>1</sup>Salt Lake City/UNITED STATES OF AMERICA, <sup>2</sup>Ann Arbor/UNITED STATES OF AMERICA, <sup>3</sup>Seoul/KOREA, <sup>4</sup>Lexington/UNITED STATES OF AMERICA, <sup>5</sup>Melbourne/AUSTRALIA, <sup>6</sup>Kosice/SLOVAK REPUBLIC, <sup>7</sup>Shreveport,/UNITED STATES OF AMERICA, <sup>8</sup>East Hanover/UNITED STATES OF AMERICA, <sup>9</sup>Sao Paulo/BRAZIL

O16.04 Everolimus With Reduced Exposure of Cyclosporine: Efficacy Results From a Randomized Prospective Study in 833 De novo Renal Transplant Recipients

H. Tedesco-Silva<sup>1</sup>, Y.S. Kim<sup>2</sup>, T. Johnston<sup>3</sup>, R. Walker<sup>4</sup>, G. Tufvetson<sup>5</sup>, G. Zibari<sup>6</sup>, K. Mange<sup>7</sup>, C. Panis<sup>7</sup>, Z. Wang<sup>7</sup>, D. Cibrik<sup>8</sup>

<sup>1</sup>Sao Paulo/BRAZIL, <sup>2</sup>Seoul/KOREA, <sup>3</sup>Lexington/UNITED STATES OF AMERICA, <sup>4</sup>Melbourne/AUSTRALIA, <sup>5</sup>Uppsala/SWEDEN, <sup>6</sup>Shreveport,/UNITED STATES OF AMERICA, <sup>7</sup>East Hanover/UNITED STATES OF AMERICA, <sup>8</sup>Ann Arbor/UNITED STATES OF AMERICA

O16.05 Correlation of Everolimus Exposure With Efficacy and Safety Outcomes: Results From a Multicenter Study in Renal Transplantation Using Reduced CsA Exposure



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

L. Chan<sup>1</sup>, D. Cibrik<sup>2</sup>, T. Johnston<sup>3</sup>, Y.S. Kim<sup>4</sup>, R. Walker<sup>5</sup>, G. Zibari<sup>6</sup>, C. Cornu-Artis<sup>7</sup>, C. Panis<sup>8</sup>, H. Jiang<sup>8</sup>, H. Tedesco-Silva<sup>9</sup>

<sup>1</sup>Aurora/UNITED STATES OF AMERICA, <sup>2</sup>Ann Arbor/UNITED STATES OF AMERICA, <sup>3</sup>Lexington/UNITED STATES OF AMERICA, <sup>4</sup>Seoul/KOREA, <sup>5</sup>Melbourne/AUSTRALIA, <sup>6</sup>Shreveport/UNITED STATES OF AMERICA, <sup>7</sup>Basel/SWITZERLAND, <sup>8</sup>East Hanover/UNITED STATES OF AMERICA, <sup>9</sup>Sao Paulo/BRAZIL

O16.06 Intensified dose of enteric-coated mycophenolate sodium (EC-MPS) for 6 weeks, in combination with anti-IL2R induction, cyclosporine micro-emulsion (CsA-ME) with or without steroids, in adult de novo low immunological risk kidney transplant recipients : Final efficacy and safety results of a prospective multicenter randomized open-label study : DOMINOS Study.

G. TOUCHARD<sup>1</sup>, Y. LEBRANCHU<sup>2</sup>, G. MOURAD<sup>2</sup>, L. Rostaing<sup>2</sup>, S. QUERE<sup>2</sup>, K. CHAUCHE-TEYARA<sup>2</sup>, F. VILLEMAIN<sup>2</sup>

<sup>1</sup>Poitiers/FRANCE, <sup>2</sup>On Behalf Of Dominos French Group/FRANCE

O16.07 Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium (EC-MPS) offers Early Adequate Mycophenolic Acid (MPA) Exposure in De Novo Renal Transplant Recipients

H. Tedesco-Silva<sup>1</sup>, C. Sommerer<sup>2</sup>, W. Arns<sup>3</sup>, F. Contier<sup>4</sup>, D.M. Kuypers<sup>5</sup>, S. Vaidya<sup>6</sup>, K. Budde<sup>7</sup>  
<sup>1</sup>Sao Paulo/BRAZIL, <sup>2</sup>Heidelberg/GERMANY, <sup>3</sup>Cologne/GERMANY, <sup>4</sup>Curitiba/BRAZIL, <sup>5</sup>Leuven/BELGIUM, <sup>6</sup>East Hanover/UNITED STATES OF AMERICA, <sup>7</sup>Berlin/GERMANY

O16.08 How delayed graft function impacts exposure to mycophenolic acid in patients following renal transplantation.

T. van Gelder  
Rotterdam/NETHERLANDS

O16.09 Immunosuppressive regimen for first kidney or kidney/pancreas transplant significantly impacts sensitization at the time of second transplantation.

K.L. Dawson, S.J. Patel, R.J. Knight, A.O. Gaber  
Houston/UNITED STATES OF AMERICA

### Session O17 Non-Viral Infections in Transplantation

**Monday, August 16, 2010 03:30 PM - 05:00 PM**  
**Room: MR 202 - 204**

Moderators: *Rainaldo . Bestetti, Michael . Ison*



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O17.01 Randomized Prospective Trial of Depleting Antibody Induction in Kidney and Pancreas Transplantation: Infectious Complications

R.J. Stratta, W. Doares, A.C. Farney, J. Rogers, L. Hart  
Winston-Salem/UNITED STATES OF AMERICA

O17.02 Reactivation of Chagas disease after renal transplantation

J. de la Fuente, C. Chiurchiu, J. Bittar, T. Alvarellos, W. Douthat, J. de Arteaga, P.U. Massari  
Córdoba/ARGENTINA

O17.03 Invasive aspergillosis after liver transplantation : Risk factors, morbidity and prophylaxis

F. Saliba<sup>1</sup>, V. Delvart<sup>1</sup>, P. Ichai<sup>1</sup>, N. Kassis<sup>1</sup>, F. Botterel-Chartier<sup>2</sup>, D. Azoulay<sup>1</sup>, M. Kouassi<sup>1</sup>, R. Adam<sup>1</sup>, D. Castaing<sup>1</sup>, D. Samuel<sup>1</sup>  
<sup>1</sup>Villejuif/FRANCE, <sup>2</sup>Creteil/FRANCE

O17.04 Pretransplant Infectious Disease Screening of Donors and Recipients from Endemic Regions

A.A. Downton, C.N. Kotton  
Boston/UNITED STATES OF AMERICA

O17.05 Immunity to pneumococcal antigens in kidney transplant recipients

M. Lindemann, F.M. Heinemann, P.A. Horn, O. Witzke  
Essen/GERMANY

O17.06 Donor-Derived Disease Transmission Events in the United States 2006 - 2009: A Report from the OPTN Ad Hoc Diseases Transmission Advisory Committee (DTAC)

M.G. Ison, S. Covington, K. Taylor, S. Taranto, K. Parker, E. Blumberg, P. Chin-Hong, M. DiMaio, J.P. Gockerman, M. Green, R. Hasz, B. Kubak, D. Lebovitz, T. Pruett, A. Smith, L. Teperman, B. Vasudev, M. Nalesnik  
Richmond/UNITED STATES OF AMERICA

O17.07 Efficacy and Long-term Outcome of Amphotericin B Lipid Complex (ABLC) Prophylaxis in High Risk Liver Transplant Recipients in the current practice

F. Saliba<sup>1</sup>, V. Delvart<sup>1</sup>, P. Ichai<sup>1</sup>, N. Kassis<sup>1</sup>, F. Botterel-Chartier<sup>2</sup>, M. Kouassi<sup>1</sup>, D. Azoulay<sup>1</sup>, R. Adam<sup>1</sup>, D. Castaing<sup>1</sup>, S. Bretagne<sup>1</sup>, D. Samuel<sup>1</sup>  
<sup>1</sup>Villejuif/FRANCE, <sup>2</sup>Creteil/FRANCE

O17.08 The Impact of Post Operative Sepsis on Outcomes in Liver Transplantation



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

A.J. Cockbain, P.J. Goldsmith, M. Gouda, M. Attia, S. Pollard, J.P.A. Lodge, K.R. Prasad, G.J. Toogood  
Leeds/UNITED KINGDOM

O17.09 First Report of Balamuthia mandrillaris Transmission through Organ Transplantation

K.E. Kokko<sup>1</sup>, E. Farnon<sup>2</sup>, F.K. Butt<sup>1</sup>, A.M. Hawxby<sup>1</sup>, J. Fratkin<sup>1</sup>, A.H. Seawright<sup>1</sup>, W.-J. Shieh<sup>2</sup>, A. Dasilva<sup>2</sup>,  
G. Visvesvara<sup>2</sup>, S. Zaki<sup>2</sup>, M. Kuehnert<sup>2</sup>, O.B.O. the Balamuthia Transplant Investigation Team<sup>3</sup>  
<sup>1</sup>Jackson/UNITED STATES OF AMERICA, <sup>2</sup>Atlanta/UNITED STATES OF AMERICA, <sup>3</sup>Jackson &  
Atlanta/UNITED STATES OF AMERICA

### Session O18 Biologic and Therapeutic Advances in Heart Transplantation I

**Monday, August 16, 2010 03:30 PM - 05:00 PM**

**Room: MR 205 - 207**

Moderators: *Richard . Kirk, Marian . Zembala*

O18.01 Effects of Donor Pretreatment with Dopamine on Graft Function after Heart Transplantation:  
Data from a randomized controlled trial.

U.T. Benck, S. Hoeger, U. Goettmann, D. Doenmez, B. Yard, P. Schnuelle  
Mannheim/GERMANY

O18.02 Initiation of Everolimus with Calcineurin Inhibitor (CNI) Minimization in Thoracic Transplant  
Patients with Impaired Renal Function: 24 Months Follow-up of a Multicenter, Randomized Study

L. Gullestad<sup>1</sup>, H. Eiskjaer<sup>2</sup>, G.C. Riise<sup>3</sup>, V. Sigurdardottir<sup>3</sup>, S.-A. Mortensen<sup>4</sup>, L. Mared<sup>5</sup>, B. Ekmehag<sup>5</sup>, S.  
Simonsen<sup>6</sup>, Ø. Bjørtuft<sup>6</sup>, B. Rundqvist<sup>3</sup>, K. Jansson<sup>7</sup>, E. Gude<sup>6</sup>, D. Solbu<sup>6</sup>, M. Iversen<sup>4</sup>  
<sup>1</sup>0027/NORWAY, <sup>2</sup>Aarhus/DENMARK, <sup>3</sup>Gothenburg/SWEDEN, <sup>4</sup>Copenhagen/DENMARK, <sup>5</sup>Lund/SWEDEN,  
<sup>6</sup>Oslo/NORWAY, <sup>7</sup>Linköping/SWEDEN

O18.03 Cardiac Transplant Candidates with LVAD may have Circulating Level of HLA-Specific Natural  
Antibodies

A. Nikaein<sup>1</sup>, N. El-Awar<sup>2</sup>, J. Hunt<sup>1</sup>  
<sup>1</sup>Dallas/UNITED STATES OF AMERICA, <sup>2</sup>Los Angeles/UNITED STATES OF AMERICA

O18.04 Donor Selection by Virtual Crossmatching for Sensitized Heart Transplant Patients

D.-F. Chen<sup>1</sup>, N.L. Reinsmoen<sup>2</sup>, B.O. Burgess<sup>1</sup>, G.F. Egnaczyk<sup>1</sup>, C.B. Patel<sup>1</sup>, C.A. Milano<sup>1</sup>, J.G. Rogers<sup>1</sup>  
<sup>1</sup>Durham/UNITED STATES OF AMERICA, <sup>2</sup>Los Angeles/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O18.05 Patients on long-term beta-receptor-antagonist treatment with peak oxygen consumption above the cut-off point for heart transplantation listing have worse survival if a restrictive pattern in lung function tests occurs

M.K. Lizak, M. Zakliczynski, A. Jarosz, M. Zembala  
Zabrze/POLAND

O18.06 Incidence and Management of Surgical Wound Complications in De Novo Heart Transplant Recipients Treated with Everolimus

M.J. Barten<sup>1</sup>, J.M. Arizon<sup>2</sup>, G. Dong<sup>3</sup>, H. Eisen<sup>4</sup>, J. Kobashigawa<sup>5</sup>, H.B. Lehmkuhl<sup>6</sup>, C. Pellegrini<sup>7</sup>, H. Ross<sup>8</sup>, A. Zuckermann<sup>9</sup>  
<sup>1</sup>Leipzig/GERMANY, <sup>2</sup>Cordoba/SPAIN, <sup>3</sup>East Hanover/UNITED STATES OF AMERICA, <sup>4</sup>Philadelphia/UNITED STATES OF AMERICA, <sup>5</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>6</sup>Berlin/GERMANY, <sup>7</sup>Pavia/ITALY, <sup>8</sup>Toronto/CANADA, <sup>9</sup>Vienna/AUSTRIA

O18.07 Incidence of ventricular arrhythmias in patients with continuous-flow left ventricular assist devices as a bridge to cardiac transplantation: HeartMate XVE versus HeartMate II

A.S. Nagji, D.J. Lapar, C.C. Ballew, J.D. Bergin, J.A. Kern  
Charlottesville/UNITED STATES OF AMERICA

O18.08 Emergency Heart Transplantation Outcome: the Italian Experience

C. De Cillia, S. Venettoni, A. Ricci, M. Caprio, F. Lolli, L. Rizzato, A. Tancredi, A. Nanni Costa  
Roma/ITALY

O18.09 Effect of Conversion From Calcineurin Inhibitors (CNIs) to Sirolimus on Renal Function in Cardiac Transplant Recipients With Mild to Moderate Renal Insufficiency: Interim Safety and Efficacy Results

M.G. Crespo-Leiro<sup>1</sup>, A. Zuckermann<sup>2</sup>, A. Keogh<sup>3</sup>, D. Mancini<sup>4</sup>, F. González-Vilchez<sup>5</sup>, L. Almenar<sup>6</sup>, S. Brozana<sup>7</sup>, H. Eisen<sup>7</sup>, S. See Tai<sup>8</sup>, S. Kushwaha<sup>9</sup>  
<sup>1</sup>La Coruña/SPAIN, <sup>2</sup>Vienna/AUSTRIA, <sup>3</sup>Sydney/AUSTRALIA, <sup>4</sup>New York/UNITED STATES OF AMERICA, <sup>5</sup>Santander/SPAIN, <sup>6</sup>Valencia/SPAIN, <sup>7</sup>Philadelphia/UNITED STATES OF AMERICA, <sup>8</sup>Collegeville/UNITED STATES OF AMERICA, <sup>9</sup>Rochester/UNITED STATES OF AMERICA

### Session O19 The Problem of Viral Hepatitis in Liver Transplantation



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

**Monday, August 16, 2010 03:30 PM - 05:00 PM**  
**Room: MR 118 - 120**

Moderators: *Sheung Tat . Fan, Norman . Kneteman*

O19.01 The impact of Sirolimus based immunosuppression on response to anti-HCV therapy after liver transplantation

S. Asthana<sup>1</sup>, K. Burak<sup>2</sup>, V. Bain<sup>1</sup>, G. Meeberg<sup>1</sup>, D. Bigam<sup>1</sup>, A.M..J. Shapiro<sup>1</sup>, N.M. Kneteman<sup>1</sup>  
<sup>1</sup>Edmonton/CANADA, <sup>2</sup>Calgary/CANADA

O19.02 Hepatitis C (HCV)-3 Study: Lessons Learned From a Multicenter Liver Transplantation (OLT) Trial.

G. Klintmalm<sup>1</sup>, C.G. Fasola<sup>2</sup>, G. Netto<sup>3</sup>, L. Jennings<sup>1</sup>, H..C..V...3. Study Group<sup>1</sup>  
<sup>1</sup>Dallas/UNITED STATES OF AMERICA, <sup>2</sup>Temple/UNITED STATES OF AMERICA, <sup>3</sup>Baltimore/UNITED STATES OF AMERICA

O19.03 Elevated CXCR3 Content on Lymphocytes from HIV/HCV Infected Patients May Facilitate T-Cell Recruitment To The Liver

P.M. Kimball, C. Glover, R. Stirling  
Richmond/UNITED STATES OF AMERICA

O19.04 Antiviral treatment of HCV recurrence after liver transplantation: impact on costs and quality of life.

C. Logge, E. Vettorazzi, L. Fischer, B. Nashan, M. Sterneck  
Hamburg/GERMANY

O19.05 Limiting HCV Progression in Transplant Recipients Through Conversion to Sirolimus Based Immunosuppression

G.J. McKenna, J.F. Trotter, E. Klintmalm, S. Chinnakotla, N. Onaca, R. Ruiz, M.F. Levy, R. Goldstein, G. Klintmalm  
Dallas/UNITED STATES OF AMERICA

O19.06 Donor Risk Index and Associated Donor Variables May Influence Serum Hepatitis C Viral Load

T.R. Flohr<sup>1</sup>, T. Hranjec<sup>1</sup>, S.C. Kumer<sup>1</sup>, J.B. Stokes<sup>1</sup>, H. Bonatti<sup>1</sup>, R.G. Sawyer<sup>1</sup>, K. Brayman<sup>1</sup>, T.L. Pruett<sup>2</sup>, T.M. Schmitt<sup>1</sup>  
<sup>1</sup>Charlottesville/UNITED STATES OF AMERICA, <sup>2</sup>Minneapolis/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O19.07 Factors Affecting Recurrence of Hepatitis C after Liver Transplantation—Correlation with Histology on Protocol Liver Biopsies.

S. Chinnakotla, G.L. Davis, J.F. Trotter, H. Randall, G.J. McKenna, R. Ruiz, N. Onaca, M. Asolati, P. Kim, K. Tomiyama, K. Cavaness, B. Yildiz, L. Jennings, M.F. Levy, R. Goldstein, G. Klintmalm  
Dallas/UNITED STATES OF AMERICA

O19.08 Risk factors and long-term prognosis of hepatitis B virus recurrence after liver transplantation under prophylaxis of combined low dosed hepatitis B immunoglobulin and nucleoside analogues after liver transplantation

L. Minru  
Guangzhou/CHINA

O19.09 Effect of MDR1 and ABCG8 polymorphisms on hepatitis C recurrence following liver transplantation

S.M. Iacob<sup>1</sup>, V.R. Cicinnati<sup>1</sup>, A. Dechene<sup>1</sup>, C.G. Klein<sup>1</sup>, M. Lindemann<sup>1</sup>, G.C. Sotiropoulos<sup>1</sup>, A. Radtke<sup>2</sup>, I. Popescu<sup>3</sup>, G. Gerken<sup>1</sup>, A. Paul<sup>1</sup>, S. Beckebaum<sup>1</sup>  
<sup>1</sup>Essen/GERMANY, <sup>2</sup>Kiel/GERMANY, <sup>3</sup>Bucharest/ROMANIA

### Session O20 Options and Outcomes in the Sensitized Kidney Recipient

**Monday, August 16, 2010 03:30 PM - 05:00 PM**  
**Room: Ballroom C**

Moderators: *Mark . Stegall, E Steve . Woodle*

O20.01 Terminal Complement Inhibition Decreases Early Acute Humoral Rejection in Sensitized Renal Transplant Recipients.

M.D. Stegall, T.S. Diwan, L. Cornell, J.M. Burns, P.G. Dean, F. Cosio, S. Raghavaiah, M.J. Gandhi, W.K. Kremers, J.M. Gloor  
Rochester/UNITED STATES OF AMERICA

O20.02 Proteasome Inhibition Depletes Alloantibody-Secreting Plasma Cells and Improves Efficacy of Plasma Exchange in Highly Sensitized Renal Allograft Candidates

S. Raghavaiah, T.S. Diwan, M.D. Stegall, J.M. Burns, J.M. Gloor  
Rochester/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O20.03 Outcomes of Patients Desensitized For a Positive Crossmatch Compared To Patients Who Are Not Offered This Option

B.E. Lonze, D.L. Segev, N.N. Dagher, C.E. Simpkins, J.E. Locke, L.M. Kucirka, A.L. Singer, A.A. Zachary, R.A. Montgomery  
Baltimore/UNITED STATES OF AMERICA

O20.04 Long-term outcome according to levels of preformed donor-specific HLA-antibodies in kidney transplantation

C. Lefaucheur, A. Loupy, G.S. Hill, J. Andrade, C. Antoine, D. Charron, C. Suberbielle, D. Glotz  
Paris/France

O20.05 Combined Liver-Kidney Transplants: Do Livers Always Protect Kidneys in Allosensitized Recipients?

M. Askar<sup>1</sup>, J.D. Schold<sup>1</sup>, B. Eghtesad<sup>1</sup>, S.M. Flechner<sup>1</sup>, B. Kaplan<sup>2</sup>, L. Klingman<sup>1</sup>, N. Zein<sup>1</sup>, J.J. Fung<sup>1</sup>, T. Srinivas<sup>1</sup>  
<sup>1</sup>Cleveland/UNITED STATES OF AMERICA, <sup>2</sup>Tucson/UNITED STATES OF AMERICA

O20.06 Report from an 80 Transplant Center Multi-regional Kidney Paired Donation Program

M. Rees<sup>1</sup>, J. Kopke<sup>2</sup>, R. Pelletier<sup>3</sup>, L. Chan<sup>4</sup>, L. Melton<sup>5</sup>, J. Rogers<sup>6</sup>, O. Pankewycz<sup>7</sup>, T. Taber<sup>8</sup>, B. Nibhanupudy<sup>9</sup>, C. Young<sup>10</sup>, A.B. Leichtman<sup>11</sup>, C. Smith<sup>12</sup>, S. Rees<sup>12</sup>, L. Reece<sup>12</sup>  
<sup>1</sup>Toledo/UNITED STATES OF AMERICA, <sup>2</sup>Cincinnati/UNITED STATES OF AMERICA, <sup>3</sup>Columbus/UNITED STATES OF AMERICA, <sup>4</sup>Denver/UNITED STATES OF AMERICA, <sup>5</sup>Dallas/UNITED STATES OF AMERICA, <sup>6</sup>Winston-Salem/UNITED STATES OF AMERICA, <sup>7</sup>Buffalo/UNITED STATES OF AMERICA, <sup>8</sup>Indianapolis/UNITED STATES OF AMERICA, <sup>9</sup>Orlando/UNITED STATES OF AMERICA, <sup>10</sup>Birmingham/UNITED STATES OF AMERICA, <sup>11</sup>Ann Arbor/UNITED STATES OF AMERICA, <sup>12</sup>Maumee/UNITED STATES OF AMERICA

O20.07 Rapid Expansion of Live Donor Kidney Transplantation at a Single Center Using Kidney Paired Donation

A. Bingaman, F. Wright, M. Kapturczak, C. Murphey  
San Antonio/UNITED STATES OF AMERICA

O20.08 Proteasome Inhibitor-Based Antihumoral Therapy Associated Peripheral Neuropathy: A Prospective Analysis in Renal Transplant Candidates and Recipients

R.C. Walsh, A.R. Shields, A. Govil, G. Mogilishetty, P. Roy-Chaudhury, G.E. Wall, E.A. Cole, S. Huang, M. Cardi, S. Safdar, R.R. Alloway, E.S. Woodle  
Cincinnati/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O20.09 Prospective, Staged Trial Of A Proteasome Inhibitor-Based Desensitization Protocol for Kidney Transplant Candidates

R.C. Walsh, A.R. Shields, G.E. Wall, A. Girnita, P. Brailey, M. Cardi, A. Govil, G. Mogilishetty, R.R. Alloway, E.S. Woodle  
Cincinnati/UNITED STATES OF AMERICA

#### Session O21 Clinical Islet Transplantation

**Monday, August 16, 2010 03:30 PM - 05:00 PM**

**Room: MR 212 - 214**

Moderators: *Thierry . Berney, Annika . Tibell*

O21.01 Effect of ASKP1240 (4D11), a Fully Human Anti-CD40 Monoclonal Antibody, on a Single Donor-derived Allogeneic Islet Transplantation in Cynomolgus Monkeys

M. Watanabe<sup>1</sup>, K. Yamashita<sup>1</sup>, D. Fukumori<sup>1</sup>, T. Suzuki<sup>1</sup>, H. Kamachi<sup>1</sup>, D. Kuraya<sup>1</sup>, Y. Koshizuka<sup>1</sup>, M. Ogura<sup>1</sup>, T. Yoshida<sup>1</sup>, F. Sakai<sup>2</sup>, T. Miura<sup>3</sup>, M. Matsushita<sup>1</sup>, S. Todo<sup>1</sup>  
<sup>1</sup>Sapporo/JAPAN, <sup>2</sup>Tsukuba/JAPAN, <sup>3</sup>Shizuoka/JAPAN

O21.02 A comparison of islet transplantation with medical therapy on the progression of diabetic complications

D.M. Thompson, Z. Ao, M. Meloche, J. Shapiro, P.A. Keown, B. Paty, M. Fung, S. Ho, D. Worsley, I. Begg, M. al Mehthel, J. Kondi, G. Meneilly, C. Harris, S.E. Kozak, S. Tong, M. Trinh, G. Warnock  
Vancouver/CANADA

O21.03 Alemtuzumab induction and Tac/MMF maintenance substantially improves long term insulin independence rates after clinical islet transplantation, and strongly suppresses both auto and alloreactivity

A.M.J. Shapiro<sup>1</sup>, C. Toso<sup>2</sup>, A. Koh<sup>1</sup>, S.R. Calne<sup>3</sup>, T. Kin<sup>1</sup>, D. O'Gorman<sup>1</sup>, A. Malcolm<sup>1</sup>, P. Dinyari<sup>1</sup>, S. Imes<sup>1</sup>, R. Owen<sup>1</sup>, N.M. Kneteman<sup>1</sup>, D. Bigam<sup>1</sup>, P. Senior<sup>1</sup>, B. Roep<sup>4</sup>  
<sup>1</sup>Edmonton/CANADA, <sup>2</sup>Geneva/SWITZERLAND, <sup>3</sup>Cb2 2as/UNITED KINGDOM, <sup>4</sup>NI-233za/NETHERLANDS

O21.04 Islet Allograft Survival in Type 1 Diabetic Patients Using Calcineurin Inhibitor-free Protocols Based on T-Cell Adhesion or Costimulation Blockade

A.M. Posselt, G. Szot, L. Frassetto, U. Masharani, M. Tavakol, F. Vincenti, L. Fong, J. Bluestone, P. Stock  
San Francisco/UNITED STATES OF AMERICA

O21.05 Double blockage of IL-1beta and TNF-alpha facilitated single donor islet transplantation



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. Matsumoto<sup>1</sup>, M. Takita<sup>1</sup>, H. Noguchi<sup>1</sup>, M. Shimoda<sup>2</sup>, K. Sugimoto<sup>1</sup>, T. Itoh<sup>1</sup>, D. Chujo<sup>2</sup>, N. Onaca<sup>2</sup>, B. Naziruddin<sup>2</sup>, M.F. Levy<sup>2</sup>

<sup>1</sup>Fort Worth/UNITED STATES OF AMERICA, <sup>2</sup>Dallas/UNITED STATES OF AMERICA

O21.06 Magnetic resonance imaging of pancreatic islets transplanted into the liver in humans

F. Saudek, D. Jirak, P. Girman, V. Herynek, M. Desortova, J. Peregrin, Z. Berkova, K. Zacharovova, M. Hajek

Praha/CZECH REPUBLIC

O21.07 Influence of donor age on islet isolation and transplantation outcome

N. Niclauss<sup>1</sup>, D. Bosco<sup>1</sup>, P. Morel<sup>1</sup>, S. Demuylder-Mischler<sup>1</sup>, C. Brault<sup>2</sup>, G. Parnaud<sup>1</sup>, L. giovannoni<sup>1</sup>, L. BADET<sup>2</sup>, P.-Y. Benhamou<sup>3</sup>, T. Berney<sup>1</sup>

<sup>1</sup>Geneva/SWITZERLAND, <sup>2</sup>Lyon/FRANCE, <sup>3</sup>Grenoble/SWITZERLAND

O21.08 Measuring of HMGB1 is a new useful potency assay to predict outcome of islet transplantation in mice.

T. Itoh<sup>1</sup>, H. Noguchi<sup>1</sup>, M. Takita<sup>1</sup>, K. Sugimoto<sup>1</sup>, M. Shimoda<sup>2</sup>, B. Naziruddin<sup>2</sup>, M.F. Levy<sup>2</sup>, Y. Yasunami<sup>3</sup>, S. Matsumoto<sup>1</sup>

<sup>1</sup>Fort Worth/UNITED STATES OF AMERICA, <sup>2</sup>Dallas/UNITED STATES OF AMERICA, <sup>3</sup>Fukuoka/JAPAN

O21.09 Viable Islet Dose Based on Oxygen Consumption Rate Predicts Clinical Islet Autotransplant Outcome

K.K. Papas<sup>1</sup>, M. Bellin<sup>1</sup>, D.E. Sutherland<sup>1</sup>, K. Mueller<sup>1</sup>, E.S. Avgoustiniatos<sup>1</sup>, A.N. Balamurugan<sup>1</sup>, P.R. Rozak<sup>1</sup>, G. Loganathan<sup>1</sup>, D. Qian<sup>2</sup>, J.C. Niland<sup>2</sup>, B.J. Hering<sup>1</sup>

<sup>1</sup>Minneapolis/UNITED STATES OF AMERICA, <sup>2</sup>Duarte/UNITED STATES OF AMERICA



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

TUESDAY, AUGUST 17

### 07:00 – 08:15 SUNRISE SYMPOSIA

#### Session SUN06 ELPAT: Altruistic Organ Donation to a Stranger

Tuesday, August 17, 2010 07:00 AM - 08:15 AM

Room: MR 211

Moderators: *Willem . Weimar, Bryce . Kiberd*

SUN06.1 Altruistic kidney and liver donors

L. Wright

Toronto/CANADA

SUN06.2 "The calculating Altruist"

L. De Castro

?/SINGAPORE

SUN06.3 Should health professionals encourage Samaritan donation?

M.T. Hilhorst

Rotterdam/NETHERLANDS

SUN06 - DISCUSSION

#### Session SUN07 Genetically Modified Pigs For Xenotransplantation

Tuesday, August 17, 2010 07:00 AM - 08:15 AM

Room: MR 212 - 214

Moderators: *Peter . Cowan, Jean-Paul . Soullillou*

SUN07.1 Gal KO and complement regulators: how far have they taken us?

D.K.C. Cooper

Pittsburgh/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

SUN07.2 Promoters and transgenes: what works and what doesn't

P. Cowan  
Melbourne/AUSTRALIA

SUN07.3 Genetic modification of islets: the case for and against

B.J. Hering  
Minneapolis/UNITED STATES OF AMERICA

SUN07 - DISCUSSION

### Session SUN08 What's new in transplant ID

**Tuesday, August 17, 2010 07:00 AM - 08:15 AM**  
**Room: MR 205 - 207**

Moderators: *Camille . Kotton, Hans . Hirsch*

SUN08.1 H1N1: Impact in solid organ transplantation

D. Kumar  
Edmonton/CANADA

SUN08.2 PML: role of rituximab and MMF

E. Major  
./UNITED STATES OF AMERICA

SUN08.3 Resistant Bacteria in Solid Organ Transplant

S. Huprikar  
New York/UNITED STATES OF AMERICA

SUN08.4 HHV-8 and solid organ transplantation

R. Razonable  
Rochester/UNITED STATES OF AMERICA

SUN08 - DISCUSSION



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

#### **Session SUN09 "How can we reduce the 30 day mortality after heart transplantation?"**

**Tuesday, August 17, 2010 07:00 AM - 08:15 AM**  
**Room: MR 220 - 222**

Moderators: *Finn . Gustafsson, Heather . Ross*

SUN09.1 Optimizing Donation and Donor Organs: Managing the Extended Donor

M. Zembala  
Zabrze/POLAND

SUN09.2 Ischemia-reperfusion injury and use of VAD

D.H. Freed  
Winnipeg/CANADA

SUN09.3 Perioperative CVICU management in the heart transplant recipient

P. Murphy  
Toronto/CANADA

SUN09 - DISCUSSION

#### **Session SUN10 Proteomics in Transplantation - a BC Proteomics Network Symposium**

**Tuesday, August 17, 2010 07:00 AM - 08:15 AM**  
**Room: MR 202 - 204**

Moderators: *Christoph . Borchers, Juergen . Kast*

SUN10.1 Innovations and applications of proteomics to transplantation biology and medicine

L. Anderson  
Washington/UNITED STATES OF AMERICA

SUN10.2 Biomarkers in Transplantation



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

C. Borchers  
Victoria/CANADA

SUN10.3 From Targets to Therapies

B. Verchere  
Vancouver/CANADA

SUN10 - DISCUSSION

### Session SUN11 The Road To Tolerance (One Lambda Symposium)

**Tuesday, August 17, 2010 07:00 AM - 08:15 AM**  
**Room: Hall A**

Moderators: *Carl . Groth*

SUN11.1 Tolerance: From Animal Models to the Clinic

D.H. Sachs  
Boston/UNITED STATES OF AMERICA

SUN11.2 Inducing Immune Tolerance and Chimerism after Kidney Transplantation

S. Strober  
Stanford/UNITED STATES OF AMERICA

SUN11.3 New Simplified Clonal Deletion Protocol with Bortezomib

H.L. Trivedi  
Ahmedabad/INDIA

SUN11.4 Paving the Road to Tolerance: DAWN versus Weaners

P. Terasaki  
Los Angeles/UNITED STATES OF AMERICA

SUN11 - DISCUSSION



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

### 08:30 – 08:30 PLENARY SESSION

Session PL02 Allorecognition and Tolerance

**Tuesday, August 17, 2010 08:30 AM - 10:00 AM**  
**Room: Ballroom A/B**

Moderators: *Gerhard . Opelz, Lori . West*

PL02.1 Why is the Alloresponse so Strong?

P. Marrack

Denver/UNITED STATES OF AMERICA

PL02.2 Inducing Transplantation Tolerance

C. Larsen

Atlanta/UNITED STATES OF AMERICA

PL02.3 Tolerance in Clinical Transplantation

D.H. Sachs

Boston/UNITED STATES OF AMERICA

### 10:30 – 12:00 CONCURRENT MORNING SYMPOSIA

Session O22 B Cells and Antibody Response

**Tuesday, August 17, 2010 10:30 AM - 12:00 PM**  
**Room: MR 202 - 204**

Moderators: *William . Baldwin, Mark . Pescovitz*

O22.01 Lack of memory-B-cells facilitates development of donor-specific blood group tolerance after ABO-incompatible heart transplantation in early childhood

S. Urschel, L.A. Ryan, M. Jeyakanthan, I.M. Larsen, D.B. Ross, L.J. West  
Edmonton/CANADA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O22.02 Is blood group antigen expression on vascular endothelium required for B cell tolerance induction following ABO-incompatible transplant during immunological immaturity?

M. Jeyakanthan, X. Zhou, K. Tao, R.V. Rajotte, M. Mengel, L.J. West  
Edmonton/CANADA

O22.03 Liver Sinusoidal Endothelial Cells expressing Carbohydrates Render Reactive B cells Tolerant

Y. Igarashi, T. Irei, H. Ohdan  
Hiroshima/JAPAN

O22.04 Blocking the Formation of Intra-graft Lymphoid Tissue Influences Effector Humoral Responses

R. Motallebzadeh<sup>1</sup>, S. Rehakova<sup>1</sup>, M. Negus<sup>1</sup>, M. Goddard<sup>1</sup>, I. Harper<sup>1</sup>, S. Sivaganesh<sup>1</sup>, E.M. Bolton<sup>1</sup>, C.J. Callaghan<sup>1</sup>, J.A. Bradley<sup>1</sup>, N. Ruddle<sup>2</sup>, G.J. Pettigrew<sup>1</sup>  
<sup>1</sup>Cambridge/UNITED KINGDOM, <sup>2</sup>New Haven/UNITED STATES OF AMERICA

O22.05 A Novel Mechanism for Alloantibody Production.

I.G. Harper, T. Conlon, C.J. Callaghan, K. Saeb-Parsy, E.M. Bolton, J.A. Bradley, G.J. Pettigrew  
Cambridge/UNITED KINGDOM

O22.06 Impaired Alloreactive CD8 T Cell Memory Response and Prolonged Allograft Survival in Sensitized Recipients in the Absence of Humoral Immunity

H. Ji, X. Shen, F. Gao, Y. Zhai, R.W. Busuttil, J.W. Kupiec-Weglinski  
Los Angeles/UNITED STATES OF AMERICA

O22.07 A New Method To Prevent Humoral Response In Skin Allografts

L. Brasile<sup>1</sup>, P. Glowacki<sup>1</sup>, B. Stubenitsky<sup>2</sup>  
<sup>1</sup>Albany/UNITED STATES OF AMERICA, <sup>2</sup>Utrecht/NETHERLANDS

O22.08 Allospecific B cells can receive effective help for generating anti-MHC class I alloantibody through the acquisition and presentation of additional graft antigens.

T.M. Conlon, R. Motallebzadeh, K. Saeb-Parsy, C.J. Callaghan, S. Sivaganesh, E.M. Bolton, J.A. Bradley, G.J. Pettigrew  
Cambridge/UNITED KINGDOM

O22.09 The reduction of Raf/MEK/ERK pathway by anti-ABO association may be the identity of accommodation in ABO-incompatible transplantation.



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

K. Iwasaki<sup>1</sup>, Y. Miwa<sup>1</sup>, M. Haneda<sup>1</sup>, H. Ogawa<sup>2</sup>, K. Uchida<sup>1</sup>, A. Takeda<sup>1</sup>, A. Nakao<sup>1</sup>, T. Kobayashi<sup>1</sup>  
<sup>1</sup>Nagoya/JAPAN, <sup>2</sup>Obihiro/JAPAN

#### Session O23 Activation and Role of T Regulatory Cells

**Tuesday, August 17, 2010 10:30 AM - 12:00 PM**  
**Room: MR 205 - 207**

Moderators: *Megan . Levings, Nader . Najafian*

O23.01 Blockade of OX40 costimulation reduces the alloreactive effector T cell pool and prevents CD8+ T cell mediated skin allograft rejection.

G. Kinnear<sup>1</sup>, K.J. Wood<sup>1</sup>, D. Marshall<sup>2</sup>, N.D. Jones<sup>1</sup>  
<sup>1</sup>Oxford/UNITED KINGDOM, <sup>2</sup>Slough/UNITED KINGDOM

O23.02 Cytotoxic CD8 T Cells Receive Help From Indirect Pathway CD4 T Cells by Presenting Processed Alloantigen on Acquired MHCII

K. Saeb-Parsy, T. Conlon, M. Negus, S. Sivaganesh, E.M. Bolton, J.A. Bradley, G.J. Pettigrew  
Cambridge/UNITED KINGDOM

O23.03 Heterologously primed T cells are required to initiate CD4-dependent skin and islet graft rejection

B. Fazekas de St Groth<sup>1</sup>, Y.W. Loh<sup>2</sup>, D. Gracey<sup>3</sup>, B. Roediger<sup>1</sup>, S.I. Alexander<sup>4</sup>  
<sup>1</sup>Newtown/AUSTRALIA, <sup>2</sup>Locked Bag #6/AUSTRALIA, <sup>3</sup>Camperdown/AUSTRALIA, <sup>4</sup>Westmead/AUSTRALIA

O23.04 A strategy to inhibit effector T cell infiltration of allograft tissues by stimulation of the chemokine receptor CXCR3

G. O'Boyle, P. Newton, Y. Jenkins, S. Ali, J.A. Kirby  
Newcastle Upon Tyne/UNITED KINGDOM

O23.05 Memory T cells migrate to and reject vascularized cardiac allografts independent of CXCR3 and CCR5

M. Oberbarnscheidt, J. Walch, Q. Li, J. Walters, A. Williams, G. Camirand, F. Lakkis  
Pittsburgh/UNITED STATES OF AMERICA

O23.06 Interleukin-33 prolongs allograft survival during chronic cardiac rejection



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S.M. Brunner, G. Schiechl, H.J. Schlitt, S. Fichtner-Feigl  
Regensburg/GERMANY

O23.07 Lymphocyte subpopulations including FoxP3+ regulatory T-cells and BAFF/BAFF-R in pediatric kidney transplantation

A. Lehnhardt, F. Dunst, M. van Husen, D.E. Müller-Wiefel, M. Koch, M.J. Kemper  
Hamburg/GERMANY

O23.08 Donor-derived Influenza-specific Memory T cells Dominate the Immune Response in Recipients Following Mouse Liver Transplantation

I. Klein<sup>1</sup>, N.K. Polakos<sup>1</sup>, D.J. Topham<sup>2</sup>, N.I. Crispe<sup>3</sup>  
<sup>1</sup>San Francisco/UNITED STATES OF AMERICA, <sup>2</sup>Rochester/UNITED STATES OF AMERICA,  
<sup>3</sup>Seattle/UNITED STATES OF AMERICA

O23.09 Regulatory T cells and Th17 T cell responses in the control of autoantibody-mediated allograft vasculopathy.

I.G. Harper, K. Saeb-Parsy, C.J. Callaghan, R. Motallebzadeh, E.M. Bolton, J.A. Bradley, G.J. Pettigrew  
Cambridge/UNITED KINGDOM

### Session O24 Molecular Mechanisms of Chronic Kidney Graft Injury

**Tuesday, August 17, 2010 10:30 AM - 12:00 PM**  
**Room: MR 211**

Moderators: *Sundaram . Hariharan, Dietmar . Abendroth*

O24.01 Molecular markers of short and long term outcomes post kidney transplantation

D. Maluf, M.J. Scian, K.J. Archer, L.J. Suh, R. Fassnacht, B.C. Whitehill, A. Cotterell, A. Sharma, D.H. Massey, A. King, T.W. Gehr, M.P. Posner, V. Mas  
Richmond/UNITED STATES OF AMERICA

O24.02 Kidney transplant injury is associated with a significant endoplasmic reticulum stress response

T.F. Mueller, T. Simmen, C. Compston, V.A. Luyckx  
Edmonton/CANADA

O24.03 Impact of polymorphisms of the renin-angiotensin-aldosterone system on long-term outcome in renal transplantation



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

K. Ivens, M. Siekierka-Harreis, C. Bantis, C. Schwandt, N. Kuhr, L.-C. Rump  
Düsseldorf/GERMANY

O24.04 Intra-graft Expression of Immune/inflammatory Genes on 1-Yr Biopsies is Associated with Subsequent Decline in GFR in Living Donor Kidney Transplantation

W. Park<sup>1</sup>, M. Griffin<sup>2</sup>, M.D. Stegall<sup>1</sup>, F. Cosio<sup>1</sup>  
<sup>1</sup>Rochester/UNITED STATES OF AMERICA, <sup>2</sup>Galway/IRELAND

O24.05 MicroRNA Expression Signatures Distinguish Human Renal Allografts with Interstitial Fibrosis/Tubular atrophy from Normal

T. Muthukumar, F. Mueller, D. Anglicheau, V. Sharma, R. Ding, D. Dadhania, M. Suthanthiran  
New York/UNITED STATES OF AMERICA

O24.06 Genetic heterogeneity of chronic rejection of kidney allografts

P. Hribova, I. Brabcova, R. Zachoval, J. Slatinska, E. Honsova, O. Viklicky  
Prague 4/CZECH REPUBLIC

O24.07 Patients with endstage renal disease have dysfunctional HDL which recovers after successful renal transplantation

M. van der Giet, M. Schuchardt, T. Huang, M. Tölle  
Berlin/GERMANY

O24.08 Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection

O. Thaunat, C. Deteix, B. McGregor, V. Dubois, E. Morelon  
Lyon/FRANCE

O24.09 Increased number of glomerular (G) CD68 + cells is the single most sensitive predictor of transplant glomerulopathy (TG) and graft loss

J.C. Papadimitriou, C. Drachenberg, A. Haririan, R. Munivenkatappa  
Baltimore/UNITED STATES OF AMERICA

### Session O25 Organ Donation and Allocation II

Tuesday, August 17, 2010 10:30 AM - 12:00 PM  
Room: MR 109 - 110



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

Moderators: *Detlef . Boesebeck, Paul . Robertson*

O25.01 Identification of a combined clinico-histological score for the allocation of kidneys from expanded criteria donors (ECD)

M. Rossini, M. Fiorentino, A. Schena, G. Lucarelli, F.P. Selvaggi, F.P. Schena, P. Ditunno, G. Grandaliano  
Bari/ITALY

O25.02 Kidneys Retrieved from Donors with Prolonged Time to Asystole Increase the Organ Pool Without Compromising DCD Outcome

A. Reid, S. Harper, C. Jackson, L. Sharples, M. Ryan, J.A. Bradley, G.J. Pettigrew  
Cambridge/UNITED KINGDOM

O25.03 A large-scale survey of the Singapore public on the awareness of the Human Organ Transplant Act and its relationship to altruistic behaviour.

T. Kee, V. Joshi, K.V.D. Erf, W.L. Chow, T.S. Swah, P. Goh, G. Tan, S. Yeo, R. Tan, C. Lim, J. Lim, C.M. Chan  
Singapore/SINGAPORE

O25.04 Global Survey Assessing Muslim Attitudes To Organ Donation

A. Sharif, P. Cockwell, G. Lipkin, S. Ball, R. Borrows  
Birmingham/UNITED KINGDOM

O25.05 Use of N-Acetylcystein during liver procurement: final report of a prospective randomized controlled trial.

F. D'Amico, A. Vitale, G. Zanus, D. Bassi, E. Gringeri, D. Neri, U. CILLO  
Padova/ITALY

O25.06 Normothermic Perfusion Induces Ischaemic Preconditioning In Livers From Donors After Cardiac Death And Protects Them From Extended Preservation and Reperfusion Injury

J.J. Plata-Munoz, J. Brockmann, D. Baban, S. Reddy, J. Ragoussis, P. Friend, S.V. Fuggle  
Oxford/UNITED KINGDOM

O25.07 Continuous Improvement of Pulsatile Perfusion Parameters Over 12 Hours in Marginal Kidney Graft Preservation.

J. Sageshima, G. Ciancio, J. Sageshima, L. Scopesi, C. Lombardo, L. Chen, J.J. Gaynor, R. Brown, D.A. Grant, S. Ganz, G.W. Burke, III  
Miami/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O25.08 Prolonged Cold Ischemia Time Before Double Kidney Transplantation Does Not Negatively Impact on Outcomes When Preserved by Pulsatile Machine Perfusion.

J. Fan, J. Sageshima, G. Ciancio, J.J. Gaynor, J. Sageshima, L. Chen, D.A. Grant, T. Urahashi, R. Brown, A. Mattiazzi, G. Guerra, W. Kupin, D. Roth, S. Ganz, P. Ruiz, G.W. Burke, III  
Miami/UNITED STATES OF AMERICA

O25.09 Is the increase in DCD organ donors in the UK contributing to a decline in DBD donors?

D.M. Summers<sup>1</sup>, C. Counter<sup>2</sup>, J.A. Bradley<sup>1</sup>, J. Neuberger<sup>2</sup>  
<sup>1</sup>Cambridge/UNITED KINGDOM, <sup>2</sup>Bristol/UNITED KINGDOM

### Session O26 New Immunosuppressive Agents

**Tuesday, August 17, 2010 10:30 AM - 12:00 PM**  
**Room: Ballroom A/B**

Moderators: *Flavio . Vincenti, Bjoern . Nashan*

O26.01 Safety Profile of Belatacept in Kidney Transplant Recipients from a Pooled Analysis of Phase II and Phase III Studies

J. Grinyo<sup>1</sup>, B. Charpentier<sup>2</sup>, J.O.M. Pestana<sup>3</sup>, H. de Jonge<sup>4</sup>, F. Vincenti<sup>5</sup>, R. Shi<sup>6</sup>, M. Agarwal<sup>7</sup>, D. Thomas<sup>7</sup>, C. Larsen<sup>8</sup>  
<sup>1</sup>Barcelona/SPAIN, <sup>2</sup>Paris/France, <sup>3</sup>São Paulo/BRAZIL, <sup>4</sup>Leuven/BELGIUM, <sup>5</sup>San Francisco/UNITED STATES OF AMERICA, <sup>6</sup>Hopewell/UNITED STATES OF AMERICA, <sup>7</sup>Princeton/UNITED STATES OF AMERICA, <sup>8</sup>Atlanta/UNITED STATES OF AMERICA

O26.02 Immunosuppression with Belatacept-based, CNI-Avoiding and Steroid-Avoiding Regimens vs a Tacrolimus-based, Steroid-avoiding Regimen in Kidney Transplant Patients: Results of a 1-year, Randomized Study

R. Ferguson<sup>1</sup>, F. Vincenti<sup>2</sup>, D. Kaufman<sup>3</sup>, E.S. Woodle<sup>4</sup>, B. Marder<sup>5</sup>, F. Citterio<sup>6</sup>, W.H. Marks<sup>7</sup>, Y. Dong<sup>8</sup>, M. Agarwal<sup>9</sup>, P. Garg<sup>9</sup>, J.M. Grinyó<sup>10</sup>  
<sup>1</sup>Columbus/UNITED STATES OF AMERICA, <sup>2</sup>San Francisco/UNITED STATES OF AMERICA, <sup>3</sup>Chicago/UNITED STATES OF AMERICA, <sup>4</sup>Cincinnati/UNITED STATES OF AMERICA, <sup>5</sup>Denver/UNITED STATES OF AMERICA, <sup>6</sup>Rome/ITALY, <sup>7</sup>Seattle/UNITED STATES OF AMERICA, <sup>8</sup>Hopewell/UNITED STATES OF AMERICA, <sup>9</sup>Princeton/UNITED STATES OF AMERICA, <sup>10</sup>Barcelona/SPAIN

O26.03 Switch From a CNI- to a Belatacept-Based Immunosuppressive Regimen in Kidney Transplant Recipients is Safe and Results in Better Renal Function: 12 Month Results from a Phase II Study



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

L. Rostaing<sup>1</sup>, G. Nainan<sup>2</sup>, M.C. Rial<sup>3</sup>, S. Steinberg<sup>4</sup>, F. Vincenti<sup>5</sup>, R. Shi<sup>6</sup>, G. Di Russo<sup>7</sup>, D. Thomas<sup>7</sup>, J.M. Grinyó<sup>8</sup>

<sup>1</sup>Toulouse/France, <sup>2</sup>Cochin/INDIA, <sup>3</sup>Buenos Aires/ARGENTINA, <sup>4</sup>San Diego/UNITED STATES OF AMERICA, <sup>5</sup>San Francisco/UNITED STATES OF AMERICA, <sup>6</sup>Hopewell/UNITED STATES OF AMERICA, <sup>7</sup>Princeton/UNITED STATES OF AMERICA, <sup>8</sup>Barcelona/SPAIN

O26.04 Belatacept vs Cyclosporine in ECD Kidney Transplants: Two-Year Outcomes from the BENEFIT-EXT Study

A. Durrbach<sup>1</sup>, C. Larsen<sup>2</sup>, J.O.M. Pestana<sup>3</sup>, H. de Jonge<sup>4</sup>, F. Vincenti<sup>5</sup>, S. Florman<sup>6</sup>, J. Xing<sup>7</sup>, A. Block<sup>8</sup>, P. Garg<sup>8</sup>, J.M. Grinyó<sup>9</sup>

<sup>1</sup>Le Kremlin-Bicêtre/France, <sup>2</sup>Atlanta/UNITED STATES OF AMERICA, <sup>3</sup>São Paulo/Brazil, <sup>4</sup>Leuven/BELGIUM, <sup>5</sup>San Francisco/UNITED STATES OF AMERICA, <sup>6</sup>New York/UNITED STATES OF AMERICA, <sup>7</sup>Hopewell/UNITED STATES OF AMERICA, <sup>8</sup>Princeton/UNITED STATES OF AMERICA, <sup>9</sup>Barcelona/SPAIN

O26.05 Belatacept vs Cyclosporine in Kidney Transplant Recipients: Two-Year Outcomes from the BENEFIT Study

C. Larsen<sup>1</sup>, J.M. Grinyó<sup>2</sup>, B. Charpentier<sup>3</sup>, J.O.M. Pestana<sup>4</sup>, N. Kamar<sup>5</sup>, H. de Jonge<sup>6</sup>, C.-S. Lin<sup>7</sup>, G. Di Russo<sup>8</sup>, P. Garg<sup>8</sup>, F. Vincenti<sup>9</sup>

<sup>1</sup>Atlanta/UNITED STATES OF AMERICA, <sup>2</sup>Barcelona/SPAIN, <sup>3</sup>Paris/France, <sup>4</sup>São Paulo/Brazil, <sup>5</sup>Toulouse/France, <sup>6</sup>Leuven/BELGIUM, <sup>7</sup>Hopewell/UNITED STATES OF AMERICA, <sup>8</sup>Princeton/UNITED STATES OF AMERICA, <sup>9</sup>San Francisco/UNITED STATES OF AMERICA

O26.06 The Effect Of Tasocitinib (CP-690,550) On The Incidence Of Acute Rejection And Renal Function In De Novo Kidney Transplant Patients: 6-Month Interim Analysis Of A Phase 2B Study

S. Busque<sup>1</sup>, J. Eris<sup>2</sup>, D. Abramowicz<sup>3</sup>, B. Nashan<sup>4</sup>, C. Legendre<sup>5</sup>, S. Vitko<sup>6</sup>, A. Mota<sup>7</sup>, N. Lawendy<sup>8</sup>, G. Chan<sup>8</sup>, F. Vincenti<sup>9</sup>

<sup>1</sup>Palo Alto/UNITED STATES OF AMERICA, <sup>2</sup>Sydney/AUSTRALIA, <sup>3</sup>Anderlecht/BELGIUM, <sup>4</sup>Hamburg/GERMANY, <sup>5</sup>Paris/France, <sup>6</sup>Prague/CZECH REPUBLIC, <sup>7</sup>Coimbra/PORTUGAL, <sup>8</sup>New London/UNITED STATES OF AMERICA, <sup>9</sup>San Francisco/UNITED STATES OF AMERICA

O26.07 Effect of terminal complement inhibition by Eculizumab on T-cell and natural killer cell depletion in living donor kidney transplant recipients induced with polyclonal rabbit antithymocyte globulin.

B.K.P. Goh, P.G. Dean, S. Raghavaiah, M.D. Stegall  
Rochester/UNITED STATES OF AMERICA

O26.08 The Excellent Results of High-Dose Mizoribine combined with Cyclosporine, Corticosteroid and Basiliximab in Renal Transplant recipients-A Japanese multicenter study-

N. Yoshimura<sup>1</sup>, K. Uchida<sup>2</sup>, K. Yuzawa<sup>3</sup>, Y. Fukuda<sup>4</sup>, Y. Ichikawa<sup>5</sup>, K. Akioka<sup>6</sup>, M. Fujisawa<sup>7</sup>, A. Sugitani<sup>8</sup>, S. Ito<sup>9</sup>, T. Nakatani<sup>10</sup>, T. Horimi<sup>11</sup>



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

<sup>1</sup>Kyoto/JAPAN, <sup>2</sup>Nagoya/JAPAN, <sup>3</sup>Ibaragi/JAPAN, <sup>4</sup>Hiroshima/JAPAN, <sup>5</sup>Hyogo/JAPAN, <sup>6</sup>Shiga/JAPAN, <sup>7</sup>Kobe/JAPAN, <sup>8</sup>Toyoake Aichi/JAPAN, <sup>9</sup>Gifu/JAPAN, <sup>10</sup>Osaka/JAPAN, <sup>11</sup>Kochi/JAPAN

O26.09 Bortezomib effectiveness in 69 patients treated in 29 centers worldwide

M.J. Everly<sup>1</sup>, P.I. Terasaki<sup>2</sup>

<sup>1</sup>Canoga Park/UNITED STATES OF AMERICA, <sup>2</sup>Los Angeles/UNITED STATES OF AMERICA

### Session O27 BK Virus Infection

**Tuesday, August 17, 2010 10:30 AM - 12:00 PM**

**Room: MR 220 - 222**

Moderators: *Henrik . Ekberg, Serdar . Yilmaz*

O27.01 New protocol of BKV-specific T cell analysis allows for improved assessment of phenotypic and functional characteristics of BKV-specific immunity

H. Trydzenskaya, A. Sattler, K. Mueller, T. Schachtner, A. Thiel, H.-D. Volk, P. Reinke, N. Babel  
Berlin/GERMANY

O27.02 Anti-BK Virus Mechanisms of Sirolimus and Leflunomide Alone and in Combination: Towards a New Therapy for BK Virus infection

A. LIACINI, L.A. Tibbles  
Calgary/CANADA

O27.03 Pilot Study of Sirolimus/Leflunomide Therapy for BK Viremia

L.A. Tibbles, M. Maric Viskovic, C.M. Rodriguez Velez, A. Sar, S. Yilmaz  
Calgary/CANADA

O27.04 Modification of immunosuppression can enhance the reconstitution of BKV-specific immunity preventing graft failure due to BKV-associated nephropathy in renal transplant patients

N. Babel, T. Schachtner, K. Mueller, A. Sattler, A. Thiel, H.-D. Volk, P. Reinke  
Berlin/GERMANY

O27.05 Pre-transplant BK-virus infection in dialyzed renal transplant candidates



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

F. Tinti, A.P. Mitterhofer, V. Pietropaolo, M. Barile, D. Fioriti, M. Mischitelli, A. Limonta, A. Meçule, G. Ferretti, L. Poli, F. Chiarini, P. Berloco, G. Taliani  
Rome/ITALY

O27.06 Alemtuzumab does not increase the risk of BK viruria or viremia following kidney, simultaneous kidney-pancreas, or pancreas after kidney transplantation.

J.L. Descourouez, D.R. Hager, B.J. Voss, G.E. Levenson, B.N. Becker, R.M. Hofmann, A. Djamali, J. Pirsch  
Madison/UNITED STATES OF AMERICA

O27.07 Multivariate Analysis of Risk Factors for Polyoma Virus Infection after Kidney Transplantation

R.P. Singh, T.B. Dunn, R. Kandaswamy, R. Fairchild, K.J. Gillingham, W.D. Payne, T.L. Pruett, D.E. Sutherland, A.J. Matas, E.B. Finger  
Minneapolis/UNITED STATES OF AMERICA

O27.08 Ureteral stent placement is associated with the development of polyoma viremia

D.J. Conti<sup>1</sup>, L. Kushnir<sup>2</sup>, K. Chambers<sup>2</sup>, M.H. Gallichio<sup>2</sup>  
<sup>1</sup>Albany, New York/UNITED STATES OF AMERICA, <sup>2</sup>Albany, New York/UNITED STATES OF AMERICA

O27.09 Risk factors of polyomavirus BKV high-level viruria and viremia in de novo renal transplantation: a multivariate analysis from the DIRECT Study comparing cyclosporine and tacrolimus

H.H. Hirsch<sup>1</sup>, F. Vincenti<sup>2</sup>, S. Friman<sup>3</sup>, A. Wiecek<sup>4</sup>, M.D. Pescovitz<sup>5</sup>, T. Jenssen<sup>6</sup>, L. Rostaing<sup>7</sup>, F. Citterio<sup>8</sup>, E. Scheuermann<sup>9</sup>, H. Prestele<sup>1</sup>  
<sup>1</sup>Basel/SWITZERLAND, <sup>2</sup>San Francisco/UNITED STATES OF AMERICA, <sup>3</sup>Gothenburg/SWEDEN,  
<sup>4</sup>Katowice/POLAND, <sup>5</sup>Indianapolis/UNITED STATES OF AMERICA, <sup>6</sup>Oslo/NORWAY, <sup>7</sup>Toulouse/FRANCE,  
<sup>8</sup>Rome/ITALY, <sup>9</sup>Frankfurt/GERMANY

### Session O28 Innovation in Composite Tissue Transplantation

**Tuesday, August 17, 2010 10:30 AM - 12:00 PM**  
**Room: MR 217 - 219**

Moderators: *Jean Michel . Dubernard, David . Cooper*

O28.01 Early Outcomes of Cell Based Immunomodulation in Upper Limb Allograft Transplantation –The Pittsburgh Experience



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

V.S. Gorantla, G. Brandacher, S. Schneeberger, K. Azari, G.S. Wachtman, J.D. Keith, J.T. Shores, T.E. Starzl, J. Imbriglia, W.P.A. Lee  
Pittsburgh/UNITED STATES OF AMERICA

O28.02 Hand Transplantation in Innsbruck: Update at 10 Years After the First Transplant

S. Schneeberger, G. Pierer, M. Gabl, M. Ninkovic, T. Hautz, A. Weissenbacher, B. Zelger, W. Loescher, M. Rieger, H. Piza-Katzer, R. Margreiter, J. Pratschke, G. Brandacher  
Innsbruck/AUSTRIA

O28.03 Results of the first pilot study on bilateral hand allotransplantation

P. Petruzzo<sup>1</sup>, E. Morelon<sup>1</sup>, A. Gazarian<sup>1</sup>, J. Kanitakis<sup>1</sup>, M. Brunet<sup>1</sup>, M. Lanzetta<sup>2</sup>, X. Martin<sup>1</sup>, J.M. Dubernard<sup>1</sup>, L. Badet<sup>1</sup>  
<sup>1</sup>Lyon/FRANCE, <sup>2</sup>Monza/ITALY

O28.04 Mouse Hind Limb Transplantation – a Novel Composite Tissue Allotransplantation (CTA) Model Utilizing a Nono-suture Cuff Technique For Revascularisation

R. Sucher<sup>1</sup>, C.-H. Lin<sup>1</sup>, R. Zanon<sup>1</sup>, I. Kronberger<sup>2</sup>, R. Jindal<sup>1</sup>, B.J. Pulikkottil<sup>1</sup>, M. Weinstock<sup>1</sup>, V.S. Gorantla<sup>1</sup>, S. Schneeberger<sup>1</sup>, J. Pratschke<sup>2</sup>, W.P.A. Lee<sup>1</sup>, G. Brandacher<sup>2</sup>  
<sup>1</sup>Pittsburgh/UNITED STATES OF AMERICA, <sup>2</sup>Innsbruck/AUSTRIA

O28.05 What are the hallmarks of chronic rejection in composite tissue allotransplantation

P. Petruzzo, L. Badet, J. Kanitakis, S. Boutray, J.-B. Pialat, P. Bureau du Colombier, A. Gazarian, J.M. Dubernard, E. Morelon  
Lyon/FRANCE

O28.06 International Registry on Hand and Composite Tissue Transplantation

P. Petruzzo<sup>1</sup>, M. Lanzetta<sup>2</sup>, J.M. Dubernard<sup>1</sup>, P. Cavadas<sup>3</sup>, R. Margreiter<sup>4</sup>, F. Schuind<sup>5</sup>, W. Breidenbach<sup>6</sup>, J. Jableki<sup>7</sup>, S. Schneeberger<sup>4</sup>, C. Kaufman<sup>6</sup>, L. Landin<sup>3</sup>  
<sup>1</sup>Lyon/FRANCE, <sup>2</sup>Monza/ITALY, <sup>3</sup>Valencia/SPAIN, <sup>4</sup>Innsbruck/AUSTRIA, <sup>5</sup>Bruxelles/BELGIUM, <sup>6</sup>Louisville/UNITED STATES OF AMERICA, <sup>7</sup>Tzbenica/POLAND

O28.07 The Influence of Rejection Episodes in Recipients of Bilateral Corneal Grafts

K.A. Williams, T.-L. Kelly, M. Lowe, D.J. Coster  
Bedford Park/AUSTRALIA

O28.08 Face Transplantation Outcomes: feasibility reproducibility and efficacy



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

L.A. LANTIERI, P. Grimbert, F. Bellivier, J.P. Meningaud, V. Oudart, M. Hivelin, M.D. Benjoar, P. Lang Creteil/France

O28.09 Regulation of Composite Tissue Allotransplantation with CD200

R. Jindal, R. Sucher, Y. Wang, M. Weinstock, R. Zanoun, T.W. Ng, K.K. Atsina, S. Schneeberger, G. Brandacher, X.X. Zheng, V.S. Gorantla, W.P.A. Lee  
Pittsburgh/UNITED STATES OF AMERICA

### Session O29 Outcomes of Liver Transplantation I

**Tuesday, August 17, 2010 10:30 AM - 12:00 PM**

**Room: MR 118 - 120**

Moderators: *John . O'Grady, Stephen . Chung*

O29.01 Long term follow-up and outcome of liver transplantation from HCV positive donors: a European multicentric case-control study

R. BALLARIN<sup>1</sup>, G. TARANTINO<sup>1</sup>, A. CUCCHETTI<sup>2</sup>, M. SPAGGIARI<sup>1</sup>, R. MONTALTI<sup>1</sup>, F. DI BENEDETTO<sup>1</sup>, M. VALMASONI<sup>3</sup>, C. LONGO<sup>3</sup>, N. DE RUVO<sup>1</sup>, N. CAUTERO<sup>1</sup>, G.P. GUERRINI<sup>1</sup>, S. NADALIN<sup>4</sup>, R. TROISI<sup>5</sup>, U. CILLO<sup>3</sup>, A.D. PINNA<sup>2</sup>, P. BURRA<sup>3</sup>, G.E. GERUNDA<sup>1</sup>  
<sup>1</sup>Modena/ITALY, <sup>2</sup>Bologna/ITALY, <sup>3</sup>Padova/ITALY, <sup>4</sup>Tübingen/GERMANY, <sup>5</sup>Ghent/BELGIUM

O29.02 A novel RNAi-based therapy for liver ischemia reperfusion injury through gene silencing of TLR4 using targeted shRNA-liposomes

N. Jiang<sup>1</sup>, X. Zhang<sup>2</sup>, X. Zheng<sup>2</sup>, D. Chen<sup>2</sup>, L.K. Siu<sup>2</sup>, A. Shunnar<sup>2</sup>, Y. Zhang<sup>2</sup>, D. Quan<sup>2</sup>, A.M. Jevnikar<sup>2</sup>, G. Chen<sup>1</sup>, W. Min<sup>2</sup>  
<sup>1</sup>Guangzhou/CHINA, <sup>2</sup>London/CANADA

O29.03 The use of livers with metabolic disorders for transplantation - current status: The Domino Liver World Transplant Register (DLTR) viewpoint

H.E. Wilczek<sup>1</sup>, M. Larsson<sup>1</sup>, A.J. Stangou<sup>2</sup>, O. Suhr<sup>3</sup>, B.-G. Ericzon<sup>1</sup>  
<sup>1</sup>Stockholm/SWEDEN, <sup>2</sup>London/UNITED KINGDOM, <sup>3</sup>Umeå/SWEDEN

O29.04 IGL-1 versus UW preservation solution in liver transplantation: a randomized comparative study.

F. Dondéro, F. Durand, D. Sommacale, C. francoz, S. Dokmak, J.. Belghiti  
Clichy/France



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O29.05 D-MELD prediction of graft survival after deceased donor Liver Transplantation. Results of the Italian retrospective multicenter Donor-Recipient match study.

A.W. Avolio<sup>1</sup>, U. Cillo<sup>2</sup>, M. Rossi<sup>1</sup>, M. Colledan<sup>3</sup>, G. Tisone<sup>1</sup>, G. Gerunda<sup>4</sup>, G. Rossi<sup>5</sup>, U. Valente<sup>6</sup>, L. Lupo<sup>7</sup>, G.M. Ettorre<sup>1</sup>, A. Risaliti<sup>8</sup>, V. Bresadola<sup>9</sup>, B. Gridelli<sup>10</sup>, M. Donataccio<sup>11</sup>, O. Cuomo<sup>12</sup>, F. Calise<sup>12</sup>, A.D. Pinna<sup>13</sup>, L. De Carlis<sup>5</sup>, F. Zamboni<sup>14</sup>, V. Mazzaferro<sup>5</sup>, N. Nicolotti<sup>1</sup>, E. Nure<sup>1</sup>, A. Vitale<sup>2</sup>, Q. Lai<sup>1</sup>, D. Pinelli<sup>3</sup>, D. Sforza<sup>1</sup>, R. Montalti<sup>4</sup>, L. Caccamo<sup>5</sup>, M. Gelli<sup>6</sup>, M. Rendina<sup>7</sup>, G. Vennarecci<sup>1</sup>, D. Nicolini<sup>8</sup>, U. Baccarani<sup>9</sup>, S. Gruttadauria<sup>10</sup>, A. Perrella<sup>12</sup>, A. Cucchetti<sup>13</sup>, J. Mangoni<sup>5</sup>, V. Tondolo<sup>14</sup>, E. Regalia<sup>5</sup>, A. Gasbarrini<sup>1</sup>, M. Angelico<sup>1</sup>, S. Agnes<sup>1</sup>

<sup>1</sup>Rome/ITALY, <sup>2</sup>Padua/ITALY, <sup>3</sup>Bergamo/ITALY, <sup>4</sup>Modena/ITALY, <sup>5</sup>Milan/ITALY, <sup>6</sup>Genua/ITALY, <sup>7</sup>Bari/ITALY, <sup>8</sup>Ancona/ITALY, <sup>9</sup>Udine/ITALY, <sup>10</sup>Palermo/ITALY, <sup>11</sup>Verona/ITALY, <sup>12</sup>Naples/ITALY, <sup>13</sup>Bologna/ITALY, <sup>14</sup>Cagliari/ITALY

O29.06 Liver transplantation for transthyretin systemic amyloidosis disorders: An updated review from The Familial Amyloidotic Polyneuropathy World Transplant Register (FAPWTR)

H.E. Wilczek<sup>1</sup>, M. Larsson<sup>1</sup>, A.J. Stangou<sup>2</sup>, O. Suhr<sup>3</sup>, B.-G. Ericzon<sup>1</sup>  
<sup>1</sup>Stockholm/SWEDEN, <sup>2</sup>London/UNITED KINGDOM, <sup>3</sup>Umeå/SWEDEN

O29.07 Survival after liver transplant in patients who develop renal insufficiency

H. Patel, A. Patel, G. Divine, D. Moonka  
Detroit/UNITED STATES OF AMERICA

O29.08 Post-Transplant Stage Progression in Liver Transplant Recipients with Chronic Kidney Disease (CKD): Single Center Analysis with 10 Years of Follow-Up

J.C. LaMattina, D.P. Foley, J. Mezrich, L.A. Fernandez, A. D'Alessandro, J. Pirsch, A. Djamali  
Madison/UNITED STATES OF AMERICA

O29.09 Over-Expression of Inducible Nitric Oxide Synthase in Ethanol-Induced Fatty Livers after Transplantation: Its Relation to Mitochondrial Dysfunction and Graft Injury

H. Rehman, V.K. Ramshesh, T.P. Theruvath, J.J. Lemasters, Z. Zhong  
Charleston/UNITED STATES OF AMERICA

### Session O30 Therapeutic Strategies for Kidney Transplantation

**Tuesday, August 17, 2010 10:30 AM - 12:00 PM**  
**Room: Ballroom C**

Moderators: *Anantharaman . Vathsala*



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O30.01 Rejection Characteristics of 200 Living Donor Kidney Transplantations Using Alemtuzumab Pretreatment and Tacrolimus Monotherapy: Mean 5-year follow-up

H.P. Tan, A. CHAUDHARY, A. Humar, J. DONALDSON, A. Basu, C. Morgan, M. UNRUH, J. McCauley, C. Wu, N. Shah, P. Randhawa, R. Shapiro  
Pittsburgh/UNITED STATES OF AMERICA

O30.02 565 Living Donor Kidney Transplants Using Alemtuzumab Pretreatment and Tacrolimus Monotherapy: 7 year Experience

H.P. Tan, A. CHAUDHARY, A. Humar, J. DONALDSON, A. Basu, C. Morgan, M. UNRUH, J. McCauley, C. Wu, N. Shah, P. Randhawa, R. Shapiro  
Pittsburgh/UNITED STATES OF AMERICA

O30.03 Defining Long Term Renal Allograft Survival Following Early Corticosteroid Withdrawal and Risk Factor Assessment

A.R. Shields, R.R. Alloway, A. Govil, M. Cardi, S. Safdar, A. Tevar, L. Arend, A. Girnita, J. Everly, E.S. Woodle  
Cincinnati/UNITED STATES OF AMERICA

O30.04 Outcomes as a Function of Donor:Recipient Characteristics from a Phase III Study of Belatacept vs Cyclosporine in Kidney Transplantation (BENEFIT)

F. Vincenti<sup>1</sup>, J.M. Grinyó<sup>2</sup>, B. Charpentier<sup>3</sup>, J.O.M. Pestana<sup>4</sup>, L. Rostaing<sup>5</sup>, C.-S. Lin<sup>6</sup>, H. de Jonge<sup>7</sup>, G. Di Russo<sup>8</sup>, C. Larsen<sup>9</sup>  
<sup>1</sup>San Francisco/UNITED STATES OF AMERICA, <sup>2</sup>Barcelona/SPAIN, <sup>3</sup>Paris/France, <sup>4</sup>São Paulo/BRAZIL, <sup>5</sup>Toulouse/France, <sup>6</sup>Hopewell/UNITED STATES OF AMERICA, <sup>7</sup>Leuven/BELGIUM, <sup>8</sup>Princeton/UNITED STATES OF AMERICA, <sup>9</sup>Atlanta/UNITED STATES OF AMERICA

O30.05 Multivariate Analyses of Acute Rejection in Renal Transplant Recipients Receiving Early Corticosteroid Withdrawal

A.R. Shields, R.R. Alloway, G. Mogilishetty, M. Cardi, S. Huang, L. Arend, P. Brailey, R. Munda, J. Everly, E.S. Woodle  
Cincinnati/UNITED STATES OF AMERICA

O30.06 Subclinical Acute Rejection is Associated with Inferior Graft Survival in Kidney Transplant Recipients on Rapid Steroid Withdrawal

R. Heilman, Y. Davarapalli, H. Chakkerla, K. Mekeel, A. Moss, J. Williams, K. Hamawi, M. Mazur, D. Mulligan, K. Reddy  
Phoenix/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O30.07 CNI-free protocol in renal transplantation: Evaluation of long term post-transplant humoral alloimmune response through protocol biopsies with analysis of C4d deposition and determination of HLA antibodies by Luminex assay

L.S. Re, J. Petroni, M.C. Rial, O.E. Guardia, T. Galdo, J. Goldberg, D. Casadei  
Buenos Aires/ARGENTINA

O30.08 Simvastatin started with donor and recipient preconditioning protects kidney allografts from chronic rejection

N. Malmström, J. Savikko, J. Rintala, P. Koskinen  
Helsinki/FINLAND

O30.09 Eculizumab Prevents Recurrence of Antiphospholipid Antibody Syndrome (APS) in Renal Allografts

B.E. Lonze<sup>1</sup>, N.N. Dagher<sup>1</sup>, C.E. Simpkins<sup>1</sup>, D.L. Segev<sup>1</sup>, A.L. Singer<sup>1</sup>, S. Cohny<sup>2</sup>, N. Alachkar<sup>1</sup>, R.A. Montgomery<sup>1</sup>  
<sup>1</sup>Baltimore/UNITED STATES OF AMERICA, <sup>2</sup>Parkville/AUSTRALIA

### Session O31 Cell Therapy and Stem Cells

**Tuesday, August 17, 2010 10:30 AM - 12:00 PM**  
**Room: MR 212 - 214**

Moderators: *Hans-Dieter . Volk, Alan . Colman*

O31.01 Modulating Inflammation and Stimulating  $\beta$ -Cell Regeneration in Diabetic NOD Mice by a DPP-IV Inhibitor

L. Tian, J. Gao, J. Hao, H. Yi, Y. Zhang, T.D. O'Brien, R. Sorenson, Z. Guo  
Minneapolis/UNITED STATES OF AMERICA

O31.02 Correction of Diabetes Following Transplantation of an Insulin-secreting Human Liver Cell Line: Melligen Cells

A.M. Simpson, C. Tao, B. Ren, M.A. Swan, B.A. O'Brien, P. Williams  
Sydney/AUSTRALIA

O31.03 Repopulation of hepatocytes simultaneously transplanted into the liver graft in the rat liver transplantation



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

K. Endo, T. Hata, K. Jobara, J. Iwasaki, S. Uemoto  
Kyoto/JAPAN

O31.04 Liver Tissue Engineering Using HGF-Transduced Hepatocytes Provides Therapeutic Effects on Lethal Liver Failure in Mice

K. Ohashi<sup>1</sup>, K.-I. Kosai<sup>2</sup>, T. Okano<sup>1</sup>  
<sup>1</sup>Tokyo Womens Medical University/JAPAN, <sup>2</sup>Kagoshima University Faculty Of Medicine/JAPAN

O31.05 MRI enables monitoring of transplanted hepatocytes in a preclinical large animal model

N. Raschzok<sup>1</sup>, N. Billecke<sup>1</sup>, A. Zielinski<sup>1</sup>, K. Steinz<sup>1</sup>, N.N. Kammer<sup>1</sup>, S. Schmeisser<sup>1</sup>, M.H. Morgul<sup>2</sup>, M.K. Adonopoulou<sup>1</sup>, J. Pinkernelle<sup>1</sup>, L. Morawietz<sup>1</sup>, B. Hiebl<sup>1</sup>, W. Rüdinger<sup>3</sup>, U. Teichgräber<sup>1</sup>, P. Neuhaus<sup>1</sup>, I.M. Sauer<sup>1</sup>  
<sup>1</sup>Berlin/GERMANY, <sup>2</sup>Leipzig/GERMANY, <sup>3</sup>Weinheim/GERMANY

O31.06 Cell therapy using MSCs and BMDCs in rat kidney transplantation

M. Franquesa<sup>1</sup>, M. Flaquer<sup>1</sup>, J.M. Cruzado<sup>2</sup>, J. Torras<sup>2</sup>, J. Grinyo<sup>2</sup>, I. Herrero-Fresneda<sup>1</sup>  
<sup>1</sup>L'Hospitalet De Llobregat/SPAIN, <sup>2</sup>Hospitalet De Llobregat/SPAIN

O31.07 Eosinophils in acute rejection of myofibers expressing donor-derived proteins following allotransplantation of myogenic cells: a study in nonhuman primates.

D. Skuk, M. Goulet, J.P. Tremblay  
Québec/CANADA

O31.08 First evidence of the mechanism of myofiber death due to acute rejection in muscles transplanted with myogenic cells.

D. Skuk, M. Goulet, J.P. Tremblay  
Québec/CANADA

O31.09 Use of amniotic membrane, amniotic fluid, and placental dressing in advanced burn patients

N. Bhattacharya  
Calcutta/INDIA

### Session O32 Late Breaking II

Tuesday, August 17, 2010 10:30 AM - 12:00 PM  
Room: MR 121 - 122



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

Moderators: *David . Landsberg, Mark . Meloche*

O32.01 Facilitating Cell Enriched Stem Cell Infusion Results in Durable Chimerism, Donor Specific Tolerance, and Allows For Immunosuppressive Drug Withdrawal in Recipients of HLA Disparate Living Donor Kidney Allografts

J.R. LEVENTHAL<sup>1</sup>, L. Gallon<sup>1</sup>, J. Miller<sup>1</sup>, M. Abecassis<sup>1</sup>, K. Ravindra<sup>2</sup>, E. Reed<sup>2</sup>, S.T. Ildstad<sup>2</sup>  
<sup>1</sup>Chicago/UNITED STATES OF AMERICA, <sup>2</sup>Louisville/UNITED STATES OF AMERICA

O32.02 Evidence that Treatment with DHRS9+ Regulatory Macrophages Induced by FcγRIII Ligation and IFN-γ Stimulation Promotes Renal Allograft Tolerance in Patients

J.A. Hutchinson<sup>1</sup>, P. Riquelme<sup>1</sup>, D.P. Brown<sup>1</sup>, B. Sawitzki<sup>2</sup>, M. Rehli<sup>1</sup>, S. Tomiuk<sup>3</sup>, J. Schröder<sup>1</sup>, A. Sotnikova<sup>4</sup>, P. Miqueu<sup>5</sup>, M. Zuhayra<sup>4</sup>, H.H. Oberg<sup>4</sup>, A. Pascher<sup>2</sup>, U. Lützen<sup>4</sup>, U. Janßen<sup>3</sup>, F. Thaiss<sup>6</sup>, E. Scheuermann<sup>7</sup>, E. Henze<sup>4</sup>, L. Chatenoud<sup>8</sup>, H.-D. Volk<sup>2</sup>, R.I. Lechler<sup>9</sup>, K.J. Wood<sup>10</sup>, D. Kabelitz<sup>4</sup>, H.J. Schlitt<sup>1</sup>, F. Fändrich<sup>4</sup>, E.K. Geissler<sup>1</sup>  
<sup>1</sup>Regensburg/GERMANY, <sup>2</sup>Berlin/GERMANY, <sup>3</sup>Bergisch Gladbach/GERMANY, <sup>4</sup>Kiel/GERMANY, <sup>5</sup>Nantes/FRANCE, <sup>6</sup>Hamburg/GERMANY, <sup>7</sup>Frankfurt/GERMANY, <sup>8</sup>Paris/FRANCE, <sup>9</sup>London/UNITED KINGDOM, <sup>10</sup>Oxford/UNITED KINGDOM

O32.03 Cross-platform biomarker signature to identify renal transplant tolerance in humans.

E. Perucha<sup>1</sup>, P. Sagoo<sup>1</sup>, B. Sawitzki<sup>2</sup>, S. Tomiuk<sup>3</sup>, D.A. Stephens<sup>4</sup>, S. Brouard<sup>5</sup>, I. Rebollo-Mesa<sup>1</sup>, R. Hilton<sup>1</sup>, K. Bourcier<sup>6</sup>, M. Goldman<sup>7</sup>, K.J. Wood<sup>8</sup>, K. Newell<sup>6</sup>, A. Warrens<sup>1</sup>, U. Janssen<sup>3</sup>, H.-D. Volk<sup>2</sup>, J.-P. Soulillou<sup>5</sup>, R.I. Lechler<sup>1</sup>, M.P. Hernandez-Fuentes<sup>1</sup>  
<sup>1</sup>London/UNITED KINGDOM, <sup>2</sup>Berlin/GERMANY, <sup>3</sup>Bergisch Gladbach/GERMANY, <sup>4</sup>Montreal/CANADA, <sup>5</sup>Nantes Cedex 1/FRANCE, <sup>6</sup>San Francisco/UNITED STATES OF AMERICA, <sup>7</sup>Charleroi/BELGIUM, <sup>8</sup>Oxford/UNITED KINGDOM

O32.04 ABO Incompatible renal transplantation with Conventional Immunosuppression alone: No antibody removal, No splenectomy or Rituximab: clinical and histological outcomes- 12 months and beyond

S.J. Cohny, R.G. Walker, A.J. Robertson, N. Suh, P. Hughes, R. Masterson, S. Flint, E. Vanhardeveld, R. Millar, B. Bennett, C. Hogan, M. Haeusler  
Parkville/AUSTRALIA

O32.05 Islet Cell Transplants Fail Due to Donor Specific Antibodies

L. Piemonti<sup>1</sup>, P.I. Terasaki<sup>2</sup>, M.J. Everly<sup>2</sup>, P. Maffi<sup>1</sup>, S. Mario<sup>3</sup>, A. Secchi<sup>1</sup>, C. Massimo<sup>3</sup>, M. Ozawa<sup>2</sup>  
<sup>1</sup>Milano/ITALY, <sup>2</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>3</sup>Milan/ITALY

O32.06 CMV Valganciclovir Prophylaxis Versus Preemptive Therapy After Renal Transplantation: One Year Results of a Randomized Clinical Trial



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O. Witzke<sup>1</sup>, M. Nitschke<sup>2</sup>, M. Bartels<sup>3</sup>, U. Ott<sup>4</sup>, I.A. Hauser<sup>5</sup>

<sup>1</sup>Essen/GERMANY, <sup>2</sup>Lübeck/GERMANY, <sup>3</sup>Leipzig/GERMANY, <sup>4</sup>Jena/GERMANY, <sup>5</sup>Frankfurt/M/GERMANY

O32.07 Successful Cross-Organ Classification of Fibrosis based on Microarray Metaanalysis applying a Classifier Model of Renal Transplant IF/TA

S. Rödder<sup>1</sup>, A. Scherer<sup>2</sup>, M. Körner<sup>1</sup>, H.-P. Marti<sup>1</sup>

<sup>1</sup>Bern/SWITZERLAND, <sup>2</sup>Kontiolahti/FINLAND

O32.08 Genomic Meta-analysis of the Integrin Pathway in Chronic Allograft Nephropathy

A. Dosanjh, D.R. Salomon, S. Kurian  
La Jolla/UNITED STATES OF AMERICA

O32.09 UK Registry of Antibody Incompatible Kidney Transplantation 2001-2010

R. Higgins<sup>1</sup>, A.J. Hudson<sup>2</sup>, R.J. Johnson<sup>2</sup>, S.V. Fuggle<sup>2</sup>, J. Galliford<sup>3</sup>, D. Taube<sup>3</sup>, N. Mamode<sup>3</sup>, S. Ball<sup>4</sup>, R. Ramanan<sup>2</sup>, N. Torpey<sup>5</sup>, R. Thuraingham<sup>3</sup>, A. Gupta<sup>3</sup>, C. Newstead<sup>6</sup>, J.A. Bradley<sup>5</sup>

<sup>1</sup>Coventry/UNITED KINGDOM, <sup>2</sup>Bristol/UNITED KINGDOM, <sup>3</sup>London/UNITED KINGDOM,  
<sup>4</sup>Birmingham/UNITED KINGDOM, <sup>5</sup>Cambridge/UNITED KINGDOM, <sup>6</sup>Leeds/UNITED KINGDOM

### 12:15 – 13:15 MINI ORAL SESSIONS

#### Session MO08 Immune Regulation and Tolerance II

Tuesday, August 17, 2010 12:15 PM - 01:15 PM

Room: MR 202 - 204

Moderators: *Alvaro . Pacheco-Silva, Willem . Weimar*

MO08.01 Bcl-2 inhibition: a new concept to prevent solid allograft rejection

P.E. Cippa<sup>1</sup>, A.K. Kraus<sup>1</sup>, S. Segerer<sup>1</sup>, J. Chen<sup>1</sup>, P.D. Bardwell<sup>2</sup>, T. Fehr<sup>1</sup>

<sup>1</sup>Zürich/SWITZERLAND, <sup>2</sup>Worcester/UNITED STATES OF AMERICA

MO08.02 A novel pan-TLR inhibitor promotes permanent acceptance of skin allografts in mice

T.W. He, P. Zhou, B.C. Xue, Y. Liu, C. Li, Z.K. Chen  
Wuhan/CHINA

MO08.03 Prevention of skin graft rejection by specific induction of apoptosis of host APC presenting graft-derived antigens



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

E.A.M. Giets, V. Carlier, L. vander elst, M. jacquemin, J.-M. saint-remy  
Leuven/BELGIUM

MO08.04 The presence of increased peripheral Th17 lymphocytes in highly sensitized renal transplant patients: implications for immune modulation.

T. Kandeve, S. Liu, J. Tchervenkov  
Montreal/CANADA

MO08.05 A novel immunosuppressive agent, DTCM-glutarimide markedly prolongs cardiac allograft survival in mouse when combined with Donor specific transfusion

Y. Tsunetoshi<sup>1</sup>, K. Yamashita<sup>1</sup>, S. Shibasaki<sup>1</sup>, R. Goto<sup>1</sup>, K. Wakayama<sup>1</sup>, H. Gentaro<sup>1</sup>, M. Zaitso<sup>1</sup>, R. Igarashi<sup>1</sup>, M. Ozaki<sup>1</sup>, K. Umezawa<sup>2</sup>, S. Todo<sup>1</sup>  
<sup>1</sup>Sapporo/JAPAN, <sup>2</sup>Yokohama/JAPAN

MO08.06 FGL2 expression induces graft survival in the absence of immunosuppression

A. Bartczak, W. He, I. Shalev, M. Mendicino, J. Zhang, X.-Z. Ma, P. Urbanellis, R. Khattar, E. Kaplovitch, M.J. Phillips, O.A. Adeyi, D.R. Grant, G.A. Levy  
Toronto/CANADA

MO08.07 A Quantitative Proteomics Approach For Identification of Potential Biomarkers In Transplant Tolerance

J. Wang, P. Urbanellis, I. Shalev, W. He, O.A. Adeyi, M.J. Phillips, D.R. Grant, G.A. Levy  
Toronto/CANADA

MO08.08 DAP12 Controls STAT3 Activation in 'Tolerogenic ' Liver Dendritic Cells

T.L. Sumpter, H. Turnquist, A.W. Thomson  
Pittsburgh/UNITED STATES OF AMERICA

MO08.09 Immunomodulatory interactions between mesenchymal stem cells and regulatory T cells after kidney transplantation

A. Grohnert, C.C. Baan, P. Koumoutsakos, A. Peeters, W. Weimar, M.J. Hoogduijn  
Rotterdam/NETHERLANDS

MO08.10 The Role of Mesenchymal Stem Cells in Stabilizing Pancreatic Islet Cell Transplant in Mice

C. Tan-Tam, V. Nguyen, P. Stock, Q. Tang  
San Francisco/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO08.11 The source of Human Mesenchymal Stromal Cells influences their TLR profile as well as their functional properties

G. Raicevic, M. Najar, B. Stamatopoulos, C. De Bruyn, N. Meuleman, D. Bron, M. Toungouz  
Neveessignsky, L. Lagneaux  
Brusseles/BELGIUM

MO08.12 Synergistic Immunomodulation by Immunosuppressive agents and Human Mesenchymal Stem Cells on T-cell proliferation and Dendritic cell maturation

T. Searcy, R. Krishnan  
Adelaide/AUSTRALIA

### Session MO09 International Trends in Organ Donation

**Tuesday, August 17, 2010 12:15 PM - 01:15 PM**

**Room: MR 109 - 110**

Moderators: *Helen . Pilmore, Maher . Ramzy*

MO09.01 Excellent Long-term Outcomes of Kidney Transplantation Using Kidneys from Deceased Donors with Acute Kidney Injury

N. Techawathanawanna, R. Kunprakan, P. Lertsithichai, K. Pipatpannawong, N. Naitook, V. Mavichak, S. Jirasiritham  
Bangkok/THAILAND

MO09.02 Liver transplantation with donor aged 70 or above: is it justified?

B.E. Wellge, L. Fischer, E.G. Achilles, J. Pollok, M. Koch, M. Sterneck, B. Nashan, T.Y. Tsui  
Hamburg/GERMANY

MO09.03 Validation of the Kidney Donor Risk Index (KDRI) Score in a UK Single Centre DCD Cohort

J.K. Pine, P.J. Goldsmith, D.M. Ridgway, K. Brady, S. Pollard, M. Attia, N. Ahmad, K.V. Menon  
Leeds/UNITED KINGDOM

MO09.04 Changes in practice and its effect on the coordination of the organ donation process in Québec: an analysis of the current situation

S. Lavigne<sup>1</sup>, M. Carrier<sup>2</sup>, C. lebeau<sup>1</sup>, I. sourdif<sup>2</sup>  
<sup>1</sup>Québec/CANADA, <sup>2</sup>Montréal/CANADA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO09.05 Donor age related conversion rates in 5 European countries: Donor Action® evidence based data demonstrating an unexploited potential

L. Roels<sup>1</sup>, J. Smits<sup>2</sup>, B. Cohen<sup>1</sup>

<sup>1</sup>Linden/BELGIUM, <sup>2</sup>Leiden/NETHERLANDS

MO09.06 Trends in organ donation in the UK

R.J. Johnson<sup>1</sup>, C. Counter<sup>1</sup>, J.A. Bradley<sup>2</sup>, C.J.E. Watson<sup>2</sup>, C. Rudge<sup>3</sup>, J. Neuberger<sup>1</sup>

<sup>1</sup>Bristol/UNITED KINGDOM, <sup>2</sup>Cambridge/UNITED KINGDOM, <sup>3</sup>London/UNITED KINGDOM

MO09.07 The possibilities of improving procurement activity in Slovakia (Five years analyses of deaths in region with 865000 people)

J. Miklušica, Ľudovít. Laca, B. Grandtnerova, B. Palkóci, Ľubomír. Strelka  
Martin/SLOVAK REPUBLIC

MO09.08 Professional experience of Critical Care staff impacting on comfort levels with donation related tasks.

L. Roels<sup>1</sup>, J. Smits<sup>2</sup>, B. Cohen<sup>1</sup>

<sup>1</sup>Linden/BELGIUM, <sup>2</sup>Leiden/NETHERLANDS

MO09.09 Extended Pancreas Donor Program - The EXPAND Study

S.A. Farkas<sup>1</sup>, A.A. Schnitzbauer<sup>1</sup>, T. Boerner<sup>1</sup>, B. Banas<sup>1</sup>, H. Arbogast<sup>2</sup>, R. Viebahn<sup>3</sup>, H.J. Schlitt<sup>1</sup>

<sup>1</sup>Regensburg/GERMANY, <sup>2</sup>Munich/GERMANY, <sup>3</sup>Bochum/GERMANY

MO09.10 Lifetime Probabilities of Needing an Organ Transplant versus Donating an Organ after Death

L. Hornby<sup>1</sup>, J. Chandler<sup>2</sup>, J. Burkell<sup>3</sup>, S.D. Shemie<sup>1</sup>

<sup>1</sup>Montreal/CANADA, <sup>2</sup>Ottawa/CANADA, <sup>3</sup>London/CANADA

### Session MO10 New Immunosuppressive Agents

**Tuesday, August 17, 2010 12:15 PM - 01:15 PM**

**Room: MR 211**

Moderators: *Barry . Kahan, Mark . Pescovitz*

MO10.01 Safety Profile Of Tasocitinib (CP-690,550)-Based CNI-Free Regimens In De Novo Kidney Transplant Patients In A Dose/Exposure-Finding Phase 2B Study: Results Of A 6-Month Interim Analysis



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

H. Tedesco-Silva<sup>1</sup>, J.M. Grinyó<sup>2</sup>, D.C. Brennan<sup>3</sup>, G. Klintmalm<sup>4</sup>, A. Hartmann<sup>5</sup>, S. Kulkarni<sup>6</sup>, F. Vincenti<sup>7</sup>, S. Steinberg<sup>8</sup>, S. Stefoni<sup>9</sup>, E. Kudlacz<sup>10</sup>, G. Chan<sup>10</sup>

<sup>1</sup>Sao Paulo/BRAZIL, <sup>2</sup>Barcelona/SPAIN, <sup>3</sup>St. Louis/UNITED STATES OF AMERICA, <sup>4</sup>Dallas/UNITED STATES OF AMERICA, <sup>5</sup>Oslo/NORWAY, <sup>6</sup>New Haven/UNITED STATES OF AMERICA, <sup>7</sup>San Francisco/UNITED STATES OF AMERICA, <sup>8</sup>San Diego/UNITED STATES OF AMERICA, <sup>9</sup>Bologna/ITALY, <sup>10</sup>New London/UNITED STATES OF AMERICA

MO10.02 Correlation Of Tasocitinib (CP-690,550) And MPA Pharmacokinetics With Clinical Events In De Novo Kidney Transplant Patients: Preliminary Results From A Phase 2B Study

P. O'Connell<sup>1</sup>, W. Weimar<sup>2</sup>, A. Wilkinson<sup>3</sup>, J. Friedewald<sup>4</sup>, M. Castegneto<sup>5</sup>, S. Jordan<sup>3</sup>, D.-J. Han<sup>6</sup>, V.D. Garcia<sup>7</sup>, M. Lamba<sup>8</sup>, G. Chan<sup>8</sup>, S. Krishnaswami<sup>8</sup>

<sup>1</sup>Westmead/AUSTRALIA, <sup>2</sup>Rotterdam/NETHERLANDS, <sup>3</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>4</sup>Chicago/UNITED STATES OF AMERICA, <sup>5</sup>Rome/ITALY, <sup>6</sup>Seoul/KOREA, <sup>7</sup>Porto Alegre/BRAZIL, <sup>8</sup>New London/UNITED STATES OF AMERICA

MO10.03 CP-690,550 Inhibits Interleukin2-Mediated STAT5 Activation In CD4+ T Cells OF Adult Kidney Recipients

R. Silva<sup>1</sup>, K. Piard-Ruster<sup>1</sup>, S.M. Krams<sup>1</sup>, O.M. Martinez<sup>1</sup>, S. Busque<sup>2</sup>

<sup>1</sup>Stanford/UNITED STATES OF AMERICA, <sup>2</sup>Palo Alto/UNITED STATES OF AMERICA

MO10.04 Protecting Renal Grafts from Immune Rejection in Kidney Transplantation through siRNAi

X. Zheng, J. Jiang, X. Zhang, A. Shunnar, N. Jiang, D. Chen, Y. Zhang, P. Luke, A.M. Jevnikar, W. Min  
London/CANADA

MO10.05 Comparative Efficacy of Proteasome Inhibitor-Based Antihumoral Therapy for Early Versus Late Post-Transplant Antibody Mediated Rejection in Kidney Transplant

R.C. Walsh, A.R. Shields, A. Girnita, G.E. Wall, P. Brailey, L. Arend, M. Cardi, A. Govil, A. Tevar, S. Safdar, R.R. Alloway, E.S. Woodle  
Cincinnati/UNITED STATES OF AMERICA

MO10.06 Proteasome Inhibitor Therapy for Antibody Mediated Rejection: Initial Report from A Multicenter Collaborative

E.S. Woodle<sup>1</sup>, J. Light<sup>2</sup>, J. Thielke<sup>3</sup>, M. Rubin<sup>4</sup>, W.R. Morrow<sup>5</sup>, W. Mahle<sup>6</sup>, C. Franklin<sup>7</sup>, S. Gabardi<sup>4</sup>, J. Gill<sup>8</sup>, I. Roberti<sup>9</sup>, R. Shapiro<sup>10</sup>, P. Eckman<sup>11</sup>, R. Lewis<sup>12</sup>, G.E. Wall<sup>1</sup>, R.C. Walsh<sup>1</sup>, M. Zand<sup>13</sup>, R.R. Alloway<sup>1</sup>

<sup>1</sup>Cincinnati/UNITED STATES OF AMERICA, <sup>2</sup>Washington Dc/UNITED STATES OF AMERICA, <sup>3</sup>Chicago/UNITED STATES OF AMERICA, <sup>4</sup>Boston/UNITED STATES OF AMERICA, <sup>5</sup>Little Rock/UNITED STATES OF AMERICA, <sup>6</sup>Atlanta/UNITED STATES OF AMERICA, <sup>7</sup>Des Moines/UNITED STATES OF AMERICA, <sup>8</sup>Vancouver/CANADA, <sup>9</sup>West Orange/UNITED STATES OF AMERICA, <sup>10</sup>Pittsburgh/UNITED STATES OF AMERICA, <sup>11</sup>Minneapolis/UNITED STATES OF AMERICA, <sup>12</sup>Austin/UNITED STATES OF AMERICA, <sup>13</sup>Rochester/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO10.07 The Role of Proteasome Inhibition with Bortezomib in the Treatment of Antibody Mediated Rejection (AMR) after Renal Transplantation

S.M. Flechner, R. Fatica, M. Askar, B. Stephany, E. Poggio, A. Koo, T. Srinivas  
Cleveland/UNITED STATES OF AMERICA

MO10.08 Sotrastaurin mediated inhibition of proteinkinase C ameliorates severe posttransplant preservation injury

L. Chaykovska, U. Hoff, A. Kusch, R. Catar, J. Pützer, F. Fuller, D. Dragan  
Berlin/GERMANY

MO10.09 Development of Cyclin Kinase Inhibitor as a Potent Immunosuppressive Drug

A.K. Khanna  
Baltimore/UNITED STATES OF AMERICA

MO10.10 Clonal deletion with bortezomib permits renal transplant with low-dose corticosteroids alone

H.L. Trivedi<sup>1</sup>, P.I. Terasaki<sup>2</sup>, A.V. Vanikar<sup>1</sup>, V.B. Trivedi<sup>1</sup>, S. Khemchandani<sup>1</sup>, S.D. Dave<sup>1</sup>, V. Shankar<sup>1</sup>, P.R. Modi<sup>1</sup>, H. Kaneku<sup>2</sup>, A. Idica<sup>3</sup>, M.J. Everly<sup>3</sup>  
<sup>1</sup>Ahmedabad/INDIA, <sup>2</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>3</sup>Canoga Park/UNITED STATES OF AMERICA

MO10.11 Reduced C0-levels and increased dose-requirements in renal allograft recipients converted from the standard twice-daily to the novel once-daily prolonged release tacrolimus formulation

Y. Vanrenterghem, H. de Jonge, K. Verbeke, D.R. Kuypers  
Leuven/BELGIUM

MO10.12 Renal function is maintained following conversion to Tacrolimus QD (Advagraf) from ciclosporin: primary results from CONCERTO

L. Rostaing<sup>1</sup>, A. Sánchez-Fructuoso<sup>2</sup>, M. Glyda<sup>3</sup>  
<sup>1</sup>Toulouse/France, <sup>2</sup>Madrid/Spain, <sup>3</sup>Poznan/Poland

### Session MO11 Societal Issues and Public Policy

**Tuesday, August 17, 2010 12:15 PM - 01:15 PM**  
**Room: MR 205 - 207**

Moderators: *Félix . Cantarovich, Haibo . Wang*



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO11.01 Changes in Health-Related Quality of Life Across Three Post-Heart Transplant Stages: Clinical Trial Plan Group vs. non-CTP Group in Taiwan

P.-H. Tseng, S.-S. Wang, F.-J. Shih  
Taipei/TAIWAN

MO11.03 Prospective Pshyciatric Follow-Up Of Renal Transplant Recipients And Donors: Impact of Procedure And Impact of Follow-Up

I. Yatkin<sup>1</sup>, C. Cerit<sup>1</sup>, G. Tellioglu<sup>1</sup>, M. Kara<sup>1</sup>, N. Yilmaz<sup>2</sup>, I. Berber<sup>1</sup>, B. Yigit<sup>1</sup>, P. Ata Eren<sup>1</sup>, M. Caliskan<sup>1</sup>, I.M. Titiz<sup>1</sup>  
<sup>1</sup>Istanbul/TURKEY, <sup>2</sup>Mugla/TURKEY

MO11.04 Projecting patient outcomes at 20 years based on graft function from randomized trials of immunosuppressants among renal transplant recipients in the United States

A. Levy<sup>1</sup>, A. Briggs<sup>2</sup>, K. Johnston<sup>3</sup>, M.A. Schnitzler<sup>4</sup>, G.J. L'Italien<sup>5</sup>, Y. Yuan<sup>5</sup>, B. Kasiske<sup>6</sup>  
<sup>1</sup>Halifax, Ns/CANADA, <sup>2</sup>Glasgow/UNITED KINGDOM, <sup>3</sup>Vancouver/CANADA, <sup>4</sup>St Louis/UNITED STATES OF AMERICA, <sup>5</sup>Princeton/UNITED STATES OF AMERICA, <sup>6</sup>Minneapolis/UNITED STATES OF AMERICA

MO11.05 Attitude towards Kidney donation among Primary care patients in developing country.

S. Joshi<sup>1</sup>, R.P. Bhandari<sup>2</sup>  
<sup>1</sup>Kathmandu/NEPAL, <sup>2</sup>Ktm/NEPAL

MO11.06 Screening tests for coronary artery disease in potential kidney transplant recipients: a systematic review of diagnostic test accuracy

L.W. Wang<sup>1</sup>, P. Macaskill<sup>1</sup>, M.A. Fahim<sup>2</sup>, J.C. Craig<sup>1</sup>, R. Mitchell<sup>1</sup>, A. Hayen<sup>1</sup>, L. Baines<sup>3</sup>, S. Lord<sup>3</sup>, A. Webster<sup>1</sup>  
<sup>1</sup>Sydney/AUSTRALIA, <sup>2</sup>Brisbane/AUSTRALIA, <sup>3</sup>Newcastle Upon Tyne/UNITED KINGDOM

MO11.07 Struggle for the historic unanimous passage of transplant law in Pakistan

S.A.H. Rizvi<sup>1</sup>, S.A.A. Naqvi<sup>1</sup>, M.N. Zafar<sup>1</sup>, F. Moazam<sup>1</sup>, F. Delmonico<sup>2</sup>, L. Noel<sup>3</sup>  
<sup>1</sup>Karachi/PAKISTAN, <sup>2</sup>Newton/UNITED STATES OF AMERICA, <sup>3</sup>Geneva/SWITZERLAND

MO11.08 Are religious communities useful in promoting the organ donation debate? Lessons from the United Kingdom

G. randhawa  
Luton/UNITED KINGDOM



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO11.09 The paradox of prohibition and how potential adverse consequences of the Istanbul Declaration may be controlled

F. Ambaqtzsheer, W. Weimar  
Rotterdam/NETHERLANDS

MO11.10 Challenging Issues of Overseas Transplantation in Mainland China: Taiwan Organ Transplant Health Professionals' Perspective

F.-J. Shih<sup>1</sup>, Y.-W. Fan<sup>1</sup>, H.-M. Chen<sup>2</sup>, C.-M. Chiu<sup>3</sup>, F.-J. Shih<sup>2</sup>, S.-S. Wang<sup>2</sup>  
<sup>1</sup>Taoyuan/TAIWAN, <sup>2</sup>Taipei/TAIWAN, <sup>3</sup>Kaohsiung/TAIWAN

MO11.11 The long-term consequences of kidney donation in the victims of trafficking in human beings (VTHBs) for the purpose of organ removal

I. Codreanu<sup>1</sup>, N. Codreanu<sup>1</sup>, F. Delmonico<sup>2</sup>  
<sup>1</sup>Chisinau/MOLDOVA, <sup>2</sup>Newton/UNITED STATES OF AMERICA

### Session MO12 Immunosuppression in Liver Transplantation

**Tuesday, August 17, 2010 12:15 PM - 01:15 PM**  
**Room: MR 217 - 219**

Moderators: *Marcus . Bahra, Goran . Klintmalm*

MO12.01 Safety of conversion from twice-daily tacrolimus (Prograf®) to once-daily prolonged-release tacrolimus (Advagraf®) in stable liver transplantation recipients

C. Comuzzi<sup>1</sup>, D. Lorenzin<sup>1</sup>, A. Rossetto<sup>1</sup>, M. Faraci<sup>2</sup>, D. Nicolini<sup>2</sup>, P. Garelli<sup>2</sup>, C. Musolino<sup>1</sup>, V. Bresadola<sup>1</sup>, G.L. Adani<sup>1</sup>, P. Toniutto<sup>1</sup>, G. Svegliati Baroni<sup>2</sup>, A. Risaliti<sup>2</sup>, U. Baccarani<sup>1</sup>  
<sup>1</sup>Udine/ITALY, <sup>2</sup>Ancona/ITALY

MO12.02 Long-term follow-up of tacrolimus once-daily prolonged release in liver transplant recipients demonstrates good efficacy and renal function

P. Trunečka<sup>1</sup>, O. Boillot<sup>2</sup>, U. Neumann<sup>3</sup>  
<sup>1</sup>Prague/CZECH REPUBLIC, <sup>2</sup>Lyon/FRANCE, <sup>3</sup>Berlin/GERMANY

MO12.03 Cost-effectiveness of Mycophenolate Mofetil and Tacrolimus compared to Azathioprine and Tacrolimus following Orthotopic liver transplantation (OLT)



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. AROORI, B. Sandhu, B. Gunson, S. Lowett, J. Isaac, P. Muiesan, D. Mirza, D. MAYER, J. Buckels, S. Bramhall  
Birmingham/UNITED KINGDOM

MO12.04 In vivo induction of bona fide CD4+CD25+ regulatory T cells after liver transplantation – the potential influence of polyclonal antithymocyte globulin

D. Stauch<sup>1</sup>, A. Yahyazadeh<sup>1</sup>, S. Olek<sup>1</sup>, U. Baron<sup>1</sup>, J. Pratschke<sup>2</sup>, K. Kotsch<sup>1</sup>, K. Kunert<sup>1</sup>  
<sup>1</sup>Berlin/GERMANY, <sup>2</sup>Innsbruck/AUSTRIA

MO12.05 The Safety of Late Conversions to Sirolimus in Liver Transplantation

G.J. McKenna, J.F. Trotter, E. Klintmalm, S. Chinnakotla, R. Ruiz, N. Onaca, M.F. Levy, R. Goldstein, G. Klintmalm  
Dallas/UNITED STATES OF AMERICA

MO12.06 Generic substitution of tacrolimus appears to be safe in the short term in clinically stable liver and kidney transplant patients, but monitoring of tacrolimus blood concentrations in individual patients is essential.

J. Momper, P. FONTES, M.E. DeVera, A. Humar, R. Shapiro, R. Venkataramanan  
Pittsburgh/UNITED STATES OF AMERICA

MO12.07 17 to 20 Years Longitudinal Follow-up of 1000 Consecutive Primary Liver Transplant under Tacrolimus

A. Jain<sup>1</sup>, P. FONTES<sup>2</sup>, G. Mazariegos<sup>2</sup>, M.E. DeVera<sup>2</sup>, K. Soltys<sup>2</sup>, T. Caccarelli<sup>2</sup>, A. Goyal<sup>1</sup>, A. Humar<sup>2</sup>, J.W. Marsh<sup>2</sup>  
<sup>1</sup>Philadelphia/UNITED STATES OF AMERICA, <sup>2</sup>Pittsburgh/UNITED STATES OF AMERICA

MO12.08 Early versus Late Conversion to mTOR-Inhibitors in Liver Transplant Recipients with Impaired Renal Function at the Time of Transplantation

C. Schleicher, D. Palmes, M. Utech, E. Bonrath, N. Senninger, H. Schmidt, H. Wolters  
Muenster/GERMANY

MO12.09 Beneficial Effect of Induction Therapy for Liver Transplant Recipients with Renal Dysfunction: an Analysis of OPTN/UNOS data

T. Shah, Y. Qazi, T.-L. Fong, Y. Genyk, L. Sher, I.V. Hutchinson, Y.W. Cho  
Los Angeles/UNITED STATES OF AMERICA

MO12.10 Acute Phase Liver Graft Injury Significantly Mobilized Circulating Endothelial Progenitor Cells, Myeloid-Derived Suppressor Cells and Regulatory T Cells through TLR4 signaling



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

C. Ling<sup>1</sup>, C.M. Lo<sup>2</sup>, X. Liu<sup>1</sup>, K.T. Ng<sup>1</sup>, Y. Shao<sup>1</sup>, C. Li<sup>1</sup>, S.T. Fan<sup>1</sup>, R.T.P. Poon<sup>1</sup>, K. Man<sup>1</sup>  
<sup>1</sup>Hong Kong/HONG KONG, <sup>2</sup>Pok Fu Lam/HONG KONG

#### Session MO13 Clinical Strategies and Outcomes in Kidney Transplantation

**Tuesday, August 17, 2010 12:15 PM - 01:15 PM**  
**Room: MR 220 - 222**

Moderators: *Stuart . Flechner, Franco . Citterio*

MO13.01 Donor and recipient age are independent determinants for acute rejection rates and transplant outcome

S.G. Tullius, H. Tran, I. Guleria, S.K. Malek, N.L. Tilney, E. Milford  
Boston/UNITED STATES OF AMERICA

MO13.02 Effect of Deceased-Donor Age on Median Kidney Recipient and Graft Survival: A Target for Intervention

A.B. Leichtman, K.P. McCullough, R. Wiggins, R. Wolfe  
Ann Arbor/UNITED STATES OF AMERICA

MO13.03 Impact Of The Strict Glycemic Control In The Post-Operative Period Of Transplantation With ECD Kidneys. Preliminary Results Of A Prospective And Randomized Trial

L.S. Re, R. Pilotti, J. Petroni, D. Yagupski, J. Goldberg, D. Casadei  
Buenos Aires/ARGENTINA

MO13.04 Post Transplant Diabetes Mellitus (PTDM) - Analysis of risk factors, effects on biochemical parameters, graft function - at 5 years of renal transplantation

D. Madhav, R. Ram, K.V. Dakshinamurthy  
Hyderbad/INDIA

MO13.05 A comparison of effects of short-term maintenance dose exposure of Advagraf® and Neoral® on renal perfusion and function in healthy volunteers.

J.S. Zaltzman  
Toronto/CANADA

MO13.06 A randomized placebo controlled trial for deceased kidney donor pretreatment with corticosteroids to prevent acute renal failure



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

A. Kainz<sup>1</sup>, J. Wilflingseder<sup>1</sup>, C. Mitterbauer<sup>1</sup>, M. Haller<sup>2</sup>, C. Burghuber<sup>1</sup>, P. Perco<sup>2</sup>, R.M. Langer<sup>3</sup>, G. Heinze<sup>1</sup>, R. Oberbauer<sup>1</sup>

<sup>1</sup>Vienna/AUSTRIA, <sup>2</sup>Linz/AUSTRIA, <sup>3</sup>Budapest/HUNGARY

MO13.07 An Appraisal on the Convenience of Early Everolimus Introduction and Calcineurin Inhibitor Withdrawal in Kidney Recipients: The ERIC Study

J.C. Ruiz<sup>1</sup>, A. Sánchez Fructuoso<sup>2</sup>, D. Hernández<sup>3</sup>, J. Sánchez Plumed<sup>4</sup>, A. Fernández<sup>2</sup>, A. Pastor Rodríguez<sup>5</sup>, J. Paul<sup>6</sup>, A. Alarcón<sup>7</sup>

<sup>1</sup>Santander/SPAIN, <sup>2</sup>Madrid/SPAIN, <sup>3</sup>Málaga/SPAIN, <sup>4</sup>Valencia/SPAIN, <sup>5</sup>Tenerife/SPAIN, <sup>6</sup>Zaragoza/SPAIN, <sup>7</sup>Mallorca/SPAIN

MO13.08 Utilization of compatible pairs to significantly expand kidney paired donation

A. Bingaman, F. Wright, M. Kapturczak, C. Murphey  
San Antonio/UNITED STATES OF AMERICA

MO13.09 A model based on donor factors for predicting long term survival of living related renal transplants

M.N. Zafar, S.A.A. Naqvi, S.A.H. Rizvi  
Karachi/PAKISTAN

MO13.10 Should we transplant all kidneys from expanded criteria donors – analysis of exclusion criteria.

M. Wszola, P. Domagala, A. Kwiatkowski, A. Perkowska-Ptasinska, M. Majkowska, L. Paczek, A. Chmura  
Warsaw/POLAND

MO13.11 Outcome of high volume live related renal transplants in a developing country

S.A.H. Rizvi, S.H. Mehdi, T. Aziz, G. Sultan, A.S. Hasan, R. Mohsin, A. Hashmi, S.A.A. Naqvi  
Karachi/PAKISTAN

### Session MO14 Islet and Pancreas Transplantation II

**Tuesday, August 17, 2010 12:15 PM - 01:15 PM**

**Room: MR 212 - 214**

Moderators: *Helmut . Arbogast, Stephen . Bartlett*

MO14.01 Quality of Life after Simultaneous Pancreas and Kidney Transplantation from Living Donors. – Evaluation both for the donors and the recipients using a Short-Form 36 v2 –



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

A. Suzuki<sup>1</sup>, T. Kenmochi<sup>2</sup>, M. Maruyama<sup>2</sup>, M. Miyazaki<sup>1</sup>

<sup>1</sup>Chiba City/JAPAN, <sup>2</sup>Chiba/JAPAN

MO14.02 Factors Influencing the Acceptance of Donor Solid-Organ Pancreata for Transplantation. An Australian Single Centre Review.

L. Lan<sup>1</sup>, W.R. Mulley<sup>1</sup>, P. Chaal<sup>1</sup>, V. Marion<sup>2</sup>, H. Opdam<sup>2</sup>, A. Saunder<sup>1</sup>, J. Kanellis<sup>1</sup>

<sup>1</sup>Clayton/AUSTRALIA, <sup>2</sup>Carlton/AUSTRALIA

MO14.03 Long-Term Survival of Pancreas Allografts Is Similar in Pancreas-After-Kidney and Simultaneous Pancreas-Kidney Transplant Recipients

R.S. Perkins, M.A. Marquez, M. Selzner, A. Norgate, F. Bazerbachi, J. Schiff, A. Ghanekar, I.D.

McGilvray, D.R. Grant, P.D. Greig, M.S. Cattral

Toronto/CANADA

MO14.04 Long-term survival of allogeneic islets in a biohybrid device by locally delivered immunosuppression

N. Bocca, S. Marzorati, C. Ricordi, R.D. Molano, S. Villate, J. Molina, E. Zahr, C. Fraker, C. Stabler, N.S.

Kenyon, L. Inverardi, P. Buchwald, A. Pileggi

Miami/UNITED STATES OF AMERICA

MO14.05 Correlation of C peptide levels with Age, Race, and BMI, but not Pancreas Transplant Outcomes.

J.A. Light, M.J. Tucker

Washington Dc/UNITED STATES OF AMERICA

MO14.06 Pancreas Transplantation: Transplanting Sensitised Patients in the UK

A.J. Hudson<sup>1</sup>, L.L. Mumford<sup>1</sup>, S.V. Fuggle<sup>1</sup>, C.J.E. Watson<sup>2</sup>

<sup>1</sup>Bristol/UNITED KINGDOM, <sup>2</sup>Cambridge/UNITED KINGDOM

MO14.07 Intestinal Complications of Pancreas Transplantation

F. Vistoli, C. Croce, S. Signori, C. Moretto, M. Del Chiaro, G. Amorese, M. Barsotti, P. Marchetti, U. Boggi

Pisa/ITALY

MO14.08 Oxygen Persufflation Increases Pancreatic ATP Levels and Viable Islet Yield Following 24 Hours Preservation Compared with the Two-Layer Method (TLM)

W.E. Scott III<sup>1</sup>, E.S. Avgoustiniatos<sup>1</sup>, J. Ferrer-Fabrega<sup>1</sup>, B.P. Weegman<sup>1</sup>, V.A. Kircner<sup>1</sup>, T. Anazawa<sup>2</sup>, M.D. Rizzari<sup>1</sup>, L.S. Kidder<sup>1</sup>, S.A. Stein<sup>1</sup>, S. Matsumoto<sup>1</sup>, J.J. Stone<sup>1</sup>, T.M. Suszynski<sup>1</sup>, T.C. Aasheim<sup>1</sup>, B.E.



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

Hammer<sup>1</sup>, A.N. Balamurugan<sup>1</sup>, T.D. O'Brien<sup>3</sup>, M.P. Murtaugh<sup>3</sup>, L.A. Tempelman<sup>4</sup>, D.E. Sutherland<sup>1</sup>, B.J. Hering<sup>1</sup>, K.K. Papas<sup>1</sup>  
<sup>1</sup>Minneapolis/UNITED STATES OF AMERICA, <sup>2</sup>Fukushima/JAPAN, <sup>3</sup>St. Paul/UNITED STATES OF AMERICA,  
<sup>4</sup>Newton/UNITED STATES OF AMERICA

MO14.09 Successful islet transplantation from a single-donor based on CD40-CD154 costimulation blockade plus NF-κB inhibition

Y. Koshizuka<sup>1</sup>, K. Yamashita<sup>1</sup>, M. Watanabe<sup>1</sup>, D. Kuraya<sup>1</sup>, M. Ogura<sup>1</sup>, T. Yoshida<sup>1</sup>, H. Kamachi<sup>1</sup>, M. Matsushita<sup>1</sup>, K. Umezawa<sup>2</sup>, M. Ozaki<sup>1</sup>, S. Todo<sup>1</sup>  
<sup>1</sup>Sapporo/JAPAN, <sup>2</sup>Yokohama/JAPAN

MO14.10 Improved Pancreatic Islet Yield and Function with a Chloride Channel Blocker during Collagenase Digestion

T. Anazawa, T. Saito, Y. Sato, A. Kenjo, T. Kimura, J. Haga, M. Miyake, A. Hazama, M. Gotoh  
Fukushima/JAPAN

MO14.11 Engineering Alternative Islet Implant Sites in a Nonhuman Primate Model

N.S. Kenyon, E. Pedraza, D.M. Berman, A.C. Brady, M. Willman, P. Latta, C. Ricordi, C. Stabler  
Miami/UNITED STATES OF AMERICA

MO14.12 IFN-gamma Modulated Fast-Dendritic Cells Promote The Generation Of CD4+CD25+Foxp3HI T-Regulatory Cells: A Potential Therapy For Clinical Islet Allotransplantation

D.M. Rojas, R. Krishnan, P.T. Coates  
Adelaide/AUSTRALIA



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

### 13:30 – 15:00 STATE OF THE ART SYMPOSIA

#### Session SOTA08 Principles and practice of living donor exchange

**Tuesday, August 17, 2010 01:30 PM - 03:00 PM**  
**Room: MR 109 - 110**

Moderators: *John . Gill, Lloyd . Ratner*

SOTA08.1 Living donor exchange for sensitized patients

D.L. Segev  
Baltimore/UNITED STATES OF AMERICA

SOTA08.2 The National Living Donor Exchange Programme in The Netherlands.

M. Klerk de  
Rotterdam/NETHERLANDS

SOTA08.3 How to organize a national living donor exchange program

E. Cole  
Toronto/CANADA

SOTA08 - DISCUSSION

#### Session SOTA09 Biology and therapeutic potential of regulatory cells

**Tuesday, August 17, 2010 01:30 PM - 03:00 PM**  
**Room: MR 212 - 214**

Moderators: *Shuiping . Jiang, Angus . Thomson*

SOTA09.1 Signaling pathways in regulatory cells

M. Levings  
Vancouver/CANADA

SOTA09.2 T-regulatory cells: phenotype and function



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

A. Rudensky

New York/UNITED STATES OF AMERICA

SOTA09.3 Regulatory B cells

T. Tedder

Durham/UNITED STATES OF AMERICA

SOTA09 - DISCUSSION

### Session SOTA10 Maintenance immunosuppression

**Tuesday, August 17, 2010 01:30 PM - 03:00 PM**

**Room: Ballroom A/B**

Moderators: *Anthony Benedict . Cosimi, Bernard . Charpentier*

SOTA10.1 Novel approaches to inhibit intracellular signals

B. Kahan

Houston/UNITED STATES OF AMERICA

SOTA10.2 Concentration-controlled immunosuppression

T. van Gelder

Rotterdam/NETHERLANDS

SOTA10.3 Translational research and maintenance immunosuppression

A. Kirk

Atlanta/UNITED STATES OF AMERICA

SOTA10.4 Strategies in transplant patients with chronic kidney disease

M. Cantarovich

Montreal/CANADA

SOTA10 - DISCUSSION



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

#### **Session SOTA11 Genome BC Symposium: Transplant genomics and biomarkers of injury**

**Tuesday, August 17, 2010 01:30 PM - 03:00 PM**

**Room: MR 211**

Moderators: *John Andrew . Bradley, Roslyn . Mannon*

SOTA11.1 Transplantomics: report of the first international meeting

M. Sarwal

Stanford/UNITED STATES OF AMERICA

SOTA11.2 Integrative genomics in organ transplantation

D.R. Salomon

La Jolla/UNITED STATES OF AMERICA

SOTA11.3 Genetic and molecular mechanisms in chronic allograft injury

P. Halloran

Edmonton/CANADA

SOTA11 - DISCUSSION

#### **Session SOTA12 Biological function and clinical relevance of antibodies to transplantation antigens**

**Tuesday, August 17, 2010 01:30 PM - 03:00 PM**

**Room: Ballroom C**

Moderators: *Paul . Terasaki, Howard . Gebel*

SOTA12.1 Determinants of biological function of anti-donor antibodies

E.F. Reed

Los Angeles/UNITED STATES OF AMERICA

SOTA12.2 Comparative clinical importance of class I and class II antibodies



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. Fidler

Perth/AUSTRALIA

SOTA12.3 Clinical relevance of antibodies to non-HLA antigens

D. Dragun

Berlin/GERMANY

SOTA12.4 The role and future of the flow and cytotoxic crossmatch

R.H. Kerman

Houston/UNITED STATES OF AMERICA

SOTA12 - DISCUSSION

#### **Session SOTA13 Liver Transplantation for Hepatocellular Cancer**

**Tuesday, August 17, 2010 01:30 PM - 03:00 PM**

**Room: MR 118 - 120**

Moderators: *Federico . Villamil, William . Wall*

SOTA13.1 Tumor selection criteria -a new approach

N.M. Kneteman

Edmonton/CANADA

SOTA13.2 Locoregional therapy pre-transplant

F. Yao

San Francisco/UNITED STATES OF AMERICA

SOTA13.3 Priority of HCC candidates on the waiting list

R. Wiesner

Rochester/UNITED STATES OF AMERICA

SOTA13 - DISCUSSION



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

#### Session SOTA14 Islet cell replacement: outcomes and allocation

**Tuesday, August 17, 2010 01:30 PM - 03:00 PM**

**Room: MR 220 - 222**

Moderators: *Anthony . Monaco, Phil . O'Connell*

SOTA14.1 Results of Pancreas Transplantation in 2010. The case for prioritized allocation to whole pancreas.

J. Shapiro

Edmonton/CANADA

SOTA14.2 Results of Islet Transplantation in 2010. The case for prioritized allocation to islet transplantation.

S.T. Bartlett

Baltimore/UNITED STATES OF AMERICA

SOTA14.3 Impact of Pancreas and Islet Transplantation on Secondary Complications

A. Secchi

Milano/ITALY

SOTA14.4 Synthesizing the data. Synthesizing the evidence: a strategy for allocation to pancreas and islet transplantation.

P.R. Johnson

Oxford/UNITED KINGDOM

SOTA14 - DISCUSSION

**15:30 – 17:00 AFTERNOON CONCURRENT SYMPOSIA**

#### Session O33 Cellular Mechanisms of Immune Regulation

**Tuesday, August 17, 2010 03:30 PM - 05:00 PM**



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

Room: MR 220 - 222

Moderators: *Alice . Mui, Shane . Grey*

O33.01 Allograft Tolerance in Mice with MGMT Chimeric Bone Marrow Engraftment

M. Hu<sup>1</sup>, B. Kramer<sup>1</sup>, B. Howden<sup>2</sup>, G. Zhang<sup>1</sup>, Y.M. Wang<sup>1</sup>, G. McCowage<sup>1</sup>, I. Alexander<sup>1</sup>, P. Gunning<sup>1</sup>, S.I. Alexander<sup>1</sup>

<sup>1</sup>Westmead/AUSTRALIA, <sup>2</sup>Blackburn/AUSTRALIA

O33.02 Effects of pretransplantation microchimerism on allograft survival in HLA-haploidentical family donor renal transplantation

S.Y. Joo, M.H. Park, E.Y. Song, Y. Shin, J. Ha, S.J. Kim  
Seoul/KOREA

O33.03 Donor Specific Immunoregulation in HLA-Identical Renal Transplant Recipients Given Alemtuzimab and Donor Stem Cells

J. Miller, J. Leventhal, L. Gallon, J. Friedewald, J. Levitsky, A. Tambur, X. Huang, J.M. Mathew  
Chicago/UNITED STATES OF AMERICA

O33.04 The Pitfalls of Myeloid-only Mixed-Chimerism: Lack of T cell chimerism correlates with transplant rejection after immunosuppression withdrawal in a novel, MHC-defined primate model.

K. Singh, S. Srinivasan, A. Page, C. Larsen, L.S. Kean  
Atlanta/UNITED STATES OF AMERICA

O33.05 Acquisition of intact alloantigen by recipient DCs provokes cytotoxic CD8 T cell and alloantibody responses.

S. Sivaganesh, C.J. Callaghan, T. Conlon, R. Motallebzadeh, K. Saeb-Parsy, M. Negus, E.M. Bolton, J.A. Bradley, G.J. Pettigrew  
Cambridge/UNITED KINGDOM

O33.06 A single infusion of the ex-vivo generated immuno-regulatory dendritic cells under a novel agent, NK026680 markedly prolongs cardiac allograft survival

S. Shibasaki<sup>1</sup>, K. Yamashita<sup>1</sup>, Y. Yanagawa<sup>2</sup>, K. Wakayama<sup>1</sup>, H. Gentaro<sup>1</sup>, Y. Tsunetoshi<sup>1</sup>, M. Zaitzu<sup>1</sup>, R. Igarashi<sup>1</sup>, S. Haga<sup>1</sup>, M. Ozaki<sup>1</sup>, S. Todo<sup>1</sup>

<sup>1</sup>Sapporo/JAPAN, <sup>2</sup>Tobetsu/JAPAN

O33.07 Role of maternally derived stem cells in non-inherited maternal antigen-specific tolerance



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

P. Dutta, S.M. Schumacher, W.J. Burlingham  
Madison/UNITED STATES OF AMERICA

O33.08 Kidney-derived mesenchymal stem cells modulate dendritic and T cell function to inhibit alloimmune responses and prolong allograft survival

Y. Huang<sup>1</sup>, C.B. Zhang<sup>1</sup>, G.-J. Ko<sup>1</sup>, P. Fiorina<sup>2</sup>, M.J. Ansari<sup>2</sup>, R. Abdi<sup>2</sup>, H. Rabb<sup>1</sup>, K.L. Womer<sup>1</sup>  
<sup>1</sup>Baltimore/UNITED STATES OF AMERICA, <sup>2</sup>Boston/UNITED STATES OF AMERICA

O33.09 In Vivo Evidence: the Role of Complement Component 3 (C3) in Induction of Myeloid-Derived Suppressor Cells (MDSC)

H.S. Chou, H.-R. Yang, C.-C. Hsieh, L. Wang, J.J. Fung, L. Lu, S. Qian  
Cleveland/UNITED STATES OF AMERICA

### Session O34 Cellular Assays of the Graft Response

**Tuesday, August 17, 2010 03:30 PM - 05:00 PM**  
**Room: MR 217 - 219**

Moderators: *Ronald . Gill, Hideki . Ohdan*

O34.01 Detailed kinetics of T-cells with direct allospecificity after liver transplantation: a novel assay

O. Tapirdamaz<sup>1</sup>, S. Mancham<sup>1</sup>, L.V.D. Laan<sup>1</sup>, G. Kazemier<sup>1</sup>, K. Thielemans<sup>2</sup>, H.J. Metselaar<sup>1</sup>, J. Kwekkeboom<sup>1</sup>  
<sup>1</sup>Rotterdam/NETHERLANDS, <sup>2</sup>Brussel/BELGIUM

O34.02 FOXP3 Regulatory T Cells And Not Th17 Cells Are Involved In Ischemia Reperfusion Injury Of Human Donor Kidneys

C. Baan, A. Peeters, S. Korevaar, J.N. IJzermans, W. Weimar  
Rotterdam/NETHERLANDS

O34.03 Effects of Donor Specific Bone Marrow Cells Infusion on Living Unrelated Kidney Transplantation

G. Solgi<sup>1</sup>, J. Mytilineos<sup>2</sup>, V.K. Gadi<sup>3</sup>, B. Paul<sup>3</sup>, G. Pourmand<sup>4</sup>, A. Mehrsai<sup>4</sup>, M. Taherimahmoudi<sup>4</sup>, M.R. EbrahimiRad<sup>4</sup>, A. Seraji<sup>4</sup>, A.A. Asadpoor<sup>4</sup>, B. Nikbin<sup>4</sup>, A.A. Amirzargar<sup>4</sup>  
<sup>1</sup>Ahvaz/IRAN, <sup>2</sup>Ulm/GERMANY, <sup>3</sup>Seattle/UNITED STATES OF AMERICA, <sup>4</sup>Tehran/IRAN

O34.04 Peripheral Blood CD8+KIR2D+ T Cell Repertoires In Liver Transplant Recipients



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

M.R. López-Álvarez<sup>1</sup>, G. Salgado<sup>1</sup>, I. Legaz<sup>1</sup>, L. Gimeno<sup>1</sup>, J. Gil<sup>2</sup>, J.A. Campillo<sup>1</sup>, B. Las Heras<sup>1</sup>, S. Soriano<sup>1</sup>, A.M. García-Alonso<sup>1</sup>, M. Salcedo-Plaza<sup>2</sup>, P. Parrilla<sup>1</sup>, M. Muro<sup>1</sup>, M. Miras<sup>1</sup>, M.R. Álvarez-López<sup>1</sup>, A. Minguela<sup>1</sup>

<sup>1</sup>El Palmar. Murcia/SPAIN, <sup>2</sup>Madrid/SPAIN

O34.05 Organ Specificity of Cross-Reactive Allogeneic Responses by Viral Specific Memory T-Cells

L.J. D'Orsogna<sup>1</sup>, E. van der Meer-Prins<sup>1</sup>, P. van der Pol<sup>1</sup>, M. Franke-van Dijk<sup>1</sup>, Y. Zoet<sup>1</sup>, M. Eikmans<sup>1</sup>, J. Anholts<sup>1</sup>, A. Mulder<sup>1</sup>, C. van Kooten<sup>1</sup>, J. Rossjohn<sup>2</sup>, J. McCluskey<sup>2</sup>, D. Roelen<sup>1</sup>, I. Doxiadis<sup>1</sup>, F. Claas<sup>1</sup>  
<sup>1</sup>Leiden/NETHERLANDS, <sup>2</sup>Melbourne/AUSTRALIA

O34.06 Do cross-reactive anti-viral T cells mediate allograft rejection in lung transplant recipients?

N. Mifsud, T. Nguyen, T. Kotsimbos  
Melbourne/AUSTRALIA

O34.07 Longevity of Direct and Indirect CD4 T cell alloimmune responses

K.M. Elliott, K. Saeb-Parsy, C.J. Callaghan, M. Negus, T. Conlon, R. Motallebzadeh, S. Sivaganesh, I. Harper, G.J. Pettigrew  
Cambridge/UNITED KINGDOM

O34.08 Increased IL-12p70 release by RAPA-conditioned human monocyte-derived DC promotes pro-inflammatory NK cell-IFN-gama help early during allo-specific CD4+ T cell priming

C. Macedo, M. Castillo-Rama, H. Turnquist, A.W. Thomson, D. Metes  
Pittsburgh/UNITED STATES OF AMERICA

O34.09 Killer Immunoglobulin like Receptors incompatibility between HLA-matched Allogeneic HCT donor and recipients is associated with Acute Graft versus host disease

F.M. Khan, S. Wang, J. Doulla, J. Storek, N. Berka  
Calgary/CANADA

### Session O35 Biomarkers in Kidney Transplantation

**Tuesday, August 17, 2010 03:30 PM - 05:00 PM**

**Room: MR 211**

Moderators: *Peter . Nickerson, Caner . Suesal*

O35.01 Discovery and Validation of Peripheral Blood Diagnostic Biomarkers for Acute Kidney Rejection: Report of the TGCG Study.



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. Kurian<sup>1</sup>, A. Williams<sup>1</sup>, D. Campbell<sup>1</sup>, T. Mondala<sup>1</sup>, S. Head<sup>1</sup>, S. Horvath<sup>2</sup>, L. Gaber<sup>3</sup>, W. Lin<sup>2</sup>, E. Robison<sup>1</sup>, R. Schaffer<sup>1</sup>, J. Fisher<sup>1</sup>, S.M. Flechner<sup>4</sup>, L. Chan<sup>5</sup>, A. Wiseman<sup>6</sup>, H. Shidban<sup>2</sup>, R. Mendez<sup>2</sup>, R. Heilman<sup>7</sup>, C. Marsh<sup>1</sup>, D.R. Salomon<sup>1</sup>

<sup>1</sup>La Jolla/UNITED STATES OF AMERICA, <sup>2</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>3</sup>Houston/UNITED STATES OF AMERICA, <sup>4</sup>Cleveland/UNITED STATES OF AMERICA, <sup>5</sup>Aurora/UNITED STATES OF AMERICA, <sup>6</sup>Denver/UNITED STATES OF AMERICA, <sup>7</sup>Phoenix/UNITED STATES OF AMERICA

O35.02 Differential regulation of positive or negative costimulatory molecules during acute rejection of human renal allografts

C. Afaneh, M. Lubetzky, T. Muthukumar, R. Ding, S. Seshan, C. Snopkowski, V. Sharma, D. Dadhania, M. Suthanthiran  
New York/UNITED STATES OF AMERICA

O35.03 Single Nucleotide Polymorphism associated with Severity of Acute Rejection on Kidney Allograft Biopsies

A. Israni, R. Leduc, P. Jacobson, D. Schladt, W. Guan, W. Oetting, A. Matas, . For DeKAF Investigators  
Minneapolis/UNITED STATES OF AMERICA

O35.04 Refinement of genomic classifiers for early acute renal allograft rejection

O.P. Gunther, V. Chen, D. Lin, R. Ng, R. Balshaw, Z. Hollander, R. McMaster, B. McManus, P. Keown  
Vancouver/CANADA

O35.05 Classification of acute renal rejection with proteogenomic ensemble classifiers

O.P. Gunther<sup>1</sup>, R. Ng<sup>1</sup>, R. Balshaw<sup>1</sup>, D. Lin<sup>1</sup>, A. Scherer<sup>2</sup>, V. Chen<sup>1</sup>, G. Cohen-Freue<sup>1</sup>, M. Takhar<sup>1</sup>, Z. Hollander<sup>1</sup>, R. McMaster<sup>1</sup>, B. McManus<sup>1</sup>, P. Keown<sup>1</sup>  
<sup>1</sup>Vancouver/CANADA, <sup>2</sup>Kontiolahiti/FINLAND

O35.06 CYP3A5 \*1 allele in Tacrolimus-based Immunosuppression: Impacts on Early Acute Cellular Rejection and 12-month Graft Function in Renal Transplantation

S.I. Min, Y.J. Park, S.H. Ahn, I.M. Jung, S.-K. Min, S.J. Kim, J.W. Ha  
Seoul/KOREA

O35.07 A longitudinal study of the mRNA transcriptional evaluation in human kidney allograft dysfunction.

G. Joelsons, E.C. Aquino Dias, R.B. Cupertino, A. Nogare, L.F.S. Gonçalves, R.C. Manfro  
Porto Alegre/BRAZIL



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O35.08 Clinical factors and single nucleotide polymorphisms associated with Chronic Allograft Dysfunction post-kidney transplant

A. Israni, R. Leduc, P. Jacobson, D. Schladt, W. Guan, W. Oetting, A. Matas, . For DeKAF Investigators  
Minneapolis/UNITED STATES OF AMERICA

O35.09 Exploratory and Inferential Statistics for the Discovery of Proteomic Biomarkers of Acute Kidney Allograft Rejection

V. Chen, M. Takhar, G. Cohen-Freue, M. Sasaki, R. Ng, R. Balshaw, P.A. Keown, B. McManus, R. McMaster  
Vancouver/CANADA

### Session O36 Ethics, Public Policy and Economics

**Tuesday, August 17, 2010 03:30 PM - 05:00 PM**

**Room: MR 109 - 110**

Moderators: *Mark . Schnitzler, Zoltan . Kalo*

O36.01 Extending Human Subject Research Protections: A Proposed Ban on Publication of Transplantation Research and Use of Data Involving Executed Prisoners

M. Valapour, A. Bodin  
Minneapolis/UNITED STATES OF AMERICA

O36.02 Ending abuse of organ transplantation in China

D. Matas  
Winnipeg/CANADA

O36.03 Fair Trade Kidney?

M. Moniruzzaman  
East Lansing/UNITED STATES OF AMERICA

O36.04 A Center Coordinated, Pre-transplant Evaluation Eliminates Barriers to Kidney Transplantation and Establishes Parity Across All Socio-economic Groups

F. Barrantes<sup>1</sup>, A. Arvelakis<sup>1</sup>, W. Asch<sup>2</sup>, S. Coca<sup>2</sup>, R. Kalyesubula<sup>1</sup>, M. Bia<sup>2</sup>, R.N. Formica<sup>1</sup>, S. Kulkarni<sup>1</sup>  
<sup>1</sup>New Haven/UNITED STATES OF AMERICA, <sup>2</sup>06520/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O36.05 The Development of Liver Transplant Registry in China

H. Wang, S. Fan  
Hong Kong/HONG KONG

O36.06 European Living Donation and Public Health. EULID project

M. Manyalich<sup>1</sup>, A. Ricart<sup>1</sup>, C. Ballesté<sup>1</sup>, D. Paredes<sup>1</sup>, I. Fehrman-Eckholm<sup>2</sup>, C. Hiesse<sup>3</sup>, L. Dias<sup>4</sup>, P.-D. Line<sup>5</sup>, A. Maxwell<sup>6</sup>, R. Turcu<sup>7</sup>, D. Avsec<sup>8</sup>, G. Kyriakides<sup>9</sup>, A. Nanni Costa<sup>10</sup>, J. Walaszewski<sup>11</sup>  
<sup>1</sup>Barcelona/SPAIN, <sup>2</sup>Göteborg/SWEDEN, <sup>3</sup>Paris/France, <sup>4</sup>Porto/PORTUGAL, <sup>5</sup>Oslo/NORWAY, <sup>6</sup>Bristol/UNITED KINGDOM, <sup>7</sup>Bucharest/ROMANIA, <sup>8</sup>Ljubljana/SLOVENIA, <sup>9</sup>Nicosia/CYPRUS, <sup>10</sup>Roma/ITALY, <sup>11</sup>Warszawa/POLAND

O36.07 Cost-benefit analysis of extended donor coordinator system to increase organ donation rates in Hungary

Z. Kalo<sup>1</sup>, J. Marton<sup>2</sup>, S. Mihaly<sup>1</sup>, P. Gerendy<sup>1</sup>, Z. Kiss<sup>1</sup>  
<sup>1</sup>Budapest/HUNGARY, <sup>2</sup>Szeged/HUNGARY

O36.08 A Business Case for Supporting Liver Alone Organ Donors

C. Stoll, J.D. Punch, A. Kowalczyk, L. Fenton, J. Gray, R. Pietroski  
Ann Arbor/UNITED STATES OF AMERICA

O36.09 Comparison the economic value of different types of organs in renal transplantation

Z. Kalo  
Budapest/HUNGARY

### Session O37 Use of mTOR Inhibitors and MPA II

**Tuesday, August 17, 2010 03:30 PM - 05:00 PM**  
**Room: Ballroom A/B**

Moderators: *Stuart . Flechner, Graeme . Russ*

O37.01 Comparative pharmacokinetics of a sotrastaurin-everolimus versus a cyclosporine-everolimus regimen in de novo kidney transplant recipients

J.M. Kovarik<sup>1</sup>, H. Tedesco-Silva<sup>2</sup>, B. Lien<sup>3</sup>, L. Toselli<sup>4</sup>, S. Vitko<sup>5</sup>, P. Peeters<sup>6</sup>, M. Soergel<sup>1</sup>  
<sup>1</sup>Basel/SWITZERLAND, <sup>2</sup>Sao Paulo/BRAZIL, <sup>3</sup>Oslo/NORWAY, <sup>4</sup>Buenos Aires/ARGENTINA, <sup>5</sup>Prague/CZECH REPUBLIC, <sup>6</sup>Ghent/BELGIUM



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O37.02 Cyclosporine and Tacrolimus Pharmacokinetics in Human Immunodeficiency Virus-Infected Liver and Kidney Transplant Recipients

C. Tan-Tam, L. Frassetto, B. Barin, M. Browne, A. Wolfe, P. Stock, M. Roland, L. Benet  
San Francisco/UNITED STATES OF AMERICA

O37.03 Individual Mycophenolat Dosing Based on IMPDH Measurement Significantly Improves Patients Outcomes After Renal Transplantation

D.K. Abendroth<sup>1</sup>, M. Raggi<sup>1</sup>, S. Siebert<sup>1</sup>, M. Stangl<sup>2</sup>  
<sup>1</sup>Ulm/GERMANY, <sup>2</sup>Munich/GERMANY

O37.04 Population pharmacokinetics of mycophenolic acid and its metabolites in combination with free or reduced doses of calcineurin inhibitors in renal transplant patients: The Symphony sub-study.

H. Colom<sup>1</sup>, A.M. Caldes<sup>2</sup>, F. Oppenheimer<sup>1</sup>, J. Sánchez Plumed<sup>3</sup>, M.A. Gentil<sup>4</sup>, D.M. Kuypers<sup>5</sup>, M. Brunet<sup>1</sup>, H. Ekberg<sup>6</sup>, J.M. Grinyó<sup>1</sup>  
<sup>1</sup>Barcelona/SPAIN, <sup>2</sup>L'Hospitalet De Llobregat/SPAIN, <sup>3</sup>Valencia/SPAIN, <sup>4</sup>Sevilla/SPAIN, <sup>5</sup>Leuven/BELGIUM, <sup>6</sup>Malmo/SWEDEN

O37.05 Pharmacokinetics of Mycophenolate Mofetil and enteric-coated Mycophenolate Sodium in Calcineurininhibitor-free treated renal transplantat patients

J. Gossmann<sup>1</sup>, J. Graff<sup>1</sup>, I. Dragutinovic<sup>1</sup>, G. Brandhorst<sup>2</sup>, E. Scheuermann<sup>1</sup>, M. Oellerich<sup>2</sup>  
<sup>1</sup>Frankfurt/GERMANY, <sup>2</sup>Goettingen/GERMANY

O37.06 Improved Renal Function Achieved With Everolimus Plus Cyclosporine Elimination Compared With Cyclosporine Minimization in Renal Transplant Recipients

J.M. Grinyó<sup>1</sup>, J. Paul<sup>2</sup>, P. Novoa<sup>3</sup>, P. Errasti<sup>4</sup>, A. Franco<sup>5</sup>, G. Aldana<sup>6</sup>, J. Pefaur<sup>7</sup>, F. Oppenheimer<sup>1</sup>  
<sup>1</sup>Barcelona/SPAIN, <sup>2</sup>Zaragoza/SPAIN, <sup>3</sup>Córdoba/ARGENTINA, <sup>4</sup>Pamplona/SPAIN, <sup>5</sup>Alicante/SPAIN, <sup>6</sup>Bogotá/COLOMBIA, <sup>7</sup>Santiago/CHILE

O37.07 EC-MPS is associated with superior efficacy outcomes compared with MMF in de novo renal transplant recipients (RTxR) : a pooled analysis

M. Salvadori<sup>1</sup>, E. Bertoni<sup>1</sup>, K. Budde<sup>2</sup>, H. Holzer<sup>3</sup>, G. Civati<sup>4</sup>, B. Lien<sup>5</sup>, W. Arns<sup>6</sup>  
<sup>1</sup>Florence/ITALY, <sup>2</sup>Berlin/GERMANY, <sup>3</sup>Graz/AUSTRIA, <sup>4</sup>Milano/ITALY, <sup>5</sup>Oslo/NORWAY, <sup>6</sup>KoIn/GERMANY

O37.08 Concentration Controlled Mycophenolate Dosing in Renal Transplantation in India

G. Basu, V.M. Annapandian, B.S. Matthew, K. Saravanakumar, A. Mohapatra, V.G. David, M. Sundaram, S. Varughese, D.H. Fleming, V. Tamarasi, C.K. Jacob, G.T. John  
Vellore/INDIA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O37.09 Lower Incidence of Cytomegalovirus and BK Virus with Everolimus versus Mycophenolate in De Novo Renal Transplant Patients: Results from a Multicenter, Prospective Study

Y.S. Kim<sup>1</sup>, H. Tedesco-Silva<sup>2</sup>, T. Johnston<sup>3</sup>, P.-H. Lee<sup>4</sup>, G. Zibari<sup>5</sup>, R. Walker<sup>6</sup>, K. Mange<sup>7</sup>, C. Panis<sup>7</sup>, Z. Wang<sup>7</sup>, D. Cibrik<sup>8</sup>

<sup>1</sup>Seoul/KOREA, <sup>2</sup>Sao Paulo/BRAZIL, <sup>3</sup>Lexington/UNITED STATES OF AMERICA, <sup>4</sup>Taipei/TAIWAN, <sup>5</sup>Shreveport/UNITED STATES OF AMERICA, <sup>6</sup>Melbourne/AUSTRALIA, <sup>7</sup>East Hanover/UNITED STATES OF AMERICA, <sup>8</sup>Ann Arbor/UNITED STATES OF AMERICA

### Session O38 Malignancy After Transplantation

**Tuesday, August 17, 2010 03:30 PM - 05:00 PM**

**Room: MR 202 - 204**

Moderators: *Edward . Geissler, Ryutaro . Hirose*

O38.01 Risk Stratified Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Defining a New Standard of Care: Results From a Prospective International Multicenter Trial

R.U. Trappe<sup>1</sup>, S. Choquet<sup>2</sup>, V. Leblond<sup>2</sup>, D. Dierickx<sup>3</sup>, P. Mollee<sup>4</sup>, J.M. Zaucha<sup>5</sup>, M. Sender<sup>6</sup>, T. Ekman<sup>6</sup>, P. Reinke<sup>1</sup>, R. Neuhaus<sup>1</sup>, H. Lehmkuhl<sup>1</sup>, M.H. Dreyling<sup>1</sup>, U. Dührsen<sup>7</sup>, G. Salles<sup>8</sup>, F. Morschhauser<sup>9</sup>, A. Jaccard<sup>10</sup>, T. Lamy<sup>11</sup>, I. Anagnostopoulos<sup>1</sup>, M. Raphael<sup>12</sup>, H. Riess<sup>1</sup>

<sup>1</sup>Berlin/GERMANY, <sup>2</sup>Paris/France, <sup>3</sup>Leuven/BELGIUM, <sup>4</sup>Brisbane/AUSTRALIA, <sup>5</sup>Gdynia/POLAND, <sup>6</sup>Gothenburg/SWEDEN, <sup>7</sup>Essen/GERMANY, <sup>8</sup>Pierre-Benite/France, <sup>9</sup>Lille/France, <sup>10</sup>Limoges/France, <sup>11</sup>Rennes/France, <sup>12</sup>Le Kremlin-Bicetre/France

O38.02 IL-6 and TNF alpha plasma levels but not IL-10 plasma levels correlate with response to treatment in patients with PTLD: a longitudinal analysis from the German PTLD registry D 2006-2012

C. Hinrichs, S. Wendland, D. Eurich, R. Neuhaus, P. Schlattmann, B. Gärtner, I. Anagnostopoulos, H. Riess, P. Reinke, R.U. Trappe  
Berlin/GERMANY

O38.03 Colorectal Cancer and Advanced Colorectal Neoplasia in Kidney Transplant Recipients: a prospective screening study comparing Faecal Immunochemical Testing for occult blood with Colonoscopy

M.G. Collins, P.A. Bampton, E. Teo, C. Chan, S.R. Cole, G.P. Young, G.R. Russ, S.P. McDonald, P.T. Coates  
Adelaide/AUSTRALIA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O38.04 Impact of malignancy on patient survival after renal transplantation: a case control population based cohort study

J. van de Wetering<sup>1</sup>, J.I. Roodnat<sup>1</sup>, A.C. Hemke<sup>2</sup>, A.J. Hoitsma<sup>2</sup>, W. Weimar<sup>1</sup>  
<sup>1</sup>Rotterdam/NETHERLANDS, <sup>2</sup>Leiden/NETHERLANDS

O38.05 Modulation of Cellular MicroRNA by Latent Membrane Protein 1 of Epstein Barr Virus in B Cell Lymphomas

A. Harris, P.J. Lund, S.L. Lambert, S.M. Krams, O.M. Martinez  
Stanford/UNITED STATES OF AMERICA

O38.06 Immunosuppressive therapy and risk of post-transplant malignancies in renal transplants: Italian multicentric study.

G. Segoloni<sup>1</sup>, P. Rigotti<sup>2</sup>, S. Sandrini<sup>3</sup>, G. Busnach<sup>4</sup>, S. Stefoni<sup>5</sup>, D. Donati<sup>6</sup>, F. Citterio<sup>7</sup>, G. Piredda<sup>8</sup>, P.G. Messa<sup>4</sup>, P. Veroux<sup>9</sup>, P. Piselli<sup>7</sup>, D. Serraino<sup>10</sup>  
<sup>1</sup>Turin/ITALY, <sup>2</sup>Padova/ITALY, <sup>3</sup>Brescia/ITALY, <sup>4</sup>Milan/ITALY, <sup>5</sup>Bologna/ITALY, <sup>6</sup>Varese/ITALY, <sup>7</sup>Rome/ITALY, <sup>8</sup>Cagliari/ITALY, <sup>9</sup>Catania/ITALY, <sup>10</sup>Aviano (pn)/ITALY

### Session O39 Biologic and Therapeutic Advances in Heart Transplantation II

**Tuesday, August 17, 2010 03:30 PM - 05:00 PM**  
**Room: MR 205 - 207**

Moderators: *Mario . Deng, Debra . Isaac*

O39.01 Targeted Whole Blood Genomic Diagnostic Biomarker Discovery of Acute Heart Rejection

Z. Hollander, V. Chen, J. Wilson-McManus, R. Ng, R. Balshaw, A. Ignaszewski, G. Cohen-Freue, R. McMaster, P.A. Keown, B. McManus  
Vancouver/CANADA

O39.02 Successful reduction of immunosuppression with a novel tolerance protocol in aged, but not in young mice transplanted with cardiac allografts

Q. Liu, Y. Dai, W.J. Shufesky, A.E. Morelli, Z. Wang, Y. Toyoda  
Pittsburgh/UNITED STATES OF AMERICA

O39.03 Total Spinal Blockade With Intrathecal Bupivacaine Preserves Cardiac Contractility in a Large Animal Model of Brainstem Death



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

W.A. Almoustadi, T.W.R. Lee, B. Xiang, R.C. Arora, H.-Y. Lin, G. Tian, D.H. Freed  
Winnipeg/CANADA

039.04 Cardiac Allograft Rejection: Expression and Regulation of the Chemokine Deocy Receptor D6

G. O'Boyle, S. Ali, H. Robertson, J.A. Kirby  
Newcastle Upon Tyne/UNITED KINGDOM

039.05 Cardiac rejection is a Th1 mediated response controlled by donor specific regulatory T cells: No role for Th17 cells

C. Baan, A. Peeters, A.H.M.M. Balk, E. Dijke, W. Weimar  
Rotterdam/NETHERLANDS

039.06 Cardiac allograft rejection correlates with increased expressions of TLR-2, TLR-4 and AIF-1.

D.O. McDaniel, X. Zhou, Z. He, C.K. Moore, G. Aru  
Jackson/UNITED STATES OF AMERICA

039.07 Homocystein, anti-cardiolipin antibodies and soluble CD40 ligand in heart transplant recipients.

O.V. Orlova, A.O. Shevchenko, E.N. Kazakov, A.J. Korner, O.P. Shevchenko  
Moscow/RUSSIAN FEDERATION

039.08 Effect of VEGF Inhibition on Luminal Narrowing and the Pro-Angiogenic Properties of Bone Marrow-Derived Cells

S. Chatur, B. Wong, S. Williams, S. Boroomand, J. Carthy, B. McManus  
Vancouver/CANADA

039.09 Positive Flow Cytometry Crossmatches and Donor-Specific HLA Antibodies May Not Be Contraindications to Heart Transplantation

R.H. Kerman, R. Radovancevic, P. Allison, E. McKissick, J.G. Saltarrelli, R. Bogaev, I. Gregoric, A. Bracey, O.H. Frazier, E. Kelley, C. Adkins, N. Acorda  
Houston/UNITED STATES OF AMERICA

### Session O40 HCC and Living Donor Transplantation

Tuesday, August 17, 2010 03:30 PM - 05:00 PM  
Room: MR 118 - 120



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

Moderators: *Johann . Pratschke, Mark . Cattral*

O40.01 Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepato-cellular carcinoma

C. Toso<sup>1</sup>, S. Merani<sup>2</sup>, D. Bigam<sup>2</sup>, J. Shapiro<sup>2</sup>, N. Kneteman<sup>2</sup>  
<sup>1</sup>Geneva/SWITZERLAND, <sup>2</sup>Edmonton/CANADA

O40.02 Liver Transplantation for Hepatocellular Carcinoma in China

H. Wang<sup>1</sup>, Y. HUANG<sup>2</sup>, W. Li<sup>2</sup>, W. JIANG<sup>2</sup>, S. Fan<sup>1</sup>  
<sup>1</sup>Hong Kong/HONG KONG, <sup>2</sup>Shenzhen/CHINA

O40.03 A pilot study: Sorafenib in patients with post liver transplant recurrence of HCC.

M. Lu, Y. Chen, C. Cai, X. Yi  
Guangzhou/CHINA

O40.04 Surgical Treatment of Hepatocellular Carcinoma: Resection Versus Transplantation

G. Otto, M. Hoppe-Lotichius, F. Bittinger, M. Pitton, M. Schuchmann  
Mainz/GERMANY

O40.05 Changing the landscape of adult to adult living donor liver transplantation: The role of the small for size grafts.

J.F. Botha<sup>1</sup>, A.N. Langnas<sup>1</sup>, C.E. Freise<sup>2</sup>, W.J. Grant<sup>1</sup>, N. Ascher<sup>2</sup>, D.F. Mercer<sup>1</sup>, J.P. Roberts<sup>2</sup>  
<sup>1</sup>Omaha/UNITED STATES OF AMERICA, <sup>2</sup>San Francisco/UNITED STATES OF AMERICA

O40.06 The significance of acute-phase small-for-size liver graft injury in mobilization of circulating EPCs/MDSCs/Tregs after LDLT for HCC patients

K. Man, Y. Shao, K.T. Ng, N. Wong, X. Liu, C. Li, S. Fan, C.-M. Lo  
Hong Kong/HONG KONG

O40.07 291 Dual Living-Donor Liver Transplantation at the Single Center

S.-G. Lee, S. Hwang, K.-H. Kim, C. Ahn, D. Moon, T. Ha, G.-W. Song, J. Dong-Hwan, S.-M. Sim, S.-R. Kim  
Seoul/KOREA

O40.08 Living donor liver transplantation for adult patients using left liver graft



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. Kawasaki<sup>1</sup>, Y. Ishizaki<sup>1</sup>, H. Imamura<sup>1</sup>, H. Sugo<sup>1</sup>, J. Yoshimoto<sup>1</sup>, S. Miyagawa<sup>2</sup>  
<sup>1</sup>Tokyo/JAPAN, <sup>2</sup>Matsumoto/JAPAN

O40.09 The potential role of early-phase graft injury in induction of late-phase chemoresistance after liver transplantation

W. Geng, K. Man, Q. Cheng, K.T.P. Ng, X.B. Liu, Y. Liu, R.T.P. Poon, S.T. Fan, C.M. Lo  
Hong Kong/HONG KONG

#### Session O41 Transplantation in ABO Mismatched and Sensitized Recipients

**Tuesday, August 17, 2010 03:30 PM - 05:00 PM**  
**Room: Ballroom C**

Moderators: *Gunnar . Tyden, James . Gloor*

O41.01 Results from an Australian National ABO Incompatible (ABOI) Renal Transplant Collaborative Group

K.R. Wyburn<sup>1</sup>, S.B. Campbell<sup>2</sup>, P.T. Coates<sup>3</sup>, A. Irish<sup>4</sup>, J. Kanellis<sup>5</sup>, W. Mulley<sup>5</sup>, G.R. Russ<sup>3</sup>, P. Trevillian<sup>6</sup>,  
F. Ierino<sup>7</sup>, J. Eris<sup>1</sup>  
<sup>1</sup>Sydney/AUSTRALIA, <sup>2</sup>Brisbane/AUSTRALIA, <sup>3</sup>Adelaide/AUSTRALIA, <sup>4</sup>Perth/AUSTRALIA,  
<sup>5</sup>Clayton/AUSTRALIA, <sup>6</sup>Newcastle/AUSTRALIA, <sup>7</sup>Heidelberg/AUSTRALIA

O41.02 Evolution of Immunosuppressive Regimen in 417 Cases of ABO-incompatible Kidney Transplantation in Single Center.

S. Teraoka, I. Koyama, T. Murakami, I. Nakajima, S. Fuchinoue, H. Ishida, K. Tanabe  
Tokyo/JAPAN

O41.03 Desensitization protocol with antibody-specific immunoabsorption strongly interferes with complement activation in ABO-incompatible kidney transplantation

A.-R. Biglarnia, B. Nilsson, G. Tufveson, T. Nilsson, J. Wadström  
Uppsala/SWEDEN

O41.04 Acute Rejection in Living Donor ABO-incompatible kidney transplantation

D. Polanska-Tamborek, G. Nordén, M. Gäbel, L. Mjörnstedt, I. Fehrman-Ekholm  
Göteborg/SWEDEN

O41.05 Unmasking Donor Specific Antibodies in Patients with Antibody Mediated Rejection



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

W.R. Mulley<sup>1</sup>, L. Cantwell<sup>2</sup>, F. Hudson<sup>2</sup>, L. Huang<sup>1</sup>, R. Holdsworth<sup>2</sup>, S. Cohny<sup>3</sup>, J. Kanellis<sup>1</sup>  
<sup>1</sup>Clayton/AUSTRALIA, <sup>2</sup>Melbourne/AUSTRALIA, <sup>3</sup>Parkville/AUSTRALIA

O41.06 The significance of IgG subclasses in HLA antibody incompatible kidney transplantation.

D. Lowe<sup>1</sup>, R. Higgins<sup>2</sup>, D. Zehnder<sup>2</sup>, M. Hathaway<sup>1</sup>, R. Hamer<sup>2</sup>, N. Krishnan<sup>2</sup>, D. Briggs<sup>1</sup>  
<sup>1</sup>Birmingham/UNITED KINGDOM, <sup>2</sup>Coventry/UNITED KINGDOM

O41.07 Clinical significance of de novo production of HLA donor-specific antibodies in kidney transplantation.

A. Piazza, E. Poggi, G. Ozzella, D. Caputo, R. Cremona, G. Iaria, G. Tisone, D. Adorno  
Rome/ITALY

O41.08 Significance of qualitative and quantitative evaluations of anti-HLA antibodies in kidney transplantation

H. Ishida, T. Shimizu, H. Shirakawa, K. Omoto, K. Tanabe  
Tokyo/JAPAN

O41.09 Low levels of donor-specific HLA antibody at transplantation are associated with an early resynthesis response

R. Higgins<sup>1</sup>, D. Lowe<sup>2</sup>, D. Zehnder<sup>1</sup>, M. Hathaway<sup>2</sup>, N. Krishnan<sup>1</sup>, R. Hamer<sup>1</sup>, H. Kashi<sup>1</sup>, F.T. Lam<sup>1</sup>, L.C. Tan<sup>1</sup>, C. Imray<sup>1</sup>, D. Briggs<sup>2</sup>  
<sup>1</sup>Coventry/UNITED KINGDOM, <sup>2</sup>Birmingham/UNITED KINGDOM

### Session O42 Clinical Pancreas Transplantation I

**Tuesday, August 17, 2010 03:30 PM - 05:00 PM**  
**Room: MR 212 - 214**

Moderators: *John . Najarian, Mark . Meloche*

O42.01 Simultaneous Pancreas and Kidney Transplantation from ABO-incompatible Living Donors. – Outcome of Six Consecutive Clinical Trials in a Single Institution–

T. Kenmochi<sup>1</sup>, T. Asano<sup>1</sup>, K. Saigo<sup>1</sup>, M. Maruyama<sup>2</sup>, N. Akutsu<sup>2</sup>, C. Iwashita<sup>2</sup>, K. Otsuki<sup>2</sup>, T. Ito<sup>2</sup>, A. Suzuki<sup>1</sup>  
<sup>1</sup>Chiba City/JAPAN, <sup>2</sup>Chiba/JAPAN



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O42.02 Risk factors for technical failure after Pancreas (px) Transplant (tx) - single center analysis of over 1000 tx in a decade

R. Kandaswamy, T. Pruett, D. Radosevich, B. Bland, J.J. Stone, R.P. Singh, D. Borja, D.E. Sutherland  
Minneapolis/UNITED STATES OF AMERICA

O42.03 Improvement of Patient and Graft Survival in Pancreas Transplants Alone (PTA)

A.C. Gruessner, D.E.R. Sutherland, R.W.G. Gruessner  
Tucson/UNITED STATES OF AMERICA

O42.04 Endoscopic biopsy as a new tool for immunological monitoring after pancreas transplantation

C. Margreiter<sup>1</sup>, T. Resch<sup>1</sup>, A.-K. Berenji<sup>1</sup>, R. Oberhuber<sup>1</sup>, C. Boesmueller<sup>1</sup>, H. Bonatti<sup>2</sup>, R. Margreiter<sup>1</sup>, J. Pratschke<sup>1</sup>, W. Mark<sup>1</sup>  
<sup>1</sup>Innsbruck/AUSTRIA, <sup>2</sup>Charlottesville/UNITED STATES OF AMERICA

O42.05 Portal Venous Drainage of Pancreas Grafts: Impact on Long-Term Results

F. Bazerbachi, M. Selzner, M. Marquez, A. Norgate, I.D. McGilvray, J. Schiff, M.S. Cattral  
Toronto/CANADA

O42.06 Cross sectional report of first year clinical outcomes in a cohort of simultaneous pancreas kidney transplant recipients with an immunosuppressive regimen containing everolimus

L. Reniero, G. Illanes, D. Casadei  
Buenos Aires/ARGENTINA

O42.07 Pancreas Transplant Alone in Type 1 Diabetic Recipients with Overt Diabetic Nephropathy: Renal Function Outcome

U. Boggi, F. Vistoli, C. Croce, S. Signori, C. Moretto, M. Del Chiaro, G. Amorese, M. Barsotti, P. Marchetti  
Pisa/ITALY

O42.08 Significant Interaction Between Donor and Recipient Age in Patients Undergoing Simultaneous Kidney/Pancreas Transplantation

P. Garzon<sup>1</sup>, V. Krishnamurthi<sup>2</sup>, J. Sokolich<sup>1</sup>, L.K. Kayler<sup>1</sup>, J.D. Schold<sup>2</sup>, J.F. Magliocca<sup>1</sup>  
<sup>1</sup>Gainesville/UNITED STATES OF AMERICA, <sup>2</sup>Cleveland/UNITED STATES OF AMERICA

O42.09 Portal Venous Drainage of Pancreas Allografts Offers No Survival Benefit to Patients Undergoing SPK and May Result in Higher Early Rejection Rates



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

J. Sokolich<sup>1</sup>, V. Krishnamurthi<sup>2</sup>, P. Garzon<sup>1</sup>, L.K. Kayler<sup>1</sup>, J.D. Schold<sup>2</sup>, J.F. Magliocca<sup>1</sup>  
<sup>1</sup>Gainesville/UNITED STATES OF AMERICA, <sup>2</sup>Cleveland/UNITED STATES OF AMERICA



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

### WEDNESDAY, AUGUST 18

#### 07:00 – 08:15 SUNRISE SYMPOSIA

**Session SUN12 TTS/IPTA Symposium on Pediatric Transplantation: Overcoming barriers to successful organ transplantation in children**

**Wednesday, August 18, 2010 07:00 AM - 08:15 AM**

**Room: MR 212 - 214**

Moderators: *Anne . Dipchand, Richard . Fine*

SUN12.1 Obstacles to generating evidence for pediatric practice: the need for randomized controlled trials in children

T. Klassen

Edmonton/CANADA

SUN12.2 Drug approval in children and the CTOT-C program

B. Harmon

SUN12.3 Ethical issues related to organ donation and transplantation in children: a global perspective

S.V. McDiarmid

Los Angeles/UNITED STATES OF AMERICA

SUN12 - DISCUSSION

**Session SUN13 Xenotransplantation: From the lab to the clinic**

**Wednesday, August 18, 2010 07:00 AM - 08:15 AM**

**Room: MR 202 - 204**

Moderators: *Henk-Jan . Schuurman, David . Cooper*

SUN13.1 Current status of xenotransplantation and prospects for clinical application



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

R.N. Pierson III

Baltimore/UNITED STATES OF AMERICA

SUN13.2 Update on clinical trials in xenotransplantation

B. Elliott

SUN13.3 Regulatory issues in the transition to clinical therapy

K. Wonnacott

Rockville/UNITED STATES OF AMERICA

SUN13 - DISCUSSION

#### **Session SUN14 Complications of transplantation**

**Wednesday, August 18, 2010 07:00 AM - 08:15 AM**

**Room: MR 205 - 207**

Moderators: *Alan . Jardine, Domingo . Casadei*

SUN14.1 Biology and biomarkers of accelerated cardiovascular disease in transplantation

B. Fellstrom

Uppsala/SWEDEN

SUN14.2 Prediction and prevention of the metabolic syndrome in transplantation

B. Kasiske

Minneapolis/UNITED STATES OF AMERICA

SUN14.3 Incidence and epidemiology of disease recurrence after transplantation

C. Legendre

Paris/France

SUN14 - DISCUSSION



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

#### **Session SUN15 Detection and monitoring of antibodies prior to transplantation**

**Wednesday, August 18, 2010 07:00 AM - 08:15 AM**

**Room: MR 217 - 219**

Moderators: *Phil . Dyer, Maria . Gerbase-DeLima*

SUN15.1 Antibody monitoring for patients on the routine waiting list

P.A. Dyer

Edinburgh/UNITED KINGDOM

SUN15.2 Determination and use of the calculated PRA

M.S. Leffell

Baltimore/UNITED STATES OF AMERICA

SUN15.3 The immunology laboratory in clinical desensitization

A.A. Zachary

Baltimore/UNITED STATES OF AMERICA

SUN15.4 The virtual crossmatch and its implications

N. Reinsmoen

Los Angeles/UNITED STATES OF AMERICA

SUN15 - DISCUSSION

#### **Session SUN16 The Biology of Patient Care**

**Wednesday, August 18, 2010 07:00 AM - 08:15 AM**

**Room: MR 211**

Moderators: *Chris . Shay, Norine . Heywood*

SUN16.1 Defining the sensitized patient: How to identify what you hope not to find.



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

L.G. Hidalgo  
Edmonton/CANADA

SUN16 - DISCUSSION

SUN16.2 Future Directions - Genetic markers of rejection

P.A. Keown  
Vancouver/CANADA

SUN16 - DISCUSSION

### **08:30 – 10:00 PLENARY SESSION**

#### **Session PL03 Stem Cells and Regeneration**

**Wednesday, August 18, 2010 08:30 AM - 10:00 AM**  
**Room: Ballroom A/B**

Moderators: *Kathryn . Wood, Lee Anne . Tibbles*

PL03.1 Generation, Programming and Applications of Induced Pluripotent Stem Cells

H.R. Schoeler  
Muenster/GERMANY

PL03.2 Advances in Regenerative Biology and Organ Biogenesis

D. Taylor  
City/UNITED STATES OF AMERICA

PL03.3 Lung Repair, Regeneration and Transplantation

S. Keshavjee  
Toronto/CANADA



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

### 08:30 – 10:00 PLENARY SESSION

#### Session PRS President's Plenary Symposium

Wednesday, August 18, 2010 10:00 AM - 12:00 PM  
Room: Ballroom A/B

Moderators: *Jeremy . Chapman, Nicholas . Tilney*

PRS.1 Presidential Address

J.R. Chapman  
Westmead/AUSTRALIA

PRS.2 Opportunities and Obstacles in Translational Medicine

C. Stiller  
London/CANADA

PRS.3 The Science and Technology of Cell Identity

S. Brenner  
UNITED STATES OF AMERICA

### 12:15 – 13:15 MINI ORAL SESSIONS

#### Session MO15 Immunological Monitoring

Wednesday, August 18, 2010 12:15 PM - 01:15 PM  
Room: MR 202 - 204

Moderators: *Manikkam . Suthanthiran, Pekka . Hayry*

MO15.01 Flow Cytometry Crossmatches Are Influenced by Levels of HLA Expression on Donor Lymphocytes

L.A.T. Baxter-Lowe, L.A. Baxter-Lowe  
San Francisco/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO15.02 Sequential analysis by immunoprecipitation-MALDI-TOF mass spectrometry for detection and identification of alloantibody specificities

A. Heinold<sup>1</sup>, B. Kuehl<sup>2</sup>, G. Brenner-Weiss<sup>2</sup>, G. Opelz<sup>1</sup>, T.H. Tran<sup>1</sup>  
<sup>1</sup>Heidelberg/GERMANY, <sup>2</sup>Eggenstein-Leopoldshafen/GERMANY

MO15.03 Post-Transplant HLA antibodies Detected by Luminex Donor-Specific Crossmatch Correlate with Poor Liver Graft Outcome

F. Monteiro, H. Rodrigues, J.E. Kalil-Filho, M. Paredes, P. Massarolo, S. Mies, M.C. Ribeiro de Castro  
Sao Paulo/BRAZIL

MO15.04 Phosphospecific Flow Cytometry demonstrates CNI based Inhibition of P38 MAP Kinase in Renal Allograft Patients

R. Vafadari, M. Quaedackers, W.M. Mol, W. Weimar, C.C. Baan  
Rotterdam/NETHERLANDS

MO15.05 The Differential Effects of Tacrolimus and Sirolimus in the Human "Treg-MLR"

J. Levitsky, L. Gallon, J. Miller, J. Leventhal, A. Tambur, X. Huang, C. Flaa, E. Wang, J.M. Mathew  
Chicago/UNITED STATES OF AMERICA

MO15.06 Increased pretransplant plasma Kynurenine levels do not protect from but predict acute kidney allograft rejection

I. LAHDOU  
Heidelberg/GERMANY

MO15.07 Graft Inflammation And Histological Indicators of Kidney Chronic Allograft Failure: Genetic predisposition to Low Expressing Interleukin-10 Genotypes is significantly correlated

F.M. Khan, A. Sar, I.I. Gonul, J. Doulla, S. Yilmaz, N. Berka  
Calgary/CANADA

MO15.08 Genetic analysis of human B lymphocyte repertoire specific to ABO blood group antigens

X. Fan, R. Yin, G. Wong, D. Cheung, Q. Wu, R. Satkunasivam, L.J. West  
Edmonton/CANADA

MO15.09 More than thousand successful deceased donor renal transplants without current serum pre-transplant crossmatch.



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. Vaidya

Galveston, UNITED STATES OF AMERICA

MO15.10 Testing for donor-specific anti-endothelial antibodies using the XM-One assay

A. Tambur, W. Wegner, N. Herrera, K. Mandal, A. Brain, P. Gough, S. McDaniel, D. ramon, J. Friedewald  
Chicago/UNITED STATES OF AMERICA

MO15.11 Correlation of B cell positive flow crossmatch and donor specific class II HLA antibody detected by Luminex

J. Downing, P. Dunn

Auckland/NEW ZEALAND

### Session MO16 Organ Donation, Preservation and Allocation

**Wednesday, August 18, 2010 12:15 PM - 01:15 PM**

**Room: MR 109 - 110**

Moderators: *Axel . Rahmel, Paul . Robertson*

MO16.01 Bayesian Modeling of the United States Renal Data System Pre-Transplant Variables Accurately Predicts Graft Survival

K.A. Stevens<sup>1</sup>, S. Phinney<sup>2</sup>, C. Graybill<sup>2</sup>, S. Gillern<sup>2</sup>, M. Salifu<sup>3</sup>, R. Jindal<sup>2</sup>, T. Brown<sup>1</sup>, E. Elster<sup>1</sup>

<sup>1</sup>Silver Spring/UNITED STATES OF AMERICA, <sup>2</sup>Dc/UNITED STATES OF AMERICA, <sup>3</sup>Brooklyn/UNITED STATES OF AMERICA

MO16.02 Expanded criteria donor kidneys for younger recipients- Acceptable Outcomes

K.R. Goplani, P.R. Shah, A.V. Vanikar, P.R. Modi, M.R. Gumber, H.V. Patel, H.L. Trivedi  
Ahmedabad/INDIA

MO16.03 Heavy water containing organ preservation solution, Dsol, ameliorates graft survival and function of the rat hearts after extended cold preservation

K. Wakayama<sup>1</sup>, M. Fukai<sup>1</sup>, K. Yamashita<sup>1</sup>, D. Fukumori<sup>1</sup>, S. Shibasaki<sup>1</sup>, H. Gentaro<sup>1</sup>, M. Zaitzu<sup>1</sup>, Y. Tsunetoshi<sup>1</sup>, M. Sugawara<sup>1</sup>, M. Taniguchi<sup>1</sup>, T. Suzuki<sup>1</sup>, T. Shimamura<sup>1</sup>, H. Furukawa<sup>2</sup>, M. Ozaki<sup>1</sup>, S. Todo<sup>1</sup>

<sup>1</sup>Sapporo/JAPAN, <sup>2</sup>Asahikawa/JAPAN

MO16.04 Renal Transplantation Following Donation after Cardiac Death (DCD): Impact of Duration From Withdrawal to Asystole



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

P.J. Goldsmith, J.K. Pine, D.M. Ridgway, C. Ecuier, S. Pollard, M. Attia, K.V. Menon, N. Ahmad  
Leeds/UNITED KINGDOM

MO16.05 Sequential transplant of paired kidneys following donation after cardiac death (DCD): Impact of Longer Cold Ischaemia time on the second kidney on graft and patient outcome.

P.J. Goldsmith, D.M. Ridgway, J.K. Pine, C. Ecuier, R. Baker, C. Newstead, L. Hostert, S. Pollard, M. Attia, K.V. Menon, N. Ahmad  
Leeds/UNITED KINGDOM

MO16.06 Impact of Donor Age on Outcome of Kidney Transplantation from Controlled Donation after Cardiac Death

T.A.K. Rana, E. Fitzgerald, J.A. Akoh  
Plymouth/UNITED KINGDOM

MO16.07 Extracorporeal normothermic abdominal perfusion "in situ" by leukocytes-free oxygenated blood as resuscitation practice for kidneys from uncontrolled donors with one-hour warm ischemic time

O. Reznik<sup>1</sup>, A. Ananyev<sup>1</sup>, I. Loginov<sup>1</sup>, A. Skvortcov<sup>1</sup>, S. Bagnenko<sup>1</sup>, Y. Mousyuk<sup>2</sup>  
<sup>1</sup>Saint-Petersburg/RUSSIAN FEDERATION, <sup>2</sup>Moscow/RUSSIAN FEDERATION

MO16.08 Outcomes Following Renal Transplantation after Multi-Organ Retrieval versus Kidney Only Retrieval in Donation after Cardiac Death Donors

P.J. Goldsmith, D.M. Ridgway, J.K. Pine, G. Speak, C. Newstead, A.J. Lewington, K.V. Menon, N. Ahmad, M. Attia  
Leeds/UNITED KINGDOM

MO16.09 Exploding the myths: the real potential for lung transplantation from Donation-after-Cardiac-Death (DCD) donor lungs

G.I. Snell, B. Levvey, A. Griffiths, S. Graham, D. Pilcher  
Melbourne/AUSTRALIA

MO16.10 Machine Measured Renal Resistance (MMRR) is the most sensitive tool for prediction of early renal allograft survival.

Y.Y. Yushkov, J. Alvarez-Casas, S. Dikman, A. Ying, W. Tajik, H.A. Lerner, J.A. Lewis, E.R. Obasare, M. Sheth, M.J. Goldstein  
New York/UNITED STATES OF AMERICA

MO16.12 Important characteristics of heavy water (D2O) containing cold preservation solution



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

M. Fukai<sup>1</sup>, K. Wakayama<sup>1</sup>, K. Yamashita<sup>1</sup>, D. Fukumori<sup>1</sup>, M. Sugawara<sup>1</sup>, S. Haga<sup>1</sup>, H. Furukawa<sup>2</sup>, M. Ozaki<sup>1</sup>, S. Todo<sup>1</sup>

<sup>1</sup>Sapporo/JAPAN, <sup>2</sup>Asahikawa/JAPAN

#### Session MO17 CNI Minimization Strategies

**Wednesday, August 18, 2010 12:15 PM - 01:15 PM**

**Room: MR 211**

Moderators: *Yvon . Lebranchu, Daniel . Seron*

MO17.01 Sirolimus-based calcineurin inhibitor-free immunosuppressive therapy in renal allograft recipients receiving kidneys from older donors – a randomised study conducted in Sweden and Norway

O. Øyen<sup>1</sup>, G. Tufveson<sup>2</sup>, B. Izay<sup>3</sup>, E. Ingman<sup>3</sup>, L. Wramner<sup>4</sup>

<sup>1</sup>Oslo/NORWAY, <sup>2</sup>Uppsala/SWEDEN, <sup>3</sup>SoIna/SWEDEN, <sup>4</sup>Gothenburg/SWEDEN

MO17.02 Calcineurin-Free Immunosuppression In Non-Heart-Beating Donor Kidney Transplant Recipients

F. Oppenheimer, V. De la Fuente, N. Esforzado, I. Revuelta, F. Cofan, V. Torregrosa, M.J. Ricart, J.M. Campistol

Barcelona/SPAIN

MO17.03 Full Dose Mycophenolate Mofetil (CellCept®) With Low Dose Tacrolimus Optimizes Renal Function in Long Term Renal Transplant Patients; Results Of The TranCept STAY Study

U. Heemann<sup>1</sup>, V. Kliem<sup>2</sup>, A. Hamza<sup>3</sup>, K. Budde<sup>4</sup>, F. Juarez de la Cruz<sup>5</sup>, W. Arns<sup>6</sup>, C. Gahlemann<sup>7</sup>, J.S. Juergensen<sup>4</sup>, H. Haller<sup>8</sup>

<sup>1</sup>Muenchen/GERMANY, <sup>2</sup>Hann. Münden/GERMANY, <sup>3</sup>Halle/Saale/GERMANY, <sup>4</sup>Berlin/GERMANY, <sup>5</sup>Torreón/MEXICO, <sup>6</sup>Koeln-Merheim/GERMANY, <sup>7</sup>Basel/SWITZERLAND, <sup>8</sup>Hannover/GERMANY

MO17.04 Impact of early conversion at 3 months from Cyclosporine ( CsA) to Sirolimus ( SRL) in association with Mycophenolate Mofetil ( MMF) on renal function

Y. LEBRANCHU<sup>1</sup>, O. TOUPANCE<sup>1</sup>, G. TOUCHARD<sup>1</sup>, E. THERVET<sup>1</sup>, I. ETIENNE<sup>1</sup>, P. WESTEEL<sup>1</sup>, B. HURAUULT DE LIGNY<sup>1</sup>, B. MOULIN<sup>1</sup>, J. REROLLE<sup>1</sup>, T. FOURGET<sup>1</sup>, L. SAADA<sup>2</sup>, M. BUCHLER<sup>1</sup>

<sup>1</sup>Tours/France, <sup>2</sup>Neuilly Sur Seine/France

MO17.05 Conversion from tacrolimus to sirolimus-based immunosuppressive regimen in kidney transplant recipients. Preliminary results



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

J.O. Medina-Pestana<sup>1</sup>, V.D. Garcia<sup>2</sup>, E. David-Neto<sup>1</sup>, D.D.B.M. Carvalho<sup>3</sup>, F.L. Contieri<sup>4</sup>, M. Abbud-Filho<sup>5</sup>,  
H. Tedesco Silva<sup>1</sup>, E. Ikehara<sup>1</sup>

<sup>1</sup>Sao Paulo/BRAZIL, <sup>2</sup>Porto Alegre/BRAZIL, <sup>3</sup>Rio De Janeiro/BRAZIL, <sup>4</sup>Curitiba/BRAZIL, <sup>5</sup>Sao Jose Do Rio Preto/BRAZIL

MO17.06 Conversion To Low Dose Tacrolimus or Rapamycin 3 Months After Kidney Transplant: A Prospective, Protocol Biopsy Guided Study

O. Pankewycz, M. Said, L. Feng, S.K. Patel, M. Alnimri, R. Kohli, M.R. Laftavi  
Buffalo/UNITED STATES OF AMERICA

MO17.07 De novo Everolimus With Early Elimination of Cyclosporine Provides Better Renal Function at Month 12 in Renal Transplant Patients With Higher Month 3 Renal Function and Graft Survival

J.M. Grinyó<sup>1</sup>, J. Paul<sup>2</sup>, P. Novoa<sup>3</sup>, P. Errasti<sup>4</sup>, A. Franco<sup>5</sup>, G. Aldana<sup>6</sup>, J. Pefaur<sup>7</sup>, F. Oppenheimer<sup>1</sup>  
<sup>1</sup>Barcelona/SPAIN, <sup>2</sup>Zaragoza/SPAIN, <sup>3</sup>Córdoba/ARGENTINA, <sup>4</sup>Pamplona/SPAIN, <sup>5</sup>Alicante/SPAIN,  
<sup>6</sup>Bogotá/COLOMBIA, <sup>7</sup>Santiago/CHILE

MO17.08 Better Renal Allograft Function with Everolimus Facilitated CNI Reduction - Graft Type, Donor Criteria and Gender Analysis

L. Chan<sup>1</sup>, H. Riad<sup>2</sup>, G. Tufveson<sup>3</sup>, D.M. Cibrik<sup>4</sup>, H. Tedesco-Silva<sup>5</sup>, H. Schwende<sup>6</sup>, Z. Wang<sup>7</sup>, G. Junge<sup>6</sup>  
<sup>1</sup>Aurora/UNITED STATES OF AMERICA, <sup>2</sup>Manchester/UNITED KINGDOM, <sup>3</sup>Uppsala/SWEDEN, <sup>4</sup>Ann Arbor/UNITED STATES OF AMERICA, <sup>5</sup>Sao Paulo/BRAZIL, <sup>6</sup>Basel/SWITZERLAND, <sup>7</sup>East Hanover/UNITED STATES OF AMERICA

MO17.09 Cyclosporine (CyA) very low dose with Everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC-MPS

E. Bertoni, G. Rosso, A. Larti, L. Di Maria, M. Zanazzi, M. Salvadori  
Florence/ITALY

MO17.10 60% Reduction in Cyclosporine Exposure with Everolimus Over 12 Months in De Novo Renal Transplant Recipients: Results from a Multicenter, Randomized Study

E. Lackova<sup>1</sup>, D. Cibrik<sup>2</sup>, T. Johnston<sup>3</sup>, Y.S. Kim<sup>4</sup>, G. Civati<sup>5</sup>, R. Walker<sup>6</sup>, G. Zibari<sup>7</sup>, K. Mange<sup>8</sup>, C. Panis<sup>8</sup>,  
Z. Wang<sup>8</sup>, H. Tedesco-Silva<sup>9</sup>

<sup>1</sup>Banská Bystrica/SLOVAK REPUBLIC, <sup>2</sup>Ann Arbor/UNITED STATES OF AMERICA, <sup>3</sup>Lexington/UNITED STATES OF AMERICA, <sup>4</sup>Seoul/KOREA, <sup>5</sup>Milano/ITALY, <sup>6</sup>Melbourne/AUSTRALIA, <sup>7</sup>Shreveport,/UNITED STATES OF AMERICA, <sup>8</sup>East Hanover/UNITED STATES OF AMERICA, <sup>9</sup>Sao Paulo/BRAZIL

MO17.11 Conversion to Tacrolimus QD (Advagraf) from ciclosporin reduces ciclosporin-related side effects: results from CONCERTO



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

M. Glyda<sup>1</sup>, L. Rostaing<sup>2</sup>, A. Sánchez-Fructuoso<sup>3</sup>  
<sup>1</sup>Poznan/POLAND, <sup>2</sup>Toulouse/France, <sup>3</sup>Madrid/SPAIN

#### Session MO18 Innovations in Heart Transplantation I

Wednesday, August 18, 2010 12:15 PM - 01:15 PM  
Room: MR 205 - 207

Moderators: *Jon . Kobashigawa, Andreas . Zuckermann*

MO18.01 Proton Pump Inhibitors Impact Cyclosporine Dose/Exposure Relation in De Novo HTxR Treated with MMF or Everolimus – Emphasis of Therapeutic Drug Monitoring

C. Bara<sup>1</sup>, G. Laufer<sup>2</sup>, M.G. Crespo<sup>3</sup>, T.J. Dengler<sup>4</sup>, A. Karpov<sup>5</sup>, L. Potena<sup>6</sup>, H. Schwende<sup>5</sup>, S. Varnous<sup>7</sup>, G. Junge<sup>5</sup>

<sup>1</sup>Hannover/GERMANY, <sup>2</sup>Wien/AUSTRIA, <sup>3</sup>Coruna/SPAIN, <sup>4</sup>Heidelberg/GERMANY, <sup>5</sup>Basel/SWITZERLAND, <sup>6</sup>Bologna/ITALY, <sup>7</sup>Paris/France

MO18.02 IgG immune restoration after intravenous immunoglobulin replacement therapy in heart recipients with post transplant antibody deficiency

J. Carbone, N. Del Pozo, J. Rodriguez-Molina, J. Navarro, A. Gallego, J. Fernandez-Yañez, J. Palomo, P. Muñoz, M. Ruiz, E. Sarmiento  
Madrid/SPAIN

MO18.03 Hormonal status influences adaptive and maladaptive signaling after mTOR inhibition in female cardiomyocytes

A. Kusch, M. Schmidt, R. Catar, B. Hegner, D. Dragun  
Berlin/GERMANY

MO18.04 Angiographic Stanford type B2 lesions indicate post-cardiac transplant microvascular dysfunction as assessed by Doppler flow velocity measurements

N.E. Hiemann<sup>1</sup>, R. Meyer<sup>2</sup>, H.B. Lehmkuhl<sup>1</sup>, C. Knosalla<sup>1</sup>, R. Hetzer<sup>1</sup>, E. Wellenhofer<sup>1</sup>  
<sup>1</sup>Berlin/GERMANY, <sup>2</sup>Nerlin/GERMANY

MO18.06 Both dopamine and its derivate N-Octanoyl-Dopamine protect cardiomyocytes against cold preservation injury

B. Yard, C. Hepp, C. Vettel, U. Benck, P. Schnuelle, S. Hoeger  
Mannheim/GERMANY



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO18.07 T-helper 1 cells play a key role in the fibro-proliferative response in Cardiac Allograft Vasculopathy.

R. De Weger, E. Sierra - de Koning, J. van Kuik, D.F. van Wichen, M.E. Schipper, K. Timmermans, H.F.J. Dullens, N. de Jonge  
Utrecht/NETHERLANDS

MO18.08 Everolimus prevents clinically silent, biopsy-proven antibody-mediated rejection in cardiac transplant recipients

N.E. Hiemann<sup>1</sup>, E. Wellnhofer<sup>1</sup>, H.B. Lehmkuhl<sup>1</sup>, C. Knosalla<sup>1</sup>, R. Hetzer<sup>1</sup>, R. Meyer<sup>2</sup>  
<sup>1</sup>Berlin/GERMANY, <sup>2</sup>Nerlin/GERMANY

MO18.09 Estimation of Cardiovascular Risk in 1007 Heart Transplants Recipients – The Framingham Risk Score

A. Zuckermann<sup>1</sup>, C. Bara<sup>2</sup>, H. Eisen<sup>3</sup>, A. Karpov<sup>4</sup>, J. Kobashigawa<sup>5</sup>, H.B. Lehmkuhl<sup>6</sup>, H. Ross<sup>7</sup>, H. Schwende<sup>4</sup>, G. Junge<sup>4</sup>  
<sup>1</sup>Vienna/AUSTRIA, <sup>2</sup>Hannover/GERMANY, <sup>3</sup>Philadelphia/UNITED STATES OF AMERICA,  
<sup>4</sup>Basel/SWITZERLAND, <sup>5</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>6</sup>Berlin/GERMANY, <sup>7</sup>Toronto/CANADA

MO18.10 Combined heart and liver transplantation for congenital heart disease and end-stage liver cirrhosis

Y. Toyoda, C. Bermudez, R. Kormos, J. Bhama, J. Thacker, T. Horai, B. Sareyyupoglu, P. Bonde, A. Bansal, N. Shigemura, A. Humar, P. FONTES  
Pittsburgh/UNITED STATES OF AMERICA

MO18.11 Biomarkers of Chronic Heart Allograft Rejection

D. Lin, G. Cohen Freue, A. Bergman, Z. Hollander, M. Sasaki, J. Wilson-McManus, R. Balshaw, R. Ng, P. Keown, R. McMaster, B. McManus  
Vancouver/CANADA

MO18.12 Efficacy of CPRA and virtual crossmatch is negatively impacted by false positive reactivity resulted from denatured HLA Class I antigens present on Luminex as well as Flow single antigen beads.

S. Vaidya  
Galveston,/UNITED STATES OF AMERICA

### Session MO19 Interventions and Outcomes in Liver Transplantation I



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

**Wednesday, August 18, 2010 12:15 PM - 01:15 PM**

**Room: MR 217 - 219**

Moderators: *Pierre . Clavien, Andrej . Buczkowski*

MO19.01 Evolution of Nonalcoholic Steatohepatitis in Liver Transplantation: Frequency and Comparative Outcomes of the SRTR database

M.R. Charlton, J.M. Burns, J. Heimbach, K. Watt, R. Pedersen, R. Dierkhising  
Rochester/UNITED STATES OF AMERICA

MO19.02 The Codman classification applied in liver transplantation: a tool for quality control and improvement of outcomes

J. Moon, A. Tzakis, S. Koonce  
Miami/UNITED STATES OF AMERICA

MO19.03 The influence of alcohol abuse history on the differential, longitudinal patterns of mental and physical quality of life following liver transplant

A. Eshelman, M. Abouljoud, T. Meyer, D. Fischer, D. Moonka, D. Paulson, K. Brown  
Detroit/UNITED STATES OF AMERICA

MO19.04 Predictors of 30 day readmissions; an analysis to identify what the cost of these are and what we might modify to reduce these.

R. Gilroy<sup>1</sup>, J. Sabah<sup>2</sup>, S. Govindan<sup>2</sup>, M. Waldron<sup>2</sup>, A.T. atav@ksu.edu<sup>3</sup>, J. Kindscher<sup>2</sup>  
<sup>1</sup>UNITED STATES OF AMERICA, <sup>2</sup>Kansas City/UNITED STATES OF AMERICA, <sup>3</sup>Manhattan/UNITED STATES OF AMERICA

MO19.05 Suramin Improves Survival of Steatotic Grafts after Partial Liver Transplantation

S. He, H. Rehman, Z. Zhong  
Charleston/UNITED STATES OF AMERICA

MO19.06 HCV infection and HLA-DRB1\*11 in liver transplantation: a 15 years marriage

R. ROMAGNOLI, P. MAGISTRONI, S. ROGGERO, M.E. FASANO, L. PRATICO' BARBATO, A. RICCHIUTI, F. TANDOI, F. LUPO, G. CATALANO, F. FOP, E.F. DAVID, M. SALIZZONI, A. AMOROSO  
Torino/ITALY

MO19.07 The Use of Hepatitis B Core Antibody Positive Donor Livers Does Not Have a Deleterious Effect on Graft Survival in Liver Transplantation for Hepatitis C



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. Rayhill, J. Schwartz, J. Ham, D. Scott, M. Chang, S. Naugler, A. Zaman, A. Sasaki, M. Yin, S. Orloff  
Portland/UNITED STATES OF AMERICA

MO19.08 Crucial Role of Post-reperfusion Allograft Biopsy in Evaluation of Follow-up Biopsies after Liver Transplantation

M. Raoufi<sup>1</sup>, M. El Atrache<sup>1</sup>, K. Brown<sup>1</sup>, D. Moonka<sup>1</sup>, A. Yoshida<sup>1</sup>, D. Kim<sup>1</sup>, M. Kazimi<sup>1</sup>, S. Sharma<sup>2</sup>, M. Abouljoud<sup>1</sup>

<sup>1</sup>Detorit/UNITED STATES OF AMERICA, <sup>2</sup>Detroit/UNITED STATES OF AMERICA

### Session MO20 Xenotransplantation

**Wednesday, August 18, 2010 12:15 PM - 01:15 PM**

**Room: MR 220 - 222**

Moderators: *Maria* . Koulmanda, *David* . White

MO20.01 siRNA-Mediated Tissue Factor Knockdown in Neonatal Porcine Islet Cell Clusters Resulted in Suppression of IBMIR in Vitro

M. Ji, S. Yi, H. Smith-Hurst, P. Phillips, J. Wu, P.J. O'Connell  
Sydney/AUSTRALIA

MO20.02 Auxiliary Transplantation of the chimeric liver graft in mouse and rat combination and evaluation of the long-term survival and proliferative capacity of the transplanted graft in the recipient rat

T. Hata<sup>1</sup>, K. Endo<sup>1</sup>, K. Jobara<sup>1</sup>, J. Iwasaki<sup>1</sup>, E. Kobayashi<sup>2</sup>, S. Uemoto<sup>1</sup>  
<sup>1</sup>Kyoto/JAPAN, <sup>2</sup>Shimotsuke/JAPAN

MO20.03 Comparison of Survival of GalT-KO Pig Skin to Allogeneic Skin on Baboons: the Role of Graft Bed Depth and of Cyclosporine treatment

A.A. Leto Barone, D.H. Sachs, J. Weiner, R. Torabi, J.S. Hanekamp, K. Yamada, C.L. Cetrulo  
Boston/UNITED STATES OF AMERICA

MO20.04 Prolonged ex-vivo pulmonary xenograft function using genetically-modified porcine donor lungs

G. Westall<sup>1</sup>, B. Levvey<sup>1</sup>, S. Marasco<sup>1</sup>, J. Gooi<sup>1</sup>, R. McEgan<sup>1</sup>, M. Meenan<sup>1</sup>, C. Egan<sup>1</sup>, F. Rosenfeldt<sup>1</sup>, E. Salvaris<sup>1</sup>, K. Dwyer<sup>1</sup>, M. Nottle<sup>2</sup>, G.I. Snell<sup>1</sup>, P. Cowan<sup>1</sup>  
<sup>1</sup>Melbourne/AUSTRALIA, <sup>2</sup>Adelaide/AUSTRALIA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO20.05 High levels of cytotoxic anti-non Gal preformed natural antibody did not induce hyperacute rejection but did cause early graft loss in a GalT-KO pig-to-baboon thymokidney model

H. Nishimura, A. Shimizu, A. Griesemer, J.R. Scalea, S. Moran, J. Weiner, B. Gillon, J. Fishman, S.C. Robson, M. Sykes, D.H. Sachs, K. Yamada  
Boston/UNITED STATES OF AMERICA

MO20.06 Increased frequency of CD4+CD25Hi Foxp3+ Treg cells in peripheral blood of long term heterotopic cardiac xenograft (Pig to Baboon) recipients

A.K. Singh, P.C. Corcoran, M.P. Thomas, R.F. Hoyt, K.A. Horvath, M.M. Mohiuddin  
Bethesda/UNITED STATES OF AMERICA

MO20.07 An analysis of pig cytidine monophospho-N-acetylneuraminic acid (CMP-NeuAc) hydroxylase.

K. Ikeda, A. Yamamoto, A. Kondo, Y. Takama, M. Fukuzawa, H. Matsunari, H. Nagashima, S. Miyagawa  
Suita/JAPAN

MO20.08 Mid-term Efficacy of Porcine Corneal Xenotransplantation in Non-Human Primates

H.J. Choi, M.K. Kim, J.H. Ko, H.J. Lee, W.R. Wee, J.H. Lee  
Seoul/KOREA

MO20.09 Immunogenicity of Islets Isolated from Three and Seven Day-Old Newborn Pigs

H. Arefanian<sup>1</sup>, D.C. Mok<sup>1</sup>, Q. Ramji<sup>1</sup>, I.R. Badell<sup>2</sup>, P.W. Thompson<sup>2</sup>, C. Larsen<sup>2</sup>, R.G. Gill<sup>1</sup>, G.S. Korbitt<sup>1</sup>,  
R.V. Rajotte<sup>1</sup>, G.R. Rayat<sup>1</sup>  
<sup>1</sup>Edmonton/CANADA, <sup>2</sup>Atlanta/UNITED STATES OF AMERICA

MO20.10 Aberrant activation of coagulation is independent of xenoreactive antibody titer and complement activation in ex vivo perfusion of porcine kidneys.

J. Klose, W. Ramackers, S. Bergmann, J. Klemphauer, M. Winkler  
Hannover/GERMANY

MO20.11 Generation of Porcine Cardiac Xenografts: AAV2/9-Mediated Gene Transfer into Myocytes using the in situ Langendorff Perfusion Model

L. Burdorf<sup>1</sup>, J. Postrach<sup>1</sup>, E. Thein<sup>1</sup>, R. Hinkel<sup>1</sup>, M. Schmidt<sup>1</sup>, A. Bauer<sup>1</sup>, S. Michel<sup>1</sup>, P. Brenner<sup>1</sup>, B. Reichart<sup>1</sup>, C. Kupatt<sup>1</sup>, M. Schmoeckel<sup>2</sup>  
<sup>1</sup>Munich/GERMANY, <sup>2</sup>Hamburg/GERMANY

**Session MO21 Late Breaking Mini Oral**



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

**Wednesday, August 18, 2010 12:15 PM - 01:15 PM**

**Room: MR 212 - 214**

Moderators: *Kareem . Abu-Elmagd*

MO21.01 FOXP3+ T-cells and TH2 immune response shift are induced by local expression of Indoleamine 2,3 dioxygenase in a composite islet graft

R. B. Jalili<sup>1</sup>, A. Moeen<sup>1</sup>, R. Hartwell<sup>1</sup>, G. Warnock<sup>1</sup>, B. Larijani<sup>2</sup>, A. Ghahary<sup>1</sup>  
<sup>1</sup>Vancouver/CANADA, <sup>2</sup>Tehran/IRAN

MO21.02 Over-expression of B7-H4 in Beta Cells from Transgenic Mice Prolongs Islet Allograft Survival in Transplantation

X. Wang<sup>1</sup>, J. Hao<sup>1</sup>, D. METZGER<sup>1</sup>, A. Mui<sup>1</sup>, Z. Ao<sup>1</sup>, C.B. Verchere<sup>1</sup>, L. Chen<sup>2</sup>, D. Ou<sup>1</sup>, G.L. Warnock<sup>1</sup>  
<sup>1</sup>Vancouver/CANADA, <sup>2</sup>Baltimore/UNITED STATES OF AMERICA

MO21.03 A New Enzyme Mixture to Consistently Achieve High Human Islet Yield and Improved Allogenic and Autograft Islet Transplantation Outcome

A.N. Balamurugan<sup>1</sup>, G. Loganathan<sup>1</sup>, M. Bellin<sup>1</sup>, J.J. Wilhelm<sup>1</sup>, J. Harmon<sup>1</sup>, T. anazawa<sup>1</sup>, D. Radosevich<sup>1</sup>, T. Yuasa<sup>1</sup>, M. Tiwari<sup>1</sup>, K.K. Papas<sup>1</sup>, R.C. McCarthy<sup>2</sup>, D.E. Sutherland<sup>1</sup>, B.J. Hering<sup>1</sup>  
<sup>1</sup>Minneapolis/UNITED STATES OF AMERICA, <sup>2</sup>Indianapolis/UNITED STATES OF AMERICA

MO21.04 Pancreatic Islet Cell Preservation by Human Endothelial Protein C Receptor Over Expression in a Syngeneic Murine Model of Intraportal Islet Transplantation

E. Lee, L. Murray-Segal, A. d'Apice, P. Cowan, H. Gock  
Fitzroy/AUSTRALIA

MO21.05 The Glucagon-Like Peptide-1 Analogue Exenatide Reduces Amyloid-Induced Beta-Cell Toxicity in Cultured Human Islets

H. Chen, T.J. Kieffer, Z. Ao, M. Meloche, A. Asadi, D. Thompson, Y.J. Park, L. Jew, G.L. Warnock, L. Marzban  
Vancouver/CANADA

MO21.06 Impact of Metabolic Demand on Islet Transplant Survival and Tolerance Induction

R.G. Gill<sup>1</sup>, M.R. Nicolls<sup>2</sup>, A. Koh<sup>3</sup>, M. Coulombe<sup>1</sup>  
<sup>1</sup>Aurora/UNITED STATES OF AMERICA, <sup>2</sup>Ca/UNITED STATES OF AMERICA, <sup>3</sup>Edmonton/CANADA

MO21.07 A health-economic analysis of clinical islet transplantation



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

H.-J. Schuurman<sup>1</sup>, J. Beckwith<sup>1</sup>, J.A. Nyman<sup>1</sup>, B. Flanagan<sup>1</sup>, R. Schrover<sup>2</sup>  
<sup>1</sup>Minneapolis/UNITED STATES OF AMERICA, <sup>2</sup>Wollstonecraft/AUSTRALIA

MO21.08 Induction of Tolerance Via Polymer Modification of Leukocytes

D. Wang, W. Toyofuku, M.D. Scott  
Vancouver/CANADA

MO21.09 1. End of Life Decisions-The Impact of Neurocritical Patients' Evolution on Organ Donation. A Multicentric Study in Catalonia, Spain.

T. Pont<sup>1</sup>, J. Gener<sup>1</sup>, E. Oliver<sup>2</sup>, M. Bodi<sup>3</sup>, M. Badia<sup>4</sup>, J. Mestre<sup>5</sup>, X. Esquirol<sup>6</sup>, S. Quintana<sup>7</sup>, N. Masnou<sup>1</sup>, E. Muñoz<sup>3</sup>, R. Deulofeu<sup>1</sup>  
<sup>1</sup>Barcelona/SPAIN, <sup>2</sup>Hospitalet De Llobregat/SPAIN, <sup>3</sup>Tarragona/SPAIN, <sup>4</sup>Lleida/SPAIN, <sup>5</sup>Sabadell/SPAIN, <sup>6</sup>Granollers/SPAIN, <sup>7</sup>Terrassa/SPAIN

MO21.10 Computed Tomographic Angiography and Perfusion in the diagnosis of brain death - Primary Report

R. Bohatyrewicz<sup>1</sup>, M. Sawicki<sup>1</sup>, A. Walecka<sup>1</sup>, J. Walecki<sup>2</sup>, O. Rowinski<sup>2</sup>, Z. Czajkowski<sup>1</sup>, A. Krzyształowski<sup>1</sup>, J. Pastuszka<sup>1</sup>, M. Zukowski<sup>1</sup>  
<sup>1</sup>Szczecin/POLAND, <sup>2</sup>Warsaw/POLAND

MO21.11 An adjuvanted Influenza A H1N1 vaccine (Pandemrix®) does not provide a protective immune response in the majority of renal transplant recipients

S. Brakemeier, B. Schweiger, P. Glander, F. Diekmann, H.H. Neumayer, K. Budde  
Berlin/GERMANY

MO21.12 Early Combination of Proteinuria at Low Grade and Impaired Renal Function Predicts Both Patient and Kidney Graft Survival.

D. Hernández<sup>1</sup>, G. Perez-Suarez<sup>2</sup>, D. Marrero<sup>2</sup>, J. Gonzalez-Posada<sup>2</sup>, M. Rufino<sup>3</sup>, P. Delgado Mallén<sup>2</sup>, A. Torres<sup>2</sup>  
<sup>1</sup>Malaga/SPAIN, <sup>2</sup>Tenerife/SPAIN, <sup>3</sup>Ofra S/n. La Laguna/SPAIN

### 13:30 – 15:00 STATE OF THE ART SYMPOSIA

Session SOTA15 Developing societal and ethical consensus on living donation

Wednesday, August 18, 2010 01:30 PM - 03:00 PM  
Room: MR 109 - 110



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### **TTS 2010 SCIENTIFIC PROGRAM**

Moderators: *Howard . Nathan, Syed Ali Anwar . Naqvi*

SOTA15.1 The Istanbul declaration and beyond

F. Delmonico

Newton/UNITED STATES OF AMERICA

SOTA15.2 The position of the WHO on living donation

L. Noel

Geneva/SWITZERLAND

SOTA15.3 Aspects of Organ donation in the Muslim Society

S.A.A. Naqvi

Karachi/PAKISTAN

SOTA15.4 Overcoming the problem of commercialism in India

G. Abraham

Chennai/INDIA

SOTA15 - DISCUSSION

### **Session SOTA16 Innovations in regenerative medicine**

**Wednesday, August 18, 2010 01:30 PM - 03:00 PM**

**Room: MR 212 - 214**

Moderators: *Alan . Colman, Doris . Taylor*

SOTA16.1 Stem cells and gene transfer in transplantation and regeneration

H.-D. Volk

Berlin/GERMANY

SOTA16.2 Tissue engineering for transplantation and regenerative medicine



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

M. Sefton  
Toronto/CANADA

SOTA16.3 Regenerative medicine and the stem cell: a marriage that is improving with time

A. Colman

SOTA16 - DISCUSSION

#### **Session SOTA17 Prevention and treatment of antibody mediated rejection**

**Wednesday, August 18, 2010 01:30 PM - 03:00 PM**  
**Room: Ballroom A/B**

Moderators: *Ulrich . Frei, Joseph . Kim*

SOTA17.1 Factors influencing tolerance and outcome in ABO incompatible transplantation

G. Tyden  
Stockholm/SWEDEN

SOTA17.2 A critical review of the transplantation response in the pre-sensitized patient

A. Peng  
Los Angeles/UNITED STATES OF AMERICA

SOTA17.3 Acute antibody-mediated rejection

M. Samaniego  
Ann Arbor/UNITED STATES OF AMERICA

SOTA17.4 Chronic antibody-mediated rejection

M.D. Stegall  
Rochester/UNITED STATES OF AMERICA

SOTA17 - DISCUSSION

#### **Session SOTA18 Immune regulation and tolerance**



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

**Wednesday, August 18, 2010 01:30 PM - 03:00 PM**

**Room: MR 220 - 222**

Moderators: *Peter . Morris, Anita . Chong*

SOTA18.1 Mechanisms of immune regulation and tolerance

M. Sayegh

Boston/UNITED STATES OF AMERICA

SOTA18.2 Mixed chimerism and human tolerance

M. Sykes

Boston/UNITED STATES OF AMERICA

SOTA18.3 Molecular signatures of human tolerance

J.-P. Souillou

Nantes/FRANCE

SOTA18 - DISCUSSION

### **Session SOTA19 Clinically Relevant Molecular Mechanisms in Lung Transplantation**

**Wednesday, August 18, 2010 01:30 PM - 03:00 PM**

**Room: MR 211**

Moderators: *Shaf . Keshavjee, Marty . Zamora*

SOTA19.1 Recipient and Donor Characteristics Associated with Primary Graft Dysfunction

J. Christie

Philadelphia/UNITED STATES OF AMERICA

SOTA19.2 Fibrosis Rather Than Alloreactivity is the Target in Chronic Lung Allograft Dysfunction

A. Boehler

SOTA19.3 Donor Specific Antibodies Post Lung Transplant - Making Sense of the Data



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

A. Zeevi

Pittsburgh/UNITED STATES OF AMERICA

SOTA19.4 Targeted Therapy for Severe Pulmonary Arterial Hypertension in Idiopathic Pulmonary Fibrosis

P. Corris

Newcastle/UNITED KINGDOM

SOTA19 - DISCUSSION

### Session SOTA20 Hepatitis C positive patient

**Wednesday, August 18, 2010 01:30 PM - 03:00 PM**

**Room: MR 118 - 120**

Moderators: *Gary . Levy, Olaf . Guckelberger*

SOTA20.1 Risk factors for HCV recurrence

M. Berenguer

Valencia/SPAIN

SOTA20.2 Immunosuppression for the HCV recipient

G.A. Levy

Toronto/CANADA

SOTA20.3 The Treatment of HCV recurrence

M.R. Charlton

Rochester/UNITED STATES OF AMERICA

SOTA20 - DISCUSSION

### Session SOTA21 Ischemia - reperfusion injury

**Wednesday, August 18, 2010 01:30 PM - 03:00 PM**

**Room: MR 121 - 122**



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### **TTS 2010 SCIENTIFIC PROGRAM**

Moderators: *Hans . Sollinger, Ferdinand . Muehlbacher*

SOTA21.1 The biology of brain death and organ damage

S.G. Tullius

Boston/UNITED STATES OF AMERICA

SOTA21.2 Tissue Inflammation and Repair

J. Bonventre

Boston/UNITED STATES OF AMERICA

SOTA21.3 Strategies for cytoprotection in ischemic organ injury

P.-A. Clavien

Zurich/SWITZERLAND

SOTA21.4 Current status of organ preservation solutions

T. van Gulik

SOTA21 - DISCUSSION



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

### 15:30 – 17:00 AFTERNOON CONCURRENT SYMPOSIA

#### Session O43 Experimental and Human Tolerance

Wednesday, August 18, 2010 03:30 PM - 05:00 PM  
Room: MR 220 - 222

Moderators: *Megan . Sykes, Maria . Hernandez-Fuentes*

O43.01 Costimulatory blockade does not promote survival of skin component in non-human-primate composite tissue allografts

G.S. Munding, L.S. Jones, H.G. Hui-Chou, C. Drachenberg, S.T. Shipley, A.M. Azimzadeh, R.N. Pierson III, E.D. Rodriguez, S.T. Bartlett, R.N. Barth, B. Vanhove  
Baltimore/UNITED STATES OF AMERICA

O43.02 Chronic rejection in a non-human primate model of facial composite tissue allotransplantation: clinical, pathological, and immunohistochemical characterization

G.S. Munding, R. Munivenkatappa, H.G. Hui-Chou, C. Drachenberg, S.T. Shipley, L.S. Jones, A. Dorafshar, E.D. Rodriguez, S.T. Bartlett, R.N. Barth  
Baltimore/UNITED STATES OF AMERICA

O43.03 Tolerance to a Composite Tissue Allografts after the Induction of Mixed Chimerism in a Pre-Clinical Large Animal Model

D.W. Mathes, B. Hwang, T. Miwongtum, S. Graves, R. Storb  
Seattle/UNITED STATES OF AMERICA

O43.04 Tolerance of Renal Allografts across HLA barriers: Follow-up on the First Trial and Initial Results of the Second

T. Kawai<sup>1</sup>, D.H. Sachs<sup>1</sup>, T. Spitzer<sup>1</sup>, N. Tolloff-Rubin<sup>1</sup>, R.B. Colvin<sup>1</sup>, S. Saidman<sup>1</sup>, D.S.C. Ko<sup>1</sup>, W. Wong<sup>1</sup>, W. Williams<sup>1</sup>, M. Sykes<sup>1</sup>, A.B. Cosimi<sup>1</sup>, I. T.N.036ST Study Group<sup>2</sup>  
<sup>1</sup>Boston/UNITED STATES OF AMERICA, <sup>2</sup>Bethesda/UNITED STATES OF AMERICA

O43.05 Inducing Tolerance in Clinical Kidney Transplantation

S. Strober, S. Busque, S. Dejbakhsh-Jones, C. Benike, L. Li, J. Shizuru, R. Lowsky, E. Engleman, M. Sarwal, J.D. Scandling  
Stanford/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O43.06 Sixteen Kidney Transplant Patients surviving for almost 2 years with No Maintenance Immunosuppression or Steroids Alone

H.L. Trivedi<sup>1</sup>, H. Kaneku<sup>2</sup>, P.I. Terasaki<sup>2</sup>, M.J. Everly<sup>3</sup>, A. Feroz<sup>1</sup>, A.V. Vanikar<sup>1</sup>, V.B. Trivedi<sup>1</sup>, P.R. Modi<sup>1</sup>, S.D. Dave<sup>1</sup>

<sup>1</sup>Ahmedabad/INDIA, <sup>2</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>3</sup>Canoga Park/UNITED STATES OF AMERICA

O43.07 Successful induction of donor-specific tolerance using Super-agonistic CD28 antibody in rat renal allografts

H. Azuma<sup>1</sup>, H. Nohmi<sup>1</sup>, N. Ibuki<sup>1</sup>, T. Inamoto<sup>1</sup>, Y. Isaka<sup>2</sup>, S. Takahara<sup>2</sup>, Y. Katsuoka<sup>1</sup>

<sup>1</sup>Takatsuki/JAPAN, <sup>2</sup>Suita/JAPAN

O43.08 Prope Tolerance : A More Realistic Approach To Improve Long-Term Outcomes For Pediatric Living-Donor Liver Transplantation

H. Ohe<sup>1</sup>, T. Koshiba<sup>1</sup>, Y. Li<sup>1</sup>, S. Sakaguchi<sup>1</sup>, K.J. Wood<sup>2</sup>, S.R. Calne<sup>3</sup>, S. Uemoto<sup>1</sup>

<sup>1</sup>Kyoto/JAPAN, <sup>2</sup>Oxford/UNITED KINGDOM, <sup>3</sup>Cb2 2as/UNITED KINGDOM

### Session O44 Xenotransplantation I

**Wednesday, August 18, 2010 03:30 PM - 05:00 PM**

**Room: MR 217 - 219**

Moderators: *Carl . Groth, Emanuele . Cozzi*

O44.01 Over Six Month Survival Of Cardiac Xenograft Is Achievable But Heterotopic Placement Of The Graft May Limit Consistent Prolonged Survival

M.M. Mohiuddin<sup>1</sup>, P.C. Corcoran<sup>1</sup>, A.K. Singh<sup>1</sup>, A.M. Azimzadeh<sup>2</sup>, R.F. Hoyt<sup>1</sup>, M.P. Thomas<sup>1</sup>, M.A. Eckhaus<sup>1</sup>, D. Ayares<sup>3</sup>, R.N. Pierson III<sup>2</sup>, K.A. Horvath<sup>1</sup>

<sup>1</sup>Bethesda/UNITED STATES OF AMERICA, <sup>2</sup>Baltimore/UNITED STATES OF AMERICA, <sup>3</sup>Blacksburg/UNITED STATES OF AMERICA

O44.02 The Worldwide First Model with Heterotopic Thoracic Xenogeneic Heart Transplantation Compared with the Heterotopic Abdominal Technique

P. Brenner<sup>1</sup>, J. Postrach<sup>1</sup>, A. Bauer<sup>1</sup>, M. Thormann<sup>1</sup>, M. Loewenthal<sup>1</sup>, S. Blanck<sup>1</sup>, S. Michel<sup>1</sup>, B. Wintersperger<sup>1</sup>, K. Sotlar<sup>1</sup>, C. Schmitz<sup>1</sup>, M. Schmoeckel<sup>2</sup>, B. Reichart<sup>1</sup>

<sup>1</sup>Munich/GERMANY, <sup>2</sup>Hamburg/GERMANY



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O44.03 Pilot evaluation of anti-GPIb effects on platelet sequestration in an ex vivo xenogeneic pig liver perfusion model

L. Burdorf<sup>1</sup>, R.N. Barth<sup>1</sup>, T. Zhang<sup>1</sup>, E. Rybak<sup>1</sup>, I.I. Salles<sup>2</sup>, K. Broos<sup>2</sup>, E. Welty<sup>1</sup>, C.J. Avon<sup>1</sup>, A. Laaris<sup>1</sup>, B. McCormick<sup>1</sup>, D. Ayares<sup>3</sup>, H. Deckmyn<sup>2</sup>, A.M. Azimzadeh<sup>1</sup>, R.N. Pierson III<sup>1</sup>

<sup>1</sup>Baltimore/UNITED STATES OF AMERICA, <sup>2</sup>Kortrijk/BELGIUM, <sup>3</sup>Blacksburg/UNITED STATES OF AMERICA

O44.04 A study of the Prevention of PERV Infection by siRNA on Pig Dolichyl-Phosphate Mannosyltransferase

A. Yamamoto, A. Kondo, S. Nakatsu, K. Ikeda, S. Firdawes, D. Wang, Y. Takama, T. Ueno, M. Fukuzawa, S. Miyagawa  
Suita/JAPAN

O44.05 Prolonged Xenograft Survival Induced By ICOS-IG Is Associated With Increased Foxp3+ Cells

R. Hodgson<sup>1</sup>, A. Ziolkowski<sup>2</sup>, D. Christiansen<sup>1</sup>, E. Mouhtouris<sup>1</sup>, C.J. Simeonovic<sup>2</sup>, F. Ierino<sup>1</sup>, M.S. Sandrin<sup>1</sup>  
<sup>1</sup>Heidelberg/AUSTRALIA, <sup>2</sup>Canberra/AUSTRALIA

O44.06 Normal glucose tolerance and long-term function of microencapsulated porcine, piscine, and human islet xenografts in spontaneously diabetic NOD mice

S. Safley<sup>1</sup>, H. Cui<sup>2</sup>, S. Cauffiel<sup>1</sup>, K. Gordon<sup>1</sup>, B.-Y. Xu<sup>3</sup>, C. Larsen<sup>1</sup>, J.R. Wright<sup>3</sup>, C.J. Weber<sup>1</sup>  
<sup>1</sup>Atlanta/UNITED STATES OF AMERICA, <sup>2</sup>New York/UNITED STATES OF AMERICA, <sup>3</sup>Calgary/CANADA

O44.07 Xenograft of Microencapsulated Sertoli cells alone cures NOD mice with spontaneous autoimmune diabetes

R. Calafiore, F. Fallarino, M. Calvitti, F. Mancuso, E. Becchetti, P. Puccetti, G. Luca  
Perugia/ITALY

O44.08 Down-regulation of NPI Tissue Factor Expression Alleviates the IBMIR in Islet Transplantation

W. Wang, X. Ma, B. Ye, F. Gao  
Changsha/CHINA

### Session O45 Molecular Diagnostics and Genomics

**Wednesday, August 18, 2010 03:30 PM - 05:00 PM**

**Room: MR 211**

Moderators: *Phil . Dyer, Andrea . Zachary*



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O45.01 Transcripts selective for donor specific antibody identify C4d positive and C4d negative antibody mediated rejection

L.G. Hidalgo, P.M. Campbell, P. Halloran  
Edmonton/CANADA

O45.02 Immunomonitoring of face and hand grafted patients by comparing mRNA markers in tissues versus blood can help to differentiate rejection versus viral infection episodes.

A. Eljaafari<sup>1</sup>, P. Petruzzo<sup>1</sup>, J. Kaniakakis<sup>1</sup>, L. BADET<sup>1</sup>, E. Morelon<sup>1</sup>, A. Gazarian<sup>1</sup>, C. Dagot<sup>1</sup>, J.-L. Beziat<sup>1</sup>, S. Testelin<sup>2</sup>, B. Devauchelle<sup>2</sup>, X. Martin<sup>1</sup>, J.M. Dubernard<sup>1</sup>, P. Miossec<sup>1</sup>  
<sup>1</sup>Lyon/FRANCE, <sup>2</sup>Amiens/FRANCE

O45.03 Temporal gene expression changes occurring in the kidney graft post-transplantation

R. Fassnacht, D. Maluf, K.J. Archer, M.J. Scian, B.C. Whitehill, L.J. Suh, A. King, A. Cotterell, A. Sharma, T.W. Gehr, M.P. Posner, V. Mas  
Richmond/UNITED STATES OF AMERICA

O45.04 Small Bowel allografts undergoing Rejection show distinct Transcriptome Profiles in formalin-fixed mucosal biopsies

T. Asaoka, E. Island, J. Moon, S. Nishida, A. Tekin, D. Levi, A. Tzakis, P. Ruiz  
Miami/UNITED STATES OF AMERICA

O45.05 Graft loss is poorly represented in the most inflamed rejection kidney transplant biopsies

L.G. Hidalgo, P. Halloran  
Edmonton/CANADA

O45.06 Identification of stable control genes for normalization of blood based biomarker panels

Y. Yang<sup>1</sup>, M. Takhar<sup>1</sup>, Z. Hollander<sup>1</sup>, D. Lin<sup>1</sup>, J. Wilson-McManus<sup>1</sup>, R.T. Ng<sup>1</sup>, P.A. Keown<sup>2</sup>, R.M. McMaster<sup>2</sup>, B. McManus<sup>1</sup>, S.J. Tebbutt<sup>2</sup>  
<sup>1</sup>Vancouver/CANADA, <sup>2</sup>Vancouver/CANADA

O45.07 Nuclear Factor of Activated T-Cells (NFAT) Gene Variations in the Onset of Posttransplant Diabetes Mellitus (PTDM)

Y. Chen, I. Hutchinson  
Los Angeles/UNITED STATES OF AMERICA

O45.08 Mycophenolic acid Induced Apoptosis in Human Jurkat Cells via Generation of ROS and Regulation HO-1 Expression



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S.Y. Chung, H.K. Lee, W.Y. Shin, S.J.N. Choi, J.H. Park  
Gwangju/KOREA

#### Session O46 Epidemiology and Clinical Outcomes II

**Wednesday, August 18, 2010 03:30 PM - 05:00 PM**  
**Room: MR 109 - 110**

Moderators: *Angela . Webster, John . Pirsch*

O46.01 Long-term compensation of renal function after donor nephrectomy is not affected by donor factors

K.H. Huh<sup>1</sup>, Y.S. Kim<sup>1</sup>, M.K. Ju<sup>1</sup>, M.S. Kim<sup>1</sup>, S.I. Kim<sup>1</sup>, K. Park<sup>2</sup>  
<sup>1</sup>Seoul/KOREA, <sup>2</sup>Seongnam/KOREA

O46.02 Age Matching of Donors to Recipients Does Not Impact on Outcome in Renal Transplantation Following Donation After Cardiac Death

J.K. Pine, P.J. Goldsmith, D.M. Ridgway, J. Barwick, R. Baker, C. Newstead, S. Pollard, K.V. Menon, N. Ahmad, M. Attia  
Leeds/UNITED KINGDOM

O46.03 Kidney Transplantation From Donation after Cardiac Death: a French Academic Hospital Experience

I. ABBOUD, C. LEFAUCHEUR, C. ANTOINE, F. FIEUX, F. GAUDEZ, M.-N. PERALDI, D. GLOTZ  
Paris/FRANCE

O46.04 Matched Analysis of Renal Transplants following Donation after Cardiac Death Verses Donation after Brainstem Death

J.K. Pine, P.J. Goldsmith, D.M. Ridgway, A.J. Cockbain, S. Farid, S. Fraser, K. Brady, S. Pollard, M. Attia, K.V. Menon, N. Ahmad  
Leeds/UNITED KINGDOM

O46.05 Outcomes of Kidneys Donated after Cardiac Death

D.M. Summers<sup>1</sup>, J. Allen<sup>2</sup>, R.J. Johnson<sup>2</sup>, S.V. Fuggle<sup>3</sup>, D. Collett<sup>2</sup>, C.J.E. Watson<sup>1</sup>, J.A. Bradley<sup>1</sup>  
<sup>1</sup>Cambridge/UNITED KINGDOM, <sup>2</sup>Bristol/UNITED KINGDOM, <sup>3</sup>Oxford/UNITED KINGDOM



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O46.06 Current long term outcomes of both controlled and uncontrolled Non Heart Beating Donor (NHBD) kidneys – a five year follow up study.

A. Kanwar<sup>1</sup>, M.A. Khurram<sup>1</sup>, S. Stamp<sup>1</sup>, L. El-Asir<sup>1</sup>, M. Reddy<sup>1</sup>, H. Wyrley-Birch<sup>1</sup>, J. Asher<sup>1</sup>, M. Gok<sup>1</sup>, A. Cunningham<sup>2</sup>, N. Carter<sup>2</sup>, B. Jacques<sup>1</sup>, N. Soomro<sup>1</sup>, D. Rix<sup>1</sup>, D. Manas<sup>1</sup>, D. Talbot<sup>1</sup>

<sup>1</sup>Newcastle Upon Tyne/UNITED KINGDOM, <sup>2</sup>Sunderland/UNITED KINGDOM

O46.07 Outcomes of graft kidney according to donor scoring system and renal biopsy in deceased kidney transplantation

K.H. Huh<sup>1</sup>, Y.S. Kim<sup>1</sup>, M.K. Ju<sup>1</sup>, M.S. Kim<sup>1</sup>, S.I. Kim<sup>1</sup>, K. Park<sup>2</sup>

<sup>1</sup>Seoul/KOREA, <sup>2</sup>Seongnam/KOREA

O46.08 Contribution of donor and recipient characteristics to short- and long-term pancreas graft survival

D.E. Hilling, A.G. Baranski, A. Haasnoot, P.J.M. van der Boog, O.T. Terpstra, P.J. Marang-van de Mheen  
Leiden/NETHERLANDS

O46.09 The Influence of Bilateral Nephrectomy (BN) on Long-term Graft and Patient Survival in Recipients (1968-1985) treated with Azathioprine and Prednisolone only

J.F. Douglas

Belfast N Ireland/UNITED KINGDOM

### Session O47 Clinical Trials of Immunosuppression

**Wednesday, August 18, 2010 03:30 PM - 05:00 PM**

**Room: Ballroom A/B**

Moderators: *Herwig-Ulf* . Meier-Kriesche, *Paul* . Trevillian

O47.01 The TranCept Trial – Final Study Results Demonstrate Benefits From Introduction of Mycophenolate Mofetil (CellCept®) Several Years After Transplantation.

H.-U. Meier-Kriesche<sup>1</sup>, U. Heemann<sup>2</sup>, P. Merville<sup>3</sup>, H. Tedesco-Silva<sup>4</sup>, J. Ferraris<sup>5</sup>, C. Bernasconi<sup>6</sup>

<sup>1</sup>Gainesville/UNITED STATES OF AMERICA, <sup>2</sup>Muenchen/GERMANY, <sup>3</sup>Bordeaux/FRANCE, <sup>4</sup>Sao Paulo/BRAZIL, <sup>5</sup>Buenos Aires/ARGENTINA, <sup>6</sup>Basel/SWITZERLAND

O47.02 Impact of maintenance immunosuppressive regimens on the immune response of renal transplant recipients – balance between graft protective suppression of immune functions and a near physiological immune response



### TTS 2010 SCIENTIFIC PROGRAM

R. Weimer<sup>1</sup>, S. Deisz<sup>1</sup>, F.C. Renner<sup>1</sup>, H. Dietrich<sup>1</sup>, V. Daniel<sup>2</sup>, S. Kamali-Ernst<sup>3</sup>, W. Ernst<sup>4</sup>, W. Padberg<sup>1</sup>, G. Opelz<sup>2</sup>

<sup>1</sup>Giessen/GERMANY, <sup>2</sup>Heidelberg/GERMANY, <sup>3</sup>Wetzlar/GERMANY, <sup>4</sup>Langenselbold/GERMANY

O47.02 Application of a Validated Long-term Renal Transplant Graft Survival Prediction Model to Expected Belatacept Phase III Trial Outcomes

M.A. Schnitzler<sup>1</sup>, D. Trivedi<sup>2</sup>, G.J. L'Italien<sup>3</sup>

<sup>1</sup>Shiloh/UNITED STATES OF AMERICA, <sup>2</sup>Plainsboro/UNITED STATES OF AMERICA, <sup>3</sup>Wallingford/UNITED STATES OF AMERICA

O47.03 Outcomes as a Function of Donor Criteria from a Phase III Study of Belatacept vs Cyclosporine in Kidney Transplantation (BENEFIT-EXT)

S. Florman<sup>1</sup>, A. Durrbach<sup>2</sup>, C. Larsen<sup>3</sup>, J.M. Pestana<sup>4</sup>, H. de Jonge<sup>5</sup>, F. Vincenti<sup>6</sup>, A. Block<sup>7</sup>, P. Garg<sup>7</sup>, B. Copley<sup>7</sup>, T. Duan<sup>7</sup>, J.M. Grinyó<sup>8</sup>

<sup>1</sup>New York/UNITED STATES OF AMERICA, <sup>2</sup>Paris/France, <sup>3</sup>Atlanta/UNITED STATES OF AMERICA, <sup>4</sup>Na/UNITED STATES OF AMERICA, <sup>5</sup>Leuven/BELGIUM, <sup>6</sup>San Francisco/UNITED STATES OF AMERICA, <sup>7</sup>Princeton/UNITED STATES OF AMERICA, <sup>8</sup>08907/SPAIN

O47.04 Long-term Post Transplantation Switch to an Everolimus-based Therapy with CNI Elimination/Minimization Does Not Overall Impact Graft Function: The Ascertain Study

H. Holdaas

Oslo/NORWAY

O47.05 Calcineurin Inhibitor Sparing in De Novo Kidney Transplantation: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

A. Sharif<sup>1</sup>, J. Moore<sup>2</sup>, S. Shabir<sup>1</sup>, A. Bentall<sup>1</sup>, S. Ball<sup>1</sup>, R. Borrows<sup>1</sup>

<sup>1</sup>Birmingham/UNITED KINGDOM, <sup>2</sup>Shrewsbury/UNITED KINGDOM

O47.06 Long Term Outcomes with Early Corticosteroid Withdrawal Regimens in Kidney Transplantation: Comparison to Long Term Corticosteroid Maintenance Therapy

A.R. Shields, R.R. Alloway, J. Everly, M. Cardi, G. Mogilishetty, A. Govil, E.S. Woodle

Cincinnati/UNITED STATES OF AMERICA

O47.07 Delayed graft function (DGF) affects early tacrolimus disposition in renal allograft recipients: a possible link to posttransplantation diabetes mellitus (PTDM).

H. de Jonge, M. Naesens, K. Verbeke, Y. Vanrenterghem, D.R. Kuypers

Leuven/BELGIUM



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O47.08 Immunosuppressive drugs change the NADPH oxidase expression pattern in kidney cells

J.G. Kosovski<sup>1</sup>, A. Blumert<sup>1</sup>, P.C. Baer<sup>1</sup>, H. Geiger<sup>1</sup>, I.A. Hauser<sup>2</sup>  
<sup>1</sup>Frankfurt/GERMANY, <sup>2</sup>Frankfurt/M/GERMANY

### Session O48 Advances in Surgery and Imaging

**Wednesday, August 18, 2010 03:30 PM - 05:00 PM**  
**Room: MR 202 - 204**

Moderators: *Christopher . Nguan, Richard . Allen*

O48.01 Management of Symptomatic Primary Lymphocele after Kidney Transplantation: A Systematic Review

A. Lucewicz, V.W.T. Lam, W. Hawthorne, R. Allen, H.C.C. Pleass  
Sydney/AUSTRALIA

O48.02 Western Australia Program Using Kidney from Urologist Referrals for Renal Transplant

B. He<sup>1</sup>, A. Mitchell<sup>2</sup>, W. Lim<sup>2</sup>, L. Delriviere<sup>2</sup>  
<sup>1</sup>Perth/AUSTRALIA, <sup>2</sup>6009/AUSTRALIA

O48.03 Renal Transplant Protection Using Perfusate-based Carbon Monoxide Releasing Molecules

P. Luke, J. Deng, H. Wang, D. Lian, B. Garcia, F. Sun, A.M. Jevnikar, G. Cepinskas  
London/CANADA

O48.04 Performance of Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula and Inulin Based Glomerular Filtration Rate Equation (IB-eGFR) Against Iothalamate Plasma Urine Clearance and 24 Hour Urine Creatinine Clearance Measurement in Live Donor Nephrectomy Evaluation

B. Tanriover, M. Ghanta, D.J. Cohen, L. Ratner, T.L. Nicholas  
New York/UNITED STATES OF AMERICA

O48.05 Older Live Kidney Donors: Safety on Long-term Follow-up

L.F. Dols, N.F. Kok, K.T. Tran, T. Terkivatan, W. Weimar, J.N. IJzermans  
Rotterdam/NETHERLANDS

O48.06 Fluorescent imaging of non-human primate composite tissue allografts demonstrates prolonged graft lymphedema independent of rejection



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

G.S. Munding<sup>1</sup>, M. Narushima<sup>2</sup>, H.G. Hui-Chou<sup>1</sup>, L.S. Jones<sup>1</sup>, A. Dorafshar<sup>1</sup>, S.T. Shipley<sup>1</sup>, S.T. Bartlett<sup>1</sup>, E.D. Rodriguez<sup>1</sup>, R.N. Barth<sup>1</sup>

<sup>1</sup>Baltimore/UNITED STATES OF AMERICA, <sup>2</sup>Tokyo/JAPAN

O48.07 Extra-anatomical hepatic artery reconstruction in living donor liver transplantation: lessons from 352 liver transplants.

H. Uchiyama, K. Shirabe, A. Taketomi, Y. Soejima, T. Yoshizumi, Y. Maehara  
Fukuoka/JAPAN

O48.08 Transient elastography and development of a non-invasive multiparameter score for assessment of allograft fibrosis in liver transplant patients

S. Beckebaum<sup>1</sup>, S.M. Iacob<sup>1</sup>, C.G. Klein<sup>1</sup>, A. Dechene<sup>1</sup>, J. Varghese<sup>1</sup>, H.A. Baba<sup>1</sup>, G.C. Sotiropoulos<sup>1</sup>, A. Radtke<sup>2</sup>, G. Gerken<sup>1</sup>, A. Paul<sup>1</sup>, V.R. Cicinnati<sup>1</sup>

<sup>1</sup>Essen/GERMANY, <sup>2</sup>Kiel/GERMANY

O48.09 Technical aspects of monolateral dual kidney transplantation (DKT) from expanded criteria donors (ECD): experience of 100 patients

B. Ekser, L. Furian, A. Broggiato, C. Silvestre, E.S. Pierobon, C. Longo, A. Soligo, N. Baldan, P. Rigotti  
Padova/ITALY

### Session O49 Molecular and Clinical Aspects of Lung Transplantation

**Wednesday, August 18, 2010 03:30 PM - 05:00 PM**

**Room: MR 205 - 207**

Moderators: *Robert . Levy, Bronwyn . Levvey*

O49.01 Intratracheal Delivery of Adenoviral Vector ex vivo Results in Reduced Vector-Associated Inflammation in Lung Pre- and Post- Transplantation

J.C. Yeung, D. Wagnetz, T. Koike, M. Rubacha, Y. Matsuda, M. Cypel, D.M. Hwang, M. Liu, T.K. Waddell, S. Keshavjee

Toronto/CANADA

O49.02 Excellent intermediate clinical outcomes from a National Donation-after-Cardiac Death (DCD) Lung Transplant Collaborative

B. Levvey<sup>1</sup>, M. Harkess<sup>2</sup>, P. Hopkins<sup>3</sup>, D. Chambers<sup>3</sup>, A.R. Glanville<sup>2</sup>, G.I. Snell<sup>1</sup>

<sup>1</sup>Melbourne/AUSTRALIA, <sup>2</sup>Sydney/AUSTRALIA, <sup>3</sup>Brisbane/AUSTRALIA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O49.03 Extracorporeal membrane oxygenation in fully awake patients with right heart failure as bridge to transplantation

G. Warnecke, C. Kühn, K.M. Olsson, O. Wiessner, J. Hadem, W. Sommer, S. Fischer, A.R. Simon, M. Strüber, J. Gottlieb, T. Welte, A. Haverich, M.M. Hoyer  
Hannover/GERMANY

O49.04 Beneficial Effects of Perioperative Low-dose Inhalation of Carbon Monoxide on Pulmonary Allograft Survival in MHC-inbred CLAWN Miniature Swine

H. Sahara, M. Tasaki, K. Setoyama, H. Nishimura, M. Oku, A. Shimizu, K. Yamada  
Kagoshima/JAPAN

O49.05 Egr1- a novel target for acute allograft rejection in an experimental lung transplant model

N. Waki, M. Yamane, M. Okazaki, S. Sugimoto, S. Yamamoto, O. Yoshida, T. Oto, S. Miyoshi  
Okayama/JAPAN

O49.06 Inhaled hydrogen gas therapy for prevention of lung transplant-induced ischemia/reperfusion injury in rats

T. KAWAMURA, C.-S. Huang, S. Lee, N. Shigemura, Z. Wang, T.R. Billiar, A. Nakao, Y. Toyoda  
Pittsburgh/UNITED STATES OF AMERICA

O49.07 Lactate and Lactate/Pyruvate Ratio During Acellular Normothermic Ex Vivo Rejected and Clinical Human Lung Perfusion

T. Koike, J.C. Yeung, M. Cypel, Y. Matsuda, M. Rubacha, M. Liu, T.K. Waddell, S. Keshavjee  
Toronto/CANADA

O49.08 An Aggressive Lung Recruitment Protocol Increases the Percentage of Lung Donors with No Increased Adverse Effect in Lung Recipients

D.J. Lebovitz, K. Reis, J. Yun, L. Herman, K.R. McCurry  
Cleveland/UNITED STATES OF AMERICA

O49.09 A World-wide Survey of Antifungal Prophylaxis in Lung Transplant (LTx) Centers

C.F. Neoh, G.I. Snell, T. Kotsimbos, B. Levvey, O. Morrissey, M. Slavin, K. Stewart, D. Kong  
Melbourne/AUSTRALIA

### Session O50 Intestine and Multivisceral Transplantation



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

Wednesday, August 18, 2010 03:30 PM - 05:00 PM

Room: MR 118 - 120

Moderators: *Satoru . Todo, Douglas . Farmer*

O50.01 Donor Specific Human Leukocyte Antigen (HLA) Antibodies and Visceral Transplantation: Outcome Analysis with Special Reference to the Liver-Contained Allografts

G. Wu, J. Lunz, G. Costa, R. Cruz, G. Mazariegos, K. Soltys, A. Zeevi, K.M. Abu-Elmagd  
Pittsburgh/UNITED STATES OF AMERICA

O50.02 Association between elevation of anti-HLA Panel Reactive Antibodies and episodes of acute small bowel rejection after intestinal or multivisceral transplantation

I.M. Gonzalez-Pinto<sup>1</sup>, A. Tzakis<sup>2</sup>, H.-L. Tsai<sup>3</sup>, J.-W. CHANG<sup>3</sup>, P. Tryphonopoulos<sup>2</sup>, G. Selvaggi<sup>2</sup>, S. Nishida<sup>2</sup>, D. Levi<sup>2</sup>, A. Tekin<sup>2</sup>, J. Moon<sup>2</sup>, E. Island<sup>2</sup>, P. Ruiz<sup>2</sup>  
<sup>1</sup>Oviedo/SPAIN, <sup>2</sup>Miami/UNITED STATES OF AMERICA, <sup>3</sup>Taipei/TAIWAN

O50.03 Anti-donor Specific Antibodies Associated with Acute Rejection in the Early Post-transplant Period of Small Bowel and Multivisceral Allograft Recipients

H. TSAI<sup>1</sup>, A. Tzakis<sup>2</sup>, I. Gonzalez-Pinto<sup>3</sup>, J.-W. CHANG<sup>1</sup>, P. Tryphonopoulos<sup>2</sup>, S. Nishida<sup>2</sup>, E. Island<sup>2</sup>, G. Selvaggi<sup>2</sup>, A. Tekin<sup>2</sup>, J. Moon<sup>2</sup>, D. Levi<sup>2</sup>, E.S. Woodle<sup>4</sup>, P. Ruiz<sup>2</sup>  
<sup>1</sup>Taipei/TAIWAN, <sup>2</sup>Miami/UNITED STATES OF AMERICA, <sup>3</sup>Oviedo/SPAIN, <sup>4</sup>Cincinnati/UNITED STATES OF AMERICA

O50.04 The Toll-like Receptor Pathway Contributes to Small Intestine Allograft Rejection

S.M. Krams, M. Wang, R.O. Castillo, T. Ito, C.O. Esquivel, O.M. Martinez  
Stanford/UNITED STATES OF AMERICA

O50.05 Ex vivo resection and autotransplantation for locally invasive tumors involving major vascular pedicles

T. Kato, R. Sandoval, B. Samstein, S. Lobritto, M. Martinez, M. Goldstein, J. Guarrera, S. Caruana, R. Brown, J. Emond  
New York/UNITED STATES OF AMERICA

O50.06 Osmotic requirements for a novel intraluminal nutrient preservation solution tailored to the intestine.

M.S. Kokotilo, A. Ochs, J. Carter, A. Thiesen, M.H. Chen, R. Khadaroo, T.A. Churchill  
Edmonton/CANADA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O50.07 Predictors of Survival after Intestinal Transplantation: Analysis of a Large, Single Center Experience

D.G. Farmer, R.S. Venick, K. Ngo, J. Colangelo, Y. Esmailian, K. Artavia, E. Haddad, J.P. Duffy, S.V. McDiarmid, R.W. Busuttil  
Los Angeles/UNITED STATES OF AMERICA

O50.08 Cambridge- Miami (CaMi) pre-transplant risk score for intestinal and multivisceral transplantation in adults

R. Sivaprakasam<sup>1</sup>, S. Nishida<sup>2</sup>, A. Butler<sup>1</sup>, M. Takahashi<sup>2</sup>, S. Gabe<sup>1</sup>, N. Jamieson<sup>1</sup>, A. Tzakis<sup>2</sup>, S. Middleton<sup>1</sup>  
<sup>1</sup>Cambridge/UNITED KINGDOM, <sup>2</sup>Miami/UNITED STATES OF AMERICA

O50.09 Assessing US Deceased Donor Intestine Organs: OPTN/SRTR Analysis of Current Practice and Determination of Potentially Underutilized Intestine Donors

G. Mazariegos<sup>1</sup>, D. Steffick<sup>2</sup>, S. Horslen<sup>3</sup>, J. Fryer<sup>4</sup>, D.L. Sudan<sup>5</sup>, J.C. Magee<sup>2</sup>  
<sup>1</sup>Pittsburgh/UNITED STATES OF AMERICA, <sup>2</sup>Ann Arbor/UNITED STATES OF AMERICA, <sup>3</sup>Seattle/UNITED STATES OF AMERICA, <sup>4</sup>Chicago/UNITED STATES OF AMERICA, <sup>5</sup>Durham/UNITED STATES OF AMERICA

### Session O51 Immunological Monitoring in Kidney Transplantation

**Wednesday, August 18, 2010 03:30 PM - 05:00 PM**  
**Room: MR 121 - 122**

Moderators: *Ferdinand* . Muehlbacher, *Patricia* . Campbell

O51.01 Imbalance of Intragraft Th1/Th2 Transcription Factors is Strongly Correlated with Different Mechanism of Acute Renal Allograft Rejection

Q. Sun, Z. Liu, D. Cheng, M. Zhang, L. Li  
Nanjing/CHINA

O51.02 Afectation of apoptotic pathways with the administration of immunosuppressive drugs to donors: the role of TNFa, Bax and Bcl-2.

F. Cicora<sup>1</sup>, N. Lausada<sup>2</sup>, P. Gonzalez<sup>1</sup>, G. Palti<sup>1</sup>, C. Raimondi<sup>1</sup>  
<sup>1</sup>Buenos Aires/ARGENTINA, <sup>2</sup>La Plata/ARGENTINA

O51.03 Allospecific CD154+T-Cytotoxic Memory Cells Associate with Acute Cellular Rejection After Renal Transplantation.



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

C. Ashokkumar, R. Shapiro, H.P. Tan, B. Elinoff, S. Fedorek, C. Morgan, R. Sindhi, A. Humar  
Pittsburgh/UNITED STATES OF AMERICA

O51.04 Potential Value of Foxp3 and Regulatory T cell-Related Gene Expression monitoring in Peripheral Blood after Renal Transplantation

H. Iwase<sup>1</sup>, T. Kobayashi<sup>1</sup>, K. Iwasaki<sup>1</sup>, M. Haneda<sup>1</sup>, A. Katayama<sup>1</sup>, A. Takeda<sup>1</sup>, K. Morozumi<sup>1</sup>, Y. Watarai<sup>1</sup>, K. Uchida<sup>2</sup>, Y. Kodera<sup>1</sup>, A. Nakao<sup>1</sup>  
<sup>1</sup>Nagoya City/JAPAN, <sup>2</sup>Nagoya/JAPAN

O51.05 Post operative monitoring of donor specific T cells response as a prognostic factor in organ transplantation by the assay using the indirect presentation of autologous dendritic cells

D.-J. Han, Y.-M. Wee, D.-G. Lim, Y.-H. Kim, M.Y. Choi, Y.-H. Kim, J.-H. Jung, S.-C. Kim  
Seoul/KOREA

O51.06 Increased frequency of CD4+CD25+FoxP3+ T cells in patients with chronic allograft dysfunction after kidney transplantation

K. Timrott, F.W.R. Vondran, S. Kollrich, F. Lehner, J. Klempnauer, R. Schwitzer  
Hannover/GERMANY

O51.07 B and Plasma Cells, but not C4d, in Renal Biopsies During Acute Rejection are Sensitive Markers of Poor Graft Outcome

A. Chang, J.W. Williams, M.Z. David, M. Josephson, J.M. Moore, M.J. Millis, A.S. Chong  
Chicago/UNITED STATES OF AMERICA

O51.08 Urine Metabolic Profiling Alterations in Response to Acute Cellular Allograft Rejection after Kidney Transplantation

X. wang, T. zhu, D. zhu, M. xu, R. rong, Y. Guo  
Shanghai/CHINA

### Session O52 Experimental Islet Transplantation

Wednesday, August 18, 2010 03:30 PM - 05:00 PM  
Room: MR 212 - 214

Moderators: *Leo . Buhler, Olle . Korsgren*



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O52.01 Interruption of a cross-talk between the complement and coagulation cascades improves early outcomes after intraportal islet transplantation

K. Tokodai<sup>1</sup>, M. Goto<sup>1</sup>, A. Inagaki<sup>1</sup>, W. Nakanishi<sup>1</sup>, N. Okada<sup>2</sup>, H. Okada<sup>3</sup>, S. Satomi<sup>1</sup>  
<sup>1</sup>Sendai/JAPAN, <sup>2</sup>Nagoya/JAPAN, <sup>3</sup>Toyohashi/JAPAN

O52.02 Recruitment of T regulatory cells to islet grafts prevents recurrent autoimmune diabetes

L. Bischoff, J. Montane, G. Soukhatcheva, D. Dai, R. Tan, C.B. Verchere  
Vancouver/CANADA

O52.03 Development of a New Strategy for Minimizing Islet Cell Mass in Type 1 Diabetic Recipients: Diannexin Reduces Proapoptotic Bid, Promotes Anti-inflammatory Interleukin-10 and Improves Early Graft Function in the Marginal Islet Mass Transplantation Model

E. Cheng, H. Yang, V. Sharma, M. Lagman, D. Leeser, M. Suthanthiran  
New York/UNITED STATES OF AMERICA

O52.04 A pathway for Human Islet Protease-Activated Receptors (PARs) in Tissue Factor mediated Immediate Blood Inflammatory Reaction.

H.S. Smith-Hurst, S.P. Stoner, P.M. Phillips, L. Williams, A. Patel, W.J. Hawthorne, P.J. O'Connell  
Westmead/AUSTRALIA

O52.05 T regulatory cell mediated protection of allograft in type 1 diabetes

J. Montane, L. Bischoff, G. Soukhatcheva, G. Hardenberg, M.K. Levings, R. Tan, C.B. Verchere  
Vancouver/CANADA

O52.06 Pancreatic islets undergo substantial molecular remodelling after islet isolation and transplantation, resulting in heparanase-mediated damage during allograft rejection

C.J. Simeonovic<sup>1</sup>, F.J. Choong<sup>1</sup>, A. Ziolkowski<sup>1</sup>, D. Brown<sup>1</sup>, S. Popp<sup>1</sup>, C. Freeman<sup>1</sup>, H. Irving-Rodgers<sup>2</sup>, R. Rodgers<sup>2</sup>, C. Parish<sup>1</sup>  
<sup>1</sup>Canberra/AUSTRALIA, <sup>2</sup>Adelaide/AUSTRALIA

O52.07 In vitro and in vivo over-induction of autophagy in pancreatic islets by rapamycin and impairs islet function

M. Tanemura, Y. Ohmura, T. Machida, T. Deguchi, H. Wada, S. Kobayashi, S. Marubashi, H. Eguchi, Y. Takeda, T. Ito, M. Mori, Y. Doki, H. Nagano  
Suita/JAPAN

O52.08 Human Islets Prepared For Clinical Transplantation Exhibit An Altered Glycolytic Profile



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. Grey<sup>1</sup>, M. Cowley<sup>1</sup>, J. Cantley<sup>1</sup>, A. Weinberg<sup>1</sup>, W. Hawthorne<sup>2</sup>, S. Alexander<sup>3</sup>, J. Gunton<sup>1</sup>, T. Loudovaris<sup>4</sup>, L. Williams<sup>2</sup>, A. Patel<sup>2</sup>, S.N. Walters<sup>1</sup>, W. Kaplan<sup>1</sup>, P.J. O'Connell<sup>2</sup>

<sup>1</sup>Darlinghurst/AUSTRALIA, <sup>2</sup>Sydney/AUSTRALIA, <sup>3</sup>Westmead/AUSTRALIA, <sup>4</sup>Fitzroy/AUSTRALIA

O52.09 Treatment with Anakinra and Tocilizumab reduce the pro-inflammatory response and enhances islet survival and function in human islets during culture: implications for clinical islet transplantation.

A. Sahraoui<sup>1</sup>, K. Kloster-Jensen<sup>1</sup>, T. Lund<sup>1</sup>, O. Korsgren<sup>2</sup>, A. Foss<sup>1</sup>, H. Scholz<sup>1</sup>

<sup>1</sup>Oslo/NORWAY, <sup>2</sup>Uppsala/SWEDEN



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

THURSDAY, AUGUST 19

### 07:00 – 08:15 SUNRISE SYMPOSIA

#### Session SUN17 Women in transplantation

Thursday, August 19, 2010 07:00 AM - 08:15 AM

Room: MR 212 - 214

Moderators: *Kathryn . Wood, Lee Anne . Tibbles*

SUN17.1 Update on the WIT initiative

K.J. Wood

Oxford/UNITED KINGDOM

SUN17.2 Women in Academic Careers: Progress and Persistent Hurdles

J. Lieberman

Boston/UNITED STATES OF AMERICA

SUN17.3 Career challenges for young women in transplantation sciences

C. Baan

Rotterdam/NETHERLANDS

SUN17.4 Career challenges for women as clinician-scientists in transplantation

S. Moffatt-Bruce

Columbus/UNITED STATES OF AMERICA

#### Session SUN18 IATDMCT Partner Symposium: Therapeutic monitoring of immunosuppression

Thursday, August 19, 2010 07:00 AM - 08:15 AM

Room: MR 202 - 204

Moderators: *Eric . Thervet, David . Holt*

SUN18.1 Evolving strategies for therapeutic drug monitoring



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

D.W. Holt  
London/UNITED KINGDOM

SUN18.2 The contribution of pharmacogenomics and pharmacogenetics

D.R. Kuypers  
Leuven/BELGIUM

SUN18.3 Biomarkers of pharmacological effect

E.S. Thervet  
Paris/FRANCE

SUN18 - DISCUSSION

### Session SUN19 Exciting updates in CMV

**Thursday, August 19, 2010 07:00 AM - 08:15 AM**  
**Room: MR 205 - 207**

Moderators: *Roberta . Lattes, Raymund . Razonable*

SUN19.1 Biology and Pathogenesis

H.-D. Volk  
Berlin/GERMANY

SUN19.2 Summary of TTS Guidelines

C.N. Kotton  
Boston/UNITED STATES OF AMERICA

SUN19.3 Immunology and Assays

M. Sester  
Homburg/GERMANY

SUN19.4 Optimal Management in Lung Transplant

M. Zamora  
Aurora/UNITED STATES OF AMERICA



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

SUN19 - DISCUSSION

### Session SUN20 Detection and monitoring of antibodies after transplantation

Thursday, August 19, 2010 07:00 AM - 08:15 AM

Room: MR 211

Moderators: *Rob . Higgins, Karen . Nelson*

SUN20.1 Update on desensitization strategies

J.M. Gloor

Rochester/UNITED STATES OF AMERICA

SUN20.2 Determinants of antibody formation and titre after transplantation

R. Bray

Atlanta/UNITED STATES OF AMERICA

SUN20.3 Long-term implications of HLA antibody

C. Suesal

SUN20.4 Monitoring and treatment of antibody-mediated rejection

R.A. Montgomery

Baltimore/UNITED STATES OF AMERICA

SUN20 - DISCUSSION

### 08:30 – 10:00 PLENARY SYMPOSIA

### Session PL04 Innovations in Immune Suppression

Thursday, August 19, 2010 08:30 AM - 10:00 AM

Room: Ballroom A/B

Moderators: *Greg . Knoll, Gary . Levy*



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

PL04.1 miRNA in Immunity and Transplantation

J. Bluestone

San Francisco/UNITED STATES OF AMERICA

PL04.2 Guidance of Immunosuppression by Biomarkers

P. Reinke

Berlin/GERMANY

PL04.3 Current Advances in Clinical Immunosuppression

R.B. Mannon

Birmingham/UNITED STATES OF AMERICA

### 10:30 – 12:00 MORNING CONCURRENT SYMPOSIA

#### Session O53 Clinical Role of HLA Antibodies

Thursday, August 19, 2010 10:30 AM - 12:00 PM

Room: MR 202 - 204

Moderators: *Samantha . Fidler, Phil . Dyer*

O53.01 Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants

R.J. Duquesnoy, M. Marrari

Pittsburgh/UNITED STATES OF AMERICA

O53.02 Anti-HLA Antibody Characteristics Influence Results of Plasma Cell Targeted Therapy For Antibody Mediated Rejection

E.S. Woodle<sup>1</sup>, A. Girnita<sup>1</sup>, P. Brailey<sup>1</sup>, M. Zand<sup>2</sup>, R.C. Walsh<sup>1</sup>, R.R. Alloway<sup>1</sup>

<sup>1</sup>Cincinnati/UNITED STATES OF AMERICA, <sup>2</sup>Rochester/UNITED STATES OF AMERICA

O53.03 HLA Antibodies Can be Detected in Kidney Allograft Biopsies and Nephrectomy Tissue Even When Not Present in Serum



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

H. Kaneku<sup>1</sup>, P.I. Terasaki<sup>1</sup>, H.L. Trivedi<sup>2</sup>, A.V. Vanikar<sup>2</sup>, V.B. Trivedi<sup>2</sup>, W. Wong<sup>3</sup>, E. Zorn<sup>3</sup>, F. Porcheray<sup>3</sup>, J. DeVito<sup>3</sup>, M.J. Everly<sup>4</sup>

<sup>1</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>2</sup>Ahmedabad/INDIA, <sup>3</sup>Boston/UNITED STATES OF AMERICA, <sup>4</sup>Canoga Park/UNITED STATES OF AMERICA

053.04 The Impact of Donor Specific Antibody on Liver Allograft Survival after Living Donor Liver Transplantation

A. Yoshizawa<sup>1</sup>, H. Egawa<sup>2</sup>, Y. Ogura<sup>1</sup>, K. Yurugi<sup>1</sup>, R. Hishida<sup>1</sup>, E. Ashihara<sup>1</sup>, A. Miyagawa-Hayashino<sup>1</sup>, H. Ohe<sup>1</sup>, T. Iida<sup>1</sup>, K. Hata<sup>1</sup>, M. Nizumoto<sup>1</sup>, A. Mori<sup>1</sup>, T. Kaido<sup>1</sup>, T. Maekawa<sup>1</sup>, S. Uemoto<sup>1</sup>

<sup>1</sup>Kyoto/JAPAN, <sup>2</sup>Gifu/JAPAN

053.05 Are Additional Antibodies Detected by Luminex Single Antigen Testing Clinically Relevant? A Collaborative Transplant Study Report

C. Süsal, K. Mahmoud, J. Ovens, A. Ruhstroth, B. Döhler, S. Scherer, G. Opelz  
Heidelberg/GERMANY

053.06 Contributions of Flow Cross Match (FXM) Results and Donor Specific Antibody (DSA) Measurements to Antibody Mediated Rejection (AMR) in Donor Sensitized Kidney Transplants

T.B. Dunn<sup>1</sup>, O. Ozturk<sup>2</sup>, H. Noreen<sup>1</sup>, D. Maurer<sup>1</sup>, R. Bray<sup>2</sup>, H. Gebel<sup>2</sup>, A.J. Matas<sup>1</sup>  
<sup>1</sup>Minneapolis/UNITED STATES OF AMERICA, <sup>2</sup>Atlanta/UNITED STATES OF AMERICA

053.07 Donor Specific Antibody Changes after Nephrectomy

B.K. Book, N.G. Higgins, G.J. Eckert, K.M. Rosner, A. Lobashevsky, M.D. Pescovitz  
Indianapolis/UNITED STATES OF AMERICA

053.08 Epitope specificity of HLA DQA1 and DQB1 antibodies detected in sera from renal transplant recipients.

A. Piazza, G. Ozzella, E. Poggi, D. Caputo, R. Cremona, V. Imbroglini, D. Adorno  
Rome/ITALY

### Session O54 NK Cells in Graft Injury and Acceptance

Thursday, August 19, 2010 10:30 AM - 12:00 PM

Room: MR 205 - 207

Moderators: *M.-J. Hébert, Alice Mui*



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O54.01 Depletion of NK cells Prevents Spontaneous Acceptance of Liver Allografts

T. Ito, M. Wang, L.-E. Wai, C.O. Esquivel, O.M. Martinez, S.M. Krams  
Stanford/UNITED STATES OF AMERICA

O54.02 Depletion of macrophages and/or NK cells in combination with T cell targeting based strategies eliminates the requirement of irradiation for engraftment

H. Xu, J. Yan, Z. Zhu, Y. Huang, Y. Wen, L.D. Bozulich, S.T. Ildstad  
Louisville/UNITED STATES OF AMERICA

O54.03 Small Intestine Allograft Survival is Prolonged in the Absence of NKG2D

L.-E. Wai, M. Wang, T. Ito, K. Piard-Ruster, O.M. Martinez, S.M. Krams  
Stanford/UNITED STATES OF AMERICA

O54.04 Reciprocal Activation of Natural Killer (NK) Cells and Dendritic Cells with a Distinct Role for NKp46 in NK Cell Activation

L.-E. Wai, S.M. Krams  
Stanford/UNITED STATES OF AMERICA

O54.05 The inhibitory receptor FcγRIIb delays chronic but not acute allograft rejection

C.J. Callaghan, T.S. Win, I. Harper, T. Conlon, R. Motallebzadeh, S. Sivaganesh, M. Goddard, E.M. Bolton, J.A. Bradley, R. Brownlie, K. Smith, G.J. Pettigrew  
Cambridge/UNITED KINGDOM

O54.06 NK cell regulation of antigen-driven T cell expansion

M. Braun, K. Weatherly, F. Gaudray, M. Noval Rivas  
Gosselies/BELGIUM

O54.07 Alloreactivity of rat NK cells is reduced by the membrane molecule rClrb (RT12) encoded by the Natural killer gene complex (NKC)

D. Poehnert<sup>1</sup>, J. Hundrieser<sup>1</sup>, M. Koch<sup>2</sup>, J. Klempnauer<sup>1</sup>, K. Wonigeit<sup>1</sup>  
<sup>1</sup>Hanover/GERMANY, <sup>2</sup>Hamburg/GERMANY

O54.08 Targeting the NK cell cytotoxicity receptor NKp46 delays acute graft rejection in a murine model of heterotopic heart transplantation

C.-T. Le, D. Stauch, K. Göldner, K. Kotsch, K. Kunert  
Berlin/GERMANY



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O54.09 Rapamycin and Mycophenolic acid, but not Cyclosporin A, impair human NK cell cytolytic activity due to differential effects on the NK cell phenotype in vitro

D.N. Eissens, A. van der Meer, B. van Cranenbroek, F.W.M.B. Preijers, I. Joosten  
Nijmegen/NETHERLANDS

#### Session O55 Molecular and Cellular Pathology of the Kidney Allograft

**Thursday, August 19, 2010 10:30 AM - 12:00 PM**  
**Room: MR 211**

Moderators: *Kim . Solez*

O55.01 Double Stains of p-53 and Cytokeratin-7 with SV-40 Staining Identify Different Phases and Location of Polyoma Virus Infection in Renal Allograft Biopsies

P.L. Zhang, W.N. Wiesend, M.A. Farinola, D. Samarapungavan, M.T. Rooney, S.K. Hicks, S.R. Cohn, G.H. Reddy, L.L. Rocher, F. Dumler, R.K. Parasuraman  
Royal Oak/UNITED STATES OF AMERICA

O55.02 Inflammation in Areas of Tubular Atrophy (iatr) Predicts Kidney Allograft Failure

R.B. Mannon<sup>1</sup>, A.J. Matas<sup>2</sup>, R. Leduc<sup>2</sup>, J.M. Cecka<sup>3</sup>, F. Cosio<sup>4</sup>, R. Gaston<sup>1</sup>, S. Gourishankar<sup>5</sup>, P. Halloran<sup>5</sup>, L. Hunsicker<sup>6</sup>, B. Kasiske<sup>2</sup>, D. Rush<sup>7</sup>, J. Grande<sup>4</sup>  
<sup>1</sup>Birmingham/UNITED STATES OF AMERICA, <sup>2</sup>Minneapolis/UNITED STATES OF AMERICA, <sup>3</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>4</sup>Rochester/UNITED STATES OF AMERICA, <sup>5</sup>Edmonton/CANADA, <sup>6</sup>Iowa City/UNITED STATES OF AMERICA, <sup>7</sup>Winnipeg/CANADA

O55.03 C4d (+) and C4d (-) chronic transplant glomerulopathy cases – clinical and histological characteristics

A. Perkowska-Ptasinska<sup>1</sup>, M. Cizek<sup>1</sup>, A.L. Urbanowicz<sup>1</sup>, A. Chmura<sup>1</sup>, S. Nazarewski<sup>1</sup>, L. Paczek<sup>1</sup>, M. Glyda<sup>2</sup>, A. Debska-Slizien<sup>3</sup>, A. Rydzewski<sup>1</sup>, K. Dziewanowski<sup>4</sup>, M. Durlik<sup>1</sup>  
<sup>1</sup>Warsaw/POLAND, <sup>2</sup>Poznan/POLAND, <sup>3</sup>Gdansk/POLAND, <sup>4</sup>Szczecin/POLAND

O55.04 Interstitial fibrosis evolution on early sequential routine renal allograft biopsies using numerical quantification analysis

A. Servais, E.S. Thervet, V. Meas-Yedid, L.H. Noel, F. Martinez, H. Kreis, J. Zuber, M.O. Timsit, J.C. Olivo Marin, C. Legendre  
Paris/FRANCE

O55.05 The Maryland Aggregate Pathology Index (MAPI) is superior to the Kidney Donor Risk Index (KDRI) as a predictor of graft outcome.



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

B. Philosophe, B.P. Neuman, R.N. Barth, E.J. Schweitzer, S.A. Fayek, S.T. Bartlett, M. Cooper, R. Munivenkatappa  
Baltimore/UNITED STATES OF AMERICA

O55.06 C4d now and then

P.S. Verghese, T.B. Dunn, K.J. Gillingham, Y. Kim, A.J. Matas  
Minneapolis/UNITED STATES OF AMERICA

O55.07 Deficiency in Donor Interleukin 6 Expression Prolongs Renal Allograft Survival

H. Wang<sup>1</sup>, Z. Lan<sup>1</sup>, W. Ge<sup>1</sup>, Q. Guan<sup>2</sup>, H. Chen<sup>3</sup>, C.Y. Nguan<sup>2</sup>, C. Du<sup>2</sup>  
<sup>1</sup>London/CANADA, <sup>2</sup>Vancouver/CANADA, <sup>3</sup>Montreal/CANADA

O55.08 Adverse impact of mild hypertension post transplant on 1 year chronic interstitial fibrosis and tubular atrophy scores in kidney allograft biopsy among a cohort on rapid steroid withdrawal protocol.

H. Chakkera, Y. Devarapalli, D. Mulligan, M. Mazur, K. Hamawi, K. Reddy, A. Moss, K. Mekeel, R. Heilman  
Phoenix/UNITED STATES OF AMERICA

### Session O56 Epidemiology and Clinical Outcomes I

**Thursday, August 19, 2010 10:30 AM - 12:00 PM**  
**Room: MR 109 - 110**

Moderators: *Herwig-Ulf . Meier-Kriesche, Jagbir . Gill*

O56.01 A prospective cohort study on return to work, functional ability and health-related quality of life after kidney transplantation

M. Korkeila, L.-M. Petersson, B. von zur Mühlen, G. Tufveson, K. Alexanderson, A. Tibell  
Stockholm/SWEDEN

O56.02 GFR Slopes Have Significantly Improved Among Renal Transplants in the US

T. Srinivas, D. Goldfarb, E. Poggio, S. Flechner, J.D. Schold  
Cleveland/UNITED STATES OF AMERICA

O56.03 The Framingham Risk Score underestimates cardiovascular events in Canadian renal transplant recipients



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S.A. Silver, M. Huang, M.M. Nash, G.V.R. Prasad  
Toronto/CANADA

O56.04 Reduced risk of renal graft loss from recurrent glomerulonephritis in the modern transplant era

P. Clayton<sup>1</sup>, S.P. McDonald<sup>2</sup>, S. Chadban<sup>1</sup>  
<sup>1</sup>Sydney/AUSTRALIA, <sup>2</sup>Adelaide/AUSTRALIA

O56.05 Evolution of Glucose Metabolism Early after Kidney Transplantation using The Latest American Diabetes Association Guideline

F.L. Luan, A.O. Ojo  
Ann Arbor/UNITED STATES OF AMERICA

O56.06 Different etiologies of graft loss and death in Asian kidney transplant recipients: A report from Thai Transplant Registry

Y. Avihingsanon<sup>1</sup>, A. Ingsathit<sup>1</sup>, N. Premasathian<sup>1</sup>, C. Pongskul<sup>2</sup>, S. Jittiganont<sup>3</sup>, V. Sumethkul<sup>1</sup>  
<sup>1</sup>Bangkok/THAILAND, <sup>2</sup>Khon Kaen/THAILAND, <sup>3</sup>Chiang-Mai/THAILAND

O56.07 Screening for renal cancer in recipients of kidney transplants

G. Wong<sup>1</sup>, K. Howard<sup>2</sup>, A. Webster<sup>2</sup>, J.R. Chapman<sup>1</sup>, J. Craig<sup>1</sup>  
<sup>1</sup>Westmead/AUSTRALIA, <sup>2</sup>Sydney/AUSTRALIA

O56.08 Racial Disparity in the Outcome of Simultaneous Pancreas and Kidney Transplantation

F.L. Luan, M. Kommareddi, D.M. Cibrik, M. Samaniego, A.O. Ojo  
Ann Arbor/UNITED STATES OF AMERICA

O56.09 Period Analysis for More Up-to-Date Graft and Patient Survival Estimates in Transplantation: An Evaluation Using United Network for Organ Sharing Data

A. Gondos, H. Brenner  
Heidelberg/GERMANY

### Session O57 Pre-Clinical Immunosuppressive Agents

**Thursday, August 19, 2010 10:30 AM - 12:00 PM**  
**Room: Ballroom A/B**

Moderators: *Randall . Morris, Daniel . Abramowicz*



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

057.01 Mechanism Analysis of Long Term Graft Survival by Monocarboxylate Transporter-1 (MCT-1) Inhibition

K. Cho, T. Yamada, C. Wynn, H. Behanna, I.-C. Hong, V. Manaves, Y. Abe, H. Jiang, K. Tamura, Y. Saita Skokie/UNITED STATES OF AMERICA

057.02 Protective Immunity Remains Intact following Antibody Removal via Proteasome Inhibition

M.J. Everly<sup>1</sup>, P.I. Terasaki<sup>2</sup>, H.L. Trivedi<sup>3</sup>, J. Hopfield<sup>1</sup>, H. Kaneku<sup>2</sup>  
<sup>1</sup>Canoga Park/UNITED STATES OF AMERICA, <sup>2</sup>Los Angeles/UNITED STATES OF AMERICA,  
<sup>3</sup>Ahmedabad/INDIA

057.03 Soluble CD83-Mediated Kidney Allograft Tolerance Associated with Prevalence of Tolerogenic Dendritic Cells and Expression of Indoleamine 2,3-dioxygenase

Z. Lan<sup>1</sup>, W. Ge<sup>1</sup>, J. Arp<sup>1</sup>, J. Jiang<sup>1</sup>, W. Liu<sup>1</sup>, D. Healey<sup>2</sup>, C. Nicolette<sup>2</sup>, A.M. Jevnikar<sup>1</sup>, B. Garcia<sup>1</sup>, H. Wang<sup>1</sup>  
<sup>1</sup>London/CANADA, <sup>2</sup>Durham/UNITED STATES OF AMERICA

057.04 Suppression of Antidonor Antibody Response by Soluble CD83 Prevents Chronic Renal Allograft Rejection

Z. Lan<sup>1</sup>, W. Ge<sup>1</sup>, J. Arp<sup>1</sup>, W. Liu<sup>1</sup>, S. Brand<sup>2</sup>, D. Healey<sup>2</sup>, C. Nicolette<sup>2</sup>, B. Garcia<sup>1</sup>, H. Wang<sup>1</sup>  
<sup>1</sup>London/CANADA, <sup>2</sup>Durham/UNITED STATES OF AMERICA

057.05 Selective CD28 inhibition prolongs graft survival and attenuates CAV in monkey heart recipients treated with CD154 blockade

T. Zhang<sup>1</sup>, L. Burdorf<sup>1</sup>, S. Kelishadi<sup>1</sup>, T. Stoddard<sup>1</sup>, C.J. Avon<sup>1</sup>, A. Laaris<sup>1</sup>, A. Ward<sup>1</sup>, X. Cheng<sup>1</sup>, E. Welty<sup>1</sup>, J.-P. Soulillou<sup>2</sup>, B. Vanhove<sup>2</sup>, A.M. Azimzadeh<sup>1</sup>, R.N. Pierson III<sup>1</sup>  
<sup>1</sup>Baltimore/UNITED STATES OF AMERICA, <sup>2</sup>Nantes/France

057.06 In vivo immunosuppressive effects of intravenous immunoglobulin on innate and adaptive immune cells involved in allograft rejection

A.S. Tjon, T. Tha-In, H.J. Metselaar, L.V.D. Laan, Z.M. Groothuisink, S. Mancham, M.V. Hagen, J. Kwekkeboom  
Rotterdam/NETHERLANDS

057.07 DTCM-glutarimide, a new activator protein-1 (AP-1) inhibitor ameliorates transplant vasculopathy in mice

M. Zaitso<sup>1</sup>, K. Yamashita<sup>1</sup>, S. Shibasaki<sup>1</sup>, R. Goto<sup>1</sup>, K. Wakayama<sup>1</sup>, H. Gentaro<sup>1</sup>, Y. Tsunetoshi<sup>1</sup>, R. Igarashi<sup>1</sup>, M. Ozaki<sup>1</sup>, K. Umezawa<sup>2</sup>, S. Todo<sup>1</sup>  
<sup>1</sup>Sapporo/JAPAN, <sup>2</sup>Yokohama/JAPAN



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O57.08 Treatment of brain dead donors with anti-IL-6R monoclonal antibody attenuates the early and late inflammatory immune response

A. Reutzel-Selke<sup>1</sup>, F. Beiglboeck<sup>1</sup>, M. Velikova<sup>1</sup>, M. Marksteiner<sup>1</sup>, D. Polenz<sup>1</sup>, S. Lippert<sup>1</sup>, P. Neuhaus<sup>1</sup>, K. Kotsch<sup>1</sup>, J. Pratschke<sup>2</sup>

<sup>1</sup>Berlin/GERMANY, <sup>2</sup>Innsbruck/AUSTRIA

O57.09 SHIP Agonist Regulation of the Immune Response

A. Ming-Lum

Vancouver/CANADA

### Session O58 Other Viral Infections in Transplantation

**Thursday, August 19, 2010 10:30 AM - 12:00 PM**

**Room: MR 220 - 222**

Moderators: *Raymund . Razonable, Dietmar . Abendroth*

O58.01 Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients: An Interim Analysis

F. Sanai<sup>1</sup>, K.I. Bzeizi<sup>1</sup>, K.A. Almeshari<sup>2</sup>, D. Mousa<sup>1</sup>, H. ashgar<sup>2</sup>, G. ALshoail<sup>1</sup>, A. AlMadani<sup>1</sup>, H.A. Aleid<sup>2</sup>

<sup>1</sup>11211/SAUDI ARABIA, <sup>2</sup>Riyadh/SAUDI ARABIA

O58.02 Beta Cell Replacement Therapy in Five HIV Infected Patients with Renal Failure Secondary to Type I Diabetes Mellitus

G.R. Roll, A.M. Posselt, C.E. Freise, S.-M. Kang, R. Hirose, G. Szot, S. Feng, P. Stock  
San Francisco/UNITED STATES OF AMERICA

O58.03 Dengue Viral Infection in Renal Transplant Recipients in Karachi Pakistan.

S. Baqi, A. Nasim, S. Anis, T. Aziz, S.A.H. Rizvi, S.M. Zeeshan  
Karachi/PAKISTAN

O58.04 Adenovirus Infection is a Significant Complication Following Kidney Transplantation: Course of Infection and Outcome in Relation to the Level of Blood Adenovirus DNA and Lymphocyte Reconstitution

S.P. Watcharananan, A. Engsathit, K. Malathum, W. Chantratitaya, V. Mavichak, S. Jirasirithum, V. Sumethkul  
Bangkok/THAILAND



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O58.05 Impaired varicella zoster virus specific memory T-cell responses in kidney transplant patients

N.M. van Besouw, G.M.G.M. Verjans, J.M. Zijderwijk, A.L. Geel, W. Weimar  
Rotterdam/NETHERLANDS

O58.06 Pandemic Influenza A/H1N1 virus infection in solid organ transplant recipients: A multicenter study

A. Smud<sup>1</sup>, C. Nagel<sup>1</sup>, E. Madsen<sup>1</sup>, M.C. Rial<sup>1</sup>, L. Barcan<sup>1</sup>, A. Gomez<sup>2</sup>, M. Bangher<sup>3</sup>, A. Martinoia<sup>4</sup>, J. Altclas<sup>1</sup>, C. Salgueira<sup>1</sup>, E. Temporiti<sup>1</sup>, P. Bonvehi<sup>1</sup>, N. Enriquez<sup>1</sup>, E. Efron<sup>1</sup>, J. Bibolini<sup>5</sup>, R. Lattes<sup>1</sup>  
<sup>1</sup>Buenos Aires/ARGENTINA, <sup>2</sup>Santa Fe/ARGENTINA, <sup>3</sup>Corrientes/ARGENTINA, <sup>4</sup>La Plata/ARGENTINA, <sup>5</sup>Formosa/ARGENTINA

O58.07 Adoptive transfer of EBV specific T-cells (EBV-CTL) for treatment of documented EBV lymphoma following allogeneic hematopoietic stem cell (HSCT) or organ transplants (OT): clinical, viral and immunologic correlates.

E. Doubrovina, B. Oflaz-Sozmen, N. Kernan, J. Young, S. Abramson, J. Barker, F. Boulad, H. Castro-Malaspina, J. Teruya-Feldstein, D. Filippa, A. Jakubowski, E. Kanaeva, E. Papadopoulos, S. Prockop, A. Scaradavou, T. Small, R. O'Reilly  
New York/UNITED STATES OF AMERICA

### Session O59 Striving to Harness the Immune System in Pediatric Solid Organ Transplantation

**Thursday, August 19, 2010 10:30 AM - 12:00 PM**

**Room: MR 217 - 219**

Moderators: *Richard . Kirk, Helen . Evans*

O59.01 Validation of a Transcriptional Profile of Tolerance in Pediatric Liver Transplant Recipients

L.J. Wozniak<sup>1</sup>, L. Li<sup>2</sup>, S. Hsieh<sup>2</sup>, R.S. Venick<sup>1</sup>, M.E. Ament<sup>1</sup>, R.W. Busuttill<sup>1</sup>, M.M. Sarwal<sup>2</sup>, S.V. McDiarmid<sup>1</sup>  
<sup>1</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>2</sup>Stanford/UNITED STATES OF AMERICA

O59.02 Circulating donor-specific anti-HLA antibody may identify rejection-prone pediatric small bowel transplant recipients

C. Ashokkumar, A. Zeevi, C. Bentejewski, J. Dobberstein, G. Mazariegos, K.M. Abu-Elmagd, R. Sindhi  
Pittsburgh/UNITED STATES OF AMERICA

O59.03 High prevalence of B-10 B-cells in human infants: Regulatory impact on immune response following heart transplantation?



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. Urschel, I.M. Larsen, I.M. Rebeyka, D.B. Ross, L.J. West  
Edmonton/CANADA

O59.04 HLA-G II genotype and low levels of soluble HLA-G post-transplant are associated with first year rejection post pediatric heart transplantation.

A. Zeevi, C. Bentlejewski, B. Feingold, R. Ferrell, J. Lunz, S. Ferrone, S. Webber  
Pittsburgh/UNITED STATES OF AMERICA

O59.05 Critical Role of Naive Regulatory T Cells in Operational Tolerance After Pediatric Living-Donor Liver Transplantation

H.A. Nafady Hego, Y. Li, H. Ohe, S. Sakaguchi, S. Uemoto, T. Koshiba  
Kyoto/JAPAN

O59.06 A Peripheral Blood 12 Gene-Set for Diagnosis of Pediatric Liver Allograft Tolerance

L. Li, A. Talisetti, S. Hsieh, K. Cox, C. Esquivel, W. Concepcion, M. Sarwal  
Stanford/UNITED STATES OF AMERICA

O59.07 Linking innate and adaptive immunity: C3d plasma levels and CD21 expressing B-cells in ABO-incompatible infant heart transplantation

S. Urschel, I.M. Larsen, K. Derkatz, L.J. West  
Edmonton/CANADA

O59.08 Epithelial-to-mesenchymal transition gene expression is associated with early tubulointerstitial damage in pediatric renal transplant recipients

M.J. Vitalone<sup>1</sup>, M. Naesens<sup>2</sup>, L. Li<sup>1</sup>, T. Sidgel<sup>1</sup>, S. Hesih<sup>1</sup>, M.M. Sarwal<sup>1</sup>  
<sup>1</sup>Stanford/UNITED STATES OF AMERICA, <sup>2</sup>Leuven/BELGIUM

O59.09 Alterations in T Regulatory Cell Levels in Pediatric Liver Transplant Recipients On Calcineurin Inhibitors Or Off Immunosuppression

K. Piard-Ruster, R. Silva, W. Berquist, B. Pham, A. Gallo, S.M. Krams, C. Esquivel, O.M. Martinez  
Stanford/UNITED STATES OF AMERICA

### Session O60 Outcomes of Liver Transplantation II

**Thursday, August 19, 2010 10:30 AM - 12:00 PM**

**Room: MR 118 - 120**

Moderators: *Sigfried . Erb, William . Wall*



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O60.01 Recipient Characteristics Associated with Early Hepatic Artery Thrombosis and Graft Loss after Liver Transplantation

T.M. Schmitt, S.C. Kumer, K. Brayman, C. Argo, P. Northup, T.R. Flohr  
Charlottesville/UNITED STATES OF AMERICA

O60.02 Liver transplantation using donation after cardiac death donors: Single-Centre long-term outcome

W. Jassem, D. Chasiotis, T. Cherian, S. Khorsandi, D. Davila, R. Valente, A. Prachalias, P. Srinivasan, H. Vilca Melendez, J. O'Grady, M. Heneghan, M. Rela, N. Heaton  
London/UNITED KINGDOM

O60.03 Can We Expand Liver Donor Pool using Donation after Cardiac Death in the United States?

M. Stapfer, Y.W. Cho, L. Sher, I.V. Hutchinson, Y. Genyk  
Los Angeles/UNITED STATES OF AMERICA

O60.04 Urinary ethyl glucuronide testing for detection of alcohol consumption is superior to common alcohol markers in liver transplant candidates and recipients

K. Stauer<sup>1</sup>, H. Andresen<sup>1</sup>, N. Tobias<sup>2</sup>, B. Nashan<sup>1</sup>, M. Sterneck<sup>1</sup>  
<sup>1</sup>Hamburg/GERMANY, <sup>2</sup>Bremen/GERMANY

O60.05 Inhibition of Sphingosine Kinase Prevents Failure of Liver Grafts from Non-Heart-Beating Donors after Transplantation

Y. Shi, H. Rehman, C.D. Smith, Z. Zhong  
Charleston/UNITED STATES OF AMERICA

O60.06 Obesity as an adverse factor for survival in sick liver transplant recipients (MELD>25)

N. Onaca, S. Chinnakotla, G.J. McKenna, R. Ruiz, M. Asolati, P. Kim, K. Cavaness, K. Tomiyama, B. Yildiz, R. Goldstein, M.F. Levy, G. Klintmalm  
Dallas/UNITED STATES OF AMERICA

O60.07 The Positive Crossmatch in Liver Transplantation: A Risk Factor for Preservation Injury?

R. Ruiz, K. Tomiyama, S. Chinnakotla, R. Goldstein, M.F. Levy, G.J. McKenna, N. Onaca, H. Randall, B. Susskind, L. Jennings, G.W. Tillery, G. Klintmalm  
Dallas/UNITED STATES OF AMERICA

O60.08 Liver transplantation in HIV+ versus HIV- patients: a case control study



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

U. Baccarani, G.L. Adani, D. Lorenzin, A. Londero, F. Bragantini, C. Comuzzi, A. Rossetto, V. Bresadola, A. Risaliti, P. Viale, M. Tavio  
Udine/ITALY

O60.09 A New Functional Definition of Initial Poor Function after Liver Transplantation

M. Stockmann, J.F. Lock, M. Malinowski, D. Seehofer, P. Neuhaus  
Berlin/GERMANY

#### Session O61 Bone Marrow Transplantation

**Thursday, August 19, 2010 10:30 AM - 12:00 PM**

**Room: Ballroom C**

Moderators: *Clay* . Smith, *Michael* . Barnett

O61.01 Transient Mixed Chimerism, Lymphocyte Recovery and Evidence for Early Donor-Specific Unresponsiveness in Patients Receiving Combined Kidney and Bone Marrow Transplantation to Induce Tolerance

S.A. LoCascio, T. Morokata, M. Chittenden, F.I. Preffer, D.M. Dombkowski, G. Andreola, K. Crisalli, T. Kawai, S. Saidman, T. Spitzer, N. Tolkoff-Rubin, B. Cosimi, D.H. Sachs, M. Sykes  
Boston/UNITED STATES OF AMERICA

O61.02 Administration of polyclonal recipient Tregs leads to mixed chimerism, skin and heart graft tolerance without irradiation

N. Pilat<sup>1</sup>, C. Klaus<sup>1</sup>, U. Baranyi<sup>1</sup>, E. Jaeckel<sup>2</sup>, R. Oberhuber<sup>3</sup>, G. Brandacher<sup>3</sup>, B. Zelger<sup>3</sup>, F. Muehlbacher<sup>1</sup>, T. Wekerle<sup>1</sup>

<sup>1</sup>Vienna/AUSTRIA, <sup>2</sup>Hannover/GERMANY, <sup>3</sup>Innsbruck/AUSTRIA

O61.03 Increased Frequency of Regulatory T cells in Patients Receiving HLA Haploidentical Combined Kidney and Bone Marrow Transplantation to Induce Tolerance

T. Morokata, S.A. LoCascio, F.I. Preffer, D.M. Dombkowski, G. Andreola, K. Crisalli, T. Kawai, S. Saidman, T. Spitzer, N. Tolkoff-Rubin, B. Cosimi, D.H. Sachs, M. Sykes  
Boston/UNITED STATES OF AMERICA

O61.04 Immune-based Conditioning to Establish Chimerism Induces Tolerance to Composite Tissue Allotransplants



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. Wu, B. Chen, H. Xu, A. Ocker, S.T. Ildstad  
Louisville/UNITED STATES OF AMERICA

O61.05 Bone Marrow Component of Hind Limb Allograft Promotes Marrow-Derived Hematopoietic Stem Cell Engraftment, Chimerism and Tolerance

Y. Wang, W. Zhang, D. Zhang, M. Solari, V.S. Gorantla, N. Murase, W.P.A. Lee, X.X. Zheng  
Pittsburgh/UNITED STATES OF AMERICA

O61.06 GVHD-associated immune suppression is the result of an intrinsic defect in MHC class II antigen presentation within donor DC

K.A. Markey, M. Koyama, R.D. Kuns, Y.A. Wilson, S.D. Olver, N.C. Raffelt, G.R. Hill, K.P.A. MacDonald  
Brisbane/AUSTRALIA

O61.07 Stem cell mobilization with G-CSF induces Th17 differentiation and promotes scleroderma.

G.R. Hill<sup>1</sup>, S.D. Olver<sup>1</sup>, R.D. Kuns<sup>1</sup>, A. Varelias<sup>2</sup>, N.C. Raffelt<sup>1</sup>, A. Don<sup>1</sup>, K.A. Markey<sup>1</sup>, Y.A. Wilson<sup>1</sup>, M.J. Smyth<sup>3</sup>, Y. Iwakura<sup>4</sup>, J. Tocker<sup>5</sup>, A. Clouston<sup>1</sup>, K.P.A. MacDonald<sup>1</sup>

<sup>1</sup>Brisbane/AUSTRALIA, <sup>2</sup>Herston/AUSTRALIA, <sup>3</sup>Melbourne/AUSTRALIA, <sup>4</sup>Tokyo/JAPAN, <sup>5</sup>Seattle/UNITED STATES OF AMERICA

### Session O62 Clinical Pancreas Transplantation II

**Thursday, August 19, 2010 10:30 AM - 12:00 PM**  
**Room: MR 212 - 214**

Moderators: *James . Shapiro, Steven . Paraskevas*

O62.01 Thymoglobulin vs Basiliximab as Induction Therapy for Combined Kidney-Pancreas Transplantation- Impact on Graft Rejection, Function, and Infectious Complications

F. Bazerbachi, M. Selzner, M. Marquez, A. Norgate, I.D. McGilvray, J. Schiff, M.S. Cattral  
Toronto/CANADA

O62.02 Occurrence and significance of de novo anti-HLA antibodies after pancreas transplantation

D. Cantarovich, S. De Amicis, A. Akl, F. Vistoli, G. Karam, M. Giral, J. Dantal, G. Blancho, J.-P. Souillou  
Nantes/FRANCE

O62.03 Outcome of Pancreas Transplantation with 5 Years Follow-up or More



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

F. Vistoli, C. Croce, S. Signori, C. Moretto, M. Del Chiaro, G. Amorese, M. Barsotti, P. Marchetti, U. Boggi  
Pisa/ITALY

O62.04 Pancreas Transplantation: A UK and US Comparison

A.J. Hudson<sup>1</sup>, L.L. Mumford<sup>1</sup>, R.J. Johnson<sup>1</sup>, S.V. Fuggle<sup>1</sup>, C.J.E. Watson<sup>2</sup>  
<sup>1</sup>Bristol/UNITED KINGDOM, <sup>2</sup>Cambridge/UNITED KINGDOM

O62.05 Import(IMP) vs Local(LOC) pancreas (px) - is there an increased risk?

R. Kandaswamy, D. Radosevich, B. Bland, D.E. Sutherland, T.B. Dunn, E.B. Finger, R. Fairchild, T. Pruett  
Minneapolis/UNITED STATES OF AMERICA

O62.06 Long-term results of pancreas transplantation in patients older than 50 years

P. Schenker<sup>1</sup>, T. Klein<sup>2</sup>, O. Vonend<sup>3</sup>, A. Wunsch<sup>1</sup>, B. Krämer<sup>2</sup>, R. Viebahn<sup>1</sup>  
<sup>1</sup>Bochum/GERMANY, <sup>2</sup>Herne/GERMANY, <sup>3</sup>Düsseldorf/GERMANY

O62.07 Antibody Mediated Rejection in Pancreas Allograft Recipients: Experience with Bortezomib-Based Therapy

A. Govil, R.C. Walsh, A. Tevar, R.R. Alloway, G. Mogilishetty, P. Brailey, A. Girnita, P. Roy-Chaudhury,  
E.S. Woodle  
Cincinnati/UNITED STATES OF AMERICA

O62.08 Dichotomy between DSA and C4d Deposition in Pancreas Allograft Rejection

A. Govil, A. Tevar, R.R. Alloway, G. Mogilishetty, P. Brailey, E.S. Woodle, P. Roy-Chaudhury  
Cincinnati/UNITED STATES OF AMERICA

O62.09 Sirolimus does not prolong wound healing in simultaneous pancreas and kidney recipients: a retrospective single center analysis

P. Girman, L. Pektorova, R. Koznarova, K. Lipar, P. Boucek, M. Adamec, F. Saudek  
Prague/CZECH REPUBLIC

### Session O63 Xenotransplantation II

**Thursday, August 19, 2010 10:30 AM - 12:00 PM**  
**Room: MR 121 - 122**

Moderators: *Henk-Jan . Schuurman, Kazuhiko . Yamada*



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

O63.01 Introduction of Human soluble TNFRI-Fc into porcine endothelial cells suppressed activation of porcine endothelial cells

B. CHO<sup>1</sup>, S. Hurh<sup>1</sup>, N.-I. Byeon<sup>1</sup>, H. Lee<sup>2</sup>, M.-G. Kim<sup>1</sup>, J. Yang<sup>1</sup>, B.C. Lee<sup>1</sup>, C. Ahn<sup>1</sup>  
<sup>1</sup>Seoul/KOREA, <sup>2</sup>Daejeon/KOREA

O63.02 Specific Humoral Non-responsiveness to Swine Antigens and Engraftment Following Administration of GalT-KO Porcine Bone Marrow to Baboons.

F. Liang<sup>1</sup>, A. Griesemer<sup>2</sup>, J.R. Scalea<sup>1</sup>, I. Wamala<sup>1</sup>, A. Tena<sup>1</sup>, S. Moran<sup>1</sup>, K. Yamada<sup>1</sup>, C.A. Huang<sup>1</sup>, D.H. Sachs<sup>1</sup>  
<sup>1</sup>Boston/UNITED STATES OF AMERICA, <sup>2</sup>New York/UNITED STATES OF AMERICA

O63.03 Anti-GPIIb Fab reduces activation and sequestration of human platelets in a xenogeneic pig lung perfusion model

L. Burdorf<sup>1</sup>, T. Zhang<sup>1</sup>, E. Rybak<sup>1</sup>, I.I. Salles<sup>2</sup>, K. Broos<sup>2</sup>, E. Welty<sup>1</sup>, C.J. Avon<sup>1</sup>, A. Laaris<sup>1</sup>, X. Cheng<sup>1</sup>, D. Ayares<sup>3</sup>, H. Deckmyn<sup>2</sup>, R.N. Pierson III<sup>1</sup>, A.M. Azimzadeh<sup>1</sup>  
<sup>1</sup>Baltimore/UNITED STATES OF AMERICA, <sup>2</sup>Kortrijk/BELGIUM, <sup>3</sup>Blacksburg/UNITED STATES OF AMERICA

O63.04 Quantification of Baboon Thymopoiesis In Porcine Thymokidney Xenografts by a Signal Joining TCR Excision Circle (sjTREC) Assay

A. Tena<sup>1</sup>, P. Vallabhajousula<sup>2</sup>, R.J. Hawley<sup>1</sup>, A. Griesemer<sup>3</sup>, K. Yamada<sup>1</sup>, D.H. Sachs<sup>1</sup>  
<sup>1</sup>Boston/UNITED STATES OF AMERICA, <sup>2</sup>Philadelphia/UNITED STATES OF AMERICA, <sup>3</sup>New York/UNITED STATES OF AMERICA

O63.05 Optimal T cell depletion is essential for successful thymokidney transplants in GalT-KO pig to baboon model

K. Yamada, H. Nishimura, J.R. Scalea, A. Griesemer, S. Moran, B. Gillon, S. Robson, J. Fishman, M. Sykes, A. Shimizu, D.H. Sachs  
Boston/UNITED STATES OF AMERICA

O63.06 Ex vivo expanded non-human primate regulatory T cells suppress effector cell response to xeno antigen.

J.L. Johnson, S. Kass, E. Hennessy, A. Pahuja, M. Graham, B.J. Hering, P. Bansal-Pakala  
Minneapolis/UNITED STATES OF AMERICA

O63.07 Humanized NOD-SCID IL-2 $\gamma$ -/- mice - A novel animal model to study human CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cell-mediated suppression in xenotransplantation



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

S. Yi, M. Ji, J. Wu, W. Hawthorne, L. Williams, P.J. O'Connell  
Sydney/AUSTRALIA

O63.08 Hepatocyte Growth Factor regimen in a life supporting xenoeneic islet transplantation CLAWN miniature swine - to - cynomologous monkey model

K. Yamada<sup>1</sup>, H. Nishimura<sup>1</sup>, H. Sahara<sup>1</sup>, T. Okitsu<sup>2</sup>, K. Setoyama<sup>1</sup>, M. Oku<sup>1</sup>, M. Tasaki<sup>1</sup>, O. Wunimenghe<sup>1</sup>,  
A. Griesemer<sup>3</sup>, H. Tsubouchi<sup>1</sup>, A. Shimizu<sup>1</sup>  
<sup>1</sup>Kagoshima/JAPAN, <sup>2</sup>Kyoto/JAPAN, <sup>3</sup>New York/UNITED STATES OF AMERICA

O63.09 Human CD47 expression prevents macrophage-mediated rejection of porcine cells in mice that express SIRPa capable of binding to human CD47

C. Wang<sup>1</sup>, H. Wang<sup>1</sup>, K. Ide<sup>2</sup>, Y. Wang<sup>1</sup>, H. Ohdan<sup>2</sup>, Y.-G. Yang<sup>1</sup>  
<sup>1</sup>Boston/UNITED STATES OF AMERICA, <sup>2</sup>Hiroshima/JAPAN

### 12:15 – 13:15 MINI ORAL SESSIONS

#### Session MO22 Immunopharmacology

**Thursday, August 19, 2010 12:15 PM - 01:15 PM**  
**Room: MR 202 - 204**

Moderators: *Dirk . Kuypers, Mario . Abbud-Filho*

MO22.01 Relationship Between Belatacept Exposure and Clinical Endpoints in Renal Transplant Patients

S. Zhou<sup>1</sup>, A. Roy<sup>1</sup>, J. Shen<sup>1</sup>, S. Kaul<sup>1</sup>, M. Pfister<sup>2</sup>  
<sup>1</sup>Princeton/UNITED STATES OF AMERICA, <sup>2</sup>Plainsboro/UNITED STATES OF AMERICA

MO22.02 Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Renal Transplant Patients

J. Shen, A. Block, R. Townsend, X. Xiaoli You, Y. Shen, S. Zhou, D. Geng, N. McGirr, K. Soucek, J. Pursley, G. Di Russo, S. Kaul  
Princeton/UNITED STATES OF AMERICA

MO22.03 Cyclosporin pharmacokinetics in Asian population and the impact of early AUC in predicting long term outcomes

M.N. Zafar, T. Aziz, H. Nawaz, E. Ahmed, R. Aziz, S.A.A. Naqvi, S.A.H. Rizvi  
Karachi/PAKISTAN



### TTS 2010 SCIENTIFIC PROGRAM

MO22.04 Multiple Regression Derived Limited Sampling Strategies for Mycophenolic Acid After Mycophenolate Mofetil Intake in Australian Adult Kidney Transplant Recipients

K.A. Barraclough, N.M. Isbel, M.E. Franklin, K.J. Lee, P.J. Taylor, S.B. Campbell, W.G. Petchy, C.E. Staatz  
Brisbane/AUSTRALIA

MO22.05 Evaluation of Limited Sampling Strategies for Simultaneous Estimation of Tacrolimus, Mycophenolic Acid and Prednisolone Exposure in Adult Kidney Transplant Recipients

K.A. Barraclough, N.M. Isbel, D.W. Johnson, G. Medley, K.J. Lee, D. Leary, S.B. Campbell, C.E. Staatz  
Brisbane/AUSTRALIA

MO22.06 Pharmacogenetic Factors affecting Mycophenolate Mofetil (MMF) Pharmacokinetic and Pharmacodynamic Variability in the Opticapt Kidney Transplant Study: Preliminary Analysis

M.C. Milone<sup>1</sup>, A. Israni<sup>2</sup>, W. Fan<sup>1</sup>, D. McGain<sup>1</sup>, N. Riccio<sup>1</sup>, R. Bloom<sup>1</sup>, U. Meier-Kriesche<sup>3</sup>, D.M. Cibrik<sup>4</sup>, B. Kaplan<sup>5</sup>, S. Mulgaonkar<sup>6</sup>, D. Patel<sup>7</sup>, L.M. Shaw<sup>1</sup>  
<sup>1</sup>Philadelphia/UNITED STATES OF AMERICA, <sup>2</sup>Minneapolis/UNITED STATES OF AMERICA,  
<sup>3</sup>Gainesville/UNITED STATES OF AMERICA, <sup>4</sup>Ann Arbor/UNITED STATES OF AMERICA, <sup>5</sup>Tucson/UNITED STATES OF AMERICA, <sup>6</sup>Livingston/UNITED STATES OF AMERICA, <sup>7</sup>East Hanover/UNITED STATES OF AMERICA

MO22.07 Early Mycophenolic Acid (MPA) Dose Modifications are Associated with Compromised Graft Outcomes: Rationale for Dose Changes and Analysis of Effects in the Mycophenolic Acid Observational Renal Transplant (MORE) Registry

F. Shihab<sup>1</sup>, R. Stratta<sup>2</sup>, A. Olyaei<sup>3</sup>, R. Carson<sup>4</sup>, O. Pankewycz<sup>5</sup>, A. Wiland<sup>6</sup>, P. Lake<sup>6</sup>  
<sup>1</sup>Salt Lake City/UNITED STATES OF AMERICA, <sup>2</sup>Winston-Salem/UNITED STATES OF AMERICA,  
<sup>3</sup>Portland/UNITED STATES OF AMERICA, <sup>4</sup>Spokane/UNITED STATES OF AMERICA, <sup>5</sup>Buffalo/UNITED STATES OF AMERICA, <sup>6</sup>E Hanover/UNITED STATES OF AMERICA

MO22.08 Initial intensified dosing of Enteric-Coated Mycophenolate Sodium (EC-MPS) versus Standard Dosing Improves Rejection Prophylaxis in De Novo Renal Transplant Recipients

D.M. Kuypers<sup>1</sup>, H. Tedesco-Silva<sup>2</sup>, W. Arns<sup>3</sup>, M. Zeier<sup>3</sup>, A. Shoker<sup>4</sup>, D. del Castillo<sup>5</sup>, G. Grandaliano<sup>6</sup>, B. Kiberd<sup>7</sup>, R. Walker<sup>8</sup>, F.T. Kawakami<sup>9</sup>, K. Budde<sup>10</sup>  
<sup>1</sup>Leuven/BELGIUM, <sup>2</sup>Sao Paulo/BRAZIL, <sup>3</sup>Cologne/GERMANY, <sup>4</sup>Saskatoon/CANADA, <sup>5</sup>Córdoba/SPAIN,  
<sup>6</sup>Bari/ITALY, <sup>7</sup>Halifax/CANADA, <sup>8</sup>Melbourne/AUSTRALIA, <sup>9</sup>Basel/SWITZERLAND, <sup>10</sup>Berlin/GERMANY

MO22.09 12-Month, Single-Center Evaluation of GI Complications in Renal Transplant Recipients Initiated on Mycophenolic Acid (MPA) Therapy



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

M. Cooper, F. Rasetto, B. Philosophe, S. Bartlett, J. Nogueira  
Baltimore/UNITED STATES OF AMERICA

MO22.10 Early Outcome Analysis of the Mycophenolic Acid Observational Renal Transplant (MORE) Registry: Initial Comparisons of EC-MPS (Myfortic®) and MMF (CellCept®).

A. Olyaei<sup>1</sup>, L. Chan<sup>2</sup>, K. Ueda<sup>3</sup>, B. Nibhanupudy<sup>4</sup>, L. Ratner<sup>5</sup>, E. Greer<sup>1</sup>, P. Lake<sup>6</sup>, A. Wiland<sup>7</sup>  
<sup>1</sup>Portland/UNITED STATES OF AMERICA, <sup>2</sup>Denver/UNITED STATES OF AMERICA, <sup>3</sup>San Francisco/UNITED STATES OF AMERICA, <sup>4</sup>Orlando/UNITED STATES OF AMERICA, <sup>5</sup>New York/UNITED STATES OF AMERICA, <sup>6</sup>E Hanover/UNITED STATES OF AMERICA, <sup>7</sup>East Hanover/UNITED STATES OF AMERICA

MO22.11 Everolimus(E) Vs Enteric Coated Mycophenolate Sodium (EC-MPS): Proteomic and Pathologic Aspects in a 1-Year Prospective Randomized Study

M. Salvadori<sup>1</sup>, E. Bertoni<sup>1</sup>, G. Ghiggeri<sup>2</sup>, M. Prunotto<sup>2</sup>, G. Candiano<sup>2</sup>, L. Santucci<sup>2</sup>, M. Bruschi<sup>2</sup>, A. Pedretto<sup>2</sup>, S. Moll<sup>3</sup>, A. Larti<sup>1</sup>  
<sup>1</sup>Florence/ITALY, <sup>2</sup>Genova/ITALY, <sup>3</sup>Geneva/SWITZERLAND

MO22.12 Maintenance immunosuppression with CNI and Everolimus after ABO incompatible living related kidney transplantation.

M. Koch, M. Strecker, W. Ternschert, A. Vernauer, L. Schewior, L. Fischer, F. Thaiss, B. Nashan  
Hamburg/GERMANY

### Session MO23 Pediatric Organ Transplantation

**Thursday, August 19, 2010 12:15 PM - 01:15 PM**  
**Room: MR 109 - 110**

Moderators: *Richard* . Thistlewaite, *Oscar* . Salvatierra

MO23.01 Immune Cell Function Assay in Pediatric Heart Transplant Recipients

M.-S. Wong<sup>1</sup>, M. Kemna<sup>2</sup>, L. Iwasaki<sup>2</sup>, J. Rutledge<sup>2</sup>, R. Boucek<sup>2</sup>, Y.M. Law<sup>2</sup>  
<sup>1</sup>Brisbane/AUSTRALIA, <sup>2</sup>Seattle/UNITED STATES OF AMERICA

MO23.02 Long-term Outcomes in Pediatric Intestinal Retransplantation

P. Abrams, K. Soltys, R. Sindhi, G. Bond, K.M. Abu-Elmagd, G. Mazariegos  
Pittsburgh/UNITED STATES OF AMERICA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO23.03 Plasma Proteomic Biomarker Candidates that Predict Acute Rejection in Pediatric Renal Transplantation

E.W. Tsai, J. LeBlanc, D.W. Gjertson, R.B. Ettenger, E.F. Reed  
Los Angeles/UNITED STATES OF AMERICA

MO23.04 BK Virus infection/replication prevalence in pediatric liver transplant recipients and its relation to long term renal function loss

G. VARELA-FASCINETTO, B. RUSSEK-PORTALES, M. MEDEIROS-DOMINGO, J.A. HERNANDEZ-PLATA, P. GARCIA-ROCA  
Mexico City/MEXICO

MO23.05 Inefficiency and ethical problems due to a pediatric priority allocation policy for deceased donor kidney in Quebec

J.-L. Wolff<sup>1</sup>, N. Philippe<sup>2</sup>  
<sup>1</sup>Sherbrooke/CANADA, <sup>2</sup>Montreal/CANADA

MO23.06 Pre-Transplant Treg Frequency Correlates with Rejection in Pediatric Renal Transplantation

J. Tong, S.-M. Kang, Q. Tang, P. Stock  
San Francisco/UNITED STATES OF AMERICA

MO23.07 Pediatric Liver Transplant Patients Exhibit Increases in Natural Killer Cell Activation Receptor Expression Post-Transplant

B. Pham, R. Silva, K. Piard-Ruster, A. Gallo, C.O. Esquivel, O.M. Martinez, S.M. Krams  
Stanford/UNITED STATES OF AMERICA

MO23.08 Prognosis and new advances in early portal vein thrombosis after pediatric liver transplantation. No-touch hilum technique

J. Bueno, C. Venturi, M. Perez Lafuente, A. Segara, I. Bilbao, R. Charco  
Barcelona/SPAIN

MO23.09 Outcome of liver retransplantation in children – impact of early and late retransplantation

U. Herden, R. Ganschow, B. Nashan, L. Fischer  
Hamburg/GERMANY

MO23.10 Outcome of focal segmental glomerulosclerosis after renal transplantation with/without podocin gene mutations in Turkish children



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

F. Mutlubas, B. Sozeri, A. Berdeli, C. Hoscoskun, S. Mir  
Izmir/TURKEY

MO23.11 Risk factors for early mortality following intestinal transplantation in children. Multivariate analysis.

C. DOPAZO-TABOADA, A. TAHA, G. GUPTA, K. SHARIF, J. Hartley, P. MUIESAN, D. MAYER, P. BROMLEY, J. BENET, D. MIRZA  
Birmingham/UNITED KINGDOM

### Session MO24 Cardiac and Metabolic Complications of Transplantation

**Thursday, August 19, 2010 12:15 PM - 01:15 PM**  
**Room: MR 211**

Moderators: *Bertram . Kasiske, Josep . Grinyo*

MO24.01 A retrospective audit of cardiac workup and outcomes in patients considered for renal transplantation at Auckland City Hospital

E. Curry, M. Webster, P. Mullins, H. Pilmore  
Auckland/NEW ZEALAND

MO24.02 Reticulated Platelets and Platelet Reactivity in Renal Transplant Recipients on anti Platelet Therapy

E. Bertoni, M. Zanazzi, F. Cesari, R. Marcucci, A.M. Gori, R. Caporale, A. Fanelli, R. Paniccia, A. Larti, R. Abbate, M. Salvadori  
Florence/ITALY

MO24.03 Similar Risk of Renal Graft Loss Due to Thrombosis for Everolimus Versus MPA-based Regimens

B. Stevens<sup>1</sup>, S. Flechner<sup>2</sup>, L.J. Wei<sup>3</sup>, G. Friedman<sup>4</sup>, M. Vergara<sup>4</sup>, H. Jiang<sup>4</sup>, H. Tedesco-Silva<sup>5</sup>, D. Cibrik<sup>6</sup>  
<sup>1</sup>Omaha/UNITED STATES OF AMERICA, <sup>2</sup>Cleveland/UNITED STATES OF AMERICA, <sup>3</sup>Boston/UNITED STATES OF AMERICA, <sup>4</sup>East Hanover/UNITED STATES OF AMERICA, <sup>5</sup>Sao Paulo/BRAZIL, <sup>6</sup>Ann Arbor/UNITED STATES OF AMERICA

MO24.04 Increased thrombogenicity associated with mTOR inhibition

M.C. Baas, V.E.A. Gerdes, J.C. Meijers, I.J.M. ten Berge, F.J. Bemelman  
Amsterdam/NETHERLANDS



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO24.05 Predictors of Cardiovascular Events in Adult Renal Transplant Recipients

D. Arlen<sup>1</sup>, E. Cole<sup>2</sup>, D. Holland<sup>3</sup>, A.M. Jevnikar<sup>4</sup>, S.J. Kim<sup>2</sup>, G. Knoll<sup>5</sup>, H. Ross<sup>2</sup>, J.S. Zaltzman<sup>2</sup>  
<sup>1</sup>Hamilton/CANADA, <sup>2</sup>Toronto/CANADA, <sup>3</sup>Kingston/CANADA, <sup>4</sup>London/CANADA, <sup>5</sup>Ottawa/CANADA

MO24.06 Anti-phospholipid antibody syndrome in end stage renal disease patients: low probability but high consequence outcome.

S. Vaidya  
Galveston, /UNITED STATES OF AMERICA

MO24.07 Reduction of Immunosuppression-Associated Diarrhea by Probiotics Following Renal Transplantation

W.H. Marks<sup>1</sup>, T.Y. Spinelli<sup>1</sup>, S.F. Olmstead<sup>2</sup>  
<sup>1</sup>Seattle/UNITED STATES OF AMERICA, <sup>2</sup>Reno/UNITED STATES OF AMERICA

MO24.08 Predicting Impending Hyperglycaemia in Normoglycaemic Renal Transplant Recipients

A. Sharif<sup>1</sup>, V. Ravindran<sup>2</sup>, G. Dunseath<sup>3</sup>, S. Luzio<sup>3</sup>, D. Owens<sup>3</sup>, K. Baboolal<sup>2</sup>  
<sup>1</sup>Birmingham/UNITED KINGDOM, <sup>2</sup>Cardiff/UNITED KINGDOM, <sup>3</sup>Penarth/UNITED KINGDOM

MO24.09 Glucose intolerance in renal transplant recipients is associated with increased albuminuria

J. Uchida, Y. Machida, T. Iwai, T. Naganuma, T. Iguchi, N. Kumada, R. Yoshimura, H. Kawashima, T. Nakatani  
Osaka/JAPAN

MO24.10 LIM-0705 is an Investigational New Drug to Prevent and/or Treat Tacrolimus-Induced Toxicities

M.P. Chang<sup>1</sup>, R. Elfont<sup>1</sup>, Y. Zhao<sup>1</sup>, D.C. Brennan<sup>2</sup>, V.J. Lee<sup>1</sup>, W.R. Robbins<sup>1</sup>  
<sup>1</sup>South San Francisco/UNITED STATES OF AMERICA, <sup>2</sup>St. Louis/UNITED STATES OF AMERICA

MO24.11 Effects of Everolimus With Very low Tacrolimus Exposure on the Incidence of NODM After Renal Transplantation in the ASSET Study

J. Pascual<sup>1</sup>, R. Hené<sup>2</sup>, S. Vitko<sup>3</sup>, M. Christiaans<sup>4</sup>, H. Tedesco Silva<sup>5</sup>, K. Ciechanowski<sup>6</sup>, L. Rostaing<sup>7</sup>, J. Dominguez<sup>8</sup>, A. Wiecek<sup>9</sup>, A. Gürkan<sup>10</sup>, R.M. Langer<sup>11</sup>  
<sup>1</sup>Barcelona/SPAIN, <sup>2</sup>Utrecht/NETHERLANDS, <sup>3</sup>Prague/CZECH REPUBLIC, <sup>4</sup>Maastricht/NETHERLANDS, <sup>5</sup>Sao Paulo/BRAZIL, <sup>6</sup>Szczecin/POLAND, <sup>7</sup>Toulouse/FRANCE, <sup>8</sup>Santiago/CHILE, <sup>9</sup>Francuska/POLAND, <sup>10</sup>Adana/TURKEY, <sup>11</sup>Budapest/HUNGARY



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

#### Session MO25 Innovations in Heart Transplantation II

**Thursday, August 19, 2010 12:15 PM - 01:15 PM**

**Room: MR 205 - 207**

Moderators: *Abbas . Khani-Hanjani, Stephan . Schueler*

MO25.01 Gender does matter – gender specific outcome analysis of 1000 heart transplants at a single centre

I. Kaczmarek, S. Eifert, P. Ueberfuhr, B. Meiser, B. Reichart  
Munich/GERMANY

MO25.02 New Onset Graft Dysfunction after Heart Transplantation – Incidence and Mechanism-Related In-Hospital Outcomes

K. Shahzad, Q.A. Aziz, M. Cadeiras, J.-P. Leva, E.K. Ho, G. Vlad, E.R. Vasilescu, F. Latif, A. Sinha, E. Burke, L.J. Addonizio, C.C. Marboe, N. Suci-Foca, M.C. Deng  
New York/UNITED STATES OF AMERICA

MO25.03 Novel supercoolant, kaempferol 7-O-beta-D-glucopyranoside (KF7G), enabled 30-hour donor heart preservation at -2°C in a rat heart transplantation model.

S. Shimada<sup>1</sup>, N. Motomura<sup>1</sup>, O. Kinoshita<sup>1</sup>, A. Murakami<sup>1</sup>, M. Ono<sup>1</sup>, S. Fujikawa<sup>2</sup>  
<sup>1</sup>Tokyo/JAPAN, <sup>2</sup>Sapporo/JAPAN

MO25.04 Characterization of Pericardial and Pleural Effusions in De Novo Heart Transplant Recipients Treated with Everolimus

A. Zuckermann<sup>1</sup>, J.M. Arizon<sup>2</sup>, G. Dong<sup>3</sup>, H. Eisen<sup>4</sup>, J. Kobashigawa<sup>5</sup>, H.B. Lehmkuhl<sup>6</sup>, C. Pellegrini<sup>7</sup>, H. Ross<sup>8</sup>, M.J. Barten<sup>9</sup>  
<sup>1</sup>Vienna/AUSTRIA, <sup>2</sup>Cordoba/SPAIN, <sup>3</sup>East Hanover/UNITED STATES OF AMERICA, <sup>4</sup>Philadelphia/UNITED STATES OF AMERICA, <sup>5</sup>Los Angeles/UNITED STATES OF AMERICA, <sup>6</sup>Berlin/GERMANY, <sup>7</sup>Pavia/ITALY, <sup>8</sup>Toronto/CANADA, <sup>9</sup>Leipzig/GERMANY

MO25.05 Impact of Anti-CD25 Monoclonal Antibody as Part of a Calcineurin Inhibitor-Free Immunosuppression Regimen on Th17 cells in Heart Transplantation Recipients

S. Kalyanasundaram, M.-T.J.-P. Nguyen, S. Liu, S. Goldstein, M. Cantarovich, J. Tchervenkov  
Montreal/CANADA

MO25.06 Blood pressure control in orthotopic heart transplant and kidney allograft recipients is far from satisfactory



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

P. Przybylowski<sup>1</sup>, J. Malyszko<sup>2</sup>, J.S. Malyszko<sup>2</sup>, M. Mysliwiec<sup>1</sup>, J. Sadowski<sup>1</sup>  
<sup>1</sup>Cracow/POLAND, <sup>2</sup>Bialystok/POLAND

MO25.07 Placenta growth factor is associated with cardiac allograft vasculopathy.

O.P. Shevchenko, O.V. Orlova, E.N. Kazakov, A.J. Korner, A.O. Shevchenko  
Moscow/RUSSIAN FEDERATION

MO25.09 The Morphologic Grading of Acute Rejections after Heart Transplantation Does not Always Reflect the Severity of Alteration in Myocardial Function

M. Dandel, H.B. Lehmkuhl, D. Kemper, C. Knosalla, R. Hetzer  
Berlin/GERMANY

MO25.10 Comparison of high-dose and low-dose therapy with everolimus in heart transplant recipients with chronic renal failure

U. Fuchs<sup>1</sup>, A. Zittermann<sup>2</sup>, B. Schulze<sup>2</sup>, W. Deyerling<sup>2</sup>, K. Hakim-Meibodi<sup>2</sup>, U. Schulz<sup>2</sup>, J. Gummert<sup>2</sup>  
<sup>1</sup>Bad Oeynhausen/GERMANY, <sup>2</sup>Bad Oeynhausen/GERMANY

MO25.11 Clinical results of immunosuppressive therapy in heart transplant recipients receiving Tacrolimus and Everolimus compared to the combination of Cyclosporin A and Everolimus

U. Fuchs, A. zittermann, B. schulze, W. deyerling, K. Hakim-Meibodi, U. Schulz, J. Gummert  
BAD Oeynhausen/GERMANY

MO25.12 Immunoabsorption Therapy in Heart Transplant Candidates With Idiopathic Dilated Cardiomyopathy who Tested Positive for Antibodies Against Beta-1 Adrenoceptors can Delay Listing for Transplantation

M. Dandel, G. Wallukat, A. Englert, H.B. Lehmkuhl, R. Hetzer  
Berlin/GERMANY

### Session MO26 Interventions and Outcomes in Liver Transplantation II

**Thursday, August 19, 2010 12:15 PM - 01:15 PM**  
**Room: MR 217 - 219**

Moderators: *Ian . Alwayn, Stephen . Lynch*

MO26.01 Risk assessment of liver donation for patients with familial amyloid polyneuropathy in domino liver transplantation: 100 cases from a single center



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

D. Azoulay, G. Tincani, S. De La Serna, C. Salloum, E. Vibert, R. Adam, D. Samuel, D. Castaing  
Villejuif/France

MO26.02 Impact of graft type on the regeneration pattern of remnant liver: Right hepatectomy versus Extended right hepatectomy

M.K. Ju, K.H. Huh, S.I. Kim, J.S. Choi, D.J. Joo, M.S. Kim  
Seoul/Korea

MO26.03 Outcome, alcohol recidivism and quality of life after liver transplantation in patients with alcohol-toxic liver cirrhosis: a single-center-experience

J. Hartl, M.N. Scherer, S.A. Farkas, M. Loss, J. Schoelmerich, H.J. Schlitt, G.I. Kirchner  
Regensburg/Germany

MO26.04 Lessons Learned from 140 Consecutive Living Donor Liver Transplantations for Biliary Atresia in a Single Center

C.-L. Chen<sup>1</sup>, A.M. Concejero<sup>1</sup>, C.-C. Wang<sup>1</sup>, S.-H. Wang<sup>1</sup>, C.-C. Lin<sup>1</sup>, Y.-W. Liu<sup>1</sup>, C.-C. Yong<sup>1</sup>, T.-S. Lin<sup>1</sup>, Y.-C. Chiang<sup>1</sup>, Y.-F. Cheng<sup>2</sup>, B. Jawan<sup>1</sup>, H.-L. Eng<sup>1</sup>  
<sup>1</sup>Kaohsiung/Taiwan, <sup>2</sup>Kaohsiung Hsien/Taiwan

MO26.05 Lobster - Liver observational study to assess the effect of CellCept therapy on clinical outcomes in liver transplant patients: Interim results after 6 months

H.J. Schlitt<sup>1</sup>, G. Grannas<sup>2</sup>, C. Moench<sup>3</sup>, F. Rauchfuss<sup>4</sup>, T.M. Ganten<sup>5</sup>, S. Jonas<sup>6</sup>, A. Risaliti<sup>7</sup>, A.D. Pinna<sup>8</sup>, S. Beckebaum<sup>9</sup>  
<sup>1</sup>Regensburg/Germany, <sup>2</sup>Hannover/Germany, <sup>3</sup>Frankfurt/Germany, <sup>4</sup>Jena/Germany, <sup>5</sup>Heidelberg/Germany, <sup>6</sup>Leipzig/Germany, <sup>7</sup>Ancona/Italy, <sup>8</sup>Bologna/Italy, <sup>9</sup>Essen/Germany

MO26.06 Primary liver team or local team for liver procurement: Can this impact graft outcome?

R. Kashyap<sup>1</sup>, P. Abt<sup>2</sup>, S. Safadjou<sup>1</sup>, S. Agarwal<sup>1</sup>, S. Ramalingam<sup>1</sup>, B. Maliakkal<sup>1</sup>, G. Ramaraju<sup>1</sup>, C. Marroquin<sup>1</sup>, C. Barry<sup>1</sup>, M. Orloff<sup>1</sup>  
<sup>1</sup>Rochester/United States of America, <sup>2</sup>Philadelphia/United States of America

MO26.07 Clinical Outcome of Patients who had been waiting for Combined Liver and Kidney Transplants during post-MELD Era

Y.A. Qazi, Y.W. Cho, T.-L. Fong, I.V. Hutchinson, T. Shah  
Los Angeles/United States of America



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO26.08 A MELD-score based liver allocation system has a negative impact on waiting list mortality and is associated with lower post-transplant survival in a country with a unique, large geographic organ procurement area

A.G. Villamil, J.C. Bandi, O.A. Galdame, S. Marciano, P.C. Casciato, E. de Santibañes, A.C. Gadano  
Buenos Aires/ARGENTINA

MO26.09 Major neurologic, renal and cardiac complications post liver transplant in recipients over 65 yrs of age – Single center experience

R. Kashyap, S. Ramalingam, S. Safadjou, S. Agarwal, P. Batzlod, L. Bryan, J. Gierlach, B. Maliakkal, G. Ramaraju, C. Marroquin, C. Barry, M. Orloff  
Rochester/UNITED STATES OF AMERICA

### Session MO27 Experimental and Clinical Lung Transplantation

**Thursday, August 19, 2010 12:15 PM - 01:15 PM**

**Room: MR 220 - 222**

Moderators: *Annette . Boehler, Martin . Strueber*

MO27.01 Blocking VEGF Receptors 1 and 2 Prevents Inflammatory Response And Experimental Obliterative Airway Disease

R. Krebs<sup>1</sup>, J. Tikkanen<sup>1</sup>, M. Hollmén<sup>1</sup>, Y. Wu<sup>2</sup>, B. Pytowski<sup>2</sup>, P. Koskinen<sup>1</sup>, K. Lemström<sup>1</sup>  
<sup>1</sup>Helsinki/FINLAND, <sup>2</sup>New York/UNITED STATES OF AMERICA

MO27.02 Alloantigen Requirements for the Induction and the Maintenance of Peripheral Tolerance following Porcine Lung Transplantation

G. Warnecke, K. Dreckmann, M. Avsar, A.-K. Knöfel, N. Madrahimov, W. Sommer, B. Kruse, S. Thissen, J. Karstens, A.R. Simon, A. Haverich, M. Strüber  
Hannover/GERMANY

MO27.03 Inhaled hydrogen gas therapy for donors mitigates ventilator-induced lung graft injury

C.-S. Huang, S. Lee, A. Nakao, T. KAWAMURA, N. Shigemura, Z. Wang, T.R. Billiar, Y. Toyoda  
Pittsburgh/UNITED STATES OF AMERICA

MO27.04 Anti-High-Mobility Group Box-1 Antibodies Reduce Pulmonary Ischemia-Reperfusion Injury in Miniature Swine



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

H. Sahara, M. Oku, K. Setoyama, M. Tasaki, H. Nishimura, O. Wunimenghe, M. Okumi, A. Shimizu, K. Yamada  
Kagoshima/JAPAN

MO27.05 Historic and Current Preformed HLA Donor-Specific Antibodies Are Associated With Increased Acute Allograft Rejection in Lung Transplantation

M. Askar, J.D. Schold, M. Budev, L. Klingman, S.C. Murthy, D.P. Mason, J. Yun, G. Pettersson, K.R. McCurry  
Cleveland/UNITED STATES OF AMERICA

MO27.06 Prediction of Short-Term Course of Right Heart Failure in Patients with Pulmonary Arterial Hypertension Referred for Transplantation

M. Dandel, H.B. Lehmkuhl, D. Kemper, C. Knosalla, R. Hetzer  
Berlin/GERMANY

MO27.07 Intermediate-term outcomes of the living donor lobar lung transplantation following hematopoietic stem cell transplantation from the same donor

F. Chen, T. Fujinaga, T. Shoji, T. Sato, M. Sonobe, H. Sakai, R. Miyahara, K. Okubo, T. Bando, H. Date  
Kyoto/JAPAN

MO27.08 Bortezomib in Lung Transplantation: A Promising Start

M.J. Everly<sup>1</sup>, J. Neumann<sup>2</sup>, S. Schio<sup>2</sup>, H. Tarrasconi<sup>2</sup>, A. Bortolotto<sup>2</sup>, C. Costa<sup>2</sup>, T. Machuca<sup>2</sup>, S. Camargo<sup>2</sup>, L. Sanchez<sup>2</sup>, T. Michelon<sup>2</sup>, R. Canabarro<sup>2</sup>, H. Sporleder<sup>2</sup>, S. Fernandes<sup>2</sup>, J. Camargo<sup>2</sup>, F. Perin<sup>2</sup>, J. Felicetti<sup>2</sup>  
<sup>1</sup>Canoga Park/UNITED STATES OF AMERICA, <sup>2</sup>Porto Alegre/BRAZIL

MO27.09 The peculiar mechanisms and graft recovery through anti-inflammatory response after lung transplantation from non-heart-beating donors

S. Yamamoto, M. Okazaki, K. Miyoshi, S. otani, T. Kakisita, O. Yoshida, N. Waki, M. Yamane, T. Oto, S. Miyoshi  
Okayama/JAPAN

MO27.10 Mitochondrial Injury in Pulmonary Ischemia-Reperfusion Injury

S.P. Sommer, S. Sommer, B. Sinha, C. Schimmer, I. Aleksic, V. Lange, J. Wiedemann, C. Otto, R.G. Leyh  
Würzburg/GERMANY

MO27.11 Systemic nicotine treatment reduces macrophage infiltration in rat lung allografts.



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

M. Hirschburger, A. Zakrzewicz, W. Kummer, W. Padberg, V. Grau  
Giessen/GERMANY

MO27.12 The variety activations of mitogen-activated protein kinases (MAPKs) and regulations of their down-stream molecules after rat lung transplantation from non-heart-beating donors (NHBDs)

S. Yamamoto, M. Yamane, K. Miyoshi, S. otani, T. Kakisita, O. Yoshida, M. Okazaki, N. Waki, T. Oto, S. Miyoshi  
Okayama/JAPAN

#### Session MO28 Stem Cells and Cellular Transplantation

**Thursday, August 19, 2010 12:15 PM - 01:15 PM**

**Room: MR 212 - 214**

Moderators: *Igor . Sauer, Clyde . Barker*

MO28.01 Immunogenicity of human Mesenchymal Stem Cells; susceptibility for CD8+ T cell and NK cell mediated lysis

M.J. Hoogduijn, M.J. Crop, S.S. Korevaar, R. de Kuiper, N.M. van Besouw, J.N. IJzermans, C. Baan, W. Weimar  
Rotterdam/NETHERLANDS

MO28.02 Function of human Mesenchymal Stem Cells under Inflammatory conditions

M.J. Hoogduijn<sup>1</sup>, M.J. Crop<sup>1</sup>, S.S. Korevaar<sup>1</sup>, J.N. IJzermans<sup>1</sup>, M. Pescatori<sup>1</sup>, A.P. Stubbs<sup>1</sup>, W.F. van IJcken<sup>1</sup>, E. Eggenhofer<sup>2</sup>, M.H. Dahlke<sup>2</sup>, W. Weimar<sup>1</sup>, C. Baan<sup>1</sup>  
<sup>1</sup>Rotterdam/NETHERLANDS, <sup>2</sup>Regensburg/GERMANY

MO28.03 Investigating Innate and Adaptive Immune Recognition of Neural Progenitor Cell Allografts.

L.K. Phillips, Z. Chen, E.A. Gould, S.M. Krams, T.D. Palmer, O.M. Martinez  
Stanford/UNITED STATES OF AMERICA

MO28.04 Experimental Study of Bone Mesenchymal Stem Cells' Differentiation into Cardiac Cells Induced by BMP-2

S. zhenya, D. Yiguo  
Suzhou/CHINA



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

MO28.05 The Experimental Research on Cardiac Function Recovery Using Autologous BM-MSCs Transplantation with Anti-inflammation Treatment in the Acute Period of MI

S. zhenya, L. Weijie, H. Yanqiu  
Suzhou/CHINA

MO28.06 Use of 'facilitator cells' to enhance fetal hepatocyte engraftment

M.G. Joshi<sup>1</sup>, P.B. Patil<sup>1</sup>, N. Hernandez<sup>1</sup>, D. Hallberg<sup>1</sup>, Z. He<sup>2</sup>, J. Holgersson<sup>1</sup>, M. Olausson<sup>1</sup>, S. Holgersson<sup>1</sup>  
<sup>1</sup>Gothenburg/SWEDEN, <sup>2</sup>Florida/UNITED STATES OF AMERICA

MO28.07 In vitro engineering of a functional human liver tissue for transplantation

J. Bierwolf<sup>1</sup>, M. Luetgehetmann<sup>1</sup>, S. Cohen<sup>2</sup>, O. Kryukov<sup>2</sup>, S. Deichmann<sup>1</sup>, P.-J. Erbes<sup>1</sup>, B. Nashan<sup>1</sup>, J. Pollok<sup>1</sup>  
<sup>1</sup>Hamburg/GERMANY, <sup>2</sup>Beer-Sheva/ISRAEL

MO28.08 Induction of Donor Specific Tolerance in Recipients of HLA Disparate Living Donor Kidney Allografts by Donor Stem Cell Infusion

J. Leventhal<sup>1</sup>, L. Gallon<sup>1</sup>, J. Miller<sup>1</sup>, M. Abecassis<sup>1</sup>, K. Ravindra<sup>2</sup>, E. Reed<sup>2</sup>, S.T. Ildstad<sup>2</sup>  
<sup>1</sup>Chicago/UNITED STATES OF AMERICA, <sup>2</sup>Louisville/UNITED STATES OF AMERICA

MO28.09 NKG2D Ligands alleles affect Clinical Outcomes following Sibling Stem Cell Transplantation

A. Antoun, D. Vekaria, S. Jobson, M. Cook, D. Briggs, P. Moss  
Birmingham/UNITED KINGDOM

MO28.10 Clinical Use Of Amniotic Fluid In Osteoarthritis : A Source Of Cell Therapy

N. Bhattacharya  
Calcutta/INDIA

MO28.11 The Combination of Autologous Mesenchymal Stem Cells, Acellular Dermal Matrix and Growth Factors for Cartilage Regeneration in Experimental Cartilage Defect Model in Nonhuman Primates

L. Jiang, A. Ma, L. Song, Y. Hu, H. Dun, P. Daloz, M. Zafarullah, H. Chen  
Montreal/CANADA

MO28.12 Outstanding Survival and Regeneration Process by the Use of Intelligent Acellular Dermal Matrices and Mesenchymal Stem Cells in a Burn Pig Model.

E. Mansilla<sup>1</sup>, G. Marin<sup>1</sup>, G. Larsen<sup>2</sup>, G. Roque<sup>1</sup>, K.E. Martire<sup>1</sup>, J.C. Raimondi<sup>1</sup>, V. Diaz Aquino<sup>1</sup>, L. Nuñez<sup>3</sup>, J.M. Tau<sup>1</sup>, H. Drago<sup>4</sup>, F. Sturla<sup>4</sup>, R. Lamonega<sup>1</sup>, C. Gardiner<sup>1</sup>, R. Spretz<sup>2</sup>, N. Lausada<sup>1</sup>, J. Cordone<sup>1</sup>, N.



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

Biassi<sup>1</sup>, A. Maceira<sup>1</sup>

<sup>1</sup>La Plata/ARGENTINA, <sup>2</sup>Nebraska/UNITED STATES OF AMERICA, <sup>3</sup>Chicago/UNITED STATES OF AMERICA,

<sup>4</sup>Buenos Aires/ARGENTINA

### 13:30 – 15:00 STATE OF THE ART SYMPOSIUM

#### Session SOTA22 Planning for donation after cardiac death

Thursday, August 19, 2010 01:30 PM - 03:00 PM

Room: MR 109 - 110

Moderators: *Ron . Shapiro, Sam . Shemie*

SOTA22.1 Uncontrolled Donation after Cardiac Death

J. Nunez

Madrid/SPAIN

SOTA22.2 Donation after cardiac death in the US

H.M. Nathan

Philadelphia/UNITED STATES OF AMERICA

SOTA22.3 Development of UK DCD program from legal and medical perspectives

C. Rudge

London/UNITED KINGDOM

SOTA22.4 Optimal preservation of NHB-donor grafts

R. Ploeg

SOTA22 - DISCUSSION

#### Session SOTA23 Tissue transplantation and reconstruction

Thursday, August 19, 2010 01:30 PM - 03:00 PM



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

**Room: MR 212 - 214**

Moderators: *Stefan . Tullius, Mark . Hardy*

SOTA23.1 Adapting the Banff Scoring System to the Biology of Vascularized Composite Allografts

L. Cendales

Atlanta/UNITED STATES OF AMERICA

SOTA23.2 Mixed tissue transplantation for facial reconstruction

M. Siemionow

Cleveland/UNITED STATES OF AMERICA

SOTA23.3 Mixed tissue transplantation for limb replacement

J.M. Dubernard

Lyon/FRANCE

SOTA23 - DISCUSSION

### **Session SOTA24 Immunosuppression and post-transplant malignancy**

**Thursday, August 19, 2010 01:30 PM - 03:00 PM**

**Room: Ballroom A/B**

Moderators: *Angela . Webster, Edward . Geissler*

SOTA24.1 Molecular signals, viral infection and immune suppression in post-transplant malignancy

E.K. Geissler

Regensburg/GERMANY

SOTA24.2 Epidemiology of malignancy after transplantation

G. Opelz

Heidelberg/GERMANY

SOTA24.3 Immunosuppressive strategies in patients with post-transplant malignancy



## XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

### TTS 2010 SCIENTIFIC PROGRAM

R. Hirose

San Francisco/UNITED STATES OF AMERICA

SOTA24.4 Innovations in therapy of cancer in transplant recipients

J. Connor

Vancouver/CANADA

SOTA24 - DISCUSSION

#### **Session SOTA25 Injury, repair and remodeling**

**Thursday, August 19, 2010 01:30 PM - 03:00 PM**

**Room: Ballroom C**

Moderators: *Bruce . McManus, Jerzy . Kupiec-Weglinski*

SOTA25.1 Innate and adaptive immunity in ischemia-reperfusion injury

J.W. Kupiec-Weglinski

Los Angeles/UNITED STATES OF AMERICA

SOTA25.2 Biomarkers of injury and response in transplanted patients

B. McManus

Vancouver/CANADA

SOTA25.3 Genomic fingerprints of tissue injury and remodeling / Role of the endothelium

M.J. Hébert

Montreal/CANADA

SOTA25 - DISCUSSION

#### **Session SOTA26 Cellular xenotransplantation**

**Thursday, August 19, 2010 01:30 PM - 03:00 PM**



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

**Room: MR 211**

Moderators: *Richard . Pierson III, J. . Tchervenkov*

SOTA26.1 Anti-gal and non-gal antibodies in xenotransplantation

M. Breimer  
Gothenburg/SWEDEN

SOTA26.2 Developments in cellular xenotransplantation

E. Cozzi  
Padua/ITALY

SOTA26.3 Islet xenotransplantation: Advances towards the clinic

B.J. Hering  
Minneapolis/UNITED STATES OF AMERICA

SOTA26 - DISCUSSION

### **Session SOTA27 Graft Injury in Liver Transplantation**

**Thursday, August 19, 2010 01:30 PM - 03:00 PM**  
**Room: MR 118 - 120**

Moderators: *Stephen . Lynch, Rui . Maio*

SOTA27.1 Clinical prevention of ischemia-reperfusion injury

R.W. Busuttil  
Los Angeles/UNITED STATES OF AMERICA

SOTA27.2 DCD grafts

N. Heaton  
London/UNITED KINGDOM

SOTA27.3 Steatotic grafts



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

P. Friend

Oxford/UNITED KINGDOM

SOTA27 - DISCUSSION

### Session SOTA28 Intestinal transplantation

**Thursday, August 19, 2010 01:30 PM - 03:00 PM**

**Room: MR 220 - 222**

Moderators: *Andreas . Tzakis, David . Grant*

SOTA28.1 Basic Science of intestinal transplantation

M. Zaslhoff

SOTA28.2 Intestine Rehabilitation Options

L. Pironi

Bologna/ITALY

SOTA28.3 ITR and SRTR Clinical Outcomes

G. Mazariegos

Pittsburgh/UNITED STATES OF AMERICA

SOTA28 - DISCUSSION

### **16:00 – 17:00 CLOSING CEREMONY**

### Session PL05 Closing Ceremony - What's Hot and What's not?

**Thursday, August 19, 2010 04:00 PM - 05:00 PM**

**Room: Ballroom A/B**

Moderators: *Peter . Neuhaus, Gerhard . Opelz*

PL05.1 Advances in Clinical Transplantation



# XXIII International Congress of The Transplantation Society

AUGUST 15 – 19, 2010 | VANCOUVER, CANADA  
VANCOUVER CONVENTION CENTRE

## TTS 2010 SCIENTIFIC PROGRAM

G.A. Levy  
Toronto/CANADA

PL05.2 Advances in Basic Science

D.H. Sachs  
Boston/UNITED STATES OF AMERICA

PL05.3 TTS 2012 - See you in Berlin, Germany

P. Neuhaus  
Berlin/GERMANY